PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 2559029-1 1989 The phosphatidylinositol-specific phospholipase C from the membrane of NG108-15 cells has been purified to homogeneity by using DEAE Bio-Gel A agarose, hydroxyapatite, and heparin agarose chromatography. Phosphatidylinositols 4-24 matrix metallopeptidase 2 Mus musculus 137-142 33538995-13 2021 The expression of Nrf-2 and HO-1 by high glucose incubation was significantly inhibited by ropivacaine treatment.Ropivacaine might alleviate high glucose-induced brain microvascular endothelial injury by suppressing oxidative stress and down-regulating MMPs. Ropivacaine 91-102 matrix metallopeptidase 2 Mus musculus 253-257 33538995-0 2021 The Protective Effects of Ropivacaine Against High Glucose-induced Brain Microvascular Endothelial Injury by Reducing MMPs and Alleviating Oxidative Stress. Ropivacaine 26-37 matrix metallopeptidase 2 Mus musculus 118-122 33538995-12 2021 Ropivacaine suppressed the expression of up-regulated iNOS, NO, MMP-2, MMP-9, ICAM-1, and VEGF induced by high glucose incubation. Ropivacaine 0-11 matrix metallopeptidase 2 Mus musculus 64-69 33538995-13 2021 The expression of Nrf-2 and HO-1 by high glucose incubation was significantly inhibited by ropivacaine treatment.Ropivacaine might alleviate high glucose-induced brain microvascular endothelial injury by suppressing oxidative stress and down-regulating MMPs. Ropivacaine 113-124 matrix metallopeptidase 2 Mus musculus 253-257 33538995-12 2021 Ropivacaine suppressed the expression of up-regulated iNOS, NO, MMP-2, MMP-9, ICAM-1, and VEGF induced by high glucose incubation. Glucose 111-118 matrix metallopeptidase 2 Mus musculus 64-69 33211285-6 2021 In addition, Ramelteon displayed a robust anti-inflammatory capacity against isoflurane-induced insults and inflammation by reducing the generation of interleukin-1beta (IL-1beta), transforming growth factor-beta (TGF-beta), monocyte chemotactic protein 1 (MCP-1), stromal cell-derived factor-1 (SDF-1), matrix metalloproteinase-2 (MMP-2), and MMP-9. ramelteon 13-22 matrix metallopeptidase 2 Mus musculus 304-330 33211285-6 2021 In addition, Ramelteon displayed a robust anti-inflammatory capacity against isoflurane-induced insults and inflammation by reducing the generation of interleukin-1beta (IL-1beta), transforming growth factor-beta (TGF-beta), monocyte chemotactic protein 1 (MCP-1), stromal cell-derived factor-1 (SDF-1), matrix metalloproteinase-2 (MMP-2), and MMP-9. ramelteon 13-22 matrix metallopeptidase 2 Mus musculus 332-337 34059044-7 2021 Silibinin considerably down-regulated the expression of COX-2, HIF-1alpha, VEGF, Ang-2, and Ang-4 as well as the expression of MMP-2, MMP-9, CCR-2 and CXCR-4. Silybin 0-9 matrix metallopeptidase 2 Mus musculus 127-132 33538995-13 2021 The expression of Nrf-2 and HO-1 by high glucose incubation was significantly inhibited by ropivacaine treatment.Ropivacaine might alleviate high glucose-induced brain microvascular endothelial injury by suppressing oxidative stress and down-regulating MMPs. Glucose 41-48 matrix metallopeptidase 2 Mus musculus 253-257 33966042-8 2021 Compared with SCI mice, ZO-treated mice exhibited less microglia pro-inflammatory activation and accumulation adjacent to injured core linked to reduced MMP2/9 expression, leading to minor tissue damage and better locomotor recovery. zo 24-26 matrix metallopeptidase 2 Mus musculus 153-159 34010605-8 2021 RT-qPCR assays of the aortic wall in male Ipo8-/- mice demonstrate decreased Smad6/7 and increased Mmp2 and Ccn2 (Ctgf) expression, reinforcing a role for dysregulation of the TGF-beta signaling pathway in TAA development. ipo8 42-46 matrix metallopeptidase 2 Mus musculus 99-103 33986189-4 2021 Treating the endothelial specific Dgke-knockout mice with a stable PGE2 analog was sufficient to reverse the clinical manifestations of thrombotic microangiopathy and proteinuria, possibly by suppressing the expression of matrix metalloproteinase 2 through PGE2-dependent upregulation of the chemokine receptor CXCR4. Dinoprostone 67-71 matrix metallopeptidase 2 Mus musculus 222-248 33986189-4 2021 Treating the endothelial specific Dgke-knockout mice with a stable PGE2 analog was sufficient to reverse the clinical manifestations of thrombotic microangiopathy and proteinuria, possibly by suppressing the expression of matrix metalloproteinase 2 through PGE2-dependent upregulation of the chemokine receptor CXCR4. Dinoprostone 257-261 matrix metallopeptidase 2 Mus musculus 222-248 33244794-9 2021 Moreover, both of ATO and canstatin increased the protein expression of caspase-3, while decreased PCNA and MMP-2, which was further strengthened upon their combination. Arsenic Trioxide 18-21 matrix metallopeptidase 2 Mus musculus 108-113 33977095-11 2021 The recruitment of WDR5 to the promoter of these target genes upregulated the histone H3 lysine 4 trimethylation (H3K4me3) level in these regions and further induced the transcription of MMP2, MMP9, CDK1, CDK2, and CDK4. Lysine 89-95 matrix metallopeptidase 2 Mus musculus 187-191 33930482-4 2021 The results showed that although 10 nM of BPA have no significant effect on the cell viability, it alters the expression of decidualization-related genes including Prl8a2, Prl3c1, Ptgs2, and Mmp2. bisphenol A 42-45 matrix metallopeptidase 2 Mus musculus 191-195 32176932-10 2021 Furthermore, celastrol inhibited the pro-thrombotic effects of HFD in apoE-/- mice, and the underlying mechanism was mediated, at least partially, through the suppression of matrix metalloproteinase-2 and -9 expression. celastrol 13-22 matrix metallopeptidase 2 Mus musculus 174-207 33910830-1 2021 BACKGROUND/AIM: This study aimed to investigate the usefulness of in vivo bioluminescence imaging (BLI) to examine the role of matrix metalloproteinases (MMP)-2 and MMP-9 activation in the development and healing of ethanol-induced damage in the cornea of mice. Ethanol 216-223 matrix metallopeptidase 2 Mus musculus 127-160 33910830-5 2021 RESULTS: BLI indicated that treatment of the eye with 20% ethanol elevated MMP-2/9 activity, which was inhibited by the application of eye drops (hyaluronic acid and serum). Ethanol 58-65 matrix metallopeptidase 2 Mus musculus 75-82 33910830-5 2021 RESULTS: BLI indicated that treatment of the eye with 20% ethanol elevated MMP-2/9 activity, which was inhibited by the application of eye drops (hyaluronic acid and serum). Hyaluronic Acid 146-161 matrix metallopeptidase 2 Mus musculus 75-82 33910830-6 2021 Treatment of corneal epithelial cells with 20% ethanol-increased the activities of MMP-2 and MMP-9, which were also inhibited by eye drops. Ethanol 47-54 matrix metallopeptidase 2 Mus musculus 83-88 33548476-13 2021 MMP-2 and MMP-9, two matrix metalloproteinases, were downregulated in cholecalciferol-treated mouse placentae and calcitriol-treated human trophoblast cells. Cholecalciferol 70-85 matrix metallopeptidase 2 Mus musculus 0-5 33548476-13 2021 MMP-2 and MMP-9, two matrix metalloproteinases, were downregulated in cholecalciferol-treated mouse placentae and calcitriol-treated human trophoblast cells. Calcitriol 114-124 matrix metallopeptidase 2 Mus musculus 0-5 33790957-6 2021 The selective PPARbeta/delta agonist GW0742 significantly decreased inflammation-related mRNA expression in hDPCs (IL6, IL1beta, TNFalpha, MMP1, and MMP2) and RAW264.7 cells (Il6 and Tnfalpha). GW0742 37-43 matrix metallopeptidase 2 Mus musculus 149-153 33923494-5 2021 Furthermore, um-PEA reduced tumor cell migration by reducing MMP2 and TIMP1 expression. um-pea 13-19 matrix metallopeptidase 2 Mus musculus 61-65 33856030-5 2021 KEY FINDINGS: It was shown that sildenafil significantly increased the levels of cGMP and Caspase-3 with a reduction of NF-kappaB, Bcl-2, Cyclin D1, intercellular adhesion molecule 1, matrix metalloproteinase-2 levels and normalisation of Nrf2 along with pronounced improvement in the histological patterns. Sildenafil Citrate 32-42 matrix metallopeptidase 2 Mus musculus 184-210 33937253-13 2021 Urantide drastically prevented endogenous and UII-induced GBM angiogenesis, MMP, and integrin activations, associated with GBM tumoral growth. urotensin II (4-11), Pen(5)-Trp(7)-Orn(8)- 0-8 matrix metallopeptidase 2 Mus musculus 76-79 33841650-9 2021 In addition, F528 treatment reduced the phosphorylation of NF-kappaB induced by smoke, and the expression of MMP-2 and MMP-9 was also obviously decreased by F528 treatment. f528 157-161 matrix metallopeptidase 2 Mus musculus 109-114 33691248-10 2021 MMP-2 mRNA expression in mouse sclera was lower after treatment with atropine, marimastat, batimastat, or doxycycline. Atropine 69-77 matrix metallopeptidase 2 Mus musculus 0-5 33711514-12 2021 Inhibition of Adra1b with terazosin abrogated Ece1, Edn1, and contrast-induced Fsp-1, Mmp-2, Mmp-9 expression, and caspase-3/7 activity in HK-2 cells. Terazosin 26-35 matrix metallopeptidase 2 Mus musculus 86-91 32910833-9 2021 RESULTS: Baicalein inhibited the invasion of EcESCs and the expression of certain invasion-related proteins, including MMP9, MMP2 and MT1-MMP. baicalein 9-18 matrix metallopeptidase 2 Mus musculus 125-129 33691248-10 2021 MMP-2 mRNA expression in mouse sclera was lower after treatment with atropine, marimastat, batimastat, or doxycycline. marimastat 79-89 matrix metallopeptidase 2 Mus musculus 0-5 33691248-10 2021 MMP-2 mRNA expression in mouse sclera was lower after treatment with atropine, marimastat, batimastat, or doxycycline. batimastat 91-101 matrix metallopeptidase 2 Mus musculus 0-5 33691248-10 2021 MMP-2 mRNA expression in mouse sclera was lower after treatment with atropine, marimastat, batimastat, or doxycycline. Doxycycline 106-117 matrix metallopeptidase 2 Mus musculus 0-5 33691248-11 2021 The protein levels and activity of MMP-2 and MMP-7 were significantly reduced after treatment with atropine, marimastat, batimastat, doxycycline, and minocycline. Atropine 99-107 matrix metallopeptidase 2 Mus musculus 35-40 33691248-11 2021 The protein levels and activity of MMP-2 and MMP-7 were significantly reduced after treatment with atropine, marimastat, batimastat, doxycycline, and minocycline. marimastat 109-119 matrix metallopeptidase 2 Mus musculus 35-40 33691248-11 2021 The protein levels and activity of MMP-2 and MMP-7 were significantly reduced after treatment with atropine, marimastat, batimastat, doxycycline, and minocycline. batimastat 121-131 matrix metallopeptidase 2 Mus musculus 35-40 33691248-11 2021 The protein levels and activity of MMP-2 and MMP-7 were significantly reduced after treatment with atropine, marimastat, batimastat, doxycycline, and minocycline. Doxycycline 133-144 matrix metallopeptidase 2 Mus musculus 35-40 33691248-11 2021 The protein levels and activity of MMP-2 and MMP-7 were significantly reduced after treatment with atropine, marimastat, batimastat, doxycycline, and minocycline. Minocycline 150-161 matrix metallopeptidase 2 Mus musculus 35-40 33276023-8 2021 Alteration in brain cytokine levels and matrix metalloproteinase enzymes MMP-2 and MMP-9 suggested that gamma-GC may lower inflammation and enhance Abeta plaque clearance in vivo. gamma-glutamylcysteine 104-112 matrix metallopeptidase 2 Mus musculus 73-78 33883980-10 2021 Moreover, metastasis and angiogenesis were reduced in Losartan-treated mice as observed by inhibited matrix metalloproteinase-2 and -9 activities and decreased tumor vasculature. Losartan 54-62 matrix metallopeptidase 2 Mus musculus 101-134 33627152-3 2021 RESULTS: In this paper, a highly efficient AS1411 aptamer modified, dsDNA and MMP-2 cleavable peptide-fabricated gold nanocage vehicle, which could load doxorubicin hydrochloride (DOX) and siRNAs to achieve a combination of tumor responsive genetic therapy, chemotherapy, and photothermal treatment is presented. Doxorubicin 153-178 matrix metallopeptidase 2 Mus musculus 78-83 33627152-3 2021 RESULTS: In this paper, a highly efficient AS1411 aptamer modified, dsDNA and MMP-2 cleavable peptide-fabricated gold nanocage vehicle, which could load doxorubicin hydrochloride (DOX) and siRNAs to achieve a combination of tumor responsive genetic therapy, chemotherapy, and photothermal treatment is presented. Doxorubicin 180-183 matrix metallopeptidase 2 Mus musculus 78-83 33708132-2 2020 We hypothesize that HFD instigates dysbiosis and cardiac muscle remodeling by inducing matrix metalloproteinases (MMPs), which leads to an increase in white adipose tissue, and treatment with lactobacillus (a ketone body donor from lactate; the substrate for the mitochondria) reverses dysbiosis-induced cardiac injury, in part, by increasing lipolysis (PGC-1alpha, and UCP1) and adipose tissue browning and decreasing lipogenesis. Lactic Acid 232-239 matrix metallopeptidase 2 Mus musculus 114-118 33246781-7 2021 However, the application of Fe3O4 magnetic albumin nanoparticles (Fe3O4@BSA) enhanced MMP-2 activity and alleviated renal tubular injury, and these changes were mediated by an autophagy-dependent mechanism. ferryl iron 28-33 matrix metallopeptidase 2 Mus musculus 86-91 33146827-7 2021 Compared with group S, groups Au and Al had significantly shorter aortic diameters (group S vs Au vs Al; 2.29 vs 1.40 vs 1.36 mm, respectively, p < 0.01), reduced MMP-2 and MMP-9 activities, downregulated IL-6 and MCP-1 and upregulated expression of IGF-1 and TIMP-2. Aluminum 37-39 matrix metallopeptidase 2 Mus musculus 163-168 33246781-7 2021 However, the application of Fe3O4 magnetic albumin nanoparticles (Fe3O4@BSA) enhanced MMP-2 activity and alleviated renal tubular injury, and these changes were mediated by an autophagy-dependent mechanism. ferryl iron 66-71 matrix metallopeptidase 2 Mus musculus 86-91 33438347-6 2021 The results showed that levo-tetrahydropalmatine alleviated liver fibrosis by inhibiting the formation of extracellular matrix (ECM) and regulating the balance between TIMP1 and MMP2 in the two mice liver fibrosis models and cell model. tetrahydropalmatine 24-48 matrix metallopeptidase 2 Mus musculus 178-182 33124885-7 2021 TAC induced myocyte hypertrophy, collagen deposition and, the expression of MMP-2 and TGF-b in the left ventricle. tac 0-3 matrix metallopeptidase 2 Mus musculus 76-81 33747866-9 2021 Regarding cancer metastasis, curcumin and PGV-1 showed inhibitory activities against cell migration and inhibited MMP-2 and MMP-9 protein expression. Curcumin 29-37 matrix metallopeptidase 2 Mus musculus 114-119 33474811-7 2021 In the IA model, BP-1-102 can reduce the expression of inflammatory factors and MMPs bound to NF-kappaB by inhibiting the activation of the JAK/STAT3/NF-kappaB pathway proteins, and then restore the vascular wall elastin to reduce blood pressure, thereby treating aneurysm. BP-1-102 17-25 matrix metallopeptidase 2 Mus musculus 80-84 32851725-10 2021 Only ASC- and WJ-derived cells reduced AKT and MMP-2 activation, while Cav-1 was increased by ASC treatment as previously reported. polyurethane-polypropylene composite 5-8 matrix metallopeptidase 2 Mus musculus 47-52 33614911-0 2021 Inhibition of tumor invasion and metastasis by targeting TGF-beta-Smad-MMP2 pathway with Asiatic acid and Naringenin. asiatic acid 89-101 matrix metallopeptidase 2 Mus musculus 71-75 33614911-0 2021 Inhibition of tumor invasion and metastasis by targeting TGF-beta-Smad-MMP2 pathway with Asiatic acid and Naringenin. naringenin 106-116 matrix metallopeptidase 2 Mus musculus 71-75 33441969-7 2021 Protein assays revealed that, after DOX treatment, the differential expression of MMP-2 (matrix metalloproteinase-2), MMP-9 (matrix metalloproteinase-9), TNF-alpha (tumor necrosis factor-alpha), and NT-pro-BNP (N-terminal pro-B-type natriuretic peptide) between saline- and DOX-treated mice was involved in the progression of HF. Doxorubicin 36-39 matrix metallopeptidase 2 Mus musculus 82-87 33441969-7 2021 Protein assays revealed that, after DOX treatment, the differential expression of MMP-2 (matrix metalloproteinase-2), MMP-9 (matrix metalloproteinase-9), TNF-alpha (tumor necrosis factor-alpha), and NT-pro-BNP (N-terminal pro-B-type natriuretic peptide) between saline- and DOX-treated mice was involved in the progression of HF. Doxorubicin 36-39 matrix metallopeptidase 2 Mus musculus 89-115 33552853-0 2021 Improved Antiglioblastoma Activity and BBB Permeability by Conjugation of Paclitaxel to a Cell-Penetrative MMP-2-Cleavable Peptide. Paclitaxel 74-84 matrix metallopeptidase 2 Mus musculus 107-112 31995179-2 2021 Doxorubicin enhances oxidative stress and stimulates matrix metalloproteinase-2 (MMP-2) in cardiomyocytes. Doxorubicin 0-11 matrix metallopeptidase 2 Mus musculus 53-79 31995179-2 2021 Doxorubicin enhances oxidative stress and stimulates matrix metalloproteinase-2 (MMP-2) in cardiomyocytes. Doxorubicin 0-11 matrix metallopeptidase 2 Mus musculus 81-86 31995179-8 2021 Doxorubicin increased myocardial MMP-2 activity in part also by upregulating N-terminal truncated MMP-2. Doxorubicin 0-11 matrix metallopeptidase 2 Mus musculus 33-38 31995179-8 2021 Doxorubicin increased myocardial MMP-2 activity in part also by upregulating N-terminal truncated MMP-2. Doxorubicin 0-11 matrix metallopeptidase 2 Mus musculus 98-103 31995179-8 2021 Doxorubicin increased myocardial MMP-2 activity in part also by upregulating N-terminal truncated MMP-2. Nitrogen 77-78 matrix metallopeptidase 2 Mus musculus 33-38 31995179-8 2021 Doxorubicin increased myocardial MMP-2 activity in part also by upregulating N-terminal truncated MMP-2. Nitrogen 77-78 matrix metallopeptidase 2 Mus musculus 98-103 31995179-9 2021 Immunogold transmission electron microscopy showed that doxorubicin elevated MMP-2 levels within the sarcomere and mitochondria which were associated with myofilament lysis, mitochondrial degeneration, and T-tubule distention. Doxorubicin 56-67 matrix metallopeptidase 2 Mus musculus 77-82 31995179-16 2021 We determined in mice whether matrix metalloproteinase-2, an intracellular and extracellular protease in the heart, contributes to doxorubicin cardiotoxicity. Doxorubicin 131-142 matrix metallopeptidase 2 Mus musculus 30-56 31995179-17 2021 Doxorubicin activated myocardial MMP-2 in mouse hearts and human cardiomyocytes, including de novo expression of an N-terminal truncated MMP-2 isoform which is exclusively expressed by increased oxidative stress. Doxorubicin 0-11 matrix metallopeptidase 2 Mus musculus 33-38 33341451-9 2021 Securinine suppressed the expression of adhesion molecules and matrix metalloproteinase-2/-9 in both ApoE KO and vascular endothelial cells (HUVEC). securinine 0-10 matrix metallopeptidase 2 Mus musculus 63-92 33065235-4 2021 Our data show that treatment of LDLr-/- mice with a specific ENaC blocker, benzamil, significantly decreased atherosclerotic lesion formation and expression of matrix metalloproteinase 2 (MMP2) and metalloproteinase 9 (MMP9) in aortic arteries. benzamil 75-83 matrix metallopeptidase 2 Mus musculus 160-186 33065235-4 2021 Our data show that treatment of LDLr-/- mice with a specific ENaC blocker, benzamil, significantly decreased atherosclerotic lesion formation and expression of matrix metalloproteinase 2 (MMP2) and metalloproteinase 9 (MMP9) in aortic arteries. benzamil 75-83 matrix metallopeptidase 2 Mus musculus 188-192 33506910-6 2021 CONCLUSIONS: To sum up, the combination of mouse NGF and nimodipine achieves good clinical efficacy in NICH, which down-regulates plasma PAF and MMP-2, up-regulates CNP, and improves neurological function. Nimodipine 57-67 matrix metallopeptidase 2 Mus musculus 145-150 33396696-0 2020 AG-9, an Elastin-Derived Peptide, Increases In Vitro Oral Tongue Carcinoma Cell Invasion, through an Increase in MMP-2 Secretion and MT1-MMP Expression, in a RPSA-Dependent Manner. tyrphostin A23 0-4 matrix metallopeptidase 2 Mus musculus 113-118 33396696-11 2020 EGCG abolished AG-9-induced invasion, MMP-2 secretion, and MT1-MMP expression. epigallocatechin gallate 0-4 matrix metallopeptidase 2 Mus musculus 38-43 33396696-11 2020 EGCG abolished AG-9-induced invasion, MMP-2 secretion, and MT1-MMP expression. tyrphostin A23 15-19 matrix metallopeptidase 2 Mus musculus 38-43 33552853-2 2021 In this study, SynB3-PVGLIG-PTX is designed and screened out by matrix metalloproteinase-2 (MMP-2), to which it exhibits the best affinity. Paclitaxel 28-31 matrix metallopeptidase 2 Mus musculus 64-90 33552853-2 2021 In this study, SynB3-PVGLIG-PTX is designed and screened out by matrix metalloproteinase-2 (MMP-2), to which it exhibits the best affinity. Paclitaxel 28-31 matrix metallopeptidase 2 Mus musculus 92-97 33552853-4 2021 Moreover, as a drug-peptide nanocomplex, SynB3-PVGLIG-PTX exhibited a high potential to form an aggregation with good solubility that can release paclitaxel (PTX) through the cleavage of MMP-2. Paclitaxel 54-57 matrix metallopeptidase 2 Mus musculus 187-192 33552853-4 2021 Moreover, as a drug-peptide nanocomplex, SynB3-PVGLIG-PTX exhibited a high potential to form an aggregation with good solubility that can release paclitaxel (PTX) through the cleavage of MMP-2. Paclitaxel 146-156 matrix metallopeptidase 2 Mus musculus 187-192 33552853-4 2021 Moreover, as a drug-peptide nanocomplex, SynB3-PVGLIG-PTX exhibited a high potential to form an aggregation with good solubility that can release paclitaxel (PTX) through the cleavage of MMP-2. Paclitaxel 158-161 matrix metallopeptidase 2 Mus musculus 187-192 33552853-5 2021 From a functional perspective, it is found that SynB3-PVGLIG-PTX can specifically inhibit the proliferation, migration, and invasion of GBM cells in vitro in the presence of MMP-2, in contrast to that observed in MMP-2 siRNA transfected cells. Paclitaxel 61-64 matrix metallopeptidase 2 Mus musculus 174-179 33324106-11 2020 Conclusion: AC118344.1 promotes gastric cancer cell proliferation and invasion and lung metastasis in nude mice by upregulating the expression of AKT2 and its downstream molecules (HK2 and MMP2). ac118344 12-20 matrix metallopeptidase 2 Mus musculus 189-193 33237730-7 2020 Our results also demonstrate that Omarigliptin reduced LPS-induced increase in expressions of matrix matalloproteinases-2 (MMP-2) and matrix matalloproteinases-9 (MMP-9) at both the mRNA and protein levels. 2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine 34-46 matrix metallopeptidase 2 Mus musculus 94-121 33237730-7 2020 Our results also demonstrate that Omarigliptin reduced LPS-induced increase in expressions of matrix matalloproteinases-2 (MMP-2) and matrix matalloproteinases-9 (MMP-9) at both the mRNA and protein levels. 2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine 34-46 matrix metallopeptidase 2 Mus musculus 123-128 33237730-9 2020 Consistently, Omarigliptin ameliorated LPS-induced exacerbation of endothelial permeability by increasing the expressions of claudin-1 and claudin-5 and reducing the expression of MMP-2 and MMP-9. 2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine 14-26 matrix metallopeptidase 2 Mus musculus 180-185 33327637-7 2020 Network pharmacology analysis with subsequent verification by molecular modeling revealed that matrix metalloproteinases MMP-2/-9 and c-Jun N-terminal protein kinase 1 (JNK1) can be considered as hypothetical primary targets of SM, mediating its marked anti-EMT activity. Samarium 228-230 matrix metallopeptidase 2 Mus musculus 121-129 33254626-0 2020 The role of miR-21 in nickel nanoparticle-induced MMP-2 and MMP-9 production in mouse primary monocytes: In vitro and in vivo studies. Nickel 22-28 matrix metallopeptidase 2 Mus musculus 50-55 33254626-9 2020 Finally, our results demonstrated that exposure of primary monocytes from WT mice to Nano-Ni and Nano-Ni-P caused downregulation of RECK, a direct miR-21 target, suggesting the involvement of miR-21/RECK pathway in Nano-Ni-induced MMP-2 and MMP-9 production. N-(4-isothiocyanatophenethyl)spiperone 102-106 matrix metallopeptidase 2 Mus musculus 231-236 33496114-1 2020 To investigate the effect of baicalin extracted from Qinbai Qingfei Concentrated Pills on the expressions of TGF-beta1, mmp2 and timp2 in mice with pulmonary fibrosis induced by bleomycin. baicalin 29-37 matrix metallopeptidase 2 Mus musculus 120-124 33141247-5 2020 In addition to its potent antiangiogenic and MMP-2/9 inhibitory activities, AARP administration also significantly increased energy expenditure, influenced the metabolic and angiogenic gene expression profiles, and attenuated obesity-induced inflammation, demonstrating its systemic beneficial effects. aarp 76-80 matrix metallopeptidase 2 Mus musculus 45-52 32612287-11 2020 In addition, Ang II-induced upregulation in matrix metalloproteinase (MMP)-9 and MMP2, two key proteases responsible for ECM degradation, in mouse aortas and hAoSMCs was reduced by miR-126-5p overexpression as well. mir-126-5p 181-191 matrix metallopeptidase 2 Mus musculus 81-85 33496117-11 2020 The results showed that Shuangdan Capsules combined with 5-FU may inhibit tumor angiogenesis by inhibiting VEGF and MMP2 expressions, thereby blocking tumor growth. Fluorouracil 57-61 matrix metallopeptidase 2 Mus musculus 116-120 33496114-10 2020 The results of immunohistochemistry showed that the deposition of cellulose in baicalin group was significantly less than that in model group, the mRNA expressions of TGF-beta1, mmp2 and timp2 were decreased in baicalin solution compared with the model group. baicalin 79-87 matrix metallopeptidase 2 Mus musculus 178-182 33496114-10 2020 The results of immunohistochemistry showed that the deposition of cellulose in baicalin group was significantly less than that in model group, the mRNA expressions of TGF-beta1, mmp2 and timp2 were decreased in baicalin solution compared with the model group. baicalin 211-219 matrix metallopeptidase 2 Mus musculus 178-182 33292347-11 2020 The expressions of mmp2 and mmp9 associated with matrix degradation in uterine tissue were also significantly down-regulated by catechins. Catechin 128-137 matrix metallopeptidase 2 Mus musculus 19-23 33155932-10 2021 KW-2449 also decreased TNF-alpha, IL-6, CCL-2 inflammatory cytokines and MMP-2 in both brain mRNA expressions and serum levels of EAE mice. KW 2449 0-7 matrix metallopeptidase 2 Mus musculus 73-78 33312336-9 2020 Interestingly, opuntiol pretreatment inhibited UVA-induced activation of iNOS, VEGF, TNF-alpha, and COX-2 proteins and consequent activation of MMP-2, MMP-9, and MMP-12 in the mouse skin. opuntiol 15-23 matrix metallopeptidase 2 Mus musculus 144-149 33169982-3 2020 Inspired by the "eat me" signal, phosphatidylserine (PS), mediated phagocytic clearance of apoptotic bodies, in this study, the matrix metalloproteinase 2 (MMP2)-sensitive PS-modified nanoparticles were developed. Phosphatidylserines 53-55 matrix metallopeptidase 2 Mus musculus 128-154 33169982-3 2020 Inspired by the "eat me" signal, phosphatidylserine (PS), mediated phagocytic clearance of apoptotic bodies, in this study, the matrix metalloproteinase 2 (MMP2)-sensitive PS-modified nanoparticles were developed. Phosphatidylserines 53-55 matrix metallopeptidase 2 Mus musculus 156-160 33169982-4 2020 In the design, the PS is externalized to the nanoparticles" surface only when the nanoparticles reach the MMP2-overexpressing tumor site, allowing for the TAM-specific phagocytosis. Phosphatidylserines 19-21 matrix metallopeptidase 2 Mus musculus 106-110 33169982-4 2020 In the design, the PS is externalized to the nanoparticles" surface only when the nanoparticles reach the MMP2-overexpressing tumor site, allowing for the TAM-specific phagocytosis. tam 155-158 matrix metallopeptidase 2 Mus musculus 106-110 33169982-7 2020 The MMP2-sensitive apoptotic body-mimicking nanoparticles might be a promising delivery tool for TAM-centered cancer diagnoses and treatments. tam 97-100 matrix metallopeptidase 2 Mus musculus 4-8 32447200-1 2020 In the current study, polyethylene glycol (PEG) was linked to polylactide (PLA) through the synthetic peptide PVGLIG which can be selectively cleaved by the tumor-associated matrix metalloproteinase 2 (MMP-2) enzyme. Polyethylene Glycols 22-41 matrix metallopeptidase 2 Mus musculus 174-200 33251135-12 2020 While, two genes respectively encoding MMP-2 and MMP-9 were simultaneously abnormal up-regulated in pancreatic cancer tissue from diabetic mice of both STZ and db/db, that could act as potential therapeutic targets for significantly suppressing the malignant progression. Streptozocin 152-155 matrix metallopeptidase 2 Mus musculus 39-44 33059492-11 2020 In vitro smooth muscle cell studies revealed that dihydrotestosterone potentiates transforming growth factor beta-induced Erk/Smad activation and MMP-2 activity, which is reversed by flutamide treatment. Dihydrotestosterone 50-69 matrix metallopeptidase 2 Mus musculus 146-151 33059492-11 2020 In vitro smooth muscle cell studies revealed that dihydrotestosterone potentiates transforming growth factor beta-induced Erk/Smad activation and MMP-2 activity, which is reversed by flutamide treatment. Flutamide 183-192 matrix metallopeptidase 2 Mus musculus 146-151 33001278-11 2020 MMP2 and VEGF levels were also elevated by saxagliptin treatment. saxagliptin 43-54 matrix metallopeptidase 2 Mus musculus 0-4 32613602-10 2020 Moreover, safinamide treatment suppressed OGD/R-caused induction of metalloproteinase 2 (MMP-2) and 9 (MMP-9). safinamide 10-20 matrix metallopeptidase 2 Mus musculus 89-101 32936248-4 2020 Vitamin D deficiency was associated with increased aortic expression of osteopontin and matrix metalloproteinase-2 and -9 than controls. Vitamin D 0-9 matrix metallopeptidase 2 Mus musculus 88-121 32982702-7 2020 In the adult mouse, it has previously been shown that in the rostral migratory stream (RMS), SCGN, annexin V (ANXA5), and matrix metalloprotease 2 (MMP2) are co-expressed forming a functioning complex that exocytoses MMP2 in response to calcium. Calcium 237-244 matrix metallopeptidase 2 Mus musculus 122-146 32982702-7 2020 In the adult mouse, it has previously been shown that in the rostral migratory stream (RMS), SCGN, annexin V (ANXA5), and matrix metalloprotease 2 (MMP2) are co-expressed forming a functioning complex that exocytoses MMP2 in response to calcium. Calcium 237-244 matrix metallopeptidase 2 Mus musculus 148-152 33121166-8 2020 Moreover, iron markedly increased EMT and MMP-2/-9 expression in endometriotic lesions in an endometriosis mouse model. Iron 10-14 matrix metallopeptidase 2 Mus musculus 42-50 33101055-10 2020 Moreover, bioactive cortisol (a factor that exacerbates osteoporosis) was also elevated in MMP-2 deficient mice and patients. Hydrocortisone 20-28 matrix metallopeptidase 2 Mus musculus 91-96 32598957-6 2020 Moreover, P-D-R8MTS exhibited superior inhibition of tumor growth and showed no apparent lung metastatic nodules on 4T1-bearing mice in vivo, which was partially via down-regulation of typical proteins associated with tumor metastasis and invasion: matrix metalloproteinases-2 (MMP-2), vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-beta). p-d-r8mts 10-19 matrix metallopeptidase 2 Mus musculus 249-276 32598957-6 2020 Moreover, P-D-R8MTS exhibited superior inhibition of tumor growth and showed no apparent lung metastatic nodules on 4T1-bearing mice in vivo, which was partially via down-regulation of typical proteins associated with tumor metastasis and invasion: matrix metalloproteinases-2 (MMP-2), vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-beta). p-d-r8mts 10-19 matrix metallopeptidase 2 Mus musculus 278-283 32447200-1 2020 In the current study, polyethylene glycol (PEG) was linked to polylactide (PLA) through the synthetic peptide PVGLIG which can be selectively cleaved by the tumor-associated matrix metalloproteinase 2 (MMP-2) enzyme. Polyethylene Glycols 22-41 matrix metallopeptidase 2 Mus musculus 202-207 32447200-1 2020 In the current study, polyethylene glycol (PEG) was linked to polylactide (PLA) through the synthetic peptide PVGLIG which can be selectively cleaved by the tumor-associated matrix metalloproteinase 2 (MMP-2) enzyme. Polyethylene Glycols 43-46 matrix metallopeptidase 2 Mus musculus 174-200 32447200-1 2020 In the current study, polyethylene glycol (PEG) was linked to polylactide (PLA) through the synthetic peptide PVGLIG which can be selectively cleaved by the tumor-associated matrix metalloproteinase 2 (MMP-2) enzyme. Polyethylene Glycols 43-46 matrix metallopeptidase 2 Mus musculus 202-207 32447200-5 2020 At the next stage, AS1411 aptamer was conjugated onto the surface of MMP-2 responsive polymersomal formulation in order to provide guided drug delivery against nucleolin positive cells. AGRO 100 19-25 matrix metallopeptidase 2 Mus musculus 69-74 32447200-8 2020 On the other hand, AS1411 aptamer-targeted MMP-2 responsive chimeric polymersomal formulation exhibited highest therapeutic index compared to other groups. AGRO 100 19-25 matrix metallopeptidase 2 Mus musculus 43-48 32570111-12 2020 Analyses of involved molecular events demonstrated that mangiferin down-regulated the expression of metastasis-associated proteins MMP2 and MMP9. mangiferin 56-66 matrix metallopeptidase 2 Mus musculus 131-135 32487324-7 2020 Yet Aspirin and Clopidogrel each comparably lowered CK-MB, AST, MMP-2, MMP-9, and the lipid peroxidation product malondialdehyde (MDA) in the hyperlipidemic animals exposed to AMI. Aspirin 4-11 matrix metallopeptidase 2 Mus musculus 64-69 32487324-7 2020 Yet Aspirin and Clopidogrel each comparably lowered CK-MB, AST, MMP-2, MMP-9, and the lipid peroxidation product malondialdehyde (MDA) in the hyperlipidemic animals exposed to AMI. Clopidogrel 16-27 matrix metallopeptidase 2 Mus musculus 64-69 32497630-8 2020 KEY FINDINGS: High glucose (HG) challenge led to increased circCOL1A2, VEGF, MMP-2, MMP-9 levels, but decreased miR-29b level in hRMECs. Glucose 19-26 matrix metallopeptidase 2 Mus musculus 77-82 33397553-0 2020 Encapsulation of Astragaloside with Matrix Metalloproteinase-2-Responsive Hyaluronic Acid End-Conjugated Polyamidoamine Dendrimers Improves Wound Healing in Diabetes. astragaloside 17-30 matrix metallopeptidase 2 Mus musculus 36-62 33397553-0 2020 Encapsulation of Astragaloside with Matrix Metalloproteinase-2-Responsive Hyaluronic Acid End-Conjugated Polyamidoamine Dendrimers Improves Wound Healing in Diabetes. Hyaluronic Acid 74-89 matrix metallopeptidase 2 Mus musculus 36-62 33397553-0 2020 Encapsulation of Astragaloside with Matrix Metalloproteinase-2-Responsive Hyaluronic Acid End-Conjugated Polyamidoamine Dendrimers Improves Wound Healing in Diabetes. polyamidoamine dendrimers 105-130 matrix metallopeptidase 2 Mus musculus 36-62 33397553-2 2020 In this study, the dendrimer polyamidoamine (PAMAM) and the polysaccharide hyaluronic acid (HA) were connected through the substrate polypeptide (Gly-PLGLAG-Cys) of MMP-2 to obtain the MMP-2-responsive nanocarrier HA-pep-PAMAM. Poly(amidoamine) 29-43 matrix metallopeptidase 2 Mus musculus 165-170 33397553-2 2020 In this study, the dendrimer polyamidoamine (PAMAM) and the polysaccharide hyaluronic acid (HA) were connected through the substrate polypeptide (Gly-PLGLAG-Cys) of MMP-2 to obtain the MMP-2-responsive nanocarrier HA-pep-PAMAM. Poly(amidoamine) 29-43 matrix metallopeptidase 2 Mus musculus 185-190 33397553-2 2020 In this study, the dendrimer polyamidoamine (PAMAM) and the polysaccharide hyaluronic acid (HA) were connected through the substrate polypeptide (Gly-PLGLAG-Cys) of MMP-2 to obtain the MMP-2-responsive nanocarrier HA-pep-PAMAM. Poly(amidoamine) 45-50 matrix metallopeptidase 2 Mus musculus 165-170 33397553-2 2020 In this study, the dendrimer polyamidoamine (PAMAM) and the polysaccharide hyaluronic acid (HA) were connected through the substrate polypeptide (Gly-PLGLAG-Cys) of MMP-2 to obtain the MMP-2-responsive nanocarrier HA-pep-PAMAM. Poly(amidoamine) 45-50 matrix metallopeptidase 2 Mus musculus 185-190 33397553-2 2020 In this study, the dendrimer polyamidoamine (PAMAM) and the polysaccharide hyaluronic acid (HA) were connected through the substrate polypeptide (Gly-PLGLAG-Cys) of MMP-2 to obtain the MMP-2-responsive nanocarrier HA-pep-PAMAM. Polysaccharides 60-74 matrix metallopeptidase 2 Mus musculus 165-170 33397553-2 2020 In this study, the dendrimer polyamidoamine (PAMAM) and the polysaccharide hyaluronic acid (HA) were connected through the substrate polypeptide (Gly-PLGLAG-Cys) of MMP-2 to obtain the MMP-2-responsive nanocarrier HA-pep-PAMAM. Polysaccharides 60-74 matrix metallopeptidase 2 Mus musculus 185-190 33397553-2 2020 In this study, the dendrimer polyamidoamine (PAMAM) and the polysaccharide hyaluronic acid (HA) were connected through the substrate polypeptide (Gly-PLGLAG-Cys) of MMP-2 to obtain the MMP-2-responsive nanocarrier HA-pep-PAMAM. Hyaluronic Acid 75-90 matrix metallopeptidase 2 Mus musculus 165-170 33397553-2 2020 In this study, the dendrimer polyamidoamine (PAMAM) and the polysaccharide hyaluronic acid (HA) were connected through the substrate polypeptide (Gly-PLGLAG-Cys) of MMP-2 to obtain the MMP-2-responsive nanocarrier HA-pep-PAMAM. Hyaluronic Acid 75-90 matrix metallopeptidase 2 Mus musculus 185-190 33397553-2 2020 In this study, the dendrimer polyamidoamine (PAMAM) and the polysaccharide hyaluronic acid (HA) were connected through the substrate polypeptide (Gly-PLGLAG-Cys) of MMP-2 to obtain the MMP-2-responsive nanocarrier HA-pep-PAMAM. Hyaluronic Acid 92-94 matrix metallopeptidase 2 Mus musculus 165-170 33397553-2 2020 In this study, the dendrimer polyamidoamine (PAMAM) and the polysaccharide hyaluronic acid (HA) were connected through the substrate polypeptide (Gly-PLGLAG-Cys) of MMP-2 to obtain the MMP-2-responsive nanocarrier HA-pep-PAMAM. Hyaluronic Acid 92-94 matrix metallopeptidase 2 Mus musculus 185-190 33397553-2 2020 In this study, the dendrimer polyamidoamine (PAMAM) and the polysaccharide hyaluronic acid (HA) were connected through the substrate polypeptide (Gly-PLGLAG-Cys) of MMP-2 to obtain the MMP-2-responsive nanocarrier HA-pep-PAMAM. gly-plglag-cys 146-160 matrix metallopeptidase 2 Mus musculus 165-170 33397553-2 2020 In this study, the dendrimer polyamidoamine (PAMAM) and the polysaccharide hyaluronic acid (HA) were connected through the substrate polypeptide (Gly-PLGLAG-Cys) of MMP-2 to obtain the MMP-2-responsive nanocarrier HA-pep-PAMAM. gly-plglag-cys 146-160 matrix metallopeptidase 2 Mus musculus 185-190 33397553-6 2020 HA-pep-PAMAM-ASI achieved 73.9% release in the presence of MMP-2, but only 13.5% in PBS. ha-pep-pamam-asi 0-16 matrix metallopeptidase 2 Mus musculus 59-64 32389938-1 2020 A series of 4-phenoxybenzenesulfonyl pyrrolidine derivatives were designed, synthesized, and evaluated as matrix metalloproteinases (MMPs) inhibitors. 4-phenoxybenzenesulfonyl pyrrolidine 12-48 matrix metallopeptidase 2 Mus musculus 133-137 32525310-0 2020 Maternal exposure to di-n-butyl phthalate promotes the formation of testicular tight junctions through down-regulation of NF-kappaB/COX-2/PGE2/MMP-2 in mouse offspring. Dibutyl Phthalate 21-41 matrix metallopeptidase 2 Mus musculus 143-148 32525310-4 2020 Our in vitro results demonstrated that 0.1 mM MBP down-regulated the expression of matrix metalloproteinase-2 (MMP-2) by inhibiting the activation of nuclear factor-kappaB (NF-kappaB)/cyclooxygenase-2 (COX-2)/ prostaglandin E2 (PGE2) cascades via attenuated binding of NF-kappaB to both MMP-2 promoter and COX-2 promoter. Dinoprostone 210-226 matrix metallopeptidase 2 Mus musculus 83-109 32525310-4 2020 Our in vitro results demonstrated that 0.1 mM MBP down-regulated the expression of matrix metalloproteinase-2 (MMP-2) by inhibiting the activation of nuclear factor-kappaB (NF-kappaB)/cyclooxygenase-2 (COX-2)/ prostaglandin E2 (PGE2) cascades via attenuated binding of NF-kappaB to both MMP-2 promoter and COX-2 promoter. Dinoprostone 210-226 matrix metallopeptidase 2 Mus musculus 111-116 32525310-4 2020 Our in vitro results demonstrated that 0.1 mM MBP down-regulated the expression of matrix metalloproteinase-2 (MMP-2) by inhibiting the activation of nuclear factor-kappaB (NF-kappaB)/cyclooxygenase-2 (COX-2)/ prostaglandin E2 (PGE2) cascades via attenuated binding of NF-kappaB to both MMP-2 promoter and COX-2 promoter. Dinoprostone 228-232 matrix metallopeptidase 2 Mus musculus 83-109 32525310-4 2020 Our in vitro results demonstrated that 0.1 mM MBP down-regulated the expression of matrix metalloproteinase-2 (MMP-2) by inhibiting the activation of nuclear factor-kappaB (NF-kappaB)/cyclooxygenase-2 (COX-2)/ prostaglandin E2 (PGE2) cascades via attenuated binding of NF-kappaB to both MMP-2 promoter and COX-2 promoter. Dinoprostone 228-232 matrix metallopeptidase 2 Mus musculus 111-116 32615991-9 2020 Western blot analysis indicated that protein levels of retinoic acid receptor alpha (RARalpha), MMP2, MMP9, and AT1 were dramatically affected by ATRA treatment. Tretinoin 146-150 matrix metallopeptidase 2 Mus musculus 96-100 32615991-10 2020 CONCLUSIONS: In conclusion, ATRA attenuates the progression of Ang II-induced AAAs, possibly by downregulating MMP2, MMP9, and AT-1 expression. Tretinoin 28-32 matrix metallopeptidase 2 Mus musculus 111-115 32315715-9 2020 Accordingly, gelatin zymography revealed lower Mmp2 activity in mutant samples upon RA-treatment (0.77-fold, 95% HDI: 0.60 - 0.96). Radium 84-86 matrix metallopeptidase 2 Mus musculus 47-51 32552811-7 2020 Interestingly, matrix metalloproteinases (MMPs), such as MMP2, MMP8 and MMP9, were altered both at the protein and mRNA transcript levels in female and male KO mice, but WT mice exposed to PG alone showed a sex-dependent phenotype. Propylene Glycol 189-191 matrix metallopeptidase 2 Mus musculus 42-46 32552811-7 2020 Interestingly, matrix metalloproteinases (MMPs), such as MMP2, MMP8 and MMP9, were altered both at the protein and mRNA transcript levels in female and male KO mice, but WT mice exposed to PG alone showed a sex-dependent phenotype. Propylene Glycol 189-191 matrix metallopeptidase 2 Mus musculus 57-61 32220805-7 2020 The results showed that pimozide combined with CpG ODN effectively inhibited the growth of melanoma and prolonged the survival of melanoma-bearing mice, inhibited the expression of MMP2 and p-Stat5, increased the infiltration of CD4+ and CD8+ T cells in tumor, raised the ratios of CD4+, CD8+ T cells and NK cells. Pimozide 24-32 matrix metallopeptidase 2 Mus musculus 181-185 32208990-0 2020 Higher MMP2 abundance and gelatinolytic activity in 28- & 70-d mdx compared with wild-type mice is alleviated in mdx mice with pre-natal taurine supplementation. Taurine 137-144 matrix metallopeptidase 2 Mus musculus 7-11 32208990-8 2020 Pre-natal supplementation with the amino acid taurine, which improved muscle strength in D28 mdx mice, produced ~2-fold lower MMP2 activity, indicating that increased MMP2 abundance is not required when muscle damage is attenuated. amino acid taurine 35-53 matrix metallopeptidase 2 Mus musculus 126-130 32208990-8 2020 Pre-natal supplementation with the amino acid taurine, which improved muscle strength in D28 mdx mice, produced ~2-fold lower MMP2 activity, indicating that increased MMP2 abundance is not required when muscle damage is attenuated. amino acid taurine 35-53 matrix metallopeptidase 2 Mus musculus 167-171 32320623-3 2020 Using mass spectrometry, we found that heparan sulfate was shed into the airspace for up to three weeks after intratracheal bleomycin-induced lung injury and coincided with induction of matrix metalloproteinases (including matrix metalloproteinase 2). Heparitin Sulfate 39-54 matrix metallopeptidase 2 Mus musculus 223-249 32320623-4 2020 Delayed inhibition of metalloproteinases, beginning seven days after bleomycin using the nonspecific MMP inhibitor doxycycline, attenuated heparan sulfate shedding and improved lung function, suggesting that heparan sulfate shedding may impair lung recovery. Doxycycline 115-126 matrix metallopeptidase 2 Mus musculus 101-104 32320623-4 2020 Delayed inhibition of metalloproteinases, beginning seven days after bleomycin using the nonspecific MMP inhibitor doxycycline, attenuated heparan sulfate shedding and improved lung function, suggesting that heparan sulfate shedding may impair lung recovery. Heparitin Sulfate 139-154 matrix metallopeptidase 2 Mus musculus 101-104 32164044-7 2020 We found Bazedoxifene decreased the mRNA expression of IL-6, MMP2, Col1A1, Col3A1 and periostin in murine hearts after 8-week surgery. bazedoxifene 9-21 matrix metallopeptidase 2 Mus musculus 61-65 32702718-7 2020 Interestingly, matrix metalloproteinases (MMPs), such as MMP2, MMP8, and MMP9 were altered both at the protein and mRNA transcript levels in female and male, but WT mice exposed to PG alone showed a sex-dependent phenotype. Propylene Glycol 181-183 matrix metallopeptidase 2 Mus musculus 42-46 32702718-7 2020 Interestingly, matrix metalloproteinases (MMPs), such as MMP2, MMP8, and MMP9 were altered both at the protein and mRNA transcript levels in female and male, but WT mice exposed to PG alone showed a sex-dependent phenotype. Propylene Glycol 181-183 matrix metallopeptidase 2 Mus musculus 57-61 32346027-7 2020 MMP-2 and MMP-9 expression was reduced in the skin of doxycycline-treated MFS mice. Doxycycline 54-65 matrix metallopeptidase 2 Mus musculus 0-5 32192327-0 2020 Integrating Polydopamine Nanosphere/Aptamers Nanoplatform with DNase-I-assisted Recycling Amplification Strategy for Simultaneous Detection of MMP-9 and MMP-2 During Renal Interstitial Fibrosis. polydopamine 12-24 matrix metallopeptidase 2 Mus musculus 153-158 32192327-3 2020 Herein, a strategy based on the nanoplatform composed of the polydopamine nanosphere and fluorescence labelled aptamers is developed to simultaneously detect MMP-9 and MMP-2 with DNase-I-assisted recycling signal amplification. polydopamine 61-73 matrix metallopeptidase 2 Mus musculus 168-173 32382533-13 2020 Furthermore, histological analyses showed that administration of MRS2578 significantly increased infiltration of macrophages, expression of monocyte chemotactic protein 1 (MCP-1) and vascular cell adhesion molecule-1 (VCAM-1), and activities of MMP-2 and MMP-9 followed by aggravating degradation elastin in vivo (p < 0.05). N,N''-1,4-butanediylbis(N'-(3-isothiocyanatophenyl))thiourea 65-72 matrix metallopeptidase 2 Mus musculus 245-250 32144443-10 2020 Furthermore, GA offered protection against ET-induced airspace enlargement and ameliorated MMP-2/MMP-9. Gallic Acid 13-15 matrix metallopeptidase 2 Mus musculus 91-96 32346027-2 2020 We have previously reported doxycycline, a nonselective matrix metalloproteinases (MMPs) inhibitor, to attenuate aortic root widening and improve aortic contractility and elasticity in MFS mice. Doxycycline 28-39 matrix metallopeptidase 2 Mus musculus 83-87 32346027-5 2020 Our results demonstrate a rescue of aortic elastic fiber fragmentation and disorganization accompanied by a decrease in MMP-2 and MMP-9 expression within the aortic wall in doxycycline-treated MFS mice. Doxycycline 173-184 matrix metallopeptidase 2 Mus musculus 120-125 32362823-8 2020 Furthermore, BAZ suppressed the stimuli-induced (IL-6 or AngII) expression of P-STAT3, MMP2 and MMP9 in vascular smooth muscle cells (VSMCs). bazedoxifene 13-16 matrix metallopeptidase 2 Mus musculus 87-91 32107809-7 2020 Immunohistochemical analysis of tumour sections showed that MMP-2+ cells and Ki-67+ cells were remarkably decreased in tumour tissues of mice after treatment of hinokiflavone, indicating that hinokiflavone inhibits not only proliferation but also metastasis of breast cancer cells. hinokiflavone 161-174 matrix metallopeptidase 2 Mus musculus 60-65 32107809-7 2020 Immunohistochemical analysis of tumour sections showed that MMP-2+ cells and Ki-67+ cells were remarkably decreased in tumour tissues of mice after treatment of hinokiflavone, indicating that hinokiflavone inhibits not only proliferation but also metastasis of breast cancer cells. hinokiflavone 192-205 matrix metallopeptidase 2 Mus musculus 60-65 32044305-11 2020 Moreover, a regulator of the extracellular matrix, matrix metalloproteinase-14 (MMP-14) in the retina, and MMP-2 and MMP-9 in plasma, were increased by METH treatment. Methamphetamine 152-156 matrix metallopeptidase 2 Mus musculus 107-112 32044305-12 2020 In conclusion, METH administration is involved in retinal degeneration with a vascular loss of PECAM-1 and the glycocalyx in the CRA and retina, and an increase of MMPs. Methamphetamine 15-19 matrix metallopeptidase 2 Mus musculus 164-168 32032616-9 2020 Lower levels of inflammatory cytokines, ROS, MMP-2, RANKL, OPN and plasmin reflected less severe arthritic destruction after etoposide treatment in arthritic mice. Etoposide 125-134 matrix metallopeptidase 2 Mus musculus 45-50 32218565-8 2020 Animals were sacrificed at 28-d. We found that targeted PGG therapy reversed the AAA by decreasing matrix metalloproteinases MMP-9 and MMP-2, and the infiltration of macrophages in the medial layer. pentagalloylglucose 56-59 matrix metallopeptidase 2 Mus musculus 135-140 31420795-4 2020 Therefore, it was evaluated if PBM could alter ECM components, such as MMP-2, -9, -13, and TIMP-2 from mice talocrural joints. pbm 31-34 matrix metallopeptidase 2 Mus musculus 71-76 31420795-8 2020 PBM can alter only mRNA relative levels of MMP-2 at 30 J cm-2 (p < 0.05), while MMP-9, MMP-13, and TIMP-2 mRNA relative levels did not demonstrate statistical differences for any of the groups (p > 0.05). pbm 0-3 matrix metallopeptidase 2 Mus musculus 43-48 32280245-10 2020 Results: Cisplatin attenuated the promoting capacity of CAFs on lung cancer cell migration and invasion, via suppressing CAFs" effect on metastasis-related genes including Twist1, vascular endothelial growth factor receptor (VEGFR), MMP2, and AKT signaling pathway. Cisplatin 9-18 matrix metallopeptidase 2 Mus musculus 233-237 31172426-10 2020 The MMP-2 and MMP-13 analyses showed that the expression of the high-Zn group was significantly higher than that of the normal group, indicating that Zn plays an important role in its expression. Zinc 150-152 matrix metallopeptidase 2 Mus musculus 4-9 32265701-12 2020 Then, 58 cancer-related targets and 66 KEGG pathways were identified, and PTGS2-, HSP90-, EGFR-, MMP2-, PPARgamma-, and GSTP-mediated pathways were predicted to be the antitumor mechanisms of HD-SB. gstp 120-124 matrix metallopeptidase 2 Mus musculus 97-101 31172426-10 2020 The MMP-2 and MMP-13 analyses showed that the expression of the high-Zn group was significantly higher than that of the normal group, indicating that Zn plays an important role in its expression. Zinc 69-71 matrix metallopeptidase 2 Mus musculus 4-9 32719827-4 2020 In 2D, the genes Mmp2 and Mmp13 increased during IDG-SW3 differentiation and were used as targets to create a MMP-sensitive poly(ethylene glycol) hydrogel containing the peptide crosslink GCGPLG-LWARCG and RGD to promote cell attachment. Polyethylene Glycols 124-145 matrix metallopeptidase 2 Mus musculus 17-21 32163857-5 2020 We found that esculentoside A suppresses the expression of IL-1beta-induced inflammatory and metabolic factors (IL-6, IL-8, TNF-alpha, MMP2, MMP3 and MMP13). esculentoside A 14-29 matrix metallopeptidase 2 Mus musculus 135-139 31989218-10 2020 Combination therapy with metformin and celastrol repressed markers of angiogenesis, metastasis and tumour proliferation, as revealed by the decreased hepatic levels of VEGF, MMP-2/9 and cyclin D1 mRNA, respectively. Metformin 25-34 matrix metallopeptidase 2 Mus musculus 174-181 31489638-13 2020 Results indicate that matrix metalloproteinase-2 (MMP-2) activity was robust in CBS+/- fed with HMD and that it was successfully attenuated by the PB treatment. Lead 147-149 matrix metallopeptidase 2 Mus musculus 22-48 31489638-13 2020 Results indicate that matrix metalloproteinase-2 (MMP-2) activity was robust in CBS+/- fed with HMD and that it was successfully attenuated by the PB treatment. Lead 147-149 matrix metallopeptidase 2 Mus musculus 50-55 32194752-8 2020 Furthermore, dioscin inhibited the phosphorylation of STAT3 and Src (an upstream kinase of STAT3), and downregulated mRNA levels of STAT3-targeted genes, including B-cell lymphoma-2, cyclin D1 and matrix metalloproteinase-2. dioscin 13-20 matrix metallopeptidase 2 Mus musculus 197-223 31989218-10 2020 Combination therapy with metformin and celastrol repressed markers of angiogenesis, metastasis and tumour proliferation, as revealed by the decreased hepatic levels of VEGF, MMP-2/9 and cyclin D1 mRNA, respectively. celastrol 39-48 matrix metallopeptidase 2 Mus musculus 174-181 31793787-6 2020 The prodrug vesicles were inert during the blood circulation, whereas they specifically accumulated and penetrated at the tumor site through matrix metalloproteinase-2 (MMP-2)-mediated cleavage of the PEG corona to achieve fluorescence-imaging-guided photodynamic therapy (PDT). pentaerythritol poly(ethylene glycol) ether tetrasuccinimidyl glutarate 201-204 matrix metallopeptidase 2 Mus musculus 141-167 31708095-7 2020 Using a mouse xenograft model, we found that Proscillaridin A treatment significantly inhibited tumor growth and lung metastasis in vivo and decreased the expression levels of Bcl-xl and MMP2. Proscillaridin 45-61 matrix metallopeptidase 2 Mus musculus 187-191 32194780-6 2020 Curcumol upregulated the expression of E-cadherin and downregulated the expression of N-cadherin, MMP2 and MMP9 in mouse melanoma B16 cell. curcumol 0-8 matrix metallopeptidase 2 Mus musculus 98-102 31793787-6 2020 The prodrug vesicles were inert during the blood circulation, whereas they specifically accumulated and penetrated at the tumor site through matrix metalloproteinase-2 (MMP-2)-mediated cleavage of the PEG corona to achieve fluorescence-imaging-guided photodynamic therapy (PDT). pentaerythritol poly(ethylene glycol) ether tetrasuccinimidyl glutarate 201-204 matrix metallopeptidase 2 Mus musculus 169-174 32749127-5 2020 In addition, naringin pretreatment inhibits UVB-stimulated matrix metalloproteinase (MMP-2, MMP-9 and MMP-13) expression in these 3T3 cells. naringin 13-21 matrix metallopeptidase 2 Mus musculus 85-90 31579944-9 2020 Moreover, delayed administration of 3-DZNeP inhibited peritoneal fibrosis progression, reversed established peritoneal fibrosis and reduced expression of tissue inhibitor of metalloproteinase 2 (TIMP2), and matrix metalloproteinase-2 and -9. 3-deazaneplanocin 36-43 matrix metallopeptidase 2 Mus musculus 207-240 31769963-4 2019 Hydrophobic CPI-613 is conjugated to the hydrophilic copolymer via a newly designed MMP-2-responsive linker to form a trigger-responsive nanopolyplex. devimistat 12-19 matrix metallopeptidase 2 Mus musculus 84-89 31869384-10 2019 In chronic gamma-irradiated (6Gy) model, the illustrated data showed enhanced wound contraction via increased TGF-beta1/MMP-2 and collagen deposition incurred by topical application of UDCA without effect on NF-kappaB level. Ursodeoxycholic Acid 185-189 matrix metallopeptidase 2 Mus musculus 120-125 31869384-11 2019 In sum, the present findings suggest that UDCA may accelerate wound healing by regulating TGF-beta1 and MMP-2 and fibroplasia/collagen deposition in either the two wound healing models. Ursodeoxycholic Acid 42-46 matrix metallopeptidase 2 Mus musculus 104-109 33132351-8 2020 Furthermore, coriander extract suppressed the phosphorylation of Erk 1 or IkB in B16F10 cells, and inhibited the expression of MMP-2 or u-PA mRNA. extract 23-30 matrix metallopeptidase 2 Mus musculus 127-132 31836811-10 2019 In addition, MBZ demonstrated anti-angiogenic, anti-metastatic, and anti-proliferative effects, as indicated by reduced VEGF levels, MMP-2:TIMP-1 ratios, and reduced cyclin D1 levels and Ki67 immunostaining, respectively. Mebendazole 13-16 matrix metallopeptidase 2 Mus musculus 133-138 31769963-4 2019 Hydrophobic CPI-613 is conjugated to the hydrophilic copolymer via a newly designed MMP-2-responsive linker to form a trigger-responsive nanopolyplex. copolymer 53-62 matrix metallopeptidase 2 Mus musculus 84-89 31683101-10 2019 The antiangiogenic activity of carnosine was partially due to the suppression of VEGFR-2-mediated ERK/AKT/eNOS signaling and MMP-2. Carnosine 31-40 matrix metallopeptidase 2 Mus musculus 125-130 31886236-9 2019 In addition, metformin effectively increased matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) levels in the placenta. Metformin 13-22 matrix metallopeptidase 2 Mus musculus 45-71 31886236-9 2019 In addition, metformin effectively increased matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) levels in the placenta. Metformin 13-22 matrix metallopeptidase 2 Mus musculus 73-78 31604526-10 2019 Furthermore, the expression of beta-catenin, p-AKT, VEGF, MMP-2 and MMP-9 proteins could be down-regulated after SMA/CORM-2 treatment. tricarbonyldichlororuthenium (II) dimer 117-123 matrix metallopeptidase 2 Mus musculus 58-63 31093976-6 2019 Furthermore, Dc significantly recovered MMP-2 expression in STRIP2-knockdown cells. Deoxycytidine 13-15 matrix metallopeptidase 2 Mus musculus 40-45 31586634-9 2019 Mechanistically, GA treatment suppressed the EMT and angiogenesis processes and reduced the enzymatic activity of MMP-2 and MMP-9. gambogic acid 17-19 matrix metallopeptidase 2 Mus musculus 114-119 31545135-4 2019 This study reveals the advantageous effects of Raffinee on PC12 cells by decreasing hypoxia-induced apoptosis in mice with permanent middle cerebral artery occlusion (pMCAO) by increasing the levels of neurotrophic factors such as S100beta, reducing serum inflammatory factors such as matrix metalloproteinases (MMP)-9/MMP-2 ratio, tumor necrosis factor-alpha, and interleukin (IL)-6 level, and increasing IL-10 levels. raffinee 47-55 matrix metallopeptidase 2 Mus musculus 319-324 31735744-5 2019 Nicotine reportedly increases the occurrence of abdominal aortic aneurysms by activating endothelin-1 (ET-1), angiotensinogen and the angiotensin II type 1 (AT1) receptor, leading to an increase in neutrophil elastase, oxidative stress, and matrix metalloproteinase (MMP)-2 expression, which causes vascular wall weakness and damage. Nicotine 0-8 matrix metallopeptidase 2 Mus musculus 241-273 31735744-7 2019 Additionally, isoflavone suppressed elastic fiber destruction and decreased areas positive for MMP-2, neutrophil elastase, and malondialdehyde in the vascular wall of nicotine-administered mice. Isoflavones 14-24 matrix metallopeptidase 2 Mus musculus 95-100 31795279-7 2019 Further testing of GlyPsi{PO2H-CH2}Ile-His-Lys-Gln THPI revealed nM inhibition of MMP-2, MMP-9, and MMP-13. JMV 449 19-55 matrix metallopeptidase 2 Mus musculus 82-87 31735744-7 2019 Additionally, isoflavone suppressed elastic fiber destruction and decreased areas positive for MMP-2, neutrophil elastase, and malondialdehyde in the vascular wall of nicotine-administered mice. Nicotine 167-175 matrix metallopeptidase 2 Mus musculus 95-100 31649548-11 2019 Furthermore, pectolinarigenin markedly impaired cancer cell migration and invasion by down-regulating phosphorylated-Stat3, and expression of matrix metalloproteinase (MMP)-2, MMP-9, while up-regulating the expression of TIMP2. pectolinarigenin 13-29 matrix metallopeptidase 2 Mus musculus 142-174 31493866-5 2019 Compared with the HFD group, rosiglitazone did not affect blood glucose levels, but it attenuated serum levels of tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL-6), ameliorated plaque lipid accumulation and the expression of matrix metalloproteinases-2 and -9, increased the collagen content of plaques, and inhibited perivascular MC degranulation and chymase expression. Rosiglitazone 29-42 matrix metallopeptidase 2 Mus musculus 239-273 31382833-8 2019 In vitro transfection of PCG/pGRIM-19 in Neuro-2a cells reduced the expression levels of Cyclin D1, BCL-2, MMPs 2 and 9, and inhibited cell proliferation, migration and stimulated apoptosis. pgrim-19 29-37 matrix metallopeptidase 2 Mus musculus 107-119 31340709-5 2019 Studying the mechanism of action indicated that OCT-modified curcumin plus docetaxel micelles downregulated MMP-2 and HIF-1alpha. Curcumin 61-69 matrix metallopeptidase 2 Mus musculus 108-113 31340709-5 2019 Studying the mechanism of action indicated that OCT-modified curcumin plus docetaxel micelles downregulated MMP-2 and HIF-1alpha. Docetaxel 75-84 matrix metallopeptidase 2 Mus musculus 108-113 31637006-4 2019 LTSLs rapidly released their payloads at 42 C. Compared with the saline control, MATT-LTSLs exhibited enhanced accumulation in the tumor and a 20-fold decrease in tumor growth in 4T1 tumor-bearing mice; moreover, MATT-LTSLs reduced MMP-2 and MMP-9 activity by 50% and 43%, respectively, and downregulated MMP-2 and MMP-9 expression in vivo by 30% and 43%, respectively. marimastat 82-86 matrix metallopeptidase 2 Mus musculus 233-238 31546727-13 2019 In a murine surgical breast cancer model, the anti-metastatic effects of lidocaine under sevoflurane anaesthesia are abolished by the Src inhibitor bosutinib, and lidocaine reduces serum MMP-2. Lidocaine 163-172 matrix metallopeptidase 2 Mus musculus 187-192 31546727-14 2019 These results suggest that lidocaine may act, at least partly, via an inhibitory effect on MMP-2 expression to reduce pulmonary metastasis, but whether this is due to an effect on Src or via another pathway remains unclear. Lidocaine 27-36 matrix metallopeptidase 2 Mus musculus 91-96 31509566-9 2019 These results demonstrate that FBP may prevent bleomycin-induced PF development through reduced expression of collagen and other ECM components mediated by a reduced TIMP-1 and MMP2 expression. Bleomycin 47-56 matrix metallopeptidase 2 Mus musculus 177-181 31825014-6 2019 Inhalation of e-cig aerosol containing PG alone significantly augmented the lung levels of various homeostasis/repair mediators (PPARgamma, ADRP, ACTA2, CTNNB1, LEF1, beta-catenin, E-cadherin, and MMP2) in a sex-dependent manner when compared to air controls. Propylene Glycol 39-41 matrix metallopeptidase 2 Mus musculus 197-201 31546727-11 2019 Only lidocaine alone reduced MMP-2 versus sevoflurane (p = 0.044). Lidocaine 5-14 matrix metallopeptidase 2 Mus musculus 29-34 31461499-3 2019 PURPOSE: We hypothesized that two discrete MMP-2 isoforms (full length MMP-2, FL-MMP-2; N-terminal truncated MMP-2, NTT-MMP-2) are induced by high glucose stimulation in vitro and in an experimental diabetic heart model. Glucose 147-154 matrix metallopeptidase 2 Mus musculus 43-48 31461499-3 2019 PURPOSE: We hypothesized that two discrete MMP-2 isoforms (full length MMP-2, FL-MMP-2; N-terminal truncated MMP-2, NTT-MMP-2) are induced by high glucose stimulation in vitro and in an experimental diabetic heart model. Glucose 147-154 matrix metallopeptidase 2 Mus musculus 71-76 31461499-3 2019 PURPOSE: We hypothesized that two discrete MMP-2 isoforms (full length MMP-2, FL-MMP-2; N-terminal truncated MMP-2, NTT-MMP-2) are induced by high glucose stimulation in vitro and in an experimental diabetic heart model. Glucose 147-154 matrix metallopeptidase 2 Mus musculus 71-76 31461499-3 2019 PURPOSE: We hypothesized that two discrete MMP-2 isoforms (full length MMP-2, FL-MMP-2; N-terminal truncated MMP-2, NTT-MMP-2) are induced by high glucose stimulation in vitro and in an experimental diabetic heart model. Glucose 147-154 matrix metallopeptidase 2 Mus musculus 71-76 31461499-3 2019 PURPOSE: We hypothesized that two discrete MMP-2 isoforms (full length MMP-2, FL-MMP-2; N-terminal truncated MMP-2, NTT-MMP-2) are induced by high glucose stimulation in vitro and in an experimental diabetic heart model. Glucose 147-154 matrix metallopeptidase 2 Mus musculus 71-76 31461499-12 2019 CONCLUSION: Two isoforms of MMP-2 were induced by high glucose stimulation in vitro and in a Type 1 DM mouse heart model. Glucose 55-62 matrix metallopeptidase 2 Mus musculus 28-33 31637006-4 2019 LTSLs rapidly released their payloads at 42 C. Compared with the saline control, MATT-LTSLs exhibited enhanced accumulation in the tumor and a 20-fold decrease in tumor growth in 4T1 tumor-bearing mice; moreover, MATT-LTSLs reduced MMP-2 and MMP-9 activity by 50% and 43%, respectively, and downregulated MMP-2 and MMP-9 expression in vivo by 30% and 43%, respectively. marimastat 82-86 matrix metallopeptidase 2 Mus musculus 306-311 31637006-4 2019 LTSLs rapidly released their payloads at 42 C. Compared with the saline control, MATT-LTSLs exhibited enhanced accumulation in the tumor and a 20-fold decrease in tumor growth in 4T1 tumor-bearing mice; moreover, MATT-LTSLs reduced MMP-2 and MMP-9 activity by 50% and 43%, respectively, and downregulated MMP-2 and MMP-9 expression in vivo by 30% and 43%, respectively. marimastat 214-218 matrix metallopeptidase 2 Mus musculus 233-238 31637006-4 2019 LTSLs rapidly released their payloads at 42 C. Compared with the saline control, MATT-LTSLs exhibited enhanced accumulation in the tumor and a 20-fold decrease in tumor growth in 4T1 tumor-bearing mice; moreover, MATT-LTSLs reduced MMP-2 and MMP-9 activity by 50% and 43%, respectively, and downregulated MMP-2 and MMP-9 expression in vivo by 30% and 43%, respectively. marimastat 214-218 matrix metallopeptidase 2 Mus musculus 306-311 30951378-7 2019 Moreover, delayed administration of MC1568 at 3 d after ureteral obstruction reversed the expression of alpha-SMA, fibronectin, and collagen 1 and increased expression of matrix metalloproteinase (MMP)-2 and -9. MC1568 36-42 matrix metallopeptidase 2 Mus musculus 171-210 31294623-9 2019 Sunitinib therapy substantially mitigated both AAA formation and further progression of established AAAs, attenuated aneurysmal aortic MMP2 (matrix metalloproteinase) and MMP9 protein expression, inhibited inflammatory monocyte and neutrophil chemotaxis to VEGF-A, and reduced MMP2, MMP9, and VEGF-A mRNA expression in macrophages and smooth muscle cells in vitro. Sunitinib 0-9 matrix metallopeptidase 2 Mus musculus 135-139 31294623-9 2019 Sunitinib therapy substantially mitigated both AAA formation and further progression of established AAAs, attenuated aneurysmal aortic MMP2 (matrix metalloproteinase) and MMP9 protein expression, inhibited inflammatory monocyte and neutrophil chemotaxis to VEGF-A, and reduced MMP2, MMP9, and VEGF-A mRNA expression in macrophages and smooth muscle cells in vitro. Sunitinib 0-9 matrix metallopeptidase 2 Mus musculus 277-281 31189740-9 2019 Moreover, overexpressed miR-613, silenced FN1 or LY294002 treatment suppressed proliferation, invasion, migration, and angiogenesis in NPC cells, which was indicated by reduced expression of AKT, mTOR, MMP-2, MMP-9, VEGF, and CD31 as well as decreased ratio of Bcl-2/Bax and increased expression of Cleaved-caspase3. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 49-57 matrix metallopeptidase 2 Mus musculus 202-207 31060006-7 2019 Mechanistically, the luciferase reporter assay showed that miR-506 targeted the 3" untranslated region of matrix metalloproteinase (MMP)-2/16, and miR-506 overexpression and rosmarinic acid treatment suppressed the expression of MMP2/16 in pancreatic cancer cells. mir-506 59-66 matrix metallopeptidase 2 Mus musculus 106-138 31060006-7 2019 Mechanistically, the luciferase reporter assay showed that miR-506 targeted the 3" untranslated region of matrix metalloproteinase (MMP)-2/16, and miR-506 overexpression and rosmarinic acid treatment suppressed the expression of MMP2/16 in pancreatic cancer cells. mir-506 59-66 matrix metallopeptidase 2 Mus musculus 229-233 31060006-7 2019 Mechanistically, the luciferase reporter assay showed that miR-506 targeted the 3" untranslated region of matrix metalloproteinase (MMP)-2/16, and miR-506 overexpression and rosmarinic acid treatment suppressed the expression of MMP2/16 in pancreatic cancer cells. rosmarinic acid 174-189 matrix metallopeptidase 2 Mus musculus 106-138 31060006-7 2019 Mechanistically, the luciferase reporter assay showed that miR-506 targeted the 3" untranslated region of matrix metalloproteinase (MMP)-2/16, and miR-506 overexpression and rosmarinic acid treatment suppressed the expression of MMP2/16 in pancreatic cancer cells. rosmarinic acid 174-189 matrix metallopeptidase 2 Mus musculus 229-233 31060006-8 2019 Overexpression of MMP2/16 attenuated the inhibitory effects of rosmarinic acid on pancreatic cell invasion and migration. rosmarinic acid 63-78 matrix metallopeptidase 2 Mus musculus 18-22 31060006-9 2019 In vivo studies showed that rosmarinic acid dose-dependently suppressed tumor growth of pancreatic cancer cells, and increased the expression of miR-506, while suppressed the expression of MMP2/16 and Ki-67 in dissected tumor tissues from xenograft nude mice. rosmarinic acid 28-43 matrix metallopeptidase 2 Mus musculus 189-196 31060006-10 2019 Collectively, our results for the first time revealed the anti-tumor effects of rosmarinic acid in pancreatic cancer, and the anti-tumor effects of rosmarinic acid were via regulating the miR-506/MMP2/16 axis in pancreatic cancer. rosmarinic acid 148-163 matrix metallopeptidase 2 Mus musculus 196-203 31375695-8 2019 Moreover, upregulation of the Fn1, Mmp2, and Snai1 mRNAs, which are hallmarks of tube-forming growth in PDAC, was demonstrated in a mouse model of carcinogenesis showing rapid progression because of the aggressive invasion of tube-forming cancer. pdac 104-108 matrix metallopeptidase 2 Mus musculus 35-39 31210194-7 2019 Furthermore, cinnamaldehyde reduced matrix metalloproteinase-2 (MMP-2) expression and attenuated the high phosphorylation level of IkappaBalpha and p65 NF-kappaB. cinnamaldehyde 13-27 matrix metallopeptidase 2 Mus musculus 36-62 31210194-7 2019 Furthermore, cinnamaldehyde reduced matrix metalloproteinase-2 (MMP-2) expression and attenuated the high phosphorylation level of IkappaBalpha and p65 NF-kappaB. cinnamaldehyde 13-27 matrix metallopeptidase 2 Mus musculus 64-69 30928802-4 2019 DFNP was nanoscopically constructed by amphiphilic self-assembly between a constantly fluorescent polymer surfactant labeled with Cy7 (F127-Cy7) and an initially nonfluorescent hydrophobic peptide (Cy5.5-MMP-Q) that is fluorogenic in response to MMP-2,9. dfnp 0-4 matrix metallopeptidase 2 Mus musculus 246-253 30928802-7 2019 Because of these two colloidal characteristics, when injected intradermally to a mouse model of lymph node metastasis, DFNP could produce reliable ratiometric signals to provide information on the MMP-2,9 activity in the lymph nodes depending on metastatic progression, which corresponded well to the temporal histologic analysis. dfnp 119-123 matrix metallopeptidase 2 Mus musculus 197-204 30910472-10 2019 Histopathological and immunohistochemical analysis showed that MMP-2+ cells and Ki-67+ cells were reduced and cleaved caspase-3+ cells were increased in tumor tissues of mice after BA administration. betulinic acid 181-183 matrix metallopeptidase 2 Mus musculus 63-68 30993494-6 2019 Further, PCR data show that olaparib administration ameliorates the elastase-induced expression of MMP-2 and MMP-9 without having much effect on the expressions of their inhibitors TIMP-1 and TIMP-2. olaparib 28-36 matrix metallopeptidase 2 Mus musculus 99-104 30993494-7 2019 Next, our data on immunoblot, gelatin zymography, and immunohistochemical analysis indeed confirm that olaparib reduced the elastase-induced expression of MMP-2 and MMP-9. olaparib 103-111 matrix metallopeptidase 2 Mus musculus 155-160 31181661-4 2019 Conversely, petunidin (>16 mug/mL) stimulated mineralized matrix formation and gene expression of Bmp2 and Ocn, whereas it suppressed Mmp13, Mmp2, and Mmp9 mRNA expression and proteolytic activities of MMP13 and MMP9 in MC3T3-E1 cells. petunidin 12-21 matrix metallopeptidase 2 Mus musculus 144-148 30904162-7 2019 Constant rapamycin administration significantly ameliorates the incidence and severity of Fbn1C1039G/+ mice characterized by decreased aortic media degradation, macrophage infiltration and MMP2/9 expression in the aortic wall. Sirolimus 9-18 matrix metallopeptidase 2 Mus musculus 189-195 30874838-10 2019 TFDG significantly suppressed the expression of IL-1beta, TNF-alpha, and IL-6, as well as the levels of MMP-1, MMP-2, and MMP-3 in the synovium. theaflavin-3,3'-digallate 0-4 matrix metallopeptidase 2 Mus musculus 111-116 31263710-10 2019 In vivo, montelukast significantly decreased aortic expansion (Saline vs Mont; 2.44 +- 0.15 mm vs 1.59 +- 0.20 mm, P<.01), reduced MMP-2 activity (Saline vs Mont; 1240 muM vs 755 muM, P<.05), and induced infiltration of M2 macrophages (Saline vs Mont; 7.51 % vs 14.7 %, P<.05). montelukast 9-20 matrix metallopeptidase 2 Mus musculus 131-136 30965234-9 2019 Treatment with TG (40, 80, and 160 mg/kg/d) ameliorated pulmonary fibrosis induced by bleomycin in mice, downregulated the expression of TGF-beta1, Smad2, Smad3, MMP-2, MMP-9, and tissue inhibitor of metalloproteinase-1, and upregulated the protein expression of Smad7. Thioguanine 15-17 matrix metallopeptidase 2 Mus musculus 162-167 31263710-9 2019 Results: Relative to control, montelukast significantly suppressed gene expressions of MMP-2, MMP-9, and IL-1beta, induced gene expressions of arginase-1 and IL-10, enhanced the expression of the arginase-1 cell surface protein, and increased the protein concentration of IL-10. montelukast 30-41 matrix metallopeptidase 2 Mus musculus 87-92 30737255-7 2019 Alamandine administration attenuated ascending aorta fibrosis induced by TAC, through a reduction in the following parameters; total collagen deposition, expression collagen III and transforming growth factor-beta (TGF-beta) transcripts, matrix metalloproteinases (MMPs) activity and vascular expression of MMP-2. alamandine 0-10 matrix metallopeptidase 2 Mus musculus 265-269 30852288-1 2019 We investigated the effect in vitro and in vivo of doxycycline hyclate (Dx), a broad-spectrum antibiotic inhibitor of matrix metaloproteinases (MMPs), on adult Schistosoma mansoni worms and granulomatous liver inflammation in infected mice. Doxycycline 51-70 matrix metallopeptidase 2 Mus musculus 144-148 30471427-7 2019 These findings suggest that MMP signaling plays a key role in paclitaxel-induced peripheral neuropathy, and MMP9 mAb may offer new therapeutic approaches for the treatment of CIPN. Paclitaxel 62-72 matrix metallopeptidase 2 Mus musculus 28-31 31380173-5 2019 CHO-PGEA/pCas9-sgFbn1 nanosystems can effectively contribute to the knockout of exon 10 in Fbn1 in vascular smooth muscle cells in vitro, which leads to the change of the phosphorylation of Smad2/3 and the increased expression of two downstream signals of Fbn1: Mmp-2 and Ctgf. Cholesterol 0-3 matrix metallopeptidase 2 Mus musculus 262-267 31380173-5 2019 CHO-PGEA/pCas9-sgFbn1 nanosystems can effectively contribute to the knockout of exon 10 in Fbn1 in vascular smooth muscle cells in vitro, which leads to the change of the phosphorylation of Smad2/3 and the increased expression of two downstream signals of Fbn1: Mmp-2 and Ctgf. pgea 4-8 matrix metallopeptidase 2 Mus musculus 262-267 30995213-8 2019 GZD treatment promoted the expression of MMP2/9 and repressed the heightened level of TIMP-1/2 in the recovery phase. N,N,N-trimethyl-5-({[(3s,5s,7s)-tricyclo[3.3.1.1~3,7~]decan-1-yl]methyl}amino)pentan-1-aminium 0-3 matrix metallopeptidase 2 Mus musculus 41-47 31057657-6 2019 CoCl2-induced accumulation of HIF-1alpha increased the level of phosphorylated Akt and upregulated the expression of VEGF and MMP-2/9. cobaltous chloride 0-5 matrix metallopeptidase 2 Mus musculus 126-133 30471427-4 2019 Here, we report that paclitaxel-induced mechanical allodynia is associated with transcriptional increase in matrix metalloproteinase (MMP) 2 and 9 and decrease in metallopeptidase inhibitor 1 (TIMP1), a strong endogenous MMP9 inhibitor. Paclitaxel 21-31 matrix metallopeptidase 2 Mus musculus 108-140 31066254-10 2019 Additionally, in skin tissues of bleomycin-treated animals, both pro and active forms of MMP9 and MMP2 were increased (p<0.05). Bleomycin 33-42 matrix metallopeptidase 2 Mus musculus 98-102 30925687-4 2019 Treatment with garcinol also decreased mRNA levels of transforming growth factor-beta, matrix metalloproteinase (MMP)-2, MMP-9, and fibronectin. garcinol 15-23 matrix metallopeptidase 2 Mus musculus 87-119 30850587-6 2019 The underlying mechanism mainly involves citrate-stimulated activation of the AKT/ERK/MMP2/9 signaling axis. Citric Acid 41-48 matrix metallopeptidase 2 Mus musculus 86-92 30737255-7 2019 Alamandine administration attenuated ascending aorta fibrosis induced by TAC, through a reduction in the following parameters; total collagen deposition, expression collagen III and transforming growth factor-beta (TGF-beta) transcripts, matrix metalloproteinases (MMPs) activity and vascular expression of MMP-2. alamandine 0-10 matrix metallopeptidase 2 Mus musculus 307-312 30585623-4 2018 Nicotine also increased alpha1nAChR, calpain-1, matrix metalloproteinase-2 (MMP-2), and MMP-9 expression in the aortic tissue. Nicotine 0-8 matrix metallopeptidase 2 Mus musculus 48-74 30535428-6 2019 Gambogic acid treatment markedly decreased the levels of proinflammatory cytokines and oxidative stress factors, and transforming growth factor-beta (TGF-beta) and matrix metalloproteinase (MMP)-2 and MMP-9 protein expression in AAA mice. gambogic acid 0-13 matrix metallopeptidase 2 Mus musculus 164-196 30396075-8 2019 Moreover, alogliptin treatment prevented OGD/R-induced induction of metalloproteinase (MMP)-2 and MMP-9, and restored expression of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. alogliptin 10-20 matrix metallopeptidase 2 Mus musculus 41-93 30289086-11 2019 However, IP treatment with D-Asp significantly reduced C-C motif chemokine ligand 2 and MMP-2 serum levels compared to control mice. D-Aspartic Acid 27-32 matrix metallopeptidase 2 Mus musculus 88-93 30798853-0 2019 Syringaresinol Reverses Age-Related Skin Atrophy by Suppressing FoxO3a-Mediated Matrix Metalloproteinase-2 Activation in Copper/Zinc Superoxide Dismutase-Deficient Mice. syringaresinol 0-14 matrix metallopeptidase 2 Mus musculus 80-106 30798853-8 2019 Syringaresinol also decreased the oxidative damage and the phosphorylation of FoxO3a protein, which was a transcriptional factor of matrix metalloproteinase-2, in Sod1-/- skin. syringaresinol 0-14 matrix metallopeptidase 2 Mus musculus 132-158 30798853-9 2019 These results strongly suggest that syringaresinol regulates the FoxO3-matrix metalloproteinase-2 axis in oxidative damaged skin and exhibits beneficial effects on age-related skin involution in Sod1-/- mice. syringaresinol 36-50 matrix metallopeptidase 2 Mus musculus 71-97 30789971-6 2019 In the Capecitabine and high dose CLG groups, the growth and liver metastasis of CRC were significantly inhibited, the protein levels of HIF-1alpha, SDF-1alpha, CXCR4, MMP-2, VEGF, PI3K, Akt, P-PI3K and P-Akt in the transplanted tumor were lower, while the content of collagen IV in the transplanted tumor was higher, than in Model group. Capecitabine 7-19 matrix metallopeptidase 2 Mus musculus 168-173 30789971-6 2019 In the Capecitabine and high dose CLG groups, the growth and liver metastasis of CRC were significantly inhibited, the protein levels of HIF-1alpha, SDF-1alpha, CXCR4, MMP-2, VEGF, PI3K, Akt, P-PI3K and P-Akt in the transplanted tumor were lower, while the content of collagen IV in the transplanted tumor was higher, than in Model group. Clorgyline 34-37 matrix metallopeptidase 2 Mus musculus 168-173 30616599-18 2019 Nano-Ni exposure also caused increased MMP-2/9 activities in the mouse lung tissues. nano-ni 0-7 matrix metallopeptidase 2 Mus musculus 39-44 30648530-5 2019 OBJECTIVES: The aim of the study was to determine the influence of subchronic exposure to three different doses of mephedrone on the activity of MMP-2 and 9 in hippocampus and prefrontal cortex and how this was correlated with memory processes in mice. mephedrone 115-125 matrix metallopeptidase 2 Mus musculus 145-156 30648530-8 2019 RESULTS: The study confirmed the dose-dependent increase in activity of MMP-2 and -9 exerted by subchronic administration of mephedrone. mephedrone 125-135 matrix metallopeptidase 2 Mus musculus 72-84 30648530-11 2019 Moreover, further studies are required to find out if elevated activities of MMPs contribute to brain damage or recovery from brain damage caused directly by mephedrone. mephedrone 158-168 matrix metallopeptidase 2 Mus musculus 77-81 30585623-4 2018 Nicotine also increased alpha1nAChR, calpain-1, matrix metalloproteinase-2 (MMP-2), and MMP-9 expression in the aortic tissue. Nicotine 0-8 matrix metallopeptidase 2 Mus musculus 76-81 30585623-6 2018 In vitro, nicotine-induced alpha1nAChR, calpain-1, MMP-2, and MMP-9 expression in mouse vascular smooth muscle cells (MOVAS) and macrophages (RAW264.7), and enhanced the migration and proliferation of these cells. Nicotine 10-18 matrix metallopeptidase 2 Mus musculus 51-56 30585623-9 2018 The effect of nicotine on atherogenesis may be mediated by alpha1nAChR-induced activation of the calpain-1/MMP-2/MMP-9 signaling pathway. Nicotine 14-22 matrix metallopeptidase 2 Mus musculus 107-112 30585623-9 2018 The effect of nicotine on atherogenesis may be mediated by alpha1nAChR-induced activation of the calpain-1/MMP-2/MMP-9 signaling pathway. alpha1nachr 59-70 matrix metallopeptidase 2 Mus musculus 107-112 30567534-7 2018 The promoted 8-hydroxyoctanoic acid formation was also found to suppress the tumors" metastatic potential via regulating MMP-2 and E-cadherin expressions. 8-hydroxyoctanoic acid 13-35 matrix metallopeptidase 2 Mus musculus 121-126 29550174-11 2018 CONCLUSIONS: CAM suppressed the progression and rupture of AA through the suppression of inflammatory macrophage infiltration, a reduction in MMP-2 and MMP-9 activity, and the inhibition of elastin degradation associated with the suppression of NF-kappaB phosphorylation. Clarithromycin 13-16 matrix metallopeptidase 2 Mus musculus 142-147 30388517-0 2018 Cryptotanshinone inhibits the growth and invasion of colon cancer by suppressing inflammation and tumor angiogenesis through modulating MMP/TIMP system, PI3K/Akt/mTOR signaling and HIF-1alpha nuclear translocation. cryptotanshinone 0-16 matrix metallopeptidase 2 Mus musculus 136-139 30371703-0 2018 An E-selectin targeting and MMP-2-responsive dextran-curcumin polymeric prodrug for targeted therapy of acute kidney injury. dextran-curcumin 45-61 matrix metallopeptidase 2 Mus musculus 28-33 30401729-3 2018 The results indicated that casticin significantly inhibited cell migration and invasion in the cells exposed to 0.25 and 0.50 microM of casticin for 24 h. Casticin treatment reduced matrix metalloproteinase (MMP) 9 (MMP-9) activity and down-regulated MMP-9 mRNA and protein expression, but not MMP-2. casticin 27-35 matrix metallopeptidase 2 Mus musculus 294-299 30401729-3 2018 The results indicated that casticin significantly inhibited cell migration and invasion in the cells exposed to 0.25 and 0.50 microM of casticin for 24 h. Casticin treatment reduced matrix metalloproteinase (MMP) 9 (MMP-9) activity and down-regulated MMP-9 mRNA and protein expression, but not MMP-2. casticin 136-144 matrix metallopeptidase 2 Mus musculus 294-299 30401729-3 2018 The results indicated that casticin significantly inhibited cell migration and invasion in the cells exposed to 0.25 and 0.50 microM of casticin for 24 h. Casticin treatment reduced matrix metalloproteinase (MMP) 9 (MMP-9) activity and down-regulated MMP-9 mRNA and protein expression, but not MMP-2. casticin 155-163 matrix metallopeptidase 2 Mus musculus 294-299 30277751-5 2018 A fluorescein-labeled derivative compound 17 shows direct binding to activated gelatinases surrounding inflammatory cuffs in the neuroinflammation model and to pancreatic beta-cells in the islets of Langerhans, colocalizing with MMP-2 and MMP-9 activity as detected using in situ zymography techniques. Fluorescein 2-13 matrix metallopeptidase 2 Mus musculus 229-234 30513758-2 2018 We evaluated a gallium-68 labeled peptide for the detection of MMP-2/9 in atherosclerotic mouse aorta. Gallium 15-22 matrix metallopeptidase 2 Mus musculus 63-70 30513758-4 2018 Distribution of intravenously-injected MMP-2/9-targeting peptide, [68Ga]Ga-DOTA-TCTP-1, was studied by combined positron emission tomography (PET) and contrast-enhanced computed tomography (CT). ga-dota 72-79 matrix metallopeptidase 2 Mus musculus 39-46 30371703-1 2018 Based on the overproduction of matrix metalloproteinase-2 (MMP-2) in renal tissue during acute kidney injury (AKI) occurrence, we developed a MMP-2 enzyme-triggered polymeric prodrug with sialic acid (SA) as the targeting group to the inflamed vascular endothelial cells for enhanced therapeutic outcomes. N-Acetylneuraminic Acid 188-199 matrix metallopeptidase 2 Mus musculus 31-57 30371703-1 2018 Based on the overproduction of matrix metalloproteinase-2 (MMP-2) in renal tissue during acute kidney injury (AKI) occurrence, we developed a MMP-2 enzyme-triggered polymeric prodrug with sialic acid (SA) as the targeting group to the inflamed vascular endothelial cells for enhanced therapeutic outcomes. N-Acetylneuraminic Acid 188-199 matrix metallopeptidase 2 Mus musculus 59-64 30371703-1 2018 Based on the overproduction of matrix metalloproteinase-2 (MMP-2) in renal tissue during acute kidney injury (AKI) occurrence, we developed a MMP-2 enzyme-triggered polymeric prodrug with sialic acid (SA) as the targeting group to the inflamed vascular endothelial cells for enhanced therapeutic outcomes. N-Acetylneuraminic Acid 188-199 matrix metallopeptidase 2 Mus musculus 142-147 30371703-1 2018 Based on the overproduction of matrix metalloproteinase-2 (MMP-2) in renal tissue during acute kidney injury (AKI) occurrence, we developed a MMP-2 enzyme-triggered polymeric prodrug with sialic acid (SA) as the targeting group to the inflamed vascular endothelial cells for enhanced therapeutic outcomes. N-Acetylneuraminic Acid 201-203 matrix metallopeptidase 2 Mus musculus 31-57 30371703-1 2018 Based on the overproduction of matrix metalloproteinase-2 (MMP-2) in renal tissue during acute kidney injury (AKI) occurrence, we developed a MMP-2 enzyme-triggered polymeric prodrug with sialic acid (SA) as the targeting group to the inflamed vascular endothelial cells for enhanced therapeutic outcomes. N-Acetylneuraminic Acid 201-203 matrix metallopeptidase 2 Mus musculus 59-64 30371703-1 2018 Based on the overproduction of matrix metalloproteinase-2 (MMP-2) in renal tissue during acute kidney injury (AKI) occurrence, we developed a MMP-2 enzyme-triggered polymeric prodrug with sialic acid (SA) as the targeting group to the inflamed vascular endothelial cells for enhanced therapeutic outcomes. N-Acetylneuraminic Acid 201-203 matrix metallopeptidase 2 Mus musculus 142-147 30371703-2 2018 An MMP-2-responsive peptide, PVGLIG, was used to endow the polymeric prodrug with the ability to rapidly release the anti-inflammatory drug, curcumin (CUR), after the targeted site is reached and to improve the drug concentration in the target tissue. pvglig 29-35 matrix metallopeptidase 2 Mus musculus 3-8 30371703-2 2018 An MMP-2-responsive peptide, PVGLIG, was used to endow the polymeric prodrug with the ability to rapidly release the anti-inflammatory drug, curcumin (CUR), after the targeted site is reached and to improve the drug concentration in the target tissue. Curcumin 141-149 matrix metallopeptidase 2 Mus musculus 3-8 30371703-5 2018 The in vitro drug release results showed that the release rate of SA-DEX-PVGLIG-CUR was significantly enhanced compared to that of SA-DEX-CUR in a dissolving medium containing the MMP-2 enzyme, suggesting that SA-DEX-PVGLIG-CUR had rapid drug release characteristics in an inflammatory environment. sa-dex 66-72 matrix metallopeptidase 2 Mus musculus 180-185 30371703-5 2018 The in vitro drug release results showed that the release rate of SA-DEX-PVGLIG-CUR was significantly enhanced compared to that of SA-DEX-CUR in a dissolving medium containing the MMP-2 enzyme, suggesting that SA-DEX-PVGLIG-CUR had rapid drug release characteristics in an inflammatory environment. sa-dex-pvglig 210-223 matrix metallopeptidase 2 Mus musculus 180-185 29405790-7 2018 Thus, a peptide, GPLGLAGDDYCDGFYACYMDV-NH2, which consists of AHNP and an MMP-2 cleavable linker GPLGLAGDD, was first designed, followed by conjugation with DOX via a glycine residue at the N-terminus to form a novel DOX-peptide conjugate MAHNP-DOX. mahnp-dox 239-248 matrix metallopeptidase 2 Mus musculus 74-79 30257322-8 2018 Mechanistically, DHS modulated the expressions of several key metastasis regulating proteins e.g., MMP-2/9, N-cadherin, E-cadherin and survivin. dhs 17-20 matrix metallopeptidase 2 Mus musculus 99-106 30021673-5 2018 Accordingly, we constructed a PD-1-based recombinantly tailored fusion protein (dFv-ePD1) that consists of bivalent variable fragments (dFv) of an MMP-2/9-targeted antibody and ePD1. EFP protocol 80-83 matrix metallopeptidase 2 Mus musculus 147-152 29405790-0 2018 Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer. Doxorubicin 0-11 matrix metallopeptidase 2 Mus musculus 57-62 29405790-7 2018 Thus, a peptide, GPLGLAGDDYCDGFYACYMDV-NH2, which consists of AHNP and an MMP-2 cleavable linker GPLGLAGDD, was first designed, followed by conjugation with DOX via a glycine residue at the N-terminus to form a novel DOX-peptide conjugate MAHNP-DOX. Doxorubicin 157-160 matrix metallopeptidase 2 Mus musculus 74-79 29405790-7 2018 Thus, a peptide, GPLGLAGDDYCDGFYACYMDV-NH2, which consists of AHNP and an MMP-2 cleavable linker GPLGLAGDD, was first designed, followed by conjugation with DOX via a glycine residue at the N-terminus to form a novel DOX-peptide conjugate MAHNP-DOX. Glycine 167-174 matrix metallopeptidase 2 Mus musculus 74-79 30152844-10 2018 Furthermore, the cell migration ability, and MMP-2 and MMP-9 protein levels, of astrocytes that received combined treatment with SB202190 and the PP2A activator DES were significantly increased compared with the levels in astrocytes treated with SB202190 alone. 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole 129-137 matrix metallopeptidase 2 Mus musculus 45-50 29405790-7 2018 Thus, a peptide, GPLGLAGDDYCDGFYACYMDV-NH2, which consists of AHNP and an MMP-2 cleavable linker GPLGLAGDD, was first designed, followed by conjugation with DOX via a glycine residue at the N-terminus to form a novel DOX-peptide conjugate MAHNP-DOX. Doxorubicin 217-220 matrix metallopeptidase 2 Mus musculus 74-79 29797576-7 2018 Expressions of Ki-67, VEGF, CD31, MMP2, MMP9, VCAM1, and NF-kappaB were significantly decreased in tumors from UMB-treated animals (P < 0.001), whereas E-Cadherin and TNFR1 expressions were markedly increased (P < 0.001). umbelliprenin 111-114 matrix metallopeptidase 2 Mus musculus 34-38 29908885-6 2018 Accordingly, increased expression of MMP-2/13 was found in hypoxic MSCs and BMCs in CNV lesions. bmcs 76-80 matrix metallopeptidase 2 Mus musculus 37-42 30019466-0 2018 Trimetazidine suppresses oxidative stress, inhibits MMP-2 and MMP-9 expression, and prevents cardiac rupture in mice with myocardial infarction. Trimetazidine 0-13 matrix metallopeptidase 2 Mus musculus 52-57 30019466-9 2018 We found that the expression of metalloproteinase (MMP) -2 and MMP-9 in the TMZ-treated group was significantly lower than the saline-treated group. Trimetazidine 76-79 matrix metallopeptidase 2 Mus musculus 32-58 30019466-9 2018 We found that the expression of metalloproteinase (MMP) -2 and MMP-9 in the TMZ-treated group was significantly lower than the saline-treated group. Sodium Chloride 127-133 matrix metallopeptidase 2 Mus musculus 32-58 30019466-12 2018 TMZ prevents CR through inhibition of oxidative stress, which is attributable to the down-regulation of MMP-2, MMP-9 expression. Trimetazidine 0-3 matrix metallopeptidase 2 Mus musculus 104-109 30019466-13 2018 CONCLUSIONS: Our findings indicate that TMZ suppresses oxidative stress, inhibits MMP-2 and MMP-9 expression, and prevents CR in mice with MI. Trimetazidine 40-43 matrix metallopeptidase 2 Mus musculus 82-87 30429794-9 2018 Mechanistically, nicotine exposure enhanced expression of MMP-2/-9 and elastolytic activity in both aortic segments. Nicotine 17-25 matrix metallopeptidase 2 Mus musculus 58-66 30099017-7 2018 Meanwhile, the antimetastasis mechanism studies confirmed that the combination of the chemotherapeutic PTX and the autophagy inhibitor HCQ further suppressed the degradation of paxillin, the expression of MMP9 and MMP2. Paclitaxel 103-106 matrix metallopeptidase 2 Mus musculus 214-218 30099017-7 2018 Meanwhile, the antimetastasis mechanism studies confirmed that the combination of the chemotherapeutic PTX and the autophagy inhibitor HCQ further suppressed the degradation of paxillin, the expression of MMP9 and MMP2. Hydroxychloroquine 135-138 matrix metallopeptidase 2 Mus musculus 214-218 30341286-5 2018 Moreover, 3-DZNep was effective in counteracting the increased expression of matrix metalloproteinase (MMP)-2 and MMP-9, as well as the phosphorylation of Raf-1 and ERK1/2 in the injured kidney. 3-dznep 10-17 matrix metallopeptidase 2 Mus musculus 77-109 30081225-5 2018 MWCNT-exposure resulted in increased coronary ROS production with concurrent increases in expression of LOX-1, VCAM-1, TNF-alpha, and MMP-2/9 activity; while ABCA-1 expression was downregulated, compared to FA-Controls. mwcnt 0-5 matrix metallopeptidase 2 Mus musculus 134-141 29936575-6 2018 Chronic ethanol/saline vehicle upregulated expression of NF-kappaB, MMP2, integrin beta1, collagen IV, and laminin, and induced vascular basement membrane degradation in primary prostate tumours, as well as increased metastatic spread to the lung and liver. Ethanol 8-15 matrix metallopeptidase 2 Mus musculus 68-72 29936575-6 2018 Chronic ethanol/saline vehicle upregulated expression of NF-kappaB, MMP2, integrin beta1, collagen IV, and laminin, and induced vascular basement membrane degradation in primary prostate tumours, as well as increased metastatic spread to the lung and liver. Sodium Chloride 16-22 matrix metallopeptidase 2 Mus musculus 68-72 30076913-0 2018 Fisetin inhibits cell migration via inducing HO-1 and reducing MMPs expression in breast cancer cell lines. fisetin 0-7 matrix metallopeptidase 2 Mus musculus 63-67 29908885-9 2018 Our study suggests that miR-188-5p regulates the contribution of BMCs to CNV development by targeting MMP-2/13-mediated extracellular matrix degeneration, and miR-188-5p serves as a therapeutic target to treat CNV-related diseases. bmcs 65-69 matrix metallopeptidase 2 Mus musculus 102-107 30253743-5 2018 A spatial distribution of two isoforms of MMP-2 was analyzed semi-quantitatively according to time after injection of STZ and with increasing age of db/db mice. Streptozocin 118-121 matrix metallopeptidase 2 Mus musculus 42-47 30076913-7 2018 Moreover, by administration of HO-1 inhibitors, tin protoporphyrin and zinc protoporphyrin, fisetin-reduced MMP-2 and MMP-9 expressions were reversed. tin protoporphyrin IX 48-66 matrix metallopeptidase 2 Mus musculus 108-113 30076913-7 2018 Moreover, by administration of HO-1 inhibitors, tin protoporphyrin and zinc protoporphyrin, fisetin-reduced MMP-2 and MMP-9 expressions were reversed. zinc protoporphyrin 71-90 matrix metallopeptidase 2 Mus musculus 108-113 30076913-7 2018 Moreover, by administration of HO-1 inhibitors, tin protoporphyrin and zinc protoporphyrin, fisetin-reduced MMP-2 and MMP-9 expressions were reversed. fisetin 92-99 matrix metallopeptidase 2 Mus musculus 108-113 30033241-0 2018 Effect of biogenic silver nanocubes on matrix metalloproteinases 2 and 9 expressions in hyperglycemic skin injury and its impact in early wound healing in streptozotocin-induced diabetic mice. Silver 19-25 matrix metallopeptidase 2 Mus musculus 39-72 30253743-7 2018 RESULTS: Both isoforms of MMP-2 were upregulated in whole kidneys from STZ and db/db mice. Streptozocin 71-74 matrix metallopeptidase 2 Mus musculus 26-31 30253743-8 2018 In the case of FL-MMP-2, mRNA levels significantly increased at 12 and 24 weeks in STZ mice, while the isoform expression was significantly increased only at 16 weeks, in the db/db mice. Streptozocin 83-86 matrix metallopeptidase 2 Mus musculus 18-23 30253743-9 2018 FL-MMP-2 protein levels increased in the cortices and outer medullae of both STZ and db/db mice as a function of the duration of diabetes. Streptozocin 77-80 matrix metallopeptidase 2 Mus musculus 3-8 30253743-10 2018 For NTT-MMP-2, mRNA levels increased earlier at 4 weeks in STZ mice and at 10 weeks of age in db/db mice. Streptozocin 59-62 matrix metallopeptidase 2 Mus musculus 8-13 30253743-11 2018 The expression of NTT-MMP-2 also increased, primarily in the cortices of STZ and db/db mice, as a function of the duration of diabetes. Streptozocin 73-76 matrix metallopeptidase 2 Mus musculus 22-27 30253743-12 2018 Quantitatively, these findings were consistent with the qPCR results in the case of NTT-MMP-2, respectively (STZ 24 weeks, 3.24 +- 3.70 fold; 16 weeks db/db, 4.49 +- 0.55 fold). Streptozocin 109-112 matrix metallopeptidase 2 Mus musculus 88-93 30101186-4 2018 Recently developed alpha-sulfonylaminohydroxamic acid based gamma-fluorinated inhibitors of MMP-2 and -9 provide promising fluorine interactions with the enzyme active site and high MMP inhibition potencies. alpha-sulfonylaminohydroxamic acid 19-53 matrix metallopeptidase 2 Mus musculus 92-104 30213073-0 2018 Resveratrol Suppresses Matrix Metalloproteinase-2 Activation Induced by Lipopolysaccharide in Mouse Osteoblasts via Interactions with AMP-Activated Protein Kinase and Suppressor of Cytokine Signaling 1. Resveratrol 0-11 matrix metallopeptidase 2 Mus musculus 23-49 30213073-10 2018 In addition, AMPK inhibition blocked the effects of resveratrol on MMP-2 expression and activity in LPS-induced MC3T3-E1 cells. Resveratrol 52-63 matrix metallopeptidase 2 Mus musculus 67-72 30213073-12 2018 SOCS1 siRNA negated the inhibitory effects of resveratrol on LPS-induced MMP-2 production. Resveratrol 46-57 matrix metallopeptidase 2 Mus musculus 73-78 30213073-13 2018 Additionally, resveratrol-induced SOCS1 upregulation was reduced by treatment with compound C. These results demonstrate that AMPK and SOCS1 activation are important signaling events during resveratrol-mediated inhibition of MMP-2 production in response to LPS in MC3T3-E1 cells, and there is crosstalk between AMPK and SOCS1 signaling. Resveratrol 14-25 matrix metallopeptidase 2 Mus musculus 225-230 30213073-13 2018 Additionally, resveratrol-induced SOCS1 upregulation was reduced by treatment with compound C. These results demonstrate that AMPK and SOCS1 activation are important signaling events during resveratrol-mediated inhibition of MMP-2 production in response to LPS in MC3T3-E1 cells, and there is crosstalk between AMPK and SOCS1 signaling. Resveratrol 190-201 matrix metallopeptidase 2 Mus musculus 225-230 29932269-8 2018 In both M2c and M2a, severe hypoxic (1%-3% O2 ) exposure significantly suppressed PlGF, Cxcl12, and Mmp2 mRNA, but not Vegfa, compared to normoxia (21% O2 ) or physiological hypoxia (5% O2 ). Oxygen 43-45 matrix metallopeptidase 2 Mus musculus 100-104 30254846-5 2018 Results: Both isoforms of MMP-2 were upregulated in the kidney tissues of STZ-induced diabetic mice and 5/6Nx mice, irrespective of age. Streptozocin 74-77 matrix metallopeptidase 2 Mus musculus 26-31 30133427-9 2018 Blocking integrin a5b1 by ATN-161 strongly inhibited nuclear factor-kappaB (NF-kappaB) activation and matrix metalloproteinase-2/9 (MMP-2/9) expression and promoted cell apoptosis, but the effect of ATN-161 on proliferation in CNV mice was indirect and required the inhibition of neovascularization. acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide 26-33 matrix metallopeptidase 2 Mus musculus 102-130 30133427-9 2018 Blocking integrin a5b1 by ATN-161 strongly inhibited nuclear factor-kappaB (NF-kappaB) activation and matrix metalloproteinase-2/9 (MMP-2/9) expression and promoted cell apoptosis, but the effect of ATN-161 on proliferation in CNV mice was indirect and required the inhibition of neovascularization. acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide 26-33 matrix metallopeptidase 2 Mus musculus 132-139 30147314-4 2018 MMP2/9-triggered-release micelles were constructed using PG and succinylated gelatin (SG) and loading paclitaxel (Ptx). Paclitaxel 102-112 matrix metallopeptidase 2 Mus musculus 0-4 30147314-4 2018 MMP2/9-triggered-release micelles were constructed using PG and succinylated gelatin (SG) and loading paclitaxel (Ptx). Paclitaxel 114-117 matrix metallopeptidase 2 Mus musculus 0-4 30147314-7 2018 Results: Ptx-release efficiency from PG-SG-Ptx micelles was MMP2/9-concentration-dependent. Paclitaxel 9-12 matrix metallopeptidase 2 Mus musculus 60-66 30147314-7 2018 Results: Ptx-release efficiency from PG-SG-Ptx micelles was MMP2/9-concentration-dependent. pg 37-39 matrix metallopeptidase 2 Mus musculus 60-66 30147314-7 2018 Results: Ptx-release efficiency from PG-SG-Ptx micelles was MMP2/9-concentration-dependent. Paclitaxel 43-46 matrix metallopeptidase 2 Mus musculus 60-66 30032844-7 2018 Intragastric application of MK-2206 at a low dose (50 mg/kg) reversed the changes of the key indicators of EMT in the lungs of CS-exposed mice, including TGF-beta1, alpha-SMA, vimentin, MMP-9, MMP-2, S100A4, collagen deposition, and E-cadherin. MK 2206 28-35 matrix metallopeptidase 2 Mus musculus 193-198 30052652-7 2018 Mice in apatinib-treated groups showed a markedly reduced expression of VEGFR-2, ERK-1/2, PI3K, and MMP-2. apatinib 8-16 matrix metallopeptidase 2 Mus musculus 100-105 30049285-11 2018 VCAM-1 and MCP-1 mRNA levels were lower (P = 0.02 and P = 0.07, respectively), while TIMP-1/MMP-2 ratio expression was higher in canagliflozin-group approaching statistical significance (P = 0.07). Canagliflozin 129-142 matrix metallopeptidase 2 Mus musculus 92-97 30049285-13 2018 Moreover, canagliflozin was found to increase the atherosclerotic plaque stability via increasing TIMP-1/MMP-2 ratio expression. Canagliflozin 10-23 matrix metallopeptidase 2 Mus musculus 105-110 30101186-4 2018 Recently developed alpha-sulfonylaminohydroxamic acid based gamma-fluorinated inhibitors of MMP-2 and -9 provide promising fluorine interactions with the enzyme active site and high MMP inhibition potencies. Fluorine 123-131 matrix metallopeptidase 2 Mus musculus 92-104 30101186-6 2018 Results: Two new fluorine-containing, enantiomerically pure inhibitors for MMP-2 and -9 were synthesized in a six step sequence. Fluorine 17-25 matrix metallopeptidase 2 Mus musculus 75-87 30127820-10 2018 Markers involved in angiogenesis including VEGF, MMP2, and MMP-9 in the cancerous mice group treated with umbelliprenin showed a significant decrease compared to the control group (P < 0.05). umbelliprenin 106-119 matrix metallopeptidase 2 Mus musculus 49-53 29997437-7 2018 Immunohistochemistry confirmed the inhibition of vascular endothelial growth factor (VEGF) and cAMP and the activation of PKA by 8-Br-cAMP; quantitative real-time-PCR (qRT-PCR) demonstrated that 8-Br-cAMP regulated the expression of vascular endothelial (VE)-cadherin, matrix metalloproteinase 2 (MMP2), ephrin type-A receptor 2 (EphA2), and VEGF in vivo. 8-Bromo Cyclic Adenosine Monophosphate 195-204 matrix metallopeptidase 2 Mus musculus 269-295 29997437-7 2018 Immunohistochemistry confirmed the inhibition of vascular endothelial growth factor (VEGF) and cAMP and the activation of PKA by 8-Br-cAMP; quantitative real-time-PCR (qRT-PCR) demonstrated that 8-Br-cAMP regulated the expression of vascular endothelial (VE)-cadherin, matrix metalloproteinase 2 (MMP2), ephrin type-A receptor 2 (EphA2), and VEGF in vivo. 8-Bromo Cyclic Adenosine Monophosphate 195-204 matrix metallopeptidase 2 Mus musculus 297-301 29635122-9 2018 Furthermore, hinokiflavone effectively impaired A375 cells migration and invasion, and down-regulated the expression of matrix metalloproteinase (MMP) MMP2 and MMP9. hinokiflavone 13-26 matrix metallopeptidase 2 Mus musculus 151-155 29532526-0 2018 Myricetin suppresses breast cancer metastasis through down-regulating the activity of matrix metalloproteinase (MMP)-2/9. myricetin 0-9 matrix metallopeptidase 2 Mus musculus 86-120 29938313-0 2018 The Effect of BSA-Based Curcumin Nanoparticles on Memory and Hippocampal MMP-2, MMP-9, and MAPKs in Adult Mice. Curcumin 24-32 matrix metallopeptidase 2 Mus musculus 73-78 29938313-11 2018 This study indicates that breaking curcumin to nanosize produces improved effects on passive avoidance memory in adult mice accompanied with MMP-2, MMP-9, p-ERK, and p-JNK changes in the hippocampus. Curcumin 35-43 matrix metallopeptidase 2 Mus musculus 141-146 29532526-8 2018 Myricetin significantly decreased the activities of MMP-2/9 and mRNA levels of ST6GALNAC5. myricetin 0-9 matrix metallopeptidase 2 Mus musculus 52-57 29929563-11 2018 Additionally, PC blocks the maturation of interleukin-1beta, which is a critical substrate of MMPs, and markedly suppresses CCI-induced MAPK phosphorylation and neuronal and microglia activation, including the reduced phosphorylation of protein kinase C gamma and NMDAR1. Proanthocyanidins 14-16 matrix metallopeptidase 2 Mus musculus 94-98 29970958-6 2018 Results: Salidroside inhibited the production of extracellular matrix (ECM) and regulated the balance between MMP2 and TIMP1 and, therefore, alleviated liver fibrosis in the two fibrosis models. rhodioloside 9-20 matrix metallopeptidase 2 Mus musculus 110-114 29377313-9 2018 Quantification of metalloproteinase (MMP) activity showed that SOSTTG had ~2-fold less MMP activation than WT or Sost-/- , and this was supported by a significant reduction in MMP2/3 protein levels, suggesting that elevated levels of SOST inhibit the activity of proteolytic enzymes known to degrade articular cartilage matrix. sosttg 63-69 matrix metallopeptidase 2 Mus musculus 37-40 29377313-9 2018 Quantification of metalloproteinase (MMP) activity showed that SOSTTG had ~2-fold less MMP activation than WT or Sost-/- , and this was supported by a significant reduction in MMP2/3 protein levels, suggesting that elevated levels of SOST inhibit the activity of proteolytic enzymes known to degrade articular cartilage matrix. sosttg 63-69 matrix metallopeptidase 2 Mus musculus 87-90 29794990-10 2018 These results demonstrated that antrodan provides a novel, complementary therapeutic strategy against cancer metastasis, by attenuating the activities of MMP-2 and -9 through the modulation of STAT3/MAPK/ERK/JNK signaling pathways, and of the host"s immune system. antrodan 32-40 matrix metallopeptidase 2 Mus musculus 154-166 29770822-3 2018 The smart size-switchable nanoplatform (DGL/DOX@PP) was prepared by conjugating small dendrigraft poly-l-lysine (DGL) to poly(ethylene glycol)-poly(caprolactone) micelles via a matrix metalloproteinase 2 (MMP-2)-sensitive peptide. D-glutamic acid 40-43 matrix metallopeptidase 2 Mus musculus 177-203 29770822-3 2018 The smart size-switchable nanoplatform (DGL/DOX@PP) was prepared by conjugating small dendrigraft poly-l-lysine (DGL) to poly(ethylene glycol)-poly(caprolactone) micelles via a matrix metalloproteinase 2 (MMP-2)-sensitive peptide. D-glutamic acid 40-43 matrix metallopeptidase 2 Mus musculus 205-210 29770822-3 2018 The smart size-switchable nanoplatform (DGL/DOX@PP) was prepared by conjugating small dendrigraft poly-l-lysine (DGL) to poly(ethylene glycol)-poly(caprolactone) micelles via a matrix metalloproteinase 2 (MMP-2)-sensitive peptide. Doxorubicin 44-47 matrix metallopeptidase 2 Mus musculus 177-203 29770822-3 2018 The smart size-switchable nanoplatform (DGL/DOX@PP) was prepared by conjugating small dendrigraft poly-l-lysine (DGL) to poly(ethylene glycol)-poly(caprolactone) micelles via a matrix metalloproteinase 2 (MMP-2)-sensitive peptide. Doxorubicin 44-47 matrix metallopeptidase 2 Mus musculus 205-210 29770822-3 2018 The smart size-switchable nanoplatform (DGL/DOX@PP) was prepared by conjugating small dendrigraft poly-l-lysine (DGL) to poly(ethylene glycol)-poly(caprolactone) micelles via a matrix metalloproteinase 2 (MMP-2)-sensitive peptide. Lysine 98-111 matrix metallopeptidase 2 Mus musculus 177-203 29770822-3 2018 The smart size-switchable nanoplatform (DGL/DOX@PP) was prepared by conjugating small dendrigraft poly-l-lysine (DGL) to poly(ethylene glycol)-poly(caprolactone) micelles via a matrix metalloproteinase 2 (MMP-2)-sensitive peptide. Lysine 98-111 matrix metallopeptidase 2 Mus musculus 205-210 29770822-3 2018 The smart size-switchable nanoplatform (DGL/DOX@PP) was prepared by conjugating small dendrigraft poly-l-lysine (DGL) to poly(ethylene glycol)-poly(caprolactone) micelles via a matrix metalloproteinase 2 (MMP-2)-sensitive peptide. D-glutamic acid 113-116 matrix metallopeptidase 2 Mus musculus 177-203 29770822-3 2018 The smart size-switchable nanoplatform (DGL/DOX@PP) was prepared by conjugating small dendrigraft poly-l-lysine (DGL) to poly(ethylene glycol)-poly(caprolactone) micelles via a matrix metalloproteinase 2 (MMP-2)-sensitive peptide. D-glutamic acid 113-116 matrix metallopeptidase 2 Mus musculus 205-210 29770822-3 2018 The smart size-switchable nanoplatform (DGL/DOX@PP) was prepared by conjugating small dendrigraft poly-l-lysine (DGL) to poly(ethylene glycol)-poly(caprolactone) micelles via a matrix metalloproteinase 2 (MMP-2)-sensitive peptide. Polyethylene Glycols 121-142 matrix metallopeptidase 2 Mus musculus 177-203 29770822-3 2018 The smart size-switchable nanoplatform (DGL/DOX@PP) was prepared by conjugating small dendrigraft poly-l-lysine (DGL) to poly(ethylene glycol)-poly(caprolactone) micelles via a matrix metalloproteinase 2 (MMP-2)-sensitive peptide. Polyethylene Glycols 121-142 matrix metallopeptidase 2 Mus musculus 205-210 29770822-5 2018 After extravasation from the tumor vessels, small DGL/DOX nanoparticles (~30 nm) were rapidly released from DGL/DOX@PP in response to MMP-2 in the TME. D-glutamic acid 50-53 matrix metallopeptidase 2 Mus musculus 134-139 29770822-5 2018 After extravasation from the tumor vessels, small DGL/DOX nanoparticles (~30 nm) were rapidly released from DGL/DOX@PP in response to MMP-2 in the TME. Doxorubicin 54-57 matrix metallopeptidase 2 Mus musculus 134-139 29770822-5 2018 After extravasation from the tumor vessels, small DGL/DOX nanoparticles (~30 nm) were rapidly released from DGL/DOX@PP in response to MMP-2 in the TME. dgl/dox 50-57 matrix metallopeptidase 2 Mus musculus 134-139 29740240-10 2018 Administration of crocin (100 mg/kg) hampered expression of tumor growth factor-beta (TGF-beta), alpha alpha smooth muscle actin (alpha-SMA) and collagen 1-alpha expression and significantly raised gene expression of matrix metalloproteinase-2 (MMP-2). crocin 18-24 matrix metallopeptidase 2 Mus musculus 217-243 29632167-7 2018 We confirmed these findings in vivo in rats after status epilepticus and in brain capillaries from male mice lacking cytosolic phospholipase A2 Together, our data support the hypothesis that glutamate released during seizures signals an increase in MMP-2 and MMP-9 protein expression and activity levels, resulting in blood-brain barrier leakage.SIGNIFICANCE STATEMENT The mechanism leading to seizure-mediated blood-brain barrier dysfunction in epilepsy is poorly understood. Glutamic Acid 191-200 matrix metallopeptidase 2 Mus musculus 249-254 29740240-10 2018 Administration of crocin (100 mg/kg) hampered expression of tumor growth factor-beta (TGF-beta), alpha alpha smooth muscle actin (alpha-SMA) and collagen 1-alpha expression and significantly raised gene expression of matrix metalloproteinase-2 (MMP-2). crocin 18-24 matrix metallopeptidase 2 Mus musculus 245-250 29506852-10 2018 Cisplatin increased mRNA levels of matrix-metalloproteinase (MMP)-2 and periostin, while vincristine increased MMP-9 and S100A8/9 levels in liver tissues. Cisplatin 0-9 matrix metallopeptidase 2 Mus musculus 35-67 29499360-8 2018 UA alleviated the degradation of elastin fibers and inflammation and decreased the expression of MMP2, MMP9, ADAM17 and phospho-STAT3 (pSTAT3) in aorta of mice induced with AngII. ursolic acid 0-2 matrix metallopeptidase 2 Mus musculus 97-101 29499360-9 2018 UA inhibited the constitutive and stimuli-induced (AngII and tumor necrosis factor-alpha) expression of MMP2, MMP9, ADAM17 and pSTAT3 in vascular smooth muscle cells (VSMCs). ursolic acid 0-2 matrix metallopeptidase 2 Mus musculus 104-108 29506852-13 2018 In addition, the mRNA expression of MMP-2 and periostin, or MMP-9 and S100A8/9 is increased by cisplatin or vincristine pretreatment, possibly resulting in fibrosis or neutrophil recruitment, respectively. Cisplatin 95-104 matrix metallopeptidase 2 Mus musculus 36-41 29506852-13 2018 In addition, the mRNA expression of MMP-2 and periostin, or MMP-9 and S100A8/9 is increased by cisplatin or vincristine pretreatment, possibly resulting in fibrosis or neutrophil recruitment, respectively. Vincristine 108-119 matrix metallopeptidase 2 Mus musculus 36-41 29467906-4 2018 Furthermore, beta-elemene-ligustrazine combination treatment resulted in the highest downregulation of G protein-coupled receptor 124, vascular endothelial growth factor, matrix metallopeptidase (MMP)-2 and MMP-9 mRNA, and protein expression levels. beta-elemene-ligustrazine 13-38 matrix metallopeptidase 2 Mus musculus 171-202 29367209-9 2018 We found that C3aR knockout decreased matrix metalloproteinase 2 (MMP2) expression in BAPN-treated mice. Aminopropionitrile 86-90 matrix metallopeptidase 2 Mus musculus 38-64 29367209-9 2018 We found that C3aR knockout decreased matrix metalloproteinase 2 (MMP2) expression in BAPN-treated mice. Aminopropionitrile 86-90 matrix metallopeptidase 2 Mus musculus 66-70 29566031-6 2018 For detection of MMP-2/-9 expression fluorescence endoscopy (FE) was used following i.v.-administration of a Cy5.5-labeled MMP-2/-9 specific tracer. CY5.5 cyanine dye 109-114 matrix metallopeptidase 2 Mus musculus 123-128 29566031-12 2018 Using FE based detection of MMPs in the anastomosis, an overall positive predictive value of 71.4% and negative predictive value of 66.6% was calculated for detection of anastomotic leakage. Iron 6-8 matrix metallopeptidase 2 Mus musculus 28-32 29155481-7 2018 The RGZ reduced leukocyte infiltration, preserved tissue structure, and dampened the 5-FU-induced expression of p53 and matrix metalloproteinase (Mmp)-2 after 5 days, and of Mmp-2 and interleukin (Il-1beta after 15 days. Fluorouracil 85-89 matrix metallopeptidase 2 Mus musculus 120-152 29155481-7 2018 The RGZ reduced leukocyte infiltration, preserved tissue structure, and dampened the 5-FU-induced expression of p53 and matrix metalloproteinase (Mmp)-2 after 5 days, and of Mmp-2 and interleukin (Il-1beta after 15 days. Fluorouracil 85-89 matrix metallopeptidase 2 Mus musculus 174-179 29328461-7 2018 Gambogic acid decreased matrix metalloproteinases (MMP)-2, MMP-9, nuclear factor (NF)-kappaB and phosphorylated-p38 protein expression, and increased tissue inhibitors of matrix metalloproteases-1 (TIMP-1) protein expression in arthritic mice. gambogic acid 0-13 matrix metallopeptidase 2 Mus musculus 24-57 29467575-10 2018 In addition, caudal vein injecting of Cs-g-PLLD-FA/siAEG-1 complexes inhibited tumor growth and lung metastasis in tumor-bearing mice by silencing AEG-1 and regulating MMP-2/9. Cesium 38-40 matrix metallopeptidase 2 Mus musculus 168-175 29428733-0 2018 Mice overexpressing latent matrix metalloproteinase-2 develop lung emphysema after short-term exposure to cigarette smoke extract. cigarette smoke 106-121 matrix metallopeptidase 2 Mus musculus 27-53 29438386-8 2018 Furthermore, DOX-administration resulted in brains of the mice in reduced expression of matrix metalloproteinase 2 (MMP2) and granzyme B, which are both factors associated with ECM pathology. Doxycycline 13-16 matrix metallopeptidase 2 Mus musculus 88-114 29438386-8 2018 Furthermore, DOX-administration resulted in brains of the mice in reduced expression of matrix metalloproteinase 2 (MMP2) and granzyme B, which are both factors associated with ECM pathology. Doxycycline 13-16 matrix metallopeptidase 2 Mus musculus 116-120 29805736-5 2018 Furthermore, bufalin inhibited ASCL2 expression and down-regulated the expression of invasion-related genes such as MMP2, MMP9, and vimentin, thereby suppressing epithelial-mesenchymal transition (EMT) in gastric cancer. bufalin 13-20 matrix metallopeptidase 2 Mus musculus 116-120 29459827-6 2018 Invasion and migration of CRC cells were inhibited and expressions of matrix metalloproteinase (MMP)-2 and MMP-9 were decreased by RA treatment. rosmarinic acid 131-133 matrix metallopeptidase 2 Mus musculus 70-102 29459827-8 2018 In particular, the effects of RA on EMT and MMPs expressions were due to the activation of AMPK. rosmarinic acid 30-32 matrix metallopeptidase 2 Mus musculus 44-48 29225190-0 2018 Scopolamine-induced passive avoidance memory retrieval deficit is accompanied with hippocampal MMP2, MMP-9 and MAPKs alteration. Scopolamine 0-11 matrix metallopeptidase 2 Mus musculus 95-99 29225190-11 2018 This scopolamine treatment resulted in hippocampal MMP-2 and MMP-9 decline while increased MAPKs in the hippocampus. Scopolamine 5-16 matrix metallopeptidase 2 Mus musculus 51-56 29113793-2 2018 AuNPs are co-functionalized with doxorubicin (DOX) and an azide-terminated polymer (DOX/N3@AuNPs), and the DOX/N3@AuNPs are associated into DOX@AuNCs in the presence of an alkyne-terminated MMP-2 cleavable peptide (alkyne-peptide-alkyne; APA) by click chemistry. Doxorubicin 33-44 matrix metallopeptidase 2 Mus musculus 190-195 29113793-2 2018 AuNPs are co-functionalized with doxorubicin (DOX) and an azide-terminated polymer (DOX/N3@AuNPs), and the DOX/N3@AuNPs are associated into DOX@AuNCs in the presence of an alkyne-terminated MMP-2 cleavable peptide (alkyne-peptide-alkyne; APA) by click chemistry. Azides 58-63 matrix metallopeptidase 2 Mus musculus 190-195 29113793-2 2018 AuNPs are co-functionalized with doxorubicin (DOX) and an azide-terminated polymer (DOX/N3@AuNPs), and the DOX/N3@AuNPs are associated into DOX@AuNCs in the presence of an alkyne-terminated MMP-2 cleavable peptide (alkyne-peptide-alkyne; APA) by click chemistry. Doxorubicin 84-87 matrix metallopeptidase 2 Mus musculus 190-195 29113793-2 2018 AuNPs are co-functionalized with doxorubicin (DOX) and an azide-terminated polymer (DOX/N3@AuNPs), and the DOX/N3@AuNPs are associated into DOX@AuNCs in the presence of an alkyne-terminated MMP-2 cleavable peptide (alkyne-peptide-alkyne; APA) by click chemistry. Doxorubicin 84-87 matrix metallopeptidase 2 Mus musculus 190-195 29081070-4 2018 In the present study, we demonstrated that paeoniflorin could alleviate postoperative pain via specific inhibition of matrix metalloproteinases (MMPs). peoniflorin 43-55 matrix metallopeptidase 2 Mus musculus 145-149 29081070-10 2018 Interestingly, the administration of paeoniflorin blocked the maturation of interleukin-1beta, which is a critical substrate of MMPs. peoniflorin 37-49 matrix metallopeptidase 2 Mus musculus 128-132 29336370-0 2018 Differences of Matrix Metalloproteinase 2 Expression between Left and Right Ventricles in Response to Nandrolone Decanoate and/or Swimming Training in Mice. Nandrolone Decanoate 102-122 matrix metallopeptidase 2 Mus musculus 15-41 29336370-2 2018 We investigated the differences of MMP-2 expression between LV and RV in response to nandrolone decanoate (ND), swimming training (ST), and combined ND and ST (NS) in mice, based on their structural, functional, and biochemical characteristics. Nandrolone Decanoate 85-105 matrix metallopeptidase 2 Mus musculus 35-40 29113793-3 2018 MMP-2-dependent dissociation shows that DOX@AuNCs are highly sensitive to the MMP-2 and are almost completed digested into single nanoparticles. Doxorubicin 40-43 matrix metallopeptidase 2 Mus musculus 0-5 29113793-3 2018 MMP-2-dependent dissociation shows that DOX@AuNCs are highly sensitive to the MMP-2 and are almost completed digested into single nanoparticles. Doxorubicin 40-43 matrix metallopeptidase 2 Mus musculus 78-83 29607740-0 2018 Effects of nano-encapsulated curcumin-chrysin on telomerase, MMPs and TIMPs gene expression in mouse B16F10 melanoma tumour model. Curcumin 29-37 matrix metallopeptidase 2 Mus musculus 61-65 29794468-12 2018 Moreover, the protein expression of MMP-2 and MMP-9 was significantly downregulated in CCA cells treated with allicin compared with CCA cells treated with control. allicin 110-117 matrix metallopeptidase 2 Mus musculus 36-41 30110702-9 2018 Bakuchiol significantly decreased bone lacunae area and attenuated MMP-2 activity induced by M-CSF plus RANKL in osteoclasts. bakuchiol 0-9 matrix metallopeptidase 2 Mus musculus 67-72 30043652-4 2018 Action mechanism studies manifested that DQA modified paclitaxel plus honokiol micelles could activate apoptotic enzymes caspase-3 and caspase-9 as well as down-regulate FAK, PI3K, MMP-2 and MMP-9. Paclitaxel 54-64 matrix metallopeptidase 2 Mus musculus 181-186 30043652-4 2018 Action mechanism studies manifested that DQA modified paclitaxel plus honokiol micelles could activate apoptotic enzymes caspase-3 and caspase-9 as well as down-regulate FAK, PI3K, MMP-2 and MMP-9. honokiol 70-78 matrix metallopeptidase 2 Mus musculus 181-186 29346804-11 2018 Parallel experiments in 3D-HTM showed that trabodenoson treatment significantly increased MMP-2 activity and MMP-14 abundance, while decreasing fibronectin and collagen IV expression. trabodenoson 43-55 matrix metallopeptidase 2 Mus musculus 90-95 29190077-2 2017 In this report, a peptide microarray-based fluorescence assay is developed for MMPs inhibitors evaluation through immobilization of biotin-modified peptides on the poly(glycidyl methacrylate-co-2-hydroxyethyl methacrylate) (P(GMA-HEMA)) brush-modified glass slides. Biotin 132-138 matrix metallopeptidase 2 Mus musculus 79-83 29862488-12 2018 The expression levels of MMP-2, MMP-9, and extracellular matrix metalloproteinase inducer (EMMPRIN) were significantly decreased by EGCG treatment. epigallocatechin gallate 132-136 matrix metallopeptidase 2 Mus musculus 25-30 29190077-2 2017 In this report, a peptide microarray-based fluorescence assay is developed for MMPs inhibitors evaluation through immobilization of biotin-modified peptides on the poly(glycidyl methacrylate-co-2-hydroxyethyl methacrylate) (P(GMA-HEMA)) brush-modified glass slides. poly(glycidyl methacrylate-co-2-hydroxyethyl methacrylate) 164-222 matrix metallopeptidase 2 Mus musculus 79-83 29190077-2 2017 In this report, a peptide microarray-based fluorescence assay is developed for MMPs inhibitors evaluation through immobilization of biotin-modified peptides on the poly(glycidyl methacrylate-co-2-hydroxyethyl methacrylate) (P(GMA-HEMA)) brush-modified glass slides. p(gma-hema) 224-235 matrix metallopeptidase 2 Mus musculus 79-83 29259201-7 2017 Finally, local transdermal application of Magnolol attenuated pressure-mediated development of varicose/spider veins in mice and was accompanied by the absence of proliferating and MMP-2 positive endothelial cells. magnolol 42-50 matrix metallopeptidase 2 Mus musculus 181-186 27923905-10 2017 In addition, a low concentration of beta-lapachone decreased the cell migration and invasion by decreasing the expression of matrix metalloproteinases-2 and -9, and increased the expression of tissue inhibitors of metalloproteinases-1 and -2. beta-lapachone 36-50 matrix metallopeptidase 2 Mus musculus 125-159 28978552-11 2017 Intraperitoneal injections of 3-HAA into Apoe-/- and Apoe-/-/IDO-/- mice for 6 weeks increased the expression and activity of matrix metallopeptidase 2 in aortas without affecting metabolic parameters. 3-Hydroxyanthranilic Acid 30-35 matrix metallopeptidase 2 Mus musculus 126-151 28822963-8 2017 Cell injury markers were reduced with A61603 treatment (serum cardiac troponin I, RV fibrosis, and expression of matrix metalloproteinase-2). A 61603 38-44 matrix metallopeptidase 2 Mus musculus 113-139 28923399-9 2017 Additionally, Dex also down-regulated the expression of tissue inhibitors of matrix metalloproteinase-2. Dexamethasone 14-17 matrix metallopeptidase 2 Mus musculus 77-103 29190653-3 2017 Inhibitory potencies of several halogenated analogues of MMP subtype-selective inhibitors (N-benzenesulfonyliminodiacetyl monohydroxamates and N-halophenoxy-benzenesulfonyl iminodiacetyl monohydroxamates) were in the nanomolar range for MMP2/9. n-benzenesulfonyliminodiacetyl monohydroxamates 91-138 matrix metallopeptidase 2 Mus musculus 237-243 28956695-9 2017 NS-398 treatment largely prevented the stimulation of cancer cell invasion, which was associated with a reduction in interstitial volume in the irradiated thighs and a complete suppression of MMP-2 stimulation. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 0-6 matrix metallopeptidase 2 Mus musculus 192-197 29214311-15 2017 The therapeutic mechanisms of fingolimod may be associated with inhibitory roles of "cytokines-MMPs/MAPKs" cycle in NOD mouse ocular surface tissues by mediating S1PRs in infiltrating leukocytes. Fingolimod Hydrochloride 30-40 matrix metallopeptidase 2 Mus musculus 95-99 29190653-3 2017 Inhibitory potencies of several halogenated analogues of MMP subtype-selective inhibitors (N-benzenesulfonyliminodiacetyl monohydroxamates and N-halophenoxy-benzenesulfonyl iminodiacetyl monohydroxamates) were in the nanomolar range for MMP2/9. n-halophenoxy-benzenesulfonyl iminodiacetyl monohydroxamates 143-203 matrix metallopeptidase 2 Mus musculus 237-243 28830677-3 2017 Our findings showed that exposure to Cd (2 muM) for 48 h or subcutaneous injection of Cd daily for 6 weeks significantly enhanced the expression of matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-2 (MMP-2), phosphorylated focal adhesion kinase (p-FAK), and HMGA2 in A549 cells or lung tissues of mice. Cadmium 37-39 matrix metallopeptidase 2 Mus musculus 184-210 28858730-8 2017 CONCLUSION: Sophoridine had anti-cance effects to suppress HepG2 activities by regulation PTEN/PI3K/AKT, Caspase-3/-9 and MMP-2/-9 signaling pathway. matrine 12-23 matrix metallopeptidase 2 Mus musculus 122-127 28775096-7 2017 Importantly, in vivo findings demonstrated that IL-13 augments matrix metalloproteinase (MMP)-2 and MMP9 activity that has also been shown to increase migration and invasiveness of fibroblasts in the lungs during bleomycin-induced pulmonary fibrosis. Bleomycin 213-222 matrix metallopeptidase 2 Mus musculus 63-95 28830677-3 2017 Our findings showed that exposure to Cd (2 muM) for 48 h or subcutaneous injection of Cd daily for 6 weeks significantly enhanced the expression of matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-2 (MMP-2), phosphorylated focal adhesion kinase (p-FAK), and HMGA2 in A549 cells or lung tissues of mice. Cadmium 37-39 matrix metallopeptidase 2 Mus musculus 212-217 28830677-3 2017 Our findings showed that exposure to Cd (2 muM) for 48 h or subcutaneous injection of Cd daily for 6 weeks significantly enhanced the expression of matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-2 (MMP-2), phosphorylated focal adhesion kinase (p-FAK), and HMGA2 in A549 cells or lung tissues of mice. Cadmium 86-88 matrix metallopeptidase 2 Mus musculus 184-210 28830677-3 2017 Our findings showed that exposure to Cd (2 muM) for 48 h or subcutaneous injection of Cd daily for 6 weeks significantly enhanced the expression of matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-2 (MMP-2), phosphorylated focal adhesion kinase (p-FAK), and HMGA2 in A549 cells or lung tissues of mice. Cadmium 86-88 matrix metallopeptidase 2 Mus musculus 212-217 29066893-5 2017 Action mechanism studies showed that multifunctional targeting epirubicin liposomes could downregulate PI3K, MMP-2, MMP-9, VE-Cadherin, and FAK and activate apoptotic enzyme caspase 3. Epirubicin 63-73 matrix metallopeptidase 2 Mus musculus 109-114 29079564-8 2017 Targeting mitochondrial reactive oxygen species with MitoTEMPO attenuated features of atherosclerotic plaque vulnerability in middle-aged Apoe-/-/Sod2+/- mice by lowering expression of calpain-2, caspase-3, and matrix metalloproteinase-2 and decreasing smooth muscle cell apoptosis and matrix degradation. Reactive Oxygen Species 24-47 matrix metallopeptidase 2 Mus musculus 211-237 29079564-8 2017 Targeting mitochondrial reactive oxygen species with MitoTEMPO attenuated features of atherosclerotic plaque vulnerability in middle-aged Apoe-/-/Sod2+/- mice by lowering expression of calpain-2, caspase-3, and matrix metalloproteinase-2 and decreasing smooth muscle cell apoptosis and matrix degradation. MitoTEMPO 53-62 matrix metallopeptidase 2 Mus musculus 211-237 28960955-1 2017 To improve tumor targetability and drug efficacy and decrease drug resistance of dasatinib (DSB), the multifunctional micellar nanoparticles that combined the matrix metalloproteinase 2 (MMP2)-sensitive tumor (site) targeting with folate receptor-mediated tumor (cell) targeting were developed. Dasatinib 92-95 matrix metallopeptidase 2 Mus musculus 187-191 28960955-2 2017 Two major functional polymers, polyethylene glycol (5000 Da)-MMP2-sensitive peptide-phosphoethanolamine (PEG5k-pp-PE) and folic acid-polyethylene glycol (2000 Da)-phosphoethanolamine (FA-PEG2k-PE), were synthesized to construct the dual-targeted micellar nanoparticles (MMP/FR micelles). Polymers 21-29 matrix metallopeptidase 2 Mus musculus 61-65 28960955-2 2017 Two major functional polymers, polyethylene glycol (5000 Da)-MMP2-sensitive peptide-phosphoethanolamine (PEG5k-pp-PE) and folic acid-polyethylene glycol (2000 Da)-phosphoethanolamine (FA-PEG2k-PE), were synthesized to construct the dual-targeted micellar nanoparticles (MMP/FR micelles). Polymers 21-29 matrix metallopeptidase 2 Mus musculus 61-64 28960955-2 2017 Two major functional polymers, polyethylene glycol (5000 Da)-MMP2-sensitive peptide-phosphoethanolamine (PEG5k-pp-PE) and folic acid-polyethylene glycol (2000 Da)-phosphoethanolamine (FA-PEG2k-PE), were synthesized to construct the dual-targeted micellar nanoparticles (MMP/FR micelles). Polyethylene Glycols 31-50 matrix metallopeptidase 2 Mus musculus 61-65 28960955-2 2017 Two major functional polymers, polyethylene glycol (5000 Da)-MMP2-sensitive peptide-phosphoethanolamine (PEG5k-pp-PE) and folic acid-polyethylene glycol (2000 Da)-phosphoethanolamine (FA-PEG2k-PE), were synthesized to construct the dual-targeted micellar nanoparticles (MMP/FR micelles). Polyethylene Glycols 31-50 matrix metallopeptidase 2 Mus musculus 61-64 28960955-2 2017 Two major functional polymers, polyethylene glycol (5000 Da)-MMP2-sensitive peptide-phosphoethanolamine (PEG5k-pp-PE) and folic acid-polyethylene glycol (2000 Da)-phosphoethanolamine (FA-PEG2k-PE), were synthesized to construct the dual-targeted micellar nanoparticles (MMP/FR micelles). peptide-phosphoethanolamine 76-103 matrix metallopeptidase 2 Mus musculus 61-65 28960955-2 2017 Two major functional polymers, polyethylene glycol (5000 Da)-MMP2-sensitive peptide-phosphoethanolamine (PEG5k-pp-PE) and folic acid-polyethylene glycol (2000 Da)-phosphoethanolamine (FA-PEG2k-PE), were synthesized to construct the dual-targeted micellar nanoparticles (MMP/FR micelles). peptide-phosphoethanolamine 76-103 matrix metallopeptidase 2 Mus musculus 61-64 28960955-2 2017 Two major functional polymers, polyethylene glycol (5000 Da)-MMP2-sensitive peptide-phosphoethanolamine (PEG5k-pp-PE) and folic acid-polyethylene glycol (2000 Da)-phosphoethanolamine (FA-PEG2k-PE), were synthesized to construct the dual-targeted micellar nanoparticles (MMP/FR micelles). peg5k-pp-pe 105-116 matrix metallopeptidase 2 Mus musculus 61-65 28960955-2 2017 Two major functional polymers, polyethylene glycol (5000 Da)-MMP2-sensitive peptide-phosphoethanolamine (PEG5k-pp-PE) and folic acid-polyethylene glycol (2000 Da)-phosphoethanolamine (FA-PEG2k-PE), were synthesized to construct the dual-targeted micellar nanoparticles (MMP/FR micelles). phosphorylethanolamine 84-103 matrix metallopeptidase 2 Mus musculus 61-65 28960955-2 2017 Two major functional polymers, polyethylene glycol (5000 Da)-MMP2-sensitive peptide-phosphoethanolamine (PEG5k-pp-PE) and folic acid-polyethylene glycol (2000 Da)-phosphoethanolamine (FA-PEG2k-PE), were synthesized to construct the dual-targeted micellar nanoparticles (MMP/FR micelles). phosphorylethanolamine 84-103 matrix metallopeptidase 2 Mus musculus 61-64 28994699-8 2017 Fisetin exerted photoprotective activity by inhibiting the expression of MMP-1, MMP-2, and cyclooxygenase-2 and increasing the expression of nuclear factor erythroid 2-related factor. fisetin 0-7 matrix metallopeptidase 2 Mus musculus 80-85 28734203-8 2017 Exenatide reduced aortic matrix metalloproteinase-9 (MMP-9) and MMP-2 gene expression and activities. Exenatide 0-9 matrix metallopeptidase 2 Mus musculus 64-69 29267793-10 2017 Thus, this study showed that 6-Gingerol might act as a hair growth suppressive drug via induction of MMP2 and MMP9 expression, which could interfere with the hair cycle. gingerol 29-39 matrix metallopeptidase 2 Mus musculus 101-105 28615299-3 2017 Ormeloxifene treatment inhibited epithelial-to-mesenchymal transition (EMT) process as evident by repression of N-cadherin, Slug, Snail, vimentin, MMPs (MMP2 and MMP3), beta-catenin/TCF-4 transcriptional activity, and induced the expression of pGSK3beta. ormeloxifene 0-12 matrix metallopeptidase 2 Mus musculus 147-151 28615299-3 2017 Ormeloxifene treatment inhibited epithelial-to-mesenchymal transition (EMT) process as evident by repression of N-cadherin, Slug, Snail, vimentin, MMPs (MMP2 and MMP3), beta-catenin/TCF-4 transcriptional activity, and induced the expression of pGSK3beta. ormeloxifene 0-12 matrix metallopeptidase 2 Mus musculus 153-157 29267793-0 2017 6-Gingerol inhibits hair cycle via induction of MMP2 and MMP9 expression. gingerol 0-10 matrix metallopeptidase 2 Mus musculus 48-52 29267793-7 2017 Moreover, 6-Gingerol (1 mg/mL) significantly reduced hair re-growth ratio, hair follicle number, and hair follicle length, which were associated with increased expression of MMP2 and MMP9. gingerol 10-20 matrix metallopeptidase 2 Mus musculus 174-178 28945330-6 2017 Taken together, nano-TiO2 -induced pulmonary inflammation and fibrosis are closely associated with increased expression of inflammatory and/or fibrotic cytokines, an imbalanced production of MMPs and TIMP-1 that favors fibrosis in mice, implying that nano-TiO2 may lead to potential health effects. titanium dioxide 21-25 matrix metallopeptidase 2 Mus musculus 191-195 28444820-5 2017 Western blotting was used to examine the protein expression of B16F10 cells after exposed to casticin and the results showed that casticin decreased the expressions of MMP-9, MMP-2, MMP-1, FAK, 14-3-3, GRB2, Akt, NF-kappaB p65, SOS-1, p-EGFR, p-JNK 1/2, uPA, and Rho A in B16F10 cells. casticin 130-138 matrix metallopeptidase 2 Mus musculus 175-180 28839206-6 2017 In in vitro experiments, GSP dose-dependently inhibited mRNA expression of interleukin (IL)-1beta, IL-6 and monocyte chemoattractant protein-1 (MCP-1), and significantly inhibited expression and activity of MMP-2 and MMP-9, thus prevented elastin from degradation. gamma-Thio-GTP 25-28 matrix metallopeptidase 2 Mus musculus 207-212 28644965-0 2017 3, 4-dihydroxybenzalacetone attenuates lipopolysaccharide-induced inflammation in acute lung injury via down-regulation of MMP-2 and MMP-9 activities through suppressing ROS-mediated MAPK and PI3K/AKT signaling pathways. 3,4-dihydroxybenzalacetone 0-27 matrix metallopeptidase 2 Mus musculus 123-128 28903498-7 2017 In vitro BPA and BPS addition increased matrix metalloproteinase-9 (MMP) protein and secreted activity in RAW264.7 macrophage cells suggesting that invivo increases in MMP2 and MMP9 in exposed infarcts were myeloid-derived. bisphenol A 9-12 matrix metallopeptidase 2 Mus musculus 168-172 28903498-7 2017 In vitro BPA and BPS addition increased matrix metalloproteinase-9 (MMP) protein and secreted activity in RAW264.7 macrophage cells suggesting that invivo increases in MMP2 and MMP9 in exposed infarcts were myeloid-derived. bis(4-hydroxyphenyl)sulfone 17-20 matrix metallopeptidase 2 Mus musculus 168-172 28644965-4 2017 In addition, DBL markedly reduced the total cell number, the leukocytes, the protein concentrations, and decreased the release of nitrite, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and the activities of matrix metalloproteinase (MMP)-2 and -9 in the bronchoalveolar lavage fluid. disialyllactose 13-16 matrix metallopeptidase 2 Mus musculus 225-264 28660304-9 2017 In WT, zaprinast and the combination of zaprinast and serelaxin significantly reduced renal interstitial fibrosis assessed by alpha-SMA, fibronectin, collagen1A1, and gelatinases (MMP2 and MMP9). zaprinast 7-16 matrix metallopeptidase 2 Mus musculus 180-184 28660304-9 2017 In WT, zaprinast and the combination of zaprinast and serelaxin significantly reduced renal interstitial fibrosis assessed by alpha-SMA, fibronectin, collagen1A1, and gelatinases (MMP2 and MMP9). zaprinast 40-49 matrix metallopeptidase 2 Mus musculus 180-184 28660304-9 2017 In WT, zaprinast and the combination of zaprinast and serelaxin significantly reduced renal interstitial fibrosis assessed by alpha-SMA, fibronectin, collagen1A1, and gelatinases (MMP2 and MMP9). serelaxin protein, human 54-63 matrix metallopeptidase 2 Mus musculus 180-184 28583810-7 2017 Action mechanism studies indicated that Lf modified daunorubicin plus honokiol liposomes could activate apoptotic enzymes caspase 3 as well as down-regulate VM protein indicators (PI3K, MMP-2, MMP-9, VE-Cadherin and FAK). Daunorubicin 52-64 matrix metallopeptidase 2 Mus musculus 186-191 28583810-7 2017 Action mechanism studies indicated that Lf modified daunorubicin plus honokiol liposomes could activate apoptotic enzymes caspase 3 as well as down-regulate VM protein indicators (PI3K, MMP-2, MMP-9, VE-Cadherin and FAK). honokiol 70-78 matrix metallopeptidase 2 Mus musculus 186-191 28661654-4 2017 P1 was further self-assembled into micellar nanoparticles (NPs) to load PTX, which show MMP-2-triggered dePEGylation due to cleavage of the peptide linkage. Paclitaxel 72-75 matrix metallopeptidase 2 Mus musculus 88-93 28646121-13 2017 Finally, adipocytes treated with TNF-alpha showed enhanced MMP-2, MMP-3, and cathepsin D, which was prevented by telmisartan. Telmisartan 113-124 matrix metallopeptidase 2 Mus musculus 59-64 28559142-0 2017 AG1296 enhances plaque stability via inhibiting inflammatory responses and decreasing MMP-2 and MMP-9 expression in ApoE-/- mice. 6,7-dimethoxy-3-phenylquinoxaline 0-6 matrix metallopeptidase 2 Mus musculus 86-91 28777298-5 2017 Short-term luseogliflozin treatment normalized the expression of inflammation-related genes such as F4/80, TNFalpha, IL-1beta, IL-6, ICAM-1, PECAM-1, MMP2 and MMP9 in the NA/STZ-treated ApoE KO mice, which showed marked elevations as compared with untreated ApoE KO mice. 1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol 11-25 matrix metallopeptidase 2 Mus musculus 150-154 28751740-8 2017 We speculate that DMDD inhibits cytokine production in the tumor cells in mice, which leads to deactivation of NF-kappaB pathway, and consequently inhibits the expression of many anti-apoptosis and metastasis-promoting genes, such as Bcl-2 and MMPs. 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione 18-22 matrix metallopeptidase 2 Mus musculus 244-248 28320710-6 2017 Using the stasis model of venous thrombosis and resolution in mice, we found that genetic deficiency of p53 or pharmacologic inhibition by pifithrin impairs thrombus resolution and is associated with increased fibrosis and altered expression of matrix metalloproteinase-2. pifithrin 139-148 matrix metallopeptidase 2 Mus musculus 245-271 28521243-8 2017 In addition, ASMCs exposed to PDGF acquired an enhanced migratory ability, and the activities of MMP9 and matrix metalloproteinase 2 (MMP2) and expression of MMP9 of these cells were significantly up-regulated. asmcs 13-18 matrix metallopeptidase 2 Mus musculus 106-132 28521243-8 2017 In addition, ASMCs exposed to PDGF acquired an enhanced migratory ability, and the activities of MMP9 and matrix metalloproteinase 2 (MMP2) and expression of MMP9 of these cells were significantly up-regulated. asmcs 13-18 matrix metallopeptidase 2 Mus musculus 134-138 29098831-7 2017 Compared with model group, HE staining in TFDM group showed obvious relief of aortic atherosclerotic tissue injury; each TFDM group showed inhibition in mRNA expressions of TGF-beta1, Smad2, Smad3, MMP-2 and MMP-9. Helium 27-29 matrix metallopeptidase 2 Mus musculus 198-203 28433630-6 2017 The activity of JNK and matrix metalloproteinase (MMP) -2 and -9 were increased in MURC-/- AAAs compared with WT AAAs at 5 days after CaCl2 treatment. Calcium Chloride 134-139 matrix metallopeptidase 2 Mus musculus 24-64 28342365-12 2017 MMP-2 and VEGF protein levels were found to be significantly lower in the P1, P2, and P3 groups as the propofol dosages increased (P<0.05), with no statistical significance in group Y (P>0.05). Propofol 103-111 matrix metallopeptidase 2 Mus musculus 0-5 28342365-13 2017 CONCLUSION: Within a certain range, propofol was found to inhibit tumor growth and expression of MMP-2 and VEGF proteins in hepatoma xenografts in BALB/C mice in a dose-dependent manner. Propofol 36-44 matrix metallopeptidase 2 Mus musculus 97-102 28550662-18 2017 Meanwhile, simvastatin reduces the invasion and motility of Lewis cell line through down-regulating the expression of RhoA and MMP-2. Simvastatin 11-22 matrix metallopeptidase 2 Mus musculus 127-132 28376402-7 2017 In addition, cell migration and invasion were significantly suppressed by metapristone through down-regulating the expression of MMP-2, MMP-9, N-cadherin and vimentin, whereas up-regulating E-cadherin expression. metapristone 74-86 matrix metallopeptidase 2 Mus musculus 129-134 28326455-11 2017 Levels of O2.- and NO also showed a significant fall in case of the group treated with MMP-2 inhibitor and TNFR1 antibody both. Oxygen 10-12 matrix metallopeptidase 2 Mus musculus 87-92 28316241-3 2017 To overcome these limitations, we developed a matrix metalloproteinase-2 sensitive surface-converting polyethylene glycol coating. Polyethylene Glycols 102-121 matrix metallopeptidase 2 Mus musculus 46-72 28316241-4 2017 This coating prevents nanoparticle-cell interaction in the bloodstream, but, once exposed to matrix metalloproteinase-2, i.e., when the nanoparticles accumulate within the tumor interstitium, the converting polyethylene glycol coating is cleaved, and targeting ligands become available for binding to tumor cells. Polyethylene Glycols 207-226 matrix metallopeptidase 2 Mus musculus 93-119 28394608-5 2017 A THPI selective for MMP-2 and MMP-9 was redesigned to incorporate non-native amino acids (Flp and mep), resulting in an increase of 18 C in thermal stability. THPI 2-6 matrix metallopeptidase 2 Mus musculus 21-26 28303501-4 2017 Here, we investigated the mechanism by which isoflurane postconditioning reduces tPA-induced MMP-2 and MMP-9 activation following hypoxia/reoxygenation (H/R) in brain endothelial cells. Isoflurane 45-55 matrix metallopeptidase 2 Mus musculus 93-98 28303501-6 2017 Cells were treated with isoflurane for 1 h of the reoxygenation condition and the effect of isoflurane postconditioning on MMP-2 and MMP-9 activation was assessed. Isoflurane 92-102 matrix metallopeptidase 2 Mus musculus 123-128 28303501-8 2017 Isoflurane postconditioning decreased tPA-induced MMP-2 and MMP-9 activation under H/R. Isoflurane 0-10 matrix metallopeptidase 2 Mus musculus 50-55 28303501-10 2017 Isoflurane postconditioning suppressed LRP expression, increased ERK-1/2 activation, and suppressed MMP-2 and MMP-9 activation, comparable to the effect of RAP. Isoflurane 0-10 matrix metallopeptidase 2 Mus musculus 100-105 28303501-11 2017 Activation of ERK-1/2, inhibition of NF-kappaB activation, and suppression of MMP-2 and MMP-9 activation by isoflurane postconditioning were abolished with PD98059 treatment. Isoflurane 108-118 matrix metallopeptidase 2 Mus musculus 78-83 28303501-11 2017 Activation of ERK-1/2, inhibition of NF-kappaB activation, and suppression of MMP-2 and MMP-9 activation by isoflurane postconditioning were abolished with PD98059 treatment. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 156-163 matrix metallopeptidase 2 Mus musculus 78-83 28303501-12 2017 These finding indicate that isoflurane postconditioning inhibits tPA-induced MMP-2 and MMP-9 activation following H/R via the LRP/ERK/NF-kappaB pathway in bEnd.3. Isoflurane 28-38 matrix metallopeptidase 2 Mus musculus 77-82 28881663-6 2017 In conclusion, these results indicated that BPA can enhance trophoblast migration and impair placentation in mice by a mechanism involving upregulation of integrin(s) and MMP(s) as well as the stimulation of MAPK and PI3K/Akt (protein kinase B) signaling pathways. bisphenol A 44-47 matrix metallopeptidase 2 Mus musculus 171-174 28131848-12 2017 Finally, DA administration effectively suppressed MMP-2 expression and tumor metastases in the oral carcinoma xenograft mouse model in vivo. dehydroandrographolide 9-11 matrix metallopeptidase 2 Mus musculus 50-55 28166590-3 2017 The aim of the present study was to evaluate the Chrysin loaded PGLA/PEG nanoparticle therapeutic effects on TIMP-1, TIMP-2, MMP-2, MMP-9 and PI3k expression in Mouse 4T1 breast tumor model.30 mice were enrolled in the current study, and the mice were randomly divided into 3 groups: untreated (n=10), Chrysin treatment (n=10) and Chrysin-loaded PLGA/PEG-based treatment (n=10). Polyethylene Glycols 69-72 matrix metallopeptidase 2 Mus musculus 125-130 27442082-8 2017 ApoEdp treatment inhibited the expression of extracellular matrix (ECM) degrading proteases heparanase and MMP-2, and restores the BRB tight junction proteins occludin and ZO-1. apoedp 0-6 matrix metallopeptidase 2 Mus musculus 107-112 28166590-8 2017 Also, the results showed that the MMP-9 and MMP-2 expressions were reduced after Chrysin loaded PLGA/PEG treatment. Polyethylene Glycols 101-104 matrix metallopeptidase 2 Mus musculus 44-49 28179583-7 2017 In VSMCs, pravastatin increased the levels of pAMPK, pAP-2alpha, and MMP2 in both basal and AngII-stressed conditions, which were abolished by tempol and compound C. Pravastatin-upregulated MMP2 was abrogated by AMPKalpha2 or AP-2alpha siRNA. Pravastatin 10-21 matrix metallopeptidase 2 Mus musculus 69-73 28069877-6 2017 Therefore, to overcome potential toxicities noted with previous broad-spectrum MMP inhibitors (MMPIs), we used highly selective bisphosphonic-based MMP-2 inhibitors (BMMPIs) that allowed for specific bone targeting. bisphosphonic 128-141 matrix metallopeptidase 2 Mus musculus 148-153 28270590-9 2017 Furthermore, both refametinib and doxycycline attenuated elastolytic cathepsin K, L, MMP-2, and MMP-9 activation, and abrogated macrophage and neutrophil infiltration in Emilin1-/- aortic valves. N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 18-29 matrix metallopeptidase 2 Mus musculus 85-90 28270590-9 2017 Furthermore, both refametinib and doxycycline attenuated elastolytic cathepsin K, L, MMP-2, and MMP-9 activation, and abrogated macrophage and neutrophil infiltration in Emilin1-/- aortic valves. Doxycycline 34-45 matrix metallopeptidase 2 Mus musculus 85-90 27530117-5 2017 Baicalein also reduced the activity and expression of matrix metalloproteinase (MMP)-2 and -9; however, the levels of tissue inhibitor of metalloproteinase-1 and -2 were concomitantly increased. baicalein 0-9 matrix metallopeptidase 2 Mus musculus 54-93 27530117-8 2017 Taken together, these results suggest that baicalein inhibits B16F10 melanoma cell migration and invasion by reducing the expression of MMPs and tightening TJ through the suppression of claudin expression, possibly in association with a suppression of the phosphoinositide 3-kinase/Akt signaling pathway. baicalein 43-52 matrix metallopeptidase 2 Mus musculus 136-140 27923483-10 2017 Treatment with PMA induced MT1-MMP-GFP internalization, enhanced phospho-Smad2, and reduced MMP-2 activation, whereas rottlerin pretreatment inhibited these effects. Tetradecanoylphorbol Acetate 15-18 matrix metallopeptidase 2 Mus musculus 92-97 28179581-3 2017 In smooth muscle cells, melatonin treatment decreases angiotensin II-induced matrix metalloproteinase 2 (MMP2) and MMP9 expression. Melatonin 24-33 matrix metallopeptidase 2 Mus musculus 77-103 28179581-3 2017 In smooth muscle cells, melatonin treatment decreases angiotensin II-induced matrix metalloproteinase 2 (MMP2) and MMP9 expression. Melatonin 24-33 matrix metallopeptidase 2 Mus musculus 105-109 28179581-6 2017 Moreover, melatonin suppresses angiotensin II-induced HuR expression through inhibiting NF-kappaB signaling, leading to decreased MMP2 and MMP9 levels. Melatonin 10-19 matrix metallopeptidase 2 Mus musculus 130-134 28179583-7 2017 In VSMCs, pravastatin increased the levels of pAMPK, pAP-2alpha, and MMP2 in both basal and AngII-stressed conditions, which were abolished by tempol and compound C. Pravastatin-upregulated MMP2 was abrogated by AMPKalpha2 or AP-2alpha siRNA. Pravastatin 10-21 matrix metallopeptidase 2 Mus musculus 190-194 28179583-7 2017 In VSMCs, pravastatin increased the levels of pAMPK, pAP-2alpha, and MMP2 in both basal and AngII-stressed conditions, which were abolished by tempol and compound C. Pravastatin-upregulated MMP2 was abrogated by AMPKalpha2 or AP-2alpha siRNA. vsmcs 3-8 matrix metallopeptidase 2 Mus musculus 69-73 28179583-7 2017 In VSMCs, pravastatin increased the levels of pAMPK, pAP-2alpha, and MMP2 in both basal and AngII-stressed conditions, which were abolished by tempol and compound C. Pravastatin-upregulated MMP2 was abrogated by AMPKalpha2 or AP-2alpha siRNA. Pravastatin 166-177 matrix metallopeptidase 2 Mus musculus 69-73 28179583-7 2017 In VSMCs, pravastatin increased the levels of pAMPK, pAP-2alpha, and MMP2 in both basal and AngII-stressed conditions, which were abolished by tempol and compound C. Pravastatin-upregulated MMP2 was abrogated by AMPKalpha2 or AP-2alpha siRNA. Pravastatin 166-177 matrix metallopeptidase 2 Mus musculus 190-194 27816554-6 2017 Abeta-induced MMP-2, cPLA2, and pcPLA2 expressions were almost completely attenuated by KHG26693 treatment, suggesting that Abeta-induced oxidative stress reduction by KHG26693 is, at least partly, caused by the downregulation of MMP-2 and cPLA2 activation. UNII-042A8N37WH 0-5 matrix metallopeptidase 2 Mus musculus 14-19 28205580-12 2017 In conclusion, 4HR-treated silk sutures exhibited anti-microbial properties and a similar level of bio-degradation to polyglactin 910 sutures and induced higher expression of MMP-2, -3, and -9 in macrophages. Hexylresorcinol 15-18 matrix metallopeptidase 2 Mus musculus 175-192 28178341-8 2017 With STZ-treated mice, renal cortical expression of both isoforms was increased (FL-MMP-2, 1.8-fold; NTT-MMP-2, greater than 7-fold). Streptozocin 5-8 matrix metallopeptidase 2 Mus musculus 105-110 27908891-9 2017 Moreover, PC-Tg serum also enhanced vascular smooth muscle cell oxidative stress resistance and further decreased the expression levels of matrix metalloproteinase-2 and matrix metalloproteinase-9, indicating that circulatory and vascular smooth muscle cell PC members suppress oxidative stress in a synergistic manner. pc-tg 10-15 matrix metallopeptidase 2 Mus musculus 139-196 27989599-6 2017 Lycopene improved hepatotoxicity acting as an antioxidant, reduced GSSG and regulated tGSH and CAT levels, reduced oxidative damage primarily by decreasing protein carbonylation, promoted the downregulation of MMP-2 and reduced areas of necrosis improving the general appearance of the lesion in C57BL/6 mice. Lycopene 0-8 matrix metallopeptidase 2 Mus musculus 210-215 27816554-6 2017 Abeta-induced MMP-2, cPLA2, and pcPLA2 expressions were almost completely attenuated by KHG26693 treatment, suggesting that Abeta-induced oxidative stress reduction by KHG26693 is, at least partly, caused by the downregulation of MMP-2 and cPLA2 activation. N-adamantyl-4-methylthiazol-2-amine 88-96 matrix metallopeptidase 2 Mus musculus 230-235 27816554-6 2017 Abeta-induced MMP-2, cPLA2, and pcPLA2 expressions were almost completely attenuated by KHG26693 treatment, suggesting that Abeta-induced oxidative stress reduction by KHG26693 is, at least partly, caused by the downregulation of MMP-2 and cPLA2 activation. UNII-042A8N37WH 0-5 matrix metallopeptidase 2 Mus musculus 230-235 27816554-6 2017 Abeta-induced MMP-2, cPLA2, and pcPLA2 expressions were almost completely attenuated by KHG26693 treatment, suggesting that Abeta-induced oxidative stress reduction by KHG26693 is, at least partly, caused by the downregulation of MMP-2 and cPLA2 activation. UNII-042A8N37WH 124-129 matrix metallopeptidase 2 Mus musculus 14-19 27816554-6 2017 Abeta-induced MMP-2, cPLA2, and pcPLA2 expressions were almost completely attenuated by KHG26693 treatment, suggesting that Abeta-induced oxidative stress reduction by KHG26693 is, at least partly, caused by the downregulation of MMP-2 and cPLA2 activation. UNII-042A8N37WH 124-129 matrix metallopeptidase 2 Mus musculus 230-235 27816554-6 2017 Abeta-induced MMP-2, cPLA2, and pcPLA2 expressions were almost completely attenuated by KHG26693 treatment, suggesting that Abeta-induced oxidative stress reduction by KHG26693 is, at least partly, caused by the downregulation of MMP-2 and cPLA2 activation. N-adamantyl-4-methylthiazol-2-amine 88-96 matrix metallopeptidase 2 Mus musculus 14-19 27816554-6 2017 Abeta-induced MMP-2, cPLA2, and pcPLA2 expressions were almost completely attenuated by KHG26693 treatment, suggesting that Abeta-induced oxidative stress reduction by KHG26693 is, at least partly, caused by the downregulation of MMP-2 and cPLA2 activation. N-adamantyl-4-methylthiazol-2-amine 168-176 matrix metallopeptidase 2 Mus musculus 14-19 27816554-6 2017 Abeta-induced MMP-2, cPLA2, and pcPLA2 expressions were almost completely attenuated by KHG26693 treatment, suggesting that Abeta-induced oxidative stress reduction by KHG26693 is, at least partly, caused by the downregulation of MMP-2 and cPLA2 activation. N-adamantyl-4-methylthiazol-2-amine 168-176 matrix metallopeptidase 2 Mus musculus 230-235 29348704-5 2017 Pretreatment with U0126 significantly suppressed phosphorylation of ERK1/2 and further attenuated nicotine-induced activation of c-Jun and upregulation of MMP-2, MMP-9, monocyte chemotactic protein- (MCP-) 1, and regulated upon activation normal T cell expressed and secreted (RANTES). U 0126 18-23 matrix metallopeptidase 2 Mus musculus 155-160 27915985-5 2017 There was an increase in BBB permeability in the hippocampus and striatum associated with an increase in the protein levels of MMP-2 in the cerebral cortex and striatum and MMP-9 in the hippocampus in adult Largemyd-/- mice. 1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)-6-HYDROXYPYRIMIDINE-2,4(1H,3H)-DIONE 25-28 matrix metallopeptidase 2 Mus musculus 127-132 26746866-9 2017 These findings support the premise that neuronal EP2 receptor activation by PGE2 protects brain against ICH injury in middle-aged mice through its anti-inflammatory and anti-oxidant effects and anti-MMP-2/9 activity. Dinoprostone 76-80 matrix metallopeptidase 2 Mus musculus 199-204 29348704-8 2017 Furthermore, nicotine-induced secretions of MMP-2, MMP-9, MCP-1, and RANTES were remarkably downregulated. Nicotine 13-21 matrix metallopeptidase 2 Mus musculus 44-49 29348704-5 2017 Pretreatment with U0126 significantly suppressed phosphorylation of ERK1/2 and further attenuated nicotine-induced activation of c-Jun and upregulation of MMP-2, MMP-9, monocyte chemotactic protein- (MCP-) 1, and regulated upon activation normal T cell expressed and secreted (RANTES). Nicotine 98-106 matrix metallopeptidase 2 Mus musculus 155-160 29348704-6 2017 Similarly, nicotine treatment also increased phosphorylation of c-Jun and expressions of MMP-2, MMP-9, MCP-1, and RANTES in MOVAS cells. Nicotine 11-19 matrix metallopeptidase 2 Mus musculus 89-94 26420756-5 2016 Gelatin zymography assay demonstrated that triptolide significantly inhibited the activities of matrix metalloproteinases-2 (MMP-2). triptolide 43-53 matrix metallopeptidase 2 Mus musculus 96-123 28262117-0 2016 Thymoquinone inhibits the migration of mouse neuroblastoma (Neuro-2a) cells by down-regulating MMP-2 and MMP-9. thymoquinone 0-12 matrix metallopeptidase 2 Mus musculus 95-100 26420756-5 2016 Gelatin zymography assay demonstrated that triptolide significantly inhibited the activities of matrix metalloproteinases-2 (MMP-2). triptolide 43-53 matrix metallopeptidase 2 Mus musculus 125-130 26420756-6 2016 Western blotting showed that triptolide markedly reduced CXCR4, SOS1, GRB2, p-ERK, FAK, p-AKT, Rho A, p-JNK, NF-kappaB, MMP-9, and MMP-2 but increased PI3K and p-p38 and COX2 after compared to the untreated (control) cells. triptolide 29-39 matrix metallopeptidase 2 Mus musculus 131-136 27768988-7 2016 Pyrogallol also inhibited the migration of Cav-1 wild type (WT) VSMC, however, by increasing TIMP-1 expression and repressing MMP-2 activity. Pyrogallol 0-10 matrix metallopeptidase 2 Mus musculus 126-131 26420756-7 2016 Real time PCR indicated that triptolide inhibited the gene expression of MMP-2, FAK, ROCK-1, and NF-kappaB but did not significantly affect TIMP-1 and -2 gene expression in B16F10 cells in vitro. triptolide 29-39 matrix metallopeptidase 2 Mus musculus 73-78 26420756-10 2016 Taken together, we suggest that triptolide inhibited B16F10 cell migration and invasion via the inhibition of NF-kappaB expression then led to suppress MMP-2 and -9 expressions. triptolide 32-42 matrix metallopeptidase 2 Mus musculus 152-164 27895584-9 2016 Mechanically, treatment with iPS cells obviously repressed the expression ratios of matrix metalloproteinase-2 (MMP-2) to its tissue inhibitor -2 (TIMP-2) and MMP-9/TIMP-1 in BLM-induced pulmonary tissues. IPS 29-32 matrix metallopeptidase 2 Mus musculus 84-110 27519148-12 2016 CS without E2 also resulted in an increase in matrix metalloproteinase-2 activity and apoptosis and a change in the ratio of estrogen receptor subtype. Cesium 0-2 matrix metallopeptidase 2 Mus musculus 46-72 27551907-3 2016 We synthesized the thiirane mechanism-based inhibitor ND-378 and document that it is a potent (nanomolar) and selective slow-binding inhibitor of MMP-2 that does not inhibit the closely related MMP-9 and MMP-14. ethylene sulfide 19-27 matrix metallopeptidase 2 Mus musculus 146-151 27551907-3 2016 We synthesized the thiirane mechanism-based inhibitor ND-378 and document that it is a potent (nanomolar) and selective slow-binding inhibitor of MMP-2 that does not inhibit the closely related MMP-9 and MMP-14. ND-378 54-60 matrix metallopeptidase 2 Mus musculus 146-151 27895584-9 2016 Mechanically, treatment with iPS cells obviously repressed the expression ratios of matrix metalloproteinase-2 (MMP-2) to its tissue inhibitor -2 (TIMP-2) and MMP-9/TIMP-1 in BLM-induced pulmonary tissues. IPS 29-32 matrix metallopeptidase 2 Mus musculus 112-117 28947953-5 2017 A transwell assay showed that DMGF could effectively attenuate the motility of B16F10 cells, and the results of real-time PCR revealed that DMGF also suppressed the expressions of matrix metalloproteinase-2 (MMP-2). 7,7''-dimethoxyagastisflavone 140-144 matrix metallopeptidase 2 Mus musculus 180-206 27605451-6 2016 In conjunction with these phenotypic changes, CFs accelerated ECM remodeling through upregulation of expression of the matrix metalloproteinase (MMP) 1 and MMP13 genes, two members of the collagenase subfamily, and enzyme activities of MMP2 and MMP9, two members of the gelatinase subfamily. thallium sulfate 46-49 matrix metallopeptidase 2 Mus musculus 236-240 27670594-9 2016 Mechanistically, VSMC-SIRT1-dependent deacetylation of histone H3 lysine 9 on the matrix metallopeptidase 2 (Mmp2) promoter was required for CR-mediated suppression of AngII-induced MMP2 expression. Lysine 66-72 matrix metallopeptidase 2 Mus musculus 82-107 27670594-9 2016 Mechanistically, VSMC-SIRT1-dependent deacetylation of histone H3 lysine 9 on the matrix metallopeptidase 2 (Mmp2) promoter was required for CR-mediated suppression of AngII-induced MMP2 expression. Lysine 66-72 matrix metallopeptidase 2 Mus musculus 109-113 27670594-9 2016 Mechanistically, VSMC-SIRT1-dependent deacetylation of histone H3 lysine 9 on the matrix metallopeptidase 2 (Mmp2) promoter was required for CR-mediated suppression of AngII-induced MMP2 expression. Chromium 141-143 matrix metallopeptidase 2 Mus musculus 82-107 27670594-9 2016 Mechanistically, VSMC-SIRT1-dependent deacetylation of histone H3 lysine 9 on the matrix metallopeptidase 2 (Mmp2) promoter was required for CR-mediated suppression of AngII-induced MMP2 expression. Chromium 141-143 matrix metallopeptidase 2 Mus musculus 109-113 27670594-9 2016 Mechanistically, VSMC-SIRT1-dependent deacetylation of histone H3 lysine 9 on the matrix metallopeptidase 2 (Mmp2) promoter was required for CR-mediated suppression of AngII-induced MMP2 expression. Chromium 141-143 matrix metallopeptidase 2 Mus musculus 182-186 27455162-0 2016 Novel 5-Hydroxy, 5-Substituted Benzenesulfonamide Pyrimidine-2,4,6-Triones Attenuate Lipopolysaccharide-Induced Acute Lung Injury via Inhibition of the Gelatinases, MMP-2 and MMP-9. 5-hydroxy, 5-substituted benzenesulfonamide pyrimidine-2,4,6-triones 6-74 matrix metallopeptidase 2 Mus musculus 165-170 27373424-11 2016 This was not paralleled by any change in alpha-SMA (myofibroblast burden) or TGF-beta1 signalling but was commensurate with DHT reducing MMP2 activity in both genotypes (p<0.05 vs genotype controls). Dihydrotestosterone 124-127 matrix metallopeptidase 2 Mus musculus 137-141 27546164-4 2016 Specifically, polymeric nanoparticles with a surface matrix metalloproteinase-2 (MMP2) peptide substrate were conjugated to the surface of porous silicon microparticles. Silicon 146-153 matrix metallopeptidase 2 Mus musculus 53-79 27546164-4 2016 Specifically, polymeric nanoparticles with a surface matrix metalloproteinase-2 (MMP2) peptide substrate were conjugated to the surface of porous silicon microparticles. Silicon 146-153 matrix metallopeptidase 2 Mus musculus 81-85 27694328-10 2016 Functional studies with mice deficient in other MMPs suggested an important role for the MMP system, as a whole, in modulation of cholesterol metabolism. Cholesterol 130-141 matrix metallopeptidase 2 Mus musculus 48-52 27575818-11 2016 RESULTS: Compared with the control group, collagen accumulation was markedly enhanced, and the content of type II collagen, kidney hydroxyproline and timp-2 were boosted in STZ group mice (P < 0.01), while the expressions of CX40,CX43, CX45, MMP-1 and MMP-2 were obviously deceased (P < 0.01). Streptozocin 173-176 matrix metallopeptidase 2 Mus musculus 255-260 28947953-5 2017 A transwell assay showed that DMGF could effectively attenuate the motility of B16F10 cells, and the results of real-time PCR revealed that DMGF also suppressed the expressions of matrix metalloproteinase-2 (MMP-2). 7,7''-dimethoxyagastisflavone 140-144 matrix metallopeptidase 2 Mus musculus 208-213 26853152-9 2016 Chlordecone also increased expression of the Col1A2, MMP-2, TIMP-1 and PAI-1 genes in CCl4-treated mice. Chlordecone 0-11 matrix metallopeptidase 2 Mus musculus 53-58 27453531-10 2016 Moreover, simvastatin improved restenosis indicators by suppressing the HIF-1alpha/calpains/MMP2/TGF-beta1 pathway. Simvastatin 10-21 matrix metallopeptidase 2 Mus musculus 92-96 27453531-11 2016 However, MMP2 supplementation eliminated the vascular protection of calpastatin induction and simvastatin. Simvastatin 94-105 matrix metallopeptidase 2 Mus musculus 9-13 27144994-8 2016 Furthermore, NTS markedly lowered the expression of MMP-2 and TIMP-1 while raised the expression of MMP-9. neotuberostemonine 13-16 matrix metallopeptidase 2 Mus musculus 52-57 27080594-6 2016 Furthermore, this study revealed that metalloproteinase-2 (MMP-2) was a FOXO1 downstream effector, which was also supported by data obtained from mouse model of ISO inhibition BBN-induced mouse-invasive bladder cancer formation. bbn 176-179 matrix metallopeptidase 2 Mus musculus 59-64 26565991-6 2016 The upregulated levels of eNOS/iNOS and upregulated levels of MMP2/MMP9 along with high collagen deposition indicated vascular and matrix remodeling in methionine fed mouse. Methionine 152-162 matrix metallopeptidase 2 Mus musculus 62-66 27222119-6 2016 In addition, daidzein strongly suppressed the gene expression of cyclooxygenase (COX)-2, matrix metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinase 1 (TIMP-1), transforming growth factor beta1 (TGF-beta1), and inhibited inducible nitric oxide synthase (iNOS) protein expression in angiotensin II-induced AAA mice. daidzein 13-21 matrix metallopeptidase 2 Mus musculus 89-115 27222119-6 2016 In addition, daidzein strongly suppressed the gene expression of cyclooxygenase (COX)-2, matrix metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinase 1 (TIMP-1), transforming growth factor beta1 (TGF-beta1), and inhibited inducible nitric oxide synthase (iNOS) protein expression in angiotensin II-induced AAA mice. daidzein 13-21 matrix metallopeptidase 2 Mus musculus 117-122 27038751-8 2016 Captopril was applied as a selective MMP-2/-9 inhibitor. Captopril 0-9 matrix metallopeptidase 2 Mus musculus 37-42 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. Proline 110-117 matrix metallopeptidase 2 Mus musculus 47-71 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. Proline 110-117 matrix metallopeptidase 2 Mus musculus 73-78 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. Valine 118-124 matrix metallopeptidase 2 Mus musculus 47-71 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. Valine 118-124 matrix metallopeptidase 2 Mus musculus 73-78 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. Glycine 125-132 matrix metallopeptidase 2 Mus musculus 47-71 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. Glycine 125-132 matrix metallopeptidase 2 Mus musculus 73-78 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. Leucine 133-140 matrix metallopeptidase 2 Mus musculus 47-71 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. Leucine 133-140 matrix metallopeptidase 2 Mus musculus 73-78 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. Isoleucine 141-151 matrix metallopeptidase 2 Mus musculus 47-71 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. Isoleucine 141-151 matrix metallopeptidase 2 Mus musculus 73-78 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. Glycine 152-159 matrix metallopeptidase 2 Mus musculus 47-71 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. Glycine 152-159 matrix metallopeptidase 2 Mus musculus 73-78 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. YLP(12) peptide 161-184 matrix metallopeptidase 2 Mus musculus 47-71 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. YLP(12) peptide 161-184 matrix metallopeptidase 2 Mus musculus 73-78 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. pvglig 186-192 matrix metallopeptidase 2 Mus musculus 47-71 32263314-3 2016 To this end, we prepared and characterized the matrix metalloprotease-2 (MMP-2)/MMP-9-sensitive linker of the proline-valine-glycine-leucine-isoleucine-glycine (Pro-Val-Gly-Leu-Ile-Gly, PVGLIG) oligopeptide via a convenient and fast liquid-phase synthesis. pvglig 186-192 matrix metallopeptidase 2 Mus musculus 73-78 27158396-6 2016 Gelatin zymography analysis of matrix metalloproteinase-2 (MMP-2) activity in conditioned medium collected from fibroblasts demonstrated that anthocyanins treatment significantly reduced MMP-2 activity. Anthocyanins 142-154 matrix metallopeptidase 2 Mus musculus 31-57 27080375-0 2016 The In Vitro and In Vivo Response to MMP-Sensitive Poly(Ethylene Glycol) Hydrogels. Polyethylene Glycols 51-72 matrix metallopeptidase 2 Mus musculus 37-40 26636416-0 2016 Immunolocalization of MMP 2, 9 and 13 in prednisolone induced osteoporosis in mice. Prednisolone 41-53 matrix metallopeptidase 2 Mus musculus 22-27 26636416-4 2016 The aim of this study was to investigate the spatial expression and the potential function of MMP 2, 9 and 13 in osteoporosis induced by prednisolone in the tibiae of mice. Prednisolone 137-149 matrix metallopeptidase 2 Mus musculus 94-99 26636416-7 2016 Compared with control group, the number of TRAP-positive osteoclasts and the immunoreactivity of MMP 2, 9 and 13 were significantly increased in the trabecular bone of mice administered with prednisolone, leading to the decrease of trabecular bone volume. Prednisolone 191-203 matrix metallopeptidase 2 Mus musculus 97-102 26636416-10 2016 Taken together, we concluded that prednisolone administration induced the increase of MMP 2, 9 and 13 expressions, while MMP 2 and MMP 13 played essential roles in the osteocytic osteolysis and the early impaired areas in the cortical bone. Prednisolone 34-46 matrix metallopeptidase 2 Mus musculus 86-91 26019015-7 2016 Additionally, we found that Hcy treatment increased protein and mRNA expression of intracellular adhesion molecule 1 (ICAM-1), matrix metalloproteinase (MMP)-2, and MMP-9 and also increased MMP-2 and MMP-9 activity in the brain. Homocysteine 28-31 matrix metallopeptidase 2 Mus musculus 127-159 26019015-7 2016 Additionally, we found that Hcy treatment increased protein and mRNA expression of intracellular adhesion molecule 1 (ICAM-1), matrix metalloproteinase (MMP)-2, and MMP-9 and also increased MMP-2 and MMP-9 activity in the brain. Homocysteine 28-31 matrix metallopeptidase 2 Mus musculus 190-195 26934979-10 2016 In conclusion, we offer evidence that microglia migration across the brain endothelial cell monolayer is increased in the presence of ATP in a manner that involves MMP secretion. Adenosine Triphosphate 134-137 matrix metallopeptidase 2 Mus musculus 164-167 27031716-4 2016 The activity of matrix metalloproteinase (MMP)-2 and -9 in tumor tissue was determined by zymography method in polyacrylamide gel. polyacrylamide 111-125 matrix metallopeptidase 2 Mus musculus 16-55 27031716-5 2016 RESULTS: Administration of L-Arg at high doses caused an inhibition of tumor growth by 48 +- 8.0%, increase of superoxide radical generation rate and NO levels to a value of 1.23 +- 0.14 and 2.26 +- 0.31 nm/g tissue min, and decreased activity of MMP-2 and -9 (3.55 +- 0.8 and 4.8 +- 1.0 r.u., respectively). Arginine 27-32 matrix metallopeptidase 2 Mus musculus 249-261 27031716-6 2016 Treatment with L-Arg at low doses stimulated tumor growth and increased the levels of MMP-2 and -9 activities (8.44 +- 2.7 and 9.8 +- 3.1 r.u., respectively). Arginine 15-20 matrix metallopeptidase 2 Mus musculus 86-98 27031716-11 2016 Upon combined use of L-Arg and SoQ10, superoxide radicals and NO form the redox state that causes decrease of MMP-2, -9 activities with consequent inhibition of tumor invasion and metastasis. Arginine 21-26 matrix metallopeptidase 2 Mus musculus 110-115 27031716-11 2016 Upon combined use of L-Arg and SoQ10, superoxide radicals and NO form the redox state that causes decrease of MMP-2, -9 activities with consequent inhibition of tumor invasion and metastasis. Superoxides 38-48 matrix metallopeptidase 2 Mus musculus 110-115 27171485-6 2016 Marked reduction in collagen-I, MMP2/9 and lung tumor weight were observed in DTXPL+telmisartan group. dtxpl 78-83 matrix metallopeptidase 2 Mus musculus 32-38 27171485-6 2016 Marked reduction in collagen-I, MMP2/9 and lung tumor weight were observed in DTXPL+telmisartan group. Telmisartan 84-95 matrix metallopeptidase 2 Mus musculus 32-38 27313765-8 2016 The present study provides evidence that the administration of indomethacin alone, or in combination with oxaliplatin, may significantly inhibit the growth of lung cancer-nude mouse transplanted tumors and the expression of CD44v6, MMP-2 and survivin inside the tumor. Indomethacin 63-75 matrix metallopeptidase 2 Mus musculus 232-237 27313765-8 2016 The present study provides evidence that the administration of indomethacin alone, or in combination with oxaliplatin, may significantly inhibit the growth of lung cancer-nude mouse transplanted tumors and the expression of CD44v6, MMP-2 and survivin inside the tumor. Oxaliplatin 106-117 matrix metallopeptidase 2 Mus musculus 232-237 26968952-8 2016 Notably, non- or sub-cytotoxic concentrations of CoQ0 markedly inhibited migration and invasion, accompanied by the down-regulation of MMP-2 and -9, and up-regulation of TIMP-1 and -2 expressions in highly metastatic B16F10 cells. ubiquinone-O 49-53 matrix metallopeptidase 2 Mus musculus 135-147 25784049-7 2016 These inhibitory effects of low-dose deguelin were mediated by suppressing TNF-alpha-induced activation of IkappaB kinase leading to the inhibition of IkappaB phosphorylation, NF-kappaB transcriptional activity, and matrix metalloproteinase-2 (MMP2) expression. deguelin 37-45 matrix metallopeptidase 2 Mus musculus 216-242 25784049-7 2016 These inhibitory effects of low-dose deguelin were mediated by suppressing TNF-alpha-induced activation of IkappaB kinase leading to the inhibition of IkappaB phosphorylation, NF-kappaB transcriptional activity, and matrix metalloproteinase-2 (MMP2) expression. deguelin 37-45 matrix metallopeptidase 2 Mus musculus 244-248 26213293-10 2016 Treatment with the potent anti-oxidant pyrrolidine dithiocarbamate (PDTC) significantly suppressed NTT-MMP-2, but not FL-MMP-2 expression and improved muscle viability following IRI. pyrrolidine dithiocarbamic acid 39-66 matrix metallopeptidase 2 Mus musculus 103-108 26213293-10 2016 Treatment with the potent anti-oxidant pyrrolidine dithiocarbamate (PDTC) significantly suppressed NTT-MMP-2, but not FL-MMP-2 expression and improved muscle viability following IRI. pyrrolidine dithiocarbamic acid 39-66 matrix metallopeptidase 2 Mus musculus 118-126 26213293-10 2016 Treatment with the potent anti-oxidant pyrrolidine dithiocarbamate (PDTC) significantly suppressed NTT-MMP-2, but not FL-MMP-2 expression and improved muscle viability following IRI. pyrrolidine dithiocarbamic acid 68-72 matrix metallopeptidase 2 Mus musculus 103-108 26213293-10 2016 Treatment with the potent anti-oxidant pyrrolidine dithiocarbamate (PDTC) significantly suppressed NTT-MMP-2, but not FL-MMP-2 expression and improved muscle viability following IRI. pyrrolidine dithiocarbamic acid 68-72 matrix metallopeptidase 2 Mus musculus 118-126 26882566-10 2016 We conclude that the novel small-molecule inhibitor AC-73 inhibits HCC mobility and invasion, probably by disrupting CD147 dimerization and thereby mainly suppressing the CD147/ERK1/2/STAT3/MMP-2 pathways, which are crucial for cancer progression. AC-73 52-57 matrix metallopeptidase 2 Mus musculus 190-195 26881424-9 2016 Pretreatment of bEND3 cells with C-PTIO (a NO scavenger) or U0126 (a specific ERK inhibitor) significantly reduced OGD-induced S-nitrosylation of Cav-1 in cells and blocked the secretion of Cav-1 and MMP2 and 9 into the media as well as the degradation of fibronectin and laminin beta-1 in OGD and tPA-treated cells. U 0126 60-65 matrix metallopeptidase 2 Mus musculus 200-210 27158396-6 2016 Gelatin zymography analysis of matrix metalloproteinase-2 (MMP-2) activity in conditioned medium collected from fibroblasts demonstrated that anthocyanins treatment significantly reduced MMP-2 activity. Anthocyanins 142-154 matrix metallopeptidase 2 Mus musculus 59-64 27158396-6 2016 Gelatin zymography analysis of matrix metalloproteinase-2 (MMP-2) activity in conditioned medium collected from fibroblasts demonstrated that anthocyanins treatment significantly reduced MMP-2 activity. Anthocyanins 142-154 matrix metallopeptidase 2 Mus musculus 187-192 26638778-2 2016 The model photosensitizer therapeutic agent chlorin e6 (Ce6) was first covalently conjugated with matrix metalloproteinase 2-cleavable polypeptide and then modified with polyethylene glycol via a redox-responsive cleavable disulfide linker. phytochlorin 44-54 matrix metallopeptidase 2 Mus musculus 98-124 26747401-10 2016 Treatment with BI113823 and dexamethasone also significantly reduced total protein content, IgE, TNF-alpha and IL-1beta in lavage fluid, reduced myeloperoxidase activity, mucus secretion in lung tissues, and reduced the expression of B1 receptors, matrix metalloproteinase (MMP)-2 and cyclooxygenase (COX)-2 compared to vehicle-treated mice. bi113823 15-23 matrix metallopeptidase 2 Mus musculus 248-280 26747401-10 2016 Treatment with BI113823 and dexamethasone also significantly reduced total protein content, IgE, TNF-alpha and IL-1beta in lavage fluid, reduced myeloperoxidase activity, mucus secretion in lung tissues, and reduced the expression of B1 receptors, matrix metalloproteinase (MMP)-2 and cyclooxygenase (COX)-2 compared to vehicle-treated mice. Dexamethasone 28-41 matrix metallopeptidase 2 Mus musculus 248-280 26841115-14 2016 Meanwhile, the expression of chondrocyte catabolic marker genes including Mmp2, Mmp9, Mmp13, Adamts4 and Adamts5 was downregulated following Icariin treatment for 14 days. icariin 141-148 matrix metallopeptidase 2 Mus musculus 74-78 26830149-5 2016 Moreover, nifuroxazide markedly impaired melanoma cell migration and invasion by down-regulating phosphorylated-Src, phosphorylated-FAK, and expression of matrix metalloproteinase (MMP) -2, MMP-9 and vimentin. nifuroxazide 10-22 matrix metallopeptidase 2 Mus musculus 155-188 26407680-8 2016 Moreover, lower levels of ERK1/2 phosphorylation and MMP-2 expression were observed in the NPC lung metastases of nude mice administered UCB. ucb 137-140 matrix metallopeptidase 2 Mus musculus 53-58 26638778-2 2016 The model photosensitizer therapeutic agent chlorin e6 (Ce6) was first covalently conjugated with matrix metalloproteinase 2-cleavable polypeptide and then modified with polyethylene glycol via a redox-responsive cleavable disulfide linker. phytochlorin 56-59 matrix metallopeptidase 2 Mus musculus 98-124 26638778-3 2016 The resultant matrix metalloproteinase 2-cleavable polypeptide modified PEGylated Ce6 (PEG-SS-Ce6-MMP2) nanoparticles, which formed via self-assembly, were observed to be monodisperse and significantly stable in aqueous solution. phytochlorin 82-85 matrix metallopeptidase 2 Mus musculus 14-40 26638778-3 2016 The resultant matrix metalloproteinase 2-cleavable polypeptide modified PEGylated Ce6 (PEG-SS-Ce6-MMP2) nanoparticles, which formed via self-assembly, were observed to be monodisperse and significantly stable in aqueous solution. phytochlorin 82-85 matrix metallopeptidase 2 Mus musculus 98-102 26638778-3 2016 The resultant matrix metalloproteinase 2-cleavable polypeptide modified PEGylated Ce6 (PEG-SS-Ce6-MMP2) nanoparticles, which formed via self-assembly, were observed to be monodisperse and significantly stable in aqueous solution. peg-ss-ce6 87-97 matrix metallopeptidase 2 Mus musculus 14-40 26638778-3 2016 The resultant matrix metalloproteinase 2-cleavable polypeptide modified PEGylated Ce6 (PEG-SS-Ce6-MMP2) nanoparticles, which formed via self-assembly, were observed to be monodisperse and significantly stable in aqueous solution. peg-ss-ce6 87-97 matrix metallopeptidase 2 Mus musculus 98-102 26638778-4 2016 In addition, owing to their cellular redox-responsiveness at the cleavable disulfide linker, the PEG-SS-Ce6-MMP2 nanoparticles were able to release Ce6 rapidly. Disulfides 75-84 matrix metallopeptidase 2 Mus musculus 108-112 26638778-4 2016 In addition, owing to their cellular redox-responsiveness at the cleavable disulfide linker, the PEG-SS-Ce6-MMP2 nanoparticles were able to release Ce6 rapidly. polyethylene glycol bis(succinimidyl succinate) 97-103 matrix metallopeptidase 2 Mus musculus 108-112 26638778-4 2016 In addition, owing to their cellular redox-responsiveness at the cleavable disulfide linker, the PEG-SS-Ce6-MMP2 nanoparticles were able to release Ce6 rapidly. phytochlorin 104-107 matrix metallopeptidase 2 Mus musculus 108-112 26638778-4 2016 In addition, owing to their cellular redox-responsiveness at the cleavable disulfide linker, the PEG-SS-Ce6-MMP2 nanoparticles were able to release Ce6 rapidly. phytochlorin 148-151 matrix metallopeptidase 2 Mus musculus 108-112 26638778-5 2016 Despite displaying enhanced intracellular internalization, the synthesized PEG-SS-Ce6-MMP2 nanoparticles did not compromise their phototoxic effects toward A549 cancer cells when compared with free Ce6 and PEGylated Ce6 nanoparticles. polyethylene glycol bis(succinimidyl succinate) 75-81 matrix metallopeptidase 2 Mus musculus 86-90 26638778-5 2016 Despite displaying enhanced intracellular internalization, the synthesized PEG-SS-Ce6-MMP2 nanoparticles did not compromise their phototoxic effects toward A549 cancer cells when compared with free Ce6 and PEGylated Ce6 nanoparticles. phytochlorin 82-85 matrix metallopeptidase 2 Mus musculus 86-90 26638778-6 2016 In vivo experiments further revealed that, in contrast with the free Ce6 or with the PEGylated Ce6 nanoparticles, the PEG-SS-Ce6-MMP2 nanoparticles showed a remarkable increase in tumor-targeting ability and a significantly improved photodynamic therapeutic efficiency in A549 tumor-bearing mice. phytochlorin 95-98 matrix metallopeptidase 2 Mus musculus 129-133 26638778-6 2016 In vivo experiments further revealed that, in contrast with the free Ce6 or with the PEGylated Ce6 nanoparticles, the PEG-SS-Ce6-MMP2 nanoparticles showed a remarkable increase in tumor-targeting ability and a significantly improved photodynamic therapeutic efficiency in A549 tumor-bearing mice. polyethylene glycol bis(succinimidyl succinate) 118-124 matrix metallopeptidase 2 Mus musculus 129-133 26406609-8 2016 In C57/BL6 mice, continuous N6-cyclopentyladenosine infusion (2 mg kg(-1) day(-1) ; 21 days) blunted phenylephrine (120 mg kg(-1) day(-1) ; 21 days) induced hypertrophy (heart weight, cardiomyocyte size and fetal genes), fibrosis, MMP 2 up-regulation and generation of oxidative stress - all hallmarks of maladaptive remodelling. N(6)-cyclopentyladenosine 28-51 matrix metallopeptidase 2 Mus musculus 233-238 26655082-11 2016 Interestingly, amounts of matrix metalloproteinase (MMP)2 and MMP9 in MCECs were augmented by NMDA. N-Methylaspartate 94-98 matrix metallopeptidase 2 Mus musculus 26-57 26576045-4 2016 Mechanism of cellular penetration into porous polymer networks was evident by a >=6 - fold increase in gene expression of MMP-13 and MMP-2 via activation of Akt and Erk. Polymers 46-53 matrix metallopeptidase 2 Mus musculus 136-141 26457379-5 2016 Twenty-four hours after intravenous injection of a nonpeptidic, Cy5.5-labeled MMP-selective tracer, tumor development was assessed in vivo by white light endoscopy and FE. CY5.5 cyanine dye 64-69 matrix metallopeptidase 2 Mus musculus 78-81 26849230-8 2016 Western blot assay was used to measure the impact of Myrtol on AKT and its downstream signaling pathway, including MMP-2 and MMP-9. myrtol 53-59 matrix metallopeptidase 2 Mus musculus 115-120 26457379-13 2016 FE allows direct visualization of a prognostic parameter (here MMP-2/-9) on a molecular level and may improve the characterization of colorectal lesions and the adenoma detection rate in the future. Iron 0-2 matrix metallopeptidase 2 Mus musculus 63-71 27688602-8 2016 In conclusion, SP600125 attenuates nicotine plus AngII-induced AAA formation likely by inhibiting MMP-2, MMP-9, MCP-1, and RANTES. pyrazolanthrone 15-23 matrix metallopeptidase 2 Mus musculus 98-103 27688602-8 2016 In conclusion, SP600125 attenuates nicotine plus AngII-induced AAA formation likely by inhibiting MMP-2, MMP-9, MCP-1, and RANTES. Nicotine 35-43 matrix metallopeptidase 2 Mus musculus 98-103 26862563-5 2016 Image analysis of the cellular penetration into PEG-PU polymer network and the mechanism via enzymatic activation of MMP-2 and MMP-13 are reported. polyethyleneglycol-polyurethane 48-62 matrix metallopeptidase 2 Mus musculus 117-122 26597054-4 2015 PRL-3 also enhanced matrix metalloproteinase-2 secretion and cellular invasiveness via activation of mTOR, attributes which were sensitive to rapamycin treatment. Sirolimus 142-151 matrix metallopeptidase 2 Mus musculus 20-46 26282096-4 2015 Furthermore, The PEG layer would detach from the NPs due to the up-regulated extracellular MMP2 and MMP9 in tumors, resulting in the exposure of folate to enhance the cellular internalization via folate receptor mediated endocytosis, which accelerated the release rate of CPT in vivo. Polyethylene Glycols 17-20 matrix metallopeptidase 2 Mus musculus 91-95 26597177-14 2015 Treatment of FLP in combination with celecoxib was more effective than FLP or celecoxib alone in inhibiting vascular endothelial growth factor, platelet-derived growth factor receptors beta, microsomal Prostaglandin E synthase-1, MMP-2, MMP-9, N-cadherin, and Vimentin expression, but increased E-cadherin expression. Celecoxib 37-46 matrix metallopeptidase 2 Mus musculus 230-235 26282096-4 2015 Furthermore, The PEG layer would detach from the NPs due to the up-regulated extracellular MMP2 and MMP9 in tumors, resulting in the exposure of folate to enhance the cellular internalization via folate receptor mediated endocytosis, which accelerated the release rate of CPT in vivo. Folic Acid 145-151 matrix metallopeptidase 2 Mus musculus 91-95 26282096-4 2015 Furthermore, The PEG layer would detach from the NPs due to the up-regulated extracellular MMP2 and MMP9 in tumors, resulting in the exposure of folate to enhance the cellular internalization via folate receptor mediated endocytosis, which accelerated the release rate of CPT in vivo. Camptothecin 272-275 matrix metallopeptidase 2 Mus musculus 91-95 26241578-1 2015 SB-3CT is a potent and selective inhibitor of matrix metalloproteinase (MMP)-2 and -9, which has shown efficacy in an animal model of severe traumatic brain injury (TBI). SB 3CT compound 0-6 matrix metallopeptidase 2 Mus musculus 46-85 26507236-7 2015 Using a murine model of METH administration and wound infection, we demonstrated that METH reduces wound healing and facilitates host-mediated collagen degradation by increased expression and production of matrix metalloproteinase-2 (MMP-2). Methamphetamine 24-28 matrix metallopeptidase 2 Mus musculus 206-232 26507236-7 2015 Using a murine model of METH administration and wound infection, we demonstrated that METH reduces wound healing and facilitates host-mediated collagen degradation by increased expression and production of matrix metalloproteinase-2 (MMP-2). Methamphetamine 24-28 matrix metallopeptidase 2 Mus musculus 234-239 26507236-7 2015 Using a murine model of METH administration and wound infection, we demonstrated that METH reduces wound healing and facilitates host-mediated collagen degradation by increased expression and production of matrix metalloproteinase-2 (MMP-2). Methamphetamine 86-90 matrix metallopeptidase 2 Mus musculus 206-232 26507236-7 2015 Using a murine model of METH administration and wound infection, we demonstrated that METH reduces wound healing and facilitates host-mediated collagen degradation by increased expression and production of matrix metalloproteinase-2 (MMP-2). Methamphetamine 86-90 matrix metallopeptidase 2 Mus musculus 234-239 26203177-0 2015 LH-Induced Steroidogenesis in the Mouse Ovary, but Not Testis, Requires Matrix Metalloproteinase 2- and 9-Mediated Cleavage of Upregulated EGF Receptor Ligands. Luteinizing Hormone 0-2 matrix metallopeptidase 2 Mus musculus 72-105 26148936-7 2015 In isolated adult mouse cardiac fibroblasts (CF), Aldo stimulated TRAF3IP2-dependent IL-18 and IL-6 production, CTGF, collagen I and III expression, MMP2 activation, and proliferation and migration. Aldosterone 50-54 matrix metallopeptidase 2 Mus musculus 149-153 26870800-8 2015 PRI-724 accelerated the resolution of CCl4-induced liver fibrosis, and this was accompanied by increased matrix metalloproteinase (MMP)-9, MMP-2, and MMP-8 expression in intrahepatic leukocytes. ICG 001 0-7 matrix metallopeptidase 2 Mus musculus 139-144 26404213-7 2015 Hinokitiol inhibited the expression and activity of MMPs-2 and -9 in B16-F10 melanoma cells, as measured by western blotting and gelatin zymography, respectively. beta-thujaplicin 0-10 matrix metallopeptidase 2 Mus musculus 52-65 26404213-8 2015 An observed increase in protein expression of MMPs 2/9 in melanoma cells was significantly inhibited by hinokitiol. beta-thujaplicin 104-114 matrix metallopeptidase 2 Mus musculus 46-50 26203177-7 2015 We demonstrate that, in primary mouse granulosa cells, LH triggers release of soluble amphiregulin that correlates with steroid production, both of which are blocked by MMP2/9 inhibition, confirming that MMP2/9 likely regulates LH-induced amphiregulin release and downstream processes. Luteinizing Hormone 55-57 matrix metallopeptidase 2 Mus musculus 169-175 26203177-7 2015 We demonstrate that, in primary mouse granulosa cells, LH triggers release of soluble amphiregulin that correlates with steroid production, both of which are blocked by MMP2/9 inhibition, confirming that MMP2/9 likely regulates LH-induced amphiregulin release and downstream processes. Luteinizing Hormone 55-57 matrix metallopeptidase 2 Mus musculus 204-210 26202311-5 2015 We used a CCK-8 assay and western blotting to explore whether the stem cell biomarkers CD44 and SOX2 and the invasion protein MMP-2 could be suppressed by treatment with rapamycin in cultured primary NPC cells and secondary tumors in BALB/c nude mice. Sirolimus 170-179 matrix metallopeptidase 2 Mus musculus 126-131 26203177-7 2015 We demonstrate that, in primary mouse granulosa cells, LH triggers release of soluble amphiregulin that correlates with steroid production, both of which are blocked by MMP2/9 inhibition, confirming that MMP2/9 likely regulates LH-induced amphiregulin release and downstream processes. Steroids 120-127 matrix metallopeptidase 2 Mus musculus 169-175 26203177-7 2015 We demonstrate that, in primary mouse granulosa cells, LH triggers release of soluble amphiregulin that correlates with steroid production, both of which are blocked by MMP2/9 inhibition, confirming that MMP2/9 likely regulates LH-induced amphiregulin release and downstream processes. Luteinizing Hormone 228-230 matrix metallopeptidase 2 Mus musculus 169-175 26203177-7 2015 We demonstrate that, in primary mouse granulosa cells, LH triggers release of soluble amphiregulin that correlates with steroid production, both of which are blocked by MMP2/9 inhibition, confirming that MMP2/9 likely regulates LH-induced amphiregulin release and downstream processes. Luteinizing Hormone 228-230 matrix metallopeptidase 2 Mus musculus 204-210 26203745-8 2015 The quercetin group also exhibited significant declines of MMP-2 (5.1-fold of control, P < 0.01), MMP-9 (2.5-fold of control, P < 0.01), ICAM-1 (2.2-fold of control, P < 0.01), and VCAM-1 (2.3-fold of control, P < 0.01) levels in the lacrimal gland than did the PBS group. Quercetin 4-13 matrix metallopeptidase 2 Mus musculus 59-64 26168035-5 2015 In the present study, we found that 17beta-estradiol (E2) suppresses nuclear factor-kappaB-dependent MMP-1b, MMP-2, MMP-3, MMP-9, MMP-10, and MMP-13 gene activation in microvessel endothelial bEnd.3 cells subjected to oxygen and glucose deprivation/reperfusion injury. Estradiol 36-52 matrix metallopeptidase 2 Mus musculus 109-114 26340635-4 2015 In vitro, Lv-shbeta-catenin significantly decreased the expression of beta-catenin, MMP2 and MMP9, and secretion of TGF-beta1. lv-shbeta-catenin 10-27 matrix metallopeptidase 2 Mus musculus 84-88 26032511-3 2015 Both genders and strains of CS-exposed mice developed pulmonary inflammation as characterized by cell counts in the bronchoalveolar lavage fluid (BALF) and the levels of matrix metalloproteinases (MMPs) in the BALF. Cesium 28-30 matrix metallopeptidase 2 Mus musculus 197-201 26133107-0 2015 Low-dose UVB irradiation prevents MMP2-induced skin hyperplasia by inhibiting inflammation and ROS. ros 95-98 matrix metallopeptidase 2 Mus musculus 34-38 25967595-2 2015 Considering the pivotal role of matrix metalloproteinase-2 (MMP-2) in plaque destabilization, this study investigated the role of SIRT1 on MMP-2 production in vascular smooth muscle cells (VSMCs) induced by platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine). vsmcs 189-194 matrix metallopeptidase 2 Mus musculus 139-144 25967595-7 2015 Moreover, PAF-induced MMP-2 production in VSMCs and aorta was attenuated by resveratrol. Resveratrol 76-87 matrix metallopeptidase 2 Mus musculus 22-27 26491703-2 2015 MMP-2 is a zinc- and calcium-dependent endoprotease with substrates including extracellular matrix proteins, vasoactive peptides and chemokines. Calcium 21-28 matrix metallopeptidase 2 Mus musculus 0-5 26711605-15 2015 CONCLUSION: UA may inhibit the formation of new blood vessels through reducing the expressions of VEGF, COX-2 and MMP-2 in retinal tissues, and promote a remission from DR by obvious resistance to oxidative stress. ursolic acid 12-14 matrix metallopeptidase 2 Mus musculus 114-119 26491703-5 2015 Additionally, MMP-2 deficient mice exhibit abnormally high prostaglandin E2 levels in various organs (i.e., the heart, brain and liver), signs of inflammation and exacerbated lipopolysaccharide-induced fever. Dinoprostone 59-75 matrix metallopeptidase 2 Mus musculus 14-19 25988725-5 2015 In vitro, the G-AuNPs-DOX-PEG could be degraded by MMP-2 proteins with a size shrink from 186.5 nm to 59.3 nm. dox-peg 22-29 matrix metallopeptidase 2 Mus musculus 51-56 25988725-9 2015 Tumor spheroid penetration and collagen gel diffusion showed G-AuNPs-DOX-PEG with pre-incubation with MMP-2 could significantly enhance its penetrating efficiency. dox-peg 69-76 matrix metallopeptidase 2 Mus musculus 102-107 26062793-15 2015 Chrysin blocks glucose-induced renal tubular cell migration with reducing MMP-2 activity. Glucose 15-22 matrix metallopeptidase 2 Mus musculus 74-79 25947075-6 2015 Furthermore, gelatin zymography and immunoblot analysis revealed that the TGF-beta2-induced release of matrix metalloproteinase (MMP)-2, MMP-3, MMP-8, and MMP-9 from RPE cells was inhibited by R667, and the MMP inhibitor GM6001 attenuated TGF-beta2-induced RPE cell contraction. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 221-227 matrix metallopeptidase 2 Mus musculus 103-135 25986148-7 2015 Moreover, MS-induced MMP-2 production was attenuated in cells treated with OPN siRNA or anti-OPN antibody as well as in OPN-deficient VSMC cultured from aorta of OPN deficient mice. vsmc 134-138 matrix metallopeptidase 2 Mus musculus 21-26 24510625-12 2015 AMR-Me suppresses the activity of MT1-MMP, MMP-2, and MMP-9 by downregulation of VEGF/pFAK397 /pJNK/pERK/NF-kappaB and activation of TIMP-1 and TIMP-2 in metastatic melanoma cell line, B16F10. methyl 25-hydroxy-3-oxoolean-12-en-28-oate 0-6 matrix metallopeptidase 2 Mus musculus 43-48 25824133-12 2015 In conclusion, these results suggested that RSDS contributed to lung cancer progression, angiogenesis and metastasis, which was partially associated with increased VEGF secretion and therefore the activation of the ERK signaling pathway, resulting in the induction of MMP-2 and MMP-9 protein expression. rsds 44-48 matrix metallopeptidase 2 Mus musculus 268-273 25862758-6 2015 Matrix metalloproteinase-2 (MMP2) protein and activity were increased 1.5-fold in BPA-exposed heart. bisphenol A 82-85 matrix metallopeptidase 2 Mus musculus 0-26 25862758-6 2015 Matrix metalloproteinase-2 (MMP2) protein and activity were increased 1.5-fold in BPA-exposed heart. bisphenol A 82-85 matrix metallopeptidase 2 Mus musculus 28-32 25862758-8 2015 Monocyte and MPhi exposure to BPA in vitro in primary bone marrow cultures or in isolated peritoneal MPhi increased polarization to an activated MPhi, increased MMP2 and MMP9 expression 2-fold and activity 3-fold, and increased uptake of microspheres 3-fold. bisphenol A 30-33 matrix metallopeptidase 2 Mus musculus 161-165 25862758-11 2015 Chronic in vivo or continuous in vitro BPA exposure ablated transforming growth factor beta-mediated differentiation of CF, reduced alphaSMA expression 50% and reduced migration 40% yet increased secreted MMP2 activity 2-fold. bisphenol A 39-42 matrix metallopeptidase 2 Mus musculus 205-209 26059793-6 2015 Meanwhile, l-THP inhibited tight junction (TJ) proteins down-expression, Src kinase phosphorylation, matrix metalloproteinases-2/9 (MMP-2/9) and caveolin-1 activation. tetrahydropalmatine 11-16 matrix metallopeptidase 2 Mus musculus 101-130 26099922-1 2015 BACKGROUND: Halofuginone (HF) is a low-molecular-weight alkaloid that has been demonstrated to interfere with Metalloproteinase-2 (MMP-2) and Tumor Growth Factor-beta (TGF-beta) function and, to present antiangiogenic, antiproliferative and proapoptotic properties in several solid tumor models. halofuginone 12-24 matrix metallopeptidase 2 Mus musculus 131-136 25881484-8 2015 ACEA-treatment decreased MMP-9 activity by 80%, 49%, and 56%, respectively (P<0.05) and had a smaller effect on MMP-2 activity. arachidonyl-2-chloroethylamide 0-4 matrix metallopeptidase 2 Mus musculus 115-120 26309547-0 2015 Curcumin inhibits lung cancer invasion and metastasis by attenuating GLUT1/MT1-MMP/MMP2 pathway. Curcumin 0-8 matrix metallopeptidase 2 Mus musculus 83-87 26309547-7 2015 Real-time PCR and Western-blotting were employed to examine the expression levels of GLUT1, membrane type 1-MMP (MT1-MMP) and matrix metalloproteinase (MMP) 2 in curcumin- incubated A549 cells. Curcumin 162-170 matrix metallopeptidase 2 Mus musculus 126-158 26309547-10 2015 Curcumin inhibited invasion and expressions of GLUT1, MT1-MMP and MMP2 untransfected A549 cells in a concentration-dependent manner. Curcumin 0-8 matrix metallopeptidase 2 Mus musculus 66-70 26309547-11 2015 pcDNA3.1-GLUT1 transfected A549 cells exhibited resistance to curcumin"s anti-invasion effect by up-regulating expressions of GLUT2, MT1-MMP and MMP2. Curcumin 62-70 matrix metallopeptidase 2 Mus musculus 145-149 26309547-13 2015 These results suggested that curcumin inhibit lung cancer invasion and metastasis by attenuating GLUT1/MT1-MMP/MMP2 pathway. Curcumin 29-37 matrix metallopeptidase 2 Mus musculus 111-115 26061387-7 2015 In retinas, DHI blocked the shrink of whole retina and retinal sub-layers by inhibiting expression of caspase 3, matrix metalloproteinase 2 (MMP-2) and MMP-9, accumulation of carbohydrate macromolecules and formation of acellular capillaries. dehydrosoyasaponin I 12-15 matrix metallopeptidase 2 Mus musculus 113-139 26061387-7 2015 In retinas, DHI blocked the shrink of whole retina and retinal sub-layers by inhibiting expression of caspase 3, matrix metalloproteinase 2 (MMP-2) and MMP-9, accumulation of carbohydrate macromolecules and formation of acellular capillaries. dehydrosoyasaponin I 12-15 matrix metallopeptidase 2 Mus musculus 141-146 26059793-6 2015 Meanwhile, l-THP inhibited tight junction (TJ) proteins down-expression, Src kinase phosphorylation, matrix metalloproteinases-2/9 (MMP-2/9) and caveolin-1 activation. tetrahydropalmatine 11-16 matrix metallopeptidase 2 Mus musculus 132-139 25975582-10 2015 In vitro, dasatinib inhibited cell proliferation and MMP-2 activity. Dasatinib 10-19 matrix metallopeptidase 2 Mus musculus 53-58 25795711-7 2015 Immunohistological staining and zymographic levels of MMP-2 and MMP-9 were reduced with either tichostatin A or suberanilohydroxamic acid treatment. tichostatin a 95-108 matrix metallopeptidase 2 Mus musculus 54-59 25795711-7 2015 Immunohistological staining and zymographic levels of MMP-2 and MMP-9 were reduced with either tichostatin A or suberanilohydroxamic acid treatment. Vorinostat 112-137 matrix metallopeptidase 2 Mus musculus 54-59 25795711-9 2015 Treatment with the selective class I HDAC inhibitor PD-106 reduced post-MI levels of both MMP-2 and MMP-9 and attenuated LV dilation and LV pump dysfunction post-MI, similar to class I/IIb HDAC inhibition. pd-106 52-58 matrix metallopeptidase 2 Mus musculus 90-95 25431338-8 2015 Mechanistic zymography studies showed that the enzyme activities of MMP-9 and MMP-2 were significantly suppressed by CS and CS + ZOL. Cesium 117-119 matrix metallopeptidase 2 Mus musculus 78-83 25431338-8 2015 Mechanistic zymography studies showed that the enzyme activities of MMP-9 and MMP-2 were significantly suppressed by CS and CS + ZOL. cs + zol 124-132 matrix metallopeptidase 2 Mus musculus 78-83 25876091-12 2015 The results conclude that oral administration of sitagliptin can prevent abdominal aortic aneurysm formation in Ang II-infused apoE-/-mice, at least in part, by increasing of GLP-1 activity, decreasing MMP-2 and MMP-9 production from macrophage infiltration. Sitagliptin Phosphate 49-60 matrix metallopeptidase 2 Mus musculus 202-207 25724785-8 2015 Further investigation showed that Dox significantly inhibited the activities of MMP-2 and MMP-9, increased autophagosomes and enhanced LC3-II in post-infarction hearts. Doxycycline 34-37 matrix metallopeptidase 2 Mus musculus 80-85 25703139-0 2015 Tamoxifen induces the development of hernia in mice by activating MMP-2 and MMP-13 expression. Tamoxifen 0-9 matrix metallopeptidase 2 Mus musculus 66-71 25703139-9 2015 In vitro, tamoxifen induced MMP-2 and MMP-13 expression in fibroblasts. Tamoxifen 10-19 matrix metallopeptidase 2 Mus musculus 28-33 25890182-9 2015 DSS treatment enhanced MMP2 and MMP9 activities (>3-fold), which were significantly reduced in mice receiving UCMSCs. Dextran Sulfate 0-3 matrix metallopeptidase 2 Mus musculus 23-27 25736483-2 2015 Cell culture studies reveal that AC significantly inhibited invasion, migration and activities of matrix metalloproteinase (MMP)-2, -9 and urokinase plasminogen activator but increased protein expression of tissue inhibitor of MMP (TIMP)-1, -2 and plasminogen activator inhibitor (PAI)-1. alpha-carotene 33-35 matrix metallopeptidase 2 Mus musculus 98-134 25724785-9 2015 This study revealed that Dox treatment could promote autophagy, reduce ANP aggregation in post-infarction hearts, and inhibit MMP-2 and MMP-9 activities. Doxycycline 25-28 matrix metallopeptidase 2 Mus musculus 126-131 25154719-6 2015 High-dose baicalin (10 mg/kg) significantly reduced the expression of matrix metalloproteinase-2 (MMP-2), MMP-9, angiotensin II, and vascular endothelial growth factor (VEGF). baicalin 10-18 matrix metallopeptidase 2 Mus musculus 70-96 25154719-6 2015 High-dose baicalin (10 mg/kg) significantly reduced the expression of matrix metalloproteinase-2 (MMP-2), MMP-9, angiotensin II, and vascular endothelial growth factor (VEGF). baicalin 10-18 matrix metallopeptidase 2 Mus musculus 98-103 25910275-6 2015 Gene array analysis indicated that MMP2, TIMP2, collagen 1alpha1 and collagen 1alpha3 were induced after 2 weeks of PO in WT but not AdKO mice. Polonium 116-118 matrix metallopeptidase 2 Mus musculus 35-39 25714673-8 2015 With 10 wk of systemic treatment using minocycline, an anti-inflammatory agent that crosses the blood-brain barrier, MMP-2, IDO, and CD39 levels normalized (P<0.05). Minocycline 39-50 matrix metallopeptidase 2 Mus musculus 117-122 25512019-11 2015 CONCLUSION: Dietary supplementation with n-3 PUFAs may have protective anti-inflammatory effects mediated through modulation of MMPs and TIMPs. Fatty Acids, Omega-3 41-50 matrix metallopeptidase 2 Mus musculus 128-132 25914628-8 2015 Moreover, MMP-2/9 protein expression increased in mice treated with a TRPV4 agonist GSK1016790A, but only MMP-9 activity was increased by GSK1016790A. N-(1-((4-(2-(((2,4-dichlorophenyl)sulfonyl)amino)-3-hydroxypropanoyl)-1-piperazinyl)carbonyl)-3-methylbutyl)-1-benzothiophene-2-carboxamide 84-95 matrix metallopeptidase 2 Mus musculus 10-17 25657308-10 2015 Intriguingly, MMP2(-/-) mice were protected against CaCl2-induced thoracic aortic aneurysm, which triggered ECM degradation but not synthesis. Calcium Chloride 52-57 matrix metallopeptidase 2 Mus musculus 14-18 25711693-4 2015 Treatment with AICAR also inhibited the increase of myeloperoxidase (MPO), the induction of TNF-alpha, IL-6, inducible nitric oxide synthase (iNOS), nitric oxide and the upregulation of matrix metalloproteinase 2 (MMP-2), MMP-3 and MMP-9 in mice exposed to CCl4. acadesine 15-20 matrix metallopeptidase 2 Mus musculus 186-212 25646300-6 2015 Interestingly, Mmp2(-/-) mice expressed greater amounts of sterol regulatory element-binding protein-2 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (a target of sterol regulatory element-binding protein-2-mediated transcription and rate limiting enzyme in cholesterol and isoprenoids biosynthesis) in addition to markers of inflammation including chemokines of the C-C motif ligand family. Cholesterol 263-274 matrix metallopeptidase 2 Mus musculus 15-19 25646300-6 2015 Interestingly, Mmp2(-/-) mice expressed greater amounts of sterol regulatory element-binding protein-2 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (a target of sterol regulatory element-binding protein-2-mediated transcription and rate limiting enzyme in cholesterol and isoprenoids biosynthesis) in addition to markers of inflammation including chemokines of the C-C motif ligand family. Terpenes 279-290 matrix metallopeptidase 2 Mus musculus 15-19 25646300-8 2015 The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, lovastatin, attenuated angiotensin II-induced cardiac hypertrophy and fibrosis in Mmp2(-/-) and wild-type (Mmp2(+/+)) mice, with Mmp2(-/-) mice showing resistance to cardioprotection by lovastatin. -3-methylglutaryl 13-30 matrix metallopeptidase 2 Mus musculus 145-149 25646300-8 2015 The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, lovastatin, attenuated angiotensin II-induced cardiac hypertrophy and fibrosis in Mmp2(-/-) and wild-type (Mmp2(+/+)) mice, with Mmp2(-/-) mice showing resistance to cardioprotection by lovastatin. Lovastatin 63-73 matrix metallopeptidase 2 Mus musculus 145-149 25646300-8 2015 The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, lovastatin, attenuated angiotensin II-induced cardiac hypertrophy and fibrosis in Mmp2(-/-) and wild-type (Mmp2(+/+)) mice, with Mmp2(-/-) mice showing resistance to cardioprotection by lovastatin. Lovastatin 63-73 matrix metallopeptidase 2 Mus musculus 170-174 25646300-8 2015 The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, lovastatin, attenuated angiotensin II-induced cardiac hypertrophy and fibrosis in Mmp2(-/-) and wild-type (Mmp2(+/+)) mice, with Mmp2(-/-) mice showing resistance to cardioprotection by lovastatin. Lovastatin 63-73 matrix metallopeptidase 2 Mus musculus 170-174 25711693-4 2015 Treatment with AICAR also inhibited the increase of myeloperoxidase (MPO), the induction of TNF-alpha, IL-6, inducible nitric oxide synthase (iNOS), nitric oxide and the upregulation of matrix metalloproteinase 2 (MMP-2), MMP-3 and MMP-9 in mice exposed to CCl4. acadesine 15-20 matrix metallopeptidase 2 Mus musculus 214-219 26148594-5 2015 RESULTS: The protein and mRNA expression levels of survivin, MMP-2, VEGF-C, and VEGFR-3 in the cisplatin group and the combined treatment group were lower than that in the control group (P < 0.05). Cisplatin 95-104 matrix metallopeptidase 2 Mus musculus 61-66 26148594-6 2015 In the metformin group, the expression of MMP-2 protein and mRNA was lower than that in the control group (P < 0.05). Metformin 7-16 matrix metallopeptidase 2 Mus musculus 42-47 26148594-8 2015 CONCLUSIONS: Metformin inhibited the expression of MMP-2, cisplatin and the combined treatment inhibited the expression of survivin, MMP-2, VEGF-C, and VEGFR-3, and the combined treatment of metformin with cisplatin resulted in enhanced anti-tumor efficacy. Metformin 13-22 matrix metallopeptidase 2 Mus musculus 51-56 26148594-8 2015 CONCLUSIONS: Metformin inhibited the expression of MMP-2, cisplatin and the combined treatment inhibited the expression of survivin, MMP-2, VEGF-C, and VEGFR-3, and the combined treatment of metformin with cisplatin resulted in enhanced anti-tumor efficacy. Metformin 13-22 matrix metallopeptidase 2 Mus musculus 133-138 26148594-8 2015 CONCLUSIONS: Metformin inhibited the expression of MMP-2, cisplatin and the combined treatment inhibited the expression of survivin, MMP-2, VEGF-C, and VEGFR-3, and the combined treatment of metformin with cisplatin resulted in enhanced anti-tumor efficacy. Metformin 191-200 matrix metallopeptidase 2 Mus musculus 51-56 26148594-8 2015 CONCLUSIONS: Metformin inhibited the expression of MMP-2, cisplatin and the combined treatment inhibited the expression of survivin, MMP-2, VEGF-C, and VEGFR-3, and the combined treatment of metformin with cisplatin resulted in enhanced anti-tumor efficacy. Cisplatin 206-215 matrix metallopeptidase 2 Mus musculus 51-56 25822152-5 2015 Moreover, acute VO-induced MMP-2 and MMP-9 upregulation was also suppressed at 24 h in both TG mice. Vanadium(II) oxide 16-18 matrix metallopeptidase 2 Mus musculus 27-32 25623334-9 2015 These results indicate that misoprostol protects brain against ICH injury through mechanisms that may involve the HMGB1, Src kinase, and matrix metalloproteinase-2/9 pathways. Misoprostol 28-39 matrix metallopeptidase 2 Mus musculus 137-165 25820137-2 2015 Here, we reveal an MMP-2-mediated mechanism that modulates the inflammatory response via secretory phospholipase A2 (sPLA2), a phospholipid hydrolase that releases fatty acids, including precursors of eicosanoids. Fatty Acids 164-175 matrix metallopeptidase 2 Mus musculus 19-24 25820137-2 2015 Here, we reveal an MMP-2-mediated mechanism that modulates the inflammatory response via secretory phospholipase A2 (sPLA2), a phospholipid hydrolase that releases fatty acids, including precursors of eicosanoids. Eicosanoids 201-212 matrix metallopeptidase 2 Mus musculus 19-24 25820137-7 2015 Treatment of wild-type (Mmp2(+/+)) mice with doxycycline (to inhibit MMP-2) recapitulated the Mmp2(-/-) phenotype of increased cardiac sPLA2 activity, prostaglandin E2 levels, and inflammatory gene expression. Doxycycline 45-56 matrix metallopeptidase 2 Mus musculus 24-28 25820137-7 2015 Treatment of wild-type (Mmp2(+/+)) mice with doxycycline (to inhibit MMP-2) recapitulated the Mmp2(-/-) phenotype of increased cardiac sPLA2 activity, prostaglandin E2 levels, and inflammatory gene expression. Doxycycline 45-56 matrix metallopeptidase 2 Mus musculus 69-74 25820137-7 2015 Treatment of wild-type (Mmp2(+/+)) mice with doxycycline (to inhibit MMP-2) recapitulated the Mmp2(-/-) phenotype of increased cardiac sPLA2 activity, prostaglandin E2 levels, and inflammatory gene expression. Doxycycline 45-56 matrix metallopeptidase 2 Mus musculus 94-98 25820137-8 2015 Treatment with either indomethacin (to inhibit cyclooxygenase-dependent eicosanoid production) or varespladib (which inhibited eicosanoid production) triggered acute hypertension in Mmp2(-/-) mice, revealing their reliance on eicosanoids for blood pressure homeostasis. Indomethacin 22-34 matrix metallopeptidase 2 Mus musculus 182-186 25820137-8 2015 Treatment with either indomethacin (to inhibit cyclooxygenase-dependent eicosanoid production) or varespladib (which inhibited eicosanoid production) triggered acute hypertension in Mmp2(-/-) mice, revealing their reliance on eicosanoids for blood pressure homeostasis. Eicosanoids 72-82 matrix metallopeptidase 2 Mus musculus 182-186 25820137-8 2015 Treatment with either indomethacin (to inhibit cyclooxygenase-dependent eicosanoid production) or varespladib (which inhibited eicosanoid production) triggered acute hypertension in Mmp2(-/-) mice, revealing their reliance on eicosanoids for blood pressure homeostasis. varespladib 98-109 matrix metallopeptidase 2 Mus musculus 182-186 25820137-8 2015 Treatment with either indomethacin (to inhibit cyclooxygenase-dependent eicosanoid production) or varespladib (which inhibited eicosanoid production) triggered acute hypertension in Mmp2(-/-) mice, revealing their reliance on eicosanoids for blood pressure homeostasis. Eicosanoids 127-137 matrix metallopeptidase 2 Mus musculus 182-186 25583024-3 2015 In the direct anti-metastatic action, antrodan (30-70 mug/mL) was found to significantly inhibit invasion and migration of LLC cells, and these effects involved up-regulation of tissue inhibitor of matrix metalloproteinase (TIMP)-1, TIMP-2, and nm23-H1 protein expression leading to decreased activities and protein expression of MMP-2 and MMP-9. antrodan 38-46 matrix metallopeptidase 2 Mus musculus 330-335 25583024-5 2015 Antrodan significantly increased interleukin (IL)-12 and IL-1beta levels, but decreased TNF-alpha, IL-6 and IL-8 levels in the MMC-CM, which also significantly inhibited invasion, migration, and the activities and protein expression of MMP-2 and MMP-9, but significantly increased protein expression of TIMP-1, TIMP-2, and nm23-H1 in LLC cells. antrodan 0-8 matrix metallopeptidase 2 Mus musculus 236-241 25575746-9 2015 Gene expression of matrix metalloproteinases (MMP)-1 and -2 was up-regulated by PGs, indicating that MMPs did not play a critical role in network growth. 2,3-di-O-phytanyl-sn-glycero-1-phospho-(3'-sn-glycerol-1'-sulfate) 80-83 matrix metallopeptidase 2 Mus musculus 19-59 25619395-9 2015 Furthermore, rosiglitazone administration significantly increased PPARgamma, HO-1 and p21 expression and HO-1 activity, decreased MMP-2 and MMP-9 activities in airway tissue. Rosiglitazone 13-26 matrix metallopeptidase 2 Mus musculus 130-135 25557114-12 2015 In the xenograft mice, sorafenib administration decreased the tumor growth by 40%, and markedly increased the expression of p53, and decreased the expression of FoxM1, MMP-2, and Ki-67 in tumor tissues. Sorafenib 23-32 matrix metallopeptidase 2 Mus musculus 168-173 25012179-5 2015 In cultured cells, indoxyl sulfate and p-cresol sulfate activated the EGF receptor and downstream signaling by enhancing receptor dimerization, and increased expression of matrix metalloproteinases 2 and 9 in an EGF receptor-dependent manner. Indican 19-34 matrix metallopeptidase 2 Mus musculus 172-205 25444919-8 2015 The in vitro migration of piperine-treated TNBC cells was impaired and expression of matrix metalloproteinase-2 and -9 mRNA was decreased, suggesting an antimetastatic effect by piperine. piperine 178-186 matrix metallopeptidase 2 Mus musculus 85-118 25012179-6 2015 Treatment of mice with indoxyl sulfate or p-cresol sulfate significantly activated the renal EGF receptor and increased the tubulointerstitial expression of matrix metalloproteinases 2 and 9. 4-cresol sulfate 42-58 matrix metallopeptidase 2 Mus musculus 157-190 25012179-6 2015 Treatment of mice with indoxyl sulfate or p-cresol sulfate significantly activated the renal EGF receptor and increased the tubulointerstitial expression of matrix metalloproteinases 2 and 9. Indican 23-38 matrix metallopeptidase 2 Mus musculus 157-190 25405459-0 2015 Inhibition of tumor growth by beta-elemene through downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9 in a murine intraocular melanoma model. beta-elemene 30-42 matrix metallopeptidase 2 Mus musculus 98-103 25405459-6 2015 Tumor size was inhibited by beta-elemene in the treatment group, and the expressions of uPA, uPAR, MMP-2, and MMP-9 were all downregulated at both the mRNA and the protein level compared with the control group. beta-elemene 28-40 matrix metallopeptidase 2 Mus musculus 99-104 25405459-7 2015 In a mouse model of intraocular melanoma, beta-elemene inhibits tumor growth by downregulating the expression of uPA, uPAR, MMP-2, and MMP-9. beta-elemene 42-54 matrix metallopeptidase 2 Mus musculus 124-129 25925976-9 2015 EPA administration and DHA administration significantly decreased the expression of tumor necrosis factor-alpha, monocyte chemoattractant protein-1, transforming growth factor-beta, matrix metalloproteinases (MMP)-2, MMP-9, and vascular cell adhesion molecule-1 in the aortas. Eicosapentaenoic Acid 0-3 matrix metallopeptidase 2 Mus musculus 182-215 25445053-4 2015 Esculetin inhibited the expressions of cyclin D1, cyclin-dependent kinase (CDK) 4 and matrix metalloproteinase (MMP)-2, and production of both transforming growth factor (TGF)-beta1 and vascular endothelial growth factor (VEGF) in LM8 cells. esculetin 0-9 matrix metallopeptidase 2 Mus musculus 86-118 25445053-6 2015 These results suggested that the antitumor and antimetastatic actions of esculetin may be partly attributed to G1 arrest by the inhibition of cyclin D1 and CDK4 expression, while its antiangiogenic action may have been due to the inhibition of MMP-2 expression and TGF-beta1 and VEGF productions at tumor sites. esculetin 73-82 matrix metallopeptidase 2 Mus musculus 244-249 25925976-9 2015 EPA administration and DHA administration significantly decreased the expression of tumor necrosis factor-alpha, monocyte chemoattractant protein-1, transforming growth factor-beta, matrix metalloproteinases (MMP)-2, MMP-9, and vascular cell adhesion molecule-1 in the aortas. Docosahexaenoic Acids 23-26 matrix metallopeptidase 2 Mus musculus 182-215 26451076-5 2015 We reveal that intravitreal NMDA injection induces MMP-2 expression to be upregulated in the Muller glia. N-Methylaspartate 28-32 matrix metallopeptidase 2 Mus musculus 51-56 24770901-8 2015 Therefore, the present study concludes that P188 can protect against ICH, and the protective effect was associated with preventing BBB disruption through NF-kappaB-MMPs-mediated TJ proteins degradation. Poloxamer 44-48 matrix metallopeptidase 2 Mus musculus 164-168 24823643-8 2015 As control, we studied the MMP-2/9 sensitive ACPP in mice bearing subcutaneous BT-20 tumors with low MMP-2/9 expression to test if probe cleavage correlates with tumoral MMP expression. acpp 45-49 matrix metallopeptidase 2 Mus musculus 27-34 26761856-6 2015 The groups that were orally administered PPE (0.05%, OL; 0.1%, OH group) showed significantly reduced Matrix Metaloproteinase-2 (MMP-2) mRNA expression levels compared with the UVB control (Con), by 33.5% and 35.2%, respectively. ppe 41-44 matrix metallopeptidase 2 Mus musculus 102-127 26761856-6 2015 The groups that were orally administered PPE (0.05%, OL; 0.1%, OH group) showed significantly reduced Matrix Metaloproteinase-2 (MMP-2) mRNA expression levels compared with the UVB control (Con), by 33.5% and 35.2%, respectively. ppe 41-44 matrix metallopeptidase 2 Mus musculus 129-134 26761856-6 2015 The groups that were orally administered PPE (0.05%, OL; 0.1%, OH group) showed significantly reduced Matrix Metaloproteinase-2 (MMP-2) mRNA expression levels compared with the UVB control (Con), by 33.5% and 35.2%, respectively. ol 53-55 matrix metallopeptidase 2 Mus musculus 102-127 26761856-6 2015 The groups that were orally administered PPE (0.05%, OL; 0.1%, OH group) showed significantly reduced Matrix Metaloproteinase-2 (MMP-2) mRNA expression levels compared with the UVB control (Con), by 33.5% and 35.2%, respectively. ol 53-55 matrix metallopeptidase 2 Mus musculus 129-134 25381636-0 2015 Nicotine-induced upregulation of VCAM-1, MMP-2, and MMP-9 through the alpha7-nAChR-JNK pathway in RAW264.7 and MOVAS cells. Nicotine 0-8 matrix metallopeptidase 2 Mus musculus 41-46 25381636-6 2015 In conclusion, nicotine-induced VCAM-1, MMP-2, and MMP-9 expressions occur in a dose-dependent fashion in both of the cell lines tested. Nicotine 15-23 matrix metallopeptidase 2 Mus musculus 40-45 25381636-2 2015 In the present experiment, both the RAW264.7 and MOVAS cell lines were employed to examine the nicotine-induced modulation of VCAM-1, MMP-2, and MMP-9 expressions in macrophages and vascular smooth muscle cells. Nicotine 95-103 matrix metallopeptidase 2 Mus musculus 134-139 25381636-7 2015 Furthermore, the nicotine exposure equivalent to plasma levels found in regular smokers can augment VCAM-1, MMP-2, and MMP-9 expressions through the alpha7-nAChR-JNK pathway. Nicotine 17-25 matrix metallopeptidase 2 Mus musculus 108-113 25381636-3 2015 Our results showed that nicotine concentrations of both 0.5 and 5 ng/ml induced VCAM-1, MMP-2, and MMP-9 upregulation, while a concentration of 50 ng/ml had a slight inhibitory effect and a concentration of 500 ng/ml showed a significant inhibitory effect. Nicotine 24-32 matrix metallopeptidase 2 Mus musculus 88-93 25381636-4 2015 When cells were pretreated with either SP600125 (JNK inhibitor) or PNU-282987 (alpha7-nAChR agonist) prior to nicotine exposure, the nicotine-induced upregulation of VCAM-1, MMP-2, MMP-9, and p-JNK was suppressed, with a joint treatment producing a more significant inhibitory effect. pyrazolanthrone 39-47 matrix metallopeptidase 2 Mus musculus 174-179 25381636-4 2015 When cells were pretreated with either SP600125 (JNK inhibitor) or PNU-282987 (alpha7-nAChR agonist) prior to nicotine exposure, the nicotine-induced upregulation of VCAM-1, MMP-2, MMP-9, and p-JNK was suppressed, with a joint treatment producing a more significant inhibitory effect. PNU-282987 67-77 matrix metallopeptidase 2 Mus musculus 174-179 25381636-4 2015 When cells were pretreated with either SP600125 (JNK inhibitor) or PNU-282987 (alpha7-nAChR agonist) prior to nicotine exposure, the nicotine-induced upregulation of VCAM-1, MMP-2, MMP-9, and p-JNK was suppressed, with a joint treatment producing a more significant inhibitory effect. Nicotine 133-141 matrix metallopeptidase 2 Mus musculus 174-179 25381636-5 2015 Moreover, PNU-282987 had a comparable inhibitory effect on VCAM-1, MMP-2, and MMP-9 expressions and JNK activation via phosphorylation as did SP600125. PNU-282987 10-20 matrix metallopeptidase 2 Mus musculus 67-72 25978595-8 2015 In conclusion, the results suggested that LQ plays an intensive role on CDDP suppressing invasion and metastasis through regulating the PI3 K/AKT signal pathway and suppressing the protein expression of MMP-2/9. liquiritigenin 42-44 matrix metallopeptidase 2 Mus musculus 203-210 25978595-0 2015 Liquiritigenin Potentiates the Inhibitory Effects of Cisplatin on Invasion and Metastasis Via Downregulation MMP-2/9 and PI3 K/AKT Signaling Pathway in B16F10 Melanoma Cells and Mice Model. liquiritigenin 0-14 matrix metallopeptidase 2 Mus musculus 109-116 25371741-10 2014 The expression levels of MMP-2 in the NM-LD and NM-HD groups were decreased by ~50% compared with the saline group as indicated by western blotting results. Sodium Chloride 102-108 matrix metallopeptidase 2 Mus musculus 25-30 25978595-0 2015 Liquiritigenin Potentiates the Inhibitory Effects of Cisplatin on Invasion and Metastasis Via Downregulation MMP-2/9 and PI3 K/AKT Signaling Pathway in B16F10 Melanoma Cells and Mice Model. Cisplatin 53-62 matrix metallopeptidase 2 Mus musculus 109-116 25978595-6 2015 Moreover, LQ/CDDP combination led to the downregulation of protein expression of MMP-2/9, PI3 K, p-AKT, and upregulated PTEN protein level that play an important role in tumor metastasis progression. liquiritigenin 10-12 matrix metallopeptidase 2 Mus musculus 81-88 25978595-6 2015 Moreover, LQ/CDDP combination led to the downregulation of protein expression of MMP-2/9, PI3 K, p-AKT, and upregulated PTEN protein level that play an important role in tumor metastasis progression. Cisplatin 13-17 matrix metallopeptidase 2 Mus musculus 81-88 25551570-10 2014 Treatment with bleomycin or Ad vectors increased expression levels of integrin alpha1, alpha5, and alphav, MMP9, whereas treatment with bleomycin but not Ad vectors induced MMP2 expression levels. Bleomycin 136-145 matrix metallopeptidase 2 Mus musculus 173-177 25502771-6 2014 RESULTS: Administration of CdCl2 significantly increased arterial blood pressure, blunted vascular responses to vasoactive agents, increased aortic stiffness, and induced hypertrophic aortic wall remodeling by increasing number of smooth muscle cells and collagen deposition, decreasing elastin, and increasing matrix metalloproteinase (MMP)-2 and MMP-9 levels in the aortic medial wall. Cadmium Chloride 27-32 matrix metallopeptidase 2 Mus musculus 311-343 24858305-7 2014 Moreover, capsaicin attenuated pressure overload-induced overexpression of metalloproteinase (MMP)-2, MMP-9 and MMP-13 in WT mice but not in TRPV1 KO mice. Capsaicin 10-19 matrix metallopeptidase 2 Mus musculus 75-100 25336627-3 2014 In this study, we report that core 1 O-glycan-deficient or desialylated PDPN was highly susceptible to proteolytic degradation by various proteases, including metalloproteinases (MMP)-2/9. 1 o-glycan 35-45 matrix metallopeptidase 2 Mus musculus 149-187 25336627-6 2014 The MMP inhibitor, GM6001, rescued these reductions. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 19-25 matrix metallopeptidase 2 Mus musculus 4-7 25336627-9 2014 These data indicate that sialylated O-glycans of PDPN are essential for platelet adhesion and prevent PDPN from proteolytic degradation primarily mediated by MMPs in the lymph. o-glycans 36-45 matrix metallopeptidase 2 Mus musculus 158-162 25371741-14 2014 Furthermore, the luciferase results indicated that site-directed mutagenesis comprising a -1306 C to T (C/T) base change in the MMP-2 promoter and a -1562 C/T base change in the MMP-9 promoter abolished the inhibitory effects of NM on MMP-2 and MMP-9 promoters. nm 229-231 matrix metallopeptidase 2 Mus musculus 235-240 25361902-0 2014 I(f) current channel inhibitor (ivabradine) deserves cardioprotective effect via down-regulating the expression of matrix metalloproteinase (MMP)-2 and attenuating apoptosis in diabetic mice. Ivabradine 32-42 matrix metallopeptidase 2 Mus musculus 115-147 25459137-0 2014 Inhibition of matrix metalloproteinase-2 and 9 by Piroxicam confer neuroprotection in cerebral ischemia: an in silico evaluation of the hypothesis. Piroxicam 50-59 matrix metallopeptidase 2 Mus musculus 14-46 25459137-7 2014 We tested the hypothesis that Piroxicam, with its larger molecular size and more number of interacting pharmacophores, can inhibit MMP-2 and MMP-9. Piroxicam 30-39 matrix metallopeptidase 2 Mus musculus 131-136 25271556-3 2014 Here we report the design and synthesis of a set of fluorine-19 dendron-based magnetic resonance imaging (MRI) probes for real-time imaging of MMP-2 activity. fluorine-19 dendron 52-71 matrix metallopeptidase 2 Mus musculus 143-148 25271556-6 2014 Our results showed that the fluorine signal increased by 8.5-fold in the presence of MMP-2. Fluorine 28-36 matrix metallopeptidase 2 Mus musculus 85-90 24919932-2 2014 METHODS: Manganese oxide nanoparticles (Mn3O4 NPs) were synthesized and modified with LHRH targeting peptide or anti-melanoma antibodies (cancer targeting moieties) and a MMP2 cleavable peptide (a possible chemotactic factor). manganese oxide 9-24 matrix metallopeptidase 2 Mus musculus 171-175 24919932-2 2014 METHODS: Manganese oxide nanoparticles (Mn3O4 NPs) were synthesized and modified with LHRH targeting peptide or anti-melanoma antibodies (cancer targeting moieties) and a MMP2 cleavable peptide (a possible chemotactic factor). manganese oxide 40-45 matrix metallopeptidase 2 Mus musculus 171-175 24602608-5 2014 Hyperbaric oxygen exposure resulted in increased levels of VEGF, MMP-2 and MMP-9, and when mice were treated with sulodexide, a dose-dependent reduction in VEGF, MMP-2 and MMP-9 levels was observed. Oxygen 11-17 matrix metallopeptidase 2 Mus musculus 65-70 24602608-5 2014 Hyperbaric oxygen exposure resulted in increased levels of VEGF, MMP-2 and MMP-9, and when mice were treated with sulodexide, a dose-dependent reduction in VEGF, MMP-2 and MMP-9 levels was observed. Oxygen 11-17 matrix metallopeptidase 2 Mus musculus 162-167 24602608-5 2014 Hyperbaric oxygen exposure resulted in increased levels of VEGF, MMP-2 and MMP-9, and when mice were treated with sulodexide, a dose-dependent reduction in VEGF, MMP-2 and MMP-9 levels was observed. glucuronyl glucosamine glycan sulfate 114-124 matrix metallopeptidase 2 Mus musculus 65-70 24602608-5 2014 Hyperbaric oxygen exposure resulted in increased levels of VEGF, MMP-2 and MMP-9, and when mice were treated with sulodexide, a dose-dependent reduction in VEGF, MMP-2 and MMP-9 levels was observed. glucuronyl glucosamine glycan sulfate 114-124 matrix metallopeptidase 2 Mus musculus 162-167 25301089-0 2014 Small molecule 1"-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathway. 1'-acetoxychavicol acetate 15-41 matrix metallopeptidase 2 Mus musculus 107-111 25175557-4 2014 Hirsutine further inhibited the constitutive expression of MMP-2 and MMP-9 in 4T1 cells, and reduced the in vivo lung metastatic potential of 4T1 cells in the experimental model. hirsutine 0-9 matrix metallopeptidase 2 Mus musculus 59-64 25361902-5 2014 RESULTS: Our results showed that ivabradine treatment attenuated the expression and staining score of matrix metalloproteinase (MMP)-2, induced the dephosphorylation of caspase 3, BAX and MMP-2, and enhanced the phosphorylation of NF-kappaB. Ivabradine 33-43 matrix metallopeptidase 2 Mus musculus 102-134 25361902-5 2014 RESULTS: Our results showed that ivabradine treatment attenuated the expression and staining score of matrix metalloproteinase (MMP)-2, induced the dephosphorylation of caspase 3, BAX and MMP-2, and enhanced the phosphorylation of NF-kappaB. Ivabradine 33-43 matrix metallopeptidase 2 Mus musculus 188-193 25361902-7 2014 CONCLUSION: Ivabradine significantly improved cardiac function by attenuating apoptosis and inhibiting the expression and activity of MMP-2 in diabetic mice, which underscored the novel clinical implications of ivabradine for diabetic patients. Ivabradine 12-22 matrix metallopeptidase 2 Mus musculus 134-139 25361902-7 2014 CONCLUSION: Ivabradine significantly improved cardiac function by attenuating apoptosis and inhibiting the expression and activity of MMP-2 in diabetic mice, which underscored the novel clinical implications of ivabradine for diabetic patients. Ivabradine 211-221 matrix metallopeptidase 2 Mus musculus 134-139 24916705-6 2014 SalA showed selectivity on gelatinase (MMP-2 and MMP-9) than on collagenase (MMP-8 and MMP-13) in vitro, and specificity on MMP-9 than MMP-2 in vivo. salvianolic acid A 0-4 matrix metallopeptidase 2 Mus musculus 39-44 25149191-10 2014 Finally, in HR-1 hairless mice, administration of GW501516 significantly reduced UVB-induced MMP-2 expression with a concomitant increase in elastin levels, and these effects were significantly reduced by the presence of GSK0660. GW 501516 50-58 matrix metallopeptidase 2 Mus musculus 93-98 25139400-8 2014 Aortic matrix metalloproteinase-2 (MMP-2) expression was decreased in CIH+DHA mice (p=0.007). cih 70-73 matrix metallopeptidase 2 Mus musculus 7-33 25139400-8 2014 Aortic matrix metalloproteinase-2 (MMP-2) expression was decreased in CIH+DHA mice (p=0.007). cih 70-73 matrix metallopeptidase 2 Mus musculus 35-40 25139400-8 2014 Aortic matrix metalloproteinase-2 (MMP-2) expression was decreased in CIH+DHA mice (p=0.007). Docosahexaenoic Acids 74-77 matrix metallopeptidase 2 Mus musculus 7-33 25139400-8 2014 Aortic matrix metalloproteinase-2 (MMP-2) expression was decreased in CIH+DHA mice (p=0.007). Docosahexaenoic Acids 74-77 matrix metallopeptidase 2 Mus musculus 35-40 25050737-8 2014 Rottlerin inhibited the markers of angiogenesis (Cox-2, VEGF, VEGFR, and IL-8), and metastasis (MMP-2 and MMP-9), thus blocking production of tumorigenic mediators in tumor microenvironment. rottlerin 0-9 matrix metallopeptidase 2 Mus musculus 96-101 24977660-0 2014 Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways. formononetin 0-12 matrix metallopeptidase 2 Mus musculus 102-107 24977660-7 2014 In vitro, formononetin reduced the expression of matrix metalloproteinase-2 (MMP-2), MMP-9 and increased the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2. formononetin 10-22 matrix metallopeptidase 2 Mus musculus 49-75 24977660-7 2014 In vitro, formononetin reduced the expression of matrix metalloproteinase-2 (MMP-2), MMP-9 and increased the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2. formononetin 10-22 matrix metallopeptidase 2 Mus musculus 77-82 24977660-9 2014 Collectively, these results suggest that formononetin inhibited breast cancer cell migration and invasion by reducing the expression of MMP-2 and MMP-9 through the PI3K/AKT signaling pathway. formononetin 41-53 matrix metallopeptidase 2 Mus musculus 136-141 25284985-6 2014 Furthermore, IFNgamma and/or celecoxib treatment decreased expression of matrix metalloproteinase (MMP)-2, MMP-9, and VEGF, as well as the density of microvessels in the tumors, compared to the control group. Celecoxib 29-38 matrix metallopeptidase 2 Mus musculus 73-105 24916705-6 2014 SalA showed selectivity on gelatinase (MMP-2 and MMP-9) than on collagenase (MMP-8 and MMP-13) in vitro, and specificity on MMP-9 than MMP-2 in vivo. salvianolic acid A 0-4 matrix metallopeptidase 2 Mus musculus 135-140 25533689-11 2014 The effect of fasudil was possibly related to increase the production of TIMP1 and decrease the production of CyclinD1 and MMP2. fasudil 14-21 matrix metallopeptidase 2 Mus musculus 123-127 24938458-0 2014 Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE-cadherin/EphA2/MMP9/MMP2 expression. Ginsenosides 0-11 matrix metallopeptidase 2 Mus musculus 121-125 24938458-8 2014 In conclusion, ginsenoside Rg3 effectively inhibited the formation of pancreatic cancer vasculogenic mimicry by downregulating the expression of VE-cadherin, EphA2, MMP9 and MMP2. Ginsenosides 15-26 matrix metallopeptidase 2 Mus musculus 174-178 24476004-10 2014 HCC tumors developed in mice by DEN-induction with administration of NSC 74859 resulted in decreased expression of c-myc, MMP-2, and MMP-9, but not SOCS3. Diethylnitrosamine 32-35 matrix metallopeptidase 2 Mus musculus 122-127 24877640-5 2014 When the administrated dose of SOPH was 600 mg/kg per day, great changes were observed in the exposed uterine morphology and up-regulated progesterone receptor (PR) and down-regulated estrogen receptor alpha (ERalpha), E-cadherin, matrix metalloproteinase-2 (MMP-2) and integrin beta3 were also found in SOPH-exposed uterine. sophoricoside 31-35 matrix metallopeptidase 2 Mus musculus 231-257 24877640-5 2014 When the administrated dose of SOPH was 600 mg/kg per day, great changes were observed in the exposed uterine morphology and up-regulated progesterone receptor (PR) and down-regulated estrogen receptor alpha (ERalpha), E-cadherin, matrix metalloproteinase-2 (MMP-2) and integrin beta3 were also found in SOPH-exposed uterine. sophoricoside 31-35 matrix metallopeptidase 2 Mus musculus 259-264 25065266-10 2014 Although HIF-1alpha expression and MMP-2 activity in the original tumor was significantly suppressed in the groups of mice treated with either DXR or S-1 alone, the addition of h-LEH to either agent showed further enhancement of oxygen-mediated degradation of HIF-1alpha and suppression of MMP-2 activity. h-leh 177-182 matrix metallopeptidase 2 Mus musculus 290-295 24115593-0 2014 p38 Signaling in titanium particle-induced MMP-2 secretion and activation in differentiating MC3T3-E1 cells. Titanium 17-25 matrix metallopeptidase 2 Mus musculus 43-48 24115593-5 2014 Our results demonstrated MC3T3-E1 cells exposed to titanium particles had significantly increased levels of MMP-2 and MT1-MMP mRNA, whereas the TIMP-2 mRNA level was unchanged. Titanium 51-59 matrix metallopeptidase 2 Mus musculus 108-113 24115593-6 2014 In MC3T3-E1 cells, the protein expression of MMP-2, MT1-MMP, and active p38 was also elevated after titanium particle exposure, as detected by Western blot and Biotrak activity analyses. Titanium 100-108 matrix metallopeptidase 2 Mus musculus 45-50 24115593-7 2014 Inhibition studies showed that the specific p38 inhibitor SB203580 completely abrogated the increase in MMP-2 and MT1-MMP production induced by the titanium particles. SB 203580 58-66 matrix metallopeptidase 2 Mus musculus 104-109 24115593-7 2014 Inhibition studies showed that the specific p38 inhibitor SB203580 completely abrogated the increase in MMP-2 and MT1-MMP production induced by the titanium particles. Titanium 148-156 matrix metallopeptidase 2 Mus musculus 104-109 24115593-8 2014 Moreover, our results revealed that conditioned media-stimulated osteoclast formation was related to the MMP-2 activity of osteoblasts that were challenged with Ti particles. Titanium 161-163 matrix metallopeptidase 2 Mus musculus 105-110 25076423-12 2014 Further, in-vivo alpha-CD147 antibody intervention decreased liver MMP-2, -9, -13, -14, TGF-beta and alpha-SMA expression in CCl4 treated mice compared to controls. Carbon Tetrachloride 125-129 matrix metallopeptidase 2 Mus musculus 67-86 24840330-13 2014 Taken together, our findings reveal that Slit2 promotes DMBA/TPA-induced skin tumorigenesis by increasing cell proliferation, microvessel density, and invasive behavior of cutaneous squamous cell carcinoma, along with loss of basement membrane, by upregulation of MMP2 expression. 6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene 56-60 matrix metallopeptidase 2 Mus musculus 264-268 24418973-11 2014 ASA and ketorolac both decreased the activity of MMP-2, MMP-9, and uPA. Aspirin 0-3 matrix metallopeptidase 2 Mus musculus 49-54 24418973-11 2014 ASA and ketorolac both decreased the activity of MMP-2, MMP-9, and uPA. Ketorolac 8-17 matrix metallopeptidase 2 Mus musculus 49-54 24840330-13 2014 Taken together, our findings reveal that Slit2 promotes DMBA/TPA-induced skin tumorigenesis by increasing cell proliferation, microvessel density, and invasive behavior of cutaneous squamous cell carcinoma, along with loss of basement membrane, by upregulation of MMP2 expression. Tetradecanoylphorbol Acetate 61-64 matrix metallopeptidase 2 Mus musculus 264-268 24659124-7 2014 In vitro, imatinib inhibited cell proliferation, MMP-2 expression and activity and also attenuated the production of proinflammatory cytokines. Imatinib Mesylate 10-18 matrix metallopeptidase 2 Mus musculus 49-54 24964198-1 2014 The aim of this study was to explore the effects of 1,2-dichloroethane (1,2-DCE) on expression of aquaporins (AQPs) and matrix metalloproteinases (MMPs) in the process of brain edema formation. ethylene dichloride 52-70 matrix metallopeptidase 2 Mus musculus 147-151 24964198-1 2014 The aim of this study was to explore the effects of 1,2-dichloroethane (1,2-DCE) on expression of aquaporins (AQPs) and matrix metalloproteinases (MMPs) in the process of brain edema formation. ethylene dichloride 72-79 matrix metallopeptidase 2 Mus musculus 147-151 24807584-0 2014 MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine. gemcitabine 100-111 matrix metallopeptidase 2 Mus musculus 0-5 24807584-1 2014 To increase the antitumor efficacy, in the present study, we proposed several settings of matrix metalloproteinase (MMP)-2/9-oriented combinations that comprise the MMP-2/9-targeting fusion protein dFv-LDP and the MMP inhibitor doxycycline (DOX) in association with EGFR/HER2-bispecific fusion protein Ec-LDP-Hr, its enediyne-energized analogue Ec-LDP-Hr-AE, and gemcitabine (GEM). Doxycycline 228-239 matrix metallopeptidase 2 Mus musculus 90-122 24807584-1 2014 To increase the antitumor efficacy, in the present study, we proposed several settings of matrix metalloproteinase (MMP)-2/9-oriented combinations that comprise the MMP-2/9-targeting fusion protein dFv-LDP and the MMP inhibitor doxycycline (DOX) in association with EGFR/HER2-bispecific fusion protein Ec-LDP-Hr, its enediyne-energized analogue Ec-LDP-Hr-AE, and gemcitabine (GEM). gemcitabine 363-374 matrix metallopeptidase 2 Mus musculus 90-122 24807584-1 2014 To increase the antitumor efficacy, in the present study, we proposed several settings of matrix metalloproteinase (MMP)-2/9-oriented combinations that comprise the MMP-2/9-targeting fusion protein dFv-LDP and the MMP inhibitor doxycycline (DOX) in association with EGFR/HER2-bispecific fusion protein Ec-LDP-Hr, its enediyne-energized analogue Ec-LDP-Hr-AE, and gemcitabine (GEM). gemcitabine 376-379 matrix metallopeptidase 2 Mus musculus 90-122 24807584-13 2014 The MMP-2/9-oriented combination strategy that employs the MMP-2/9-targeting antibody-based fusion protein and the small molecular inhibitor DOX as the basic composed agents may enhance antitumor efficacy in association with the EGFR/HER2-targeting fusion protein and GEM. Doxycycline 141-144 matrix metallopeptidase 2 Mus musculus 4-9 24447911-7 2014 Notably, while both EPA and DHA reversed Ang II-mediated RECK suppression, DHA appeared to be more effective, and reversed Ang II-induced miR-21 expression, RECK suppression, MMP2 induction, and CF migration. Docosahexaenoic Acids 75-78 matrix metallopeptidase 2 Mus musculus 175-179 24746828-6 2014 In addition, the enzymatic activity and expression of matrix metalloproteinase (MMP)-2 was suppressed following beta-carotene treatment under both normoxia and hypoxia. beta Carotene 112-125 matrix metallopeptidase 2 Mus musculus 54-86 24746828-9 2014 Furthermore, mRNA levels of MMPs, membrane-type (MT) 2 MMP and tissue inhibitors of metalloproteinases in liver tumor tissues were also lower following beta-carotene treatment. beta Carotene 152-165 matrix metallopeptidase 2 Mus musculus 28-32 24997814-12 2014 The protein expression levels of CXCL9, CXCL10, CXCL11, MMP2, MMP9, MMP12, and TGF-Beta1 were significantly higher in CS group and SC group than those in the normal control group (all P<0.05). Cesium 118-120 matrix metallopeptidase 2 Mus musculus 56-60 24811863-10 2014 Tumors derived from Met-F-AEA and URB597 combination treated mice showed reduced EGFR, AKT and ERK activation and MMP2/MMP9 expressions when compared to Met-F-AEA or URB597 alone. cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester 34-40 matrix metallopeptidase 2 Mus musculus 114-118 24798452-7 2014 Mechanistically, MMP2, MMP9, and TNFSF11 levels in the aortas were reduced after EPA treatment. Eicosapentaenoic Acid 81-84 matrix metallopeptidase 2 Mus musculus 17-21 24656780-9 2014 Gallium nitrate reduced the serum levels of TNF-alpha, IL-6 and IFN-gamma (p<0.05) and the mRNA expression levels of these cytokine and MMPs (MMP2 and MMP9) in joint tissues. gallium nitrate 0-15 matrix metallopeptidase 2 Mus musculus 139-143 24256203-9 2014 Expression of cytokines and the activities of MMPs were already increased after 1 week of CaCl2 treatment, but were suppressed by CoCl2 treatment in association with reduced NF-kappaB (nuclear factor kappaB) phosphorylation. Calcium Chloride 90-95 matrix metallopeptidase 2 Mus musculus 46-50 24256203-9 2014 Expression of cytokines and the activities of MMPs were already increased after 1 week of CaCl2 treatment, but were suppressed by CoCl2 treatment in association with reduced NF-kappaB (nuclear factor kappaB) phosphorylation. cobaltous chloride 130-135 matrix metallopeptidase 2 Mus musculus 46-50 24631289-6 2014 The treatment with SB-3CT, a potent MMP inhibitor, prevented in these cells, the decrease of alpha-smooth actin and type-I collagen expression induced by MSC-CM, suggesting that MSC-CM could attenuate the fibrogenic response through mechanisms mediated by MMPs. SB 3CT compound 19-25 matrix metallopeptidase 2 Mus musculus 256-260 24656780-9 2014 Gallium nitrate reduced the serum levels of TNF-alpha, IL-6 and IFN-gamma (p<0.05) and the mRNA expression levels of these cytokine and MMPs (MMP2 and MMP9) in joint tissues. gallium nitrate 0-15 matrix metallopeptidase 2 Mus musculus 145-149 24677090-0 2014 Polysaccharide from Inonotus obliquus inhibits migration and invasion in B16-F10 cells by suppressing MMP-2 and MMP-9 via downregulation of NF-kappaB signaling pathway. Polysaccharides 0-14 matrix metallopeptidase 2 Mus musculus 102-107 24444547-8 2014 The results of this study indicate that topical application of GA inhibits DMBA/Croton oil induced two-stage skin carcinogenic process by modulating the antioxidants and MMPs (-2 & -9) in the mouse skin. Gallium 63-65 matrix metallopeptidase 2 Mus musculus 170-174 24464789-7 2014 Doxorubicin-induced cardiotoxicity was accompanied instead by elevations in atrial natriuretic peptide (ANP), BNP, connective tissue growth factor (CTGF), and matrix metalloproteinase 2 (MMP2) mRNAs, which were not elevated on co-treatment with ranolazine. Doxorubicin 0-11 matrix metallopeptidase 2 Mus musculus 159-185 24464789-7 2014 Doxorubicin-induced cardiotoxicity was accompanied instead by elevations in atrial natriuretic peptide (ANP), BNP, connective tissue growth factor (CTGF), and matrix metalloproteinase 2 (MMP2) mRNAs, which were not elevated on co-treatment with ranolazine. Doxorubicin 0-11 matrix metallopeptidase 2 Mus musculus 187-191 24444547-0 2014 Topical application of Gallic acid suppresses the 7,12-DMBA/Croton oil induced two-step skin carcinogenesis by modulating anti-oxidants and MMP-2/MMP-9 in Swiss albino mice. Gallic Acid 23-34 matrix metallopeptidase 2 Mus musculus 140-145 24444547-0 2014 Topical application of Gallic acid suppresses the 7,12-DMBA/Croton oil induced two-step skin carcinogenesis by modulating anti-oxidants and MMP-2/MMP-9 in Swiss albino mice. 6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene 50-59 matrix metallopeptidase 2 Mus musculus 140-145 24444547-6 2014 Skin collagen content, MMPs activities, LDH-isoenzymes and MMP-2/-9 expressions were increased in DMBA/Croton oil induced skin while decreased levels of enzymatic (GST, SOD, CAT & GPx) and non-enzymatic anti-oxidant (GSH) were noticed. 9,10-Dimethyl-1,2-benzanthracene 98-102 matrix metallopeptidase 2 Mus musculus 23-27 24444547-6 2014 Skin collagen content, MMPs activities, LDH-isoenzymes and MMP-2/-9 expressions were increased in DMBA/Croton oil induced skin while decreased levels of enzymatic (GST, SOD, CAT & GPx) and non-enzymatic anti-oxidant (GSH) were noticed. 9,10-Dimethyl-1,2-benzanthracene 98-102 matrix metallopeptidase 2 Mus musculus 59-67 24444547-6 2014 Skin collagen content, MMPs activities, LDH-isoenzymes and MMP-2/-9 expressions were increased in DMBA/Croton oil induced skin while decreased levels of enzymatic (GST, SOD, CAT & GPx) and non-enzymatic anti-oxidant (GSH) were noticed. Croton Oil 103-113 matrix metallopeptidase 2 Mus musculus 59-67 24444547-7 2014 On the other hand, GA co-treatment exhibited a significant protection by reverting back the altered levels of LDH-isoenzymes, antioxidants, collagen and MMP-2/MMP-9 activities. Gallium 19-21 matrix metallopeptidase 2 Mus musculus 153-158 24535052-0 2014 beta-Elemene inhibits the metastasis of B16F10 melanoma cells by downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9. beta-elemene 0-12 matrix metallopeptidase 2 Mus musculus 112-117 24535052-9 2014 The expression of uPA, uPAR, MMP-2, and MMP-9 was reduced by beta-elemene at both the mRNA and protein level. beta-elemene 61-73 matrix metallopeptidase 2 Mus musculus 29-34 24535052-10 2014 beta-Elemene inhibits the metastasis of B16F10 melanoma cells through downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9. beta-elemene 0-12 matrix metallopeptidase 2 Mus musculus 117-122 24453131-9 2014 Furthermore, DHA supplementation attenuated pulmonary fibrosis, which was associated with the reduction of matrix metalloproteinases 2, 3, and 8 (P <= 0.03) and collagen mRNA (P <= 0.05), and decreased collagen (P < 0.01) and vimentin (P <= 0.03) protein concentrations. Docosahexaenoic Acids 13-16 matrix metallopeptidase 2 Mus musculus 107-144 24412388-8 2014 KEY FINDINGS: The data indicate that alteronol can inhibit the proliferation, invasion, and migration of B16F1 and B16F10 cells in vitro and in vivo, decrease the activity and expression of MMP-2, enhance the expression level of Tissue Inhibitor of Metalloproteinase-2 (TIMP-2), and inhibit the experimental lung metastasis of B16F1 and B16F10 cells. alteronol 37-46 matrix metallopeptidase 2 Mus musculus 190-195 24442316-12 2014 Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum ALT/AST, attenuated hepatic inflammation and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1. 1,10-phenanthroline 40-59 matrix metallopeptidase 2 Mus musculus 183-190 23518214-11 2014 CONCLUSIONS AND IMPLICATIONS: KMUP-1 and KMUP-S restore eNOS, inhibit iNOS/ROCKII/MMP-2/MMP-9, attenuate histologic collagen disposition and reduce BALF inflammatory cells, potentially useful for the treatment of BLM-lung PF. kmup-s 41-47 matrix metallopeptidase 2 Mus musculus 82-87 23676189-13 2014 CONCLUSIONS: BaP promotes Ang II-induced AAA formation in mice via elevating infiltration of macrophages, activating nuclear factor-kappaB, upregulating the expression of MMP-2, MMP-9, and MMP-12, and increasing the apoptosis of vascular muscle cells in its synergistic effect with Ang II in aortic wall. Benzo(a)pyrene 13-16 matrix metallopeptidase 2 Mus musculus 171-176 24337353-8 2014 Gelatin zymography showed that quercetin eliminated matrix metalloproteinase (MMP)-2 and MMP-9 activation during AAA formation. Quercetin 31-40 matrix metallopeptidase 2 Mus musculus 52-84 24337353-9 2014 In conclusion, the inhibitory effects of quercetin on oxidative stress and MMP activation, through modulation of JNK/AP-1 signaling, may partly account for its benefit in CaCl2-induced AAA. Quercetin 41-50 matrix metallopeptidase 2 Mus musculus 75-78 24337353-9 2014 In conclusion, the inhibitory effects of quercetin on oxidative stress and MMP activation, through modulation of JNK/AP-1 signaling, may partly account for its benefit in CaCl2-induced AAA. Calcium Chloride 171-176 matrix metallopeptidase 2 Mus musculus 75-78 24463094-7 2014 In addition, betulinic acid inhibited RANKL-induced osteoclastogenesis in murine bone marrow macrophages and decreased the production of resorbed area in plates with a bone biomimetic synthetic surface by suppressing the secretion of matrix metalloproteinase (MMP)-2, MMP-9, and cathepsin K in RANKL-induced osteoclasts. betulinic acid 13-27 matrix metallopeptidase 2 Mus musculus 234-266 24587397-8 2014 Combined stimulation with both smoke and RSV synergistically induced cytokine (IL-1alpha, IL-17, IFN-gamma, KC, IL-13, CXCL9, RANTES, MIF and GM-CSF) and protease (MMP-2, -8, -12, -13, -16 and cathepsins E, S, W and Z) expression. Respiratory Syncytial Virus Vaccines 41-44 matrix metallopeptidase 2 Mus musculus 164-169 24333535-7 2014 Activated MMP-2 was completely suppressed by pyridine6-PGLA-pre-treatment. pyridine6-pgla 45-59 matrix metallopeptidase 2 Mus musculus 10-15 24247590-8 2014 Furthermore, selenium increased 3T3-L1 cell migration, which was associated with the induction of matrix metalloproteinase (MMP)-2 and MMP-9. Selenium 13-21 matrix metallopeptidase 2 Mus musculus 98-130 24860243-8 2014 In addition, astaxanthin inhibited hepatic stellate cells (HSCs) activation and formation of extracellular matrix (ECM) by decreasing the expression of NF-kappaB and TGF-beta1 and maintaining the balance between MMP2 and TIMP1. astaxanthine 13-24 matrix metallopeptidase 2 Mus musculus 212-216 24859779-9 2014 YWPC and rosuvastatin decreased the expression and activity of matrix metalloproteinases (MMP)-2, 9, whereas the expression of the endogenous inhibitors of these proteins, namely, tissue inhibitors of matrix metalloproteinases (TIMP)-1, 2, increased when compared to the control group. ywpc 0-4 matrix metallopeptidase 2 Mus musculus 90-93 24859779-9 2014 YWPC and rosuvastatin decreased the expression and activity of matrix metalloproteinases (MMP)-2, 9, whereas the expression of the endogenous inhibitors of these proteins, namely, tissue inhibitors of matrix metalloproteinases (TIMP)-1, 2, increased when compared to the control group. Rosuvastatin Calcium 9-21 matrix metallopeptidase 2 Mus musculus 90-93 23535154-13 2013 Azelnidipine also reduced the number of macrophage antigen-3 (MAC-3)-positive cells in the periaortic adipose tissue and reduced the gene expression levels of tumor necrosis factor-alpha and matrix metalloproteinase-2 and -9 within the aortic wall. azelnidipine 0-12 matrix metallopeptidase 2 Mus musculus 191-224 25711080-1 2014 We have shown that antioxidant N-acetylcysteine (NAC, 2-10 mM) quickly (for 2 hours) and completely inactivates the activity of matrix metalloproteinases (gelatinases MMP-2 and MMP-9, and collagenases MMP-1 and MMP-8) secreted by transformed mouse fibroblasts 3T3-SV40 into the medium. Acetylcysteine 31-47 matrix metallopeptidase 2 Mus musculus 167-172 25711080-1 2014 We have shown that antioxidant N-acetylcysteine (NAC, 2-10 mM) quickly (for 2 hours) and completely inactivates the activity of matrix metalloproteinases (gelatinases MMP-2 and MMP-9, and collagenases MMP-1 and MMP-8) secreted by transformed mouse fibroblasts 3T3-SV40 into the medium. Acetylcysteine 49-52 matrix metallopeptidase 2 Mus musculus 167-172 24035828-2 2013 Here, we assessed the role of the MMP-2 KO in BBB injury, HT and other brain injuries after 1h of ischemia and 23 h of reperfusion. Hydrogen 92-94 matrix metallopeptidase 2 Mus musculus 34-39 24225494-7 2013 Treatment with zoledronate decreased matrix metalloproteinase-2 (MMP-2) in aortic tissues. Zoledronic Acid 15-26 matrix metallopeptidase 2 Mus musculus 37-63 24225494-7 2013 Treatment with zoledronate decreased matrix metalloproteinase-2 (MMP-2) in aortic tissues. Zoledronic Acid 15-26 matrix metallopeptidase 2 Mus musculus 65-70 24225494-10 2013 CONCLUSION: Zoledronate-attenuated Ang II induced AAA formation by suppression of MMP-2 activity and suppressed vascular inflammation and Ang II-induced Rho/ROCK activities. Zoledronic Acid 12-23 matrix metallopeptidase 2 Mus musculus 82-87 24314187-8 2013 Furthermore, vascular endothelial growth factor (VEGF), metalloproteinase-2 (MMP-2), and metalloproteinase-9 (MMP-9) levels were significantly lower in the groups with propranolol treated dosage of 5 and 10 mg kg(-1)day(-1) than in the control group. Propranolol 168-179 matrix metallopeptidase 2 Mus musculus 77-82 23959951-6 2013 Activity levels of matrix metalloproteinase-2 mirrored these changes and demonstrated clear additivity between nicotine and Ang II. Nicotine 111-119 matrix metallopeptidase 2 Mus musculus 19-45 24071448-3 2013 In an attempt to devise new approaches to selective inhibitor derivatives, we describe novel bisphosphonate bone seeking MMP inhibitors (BP-MMPIs), capable to be selectively targeted and to overcome undesired side effects of broad spectrum MMPIs. Diphosphonates 93-107 matrix metallopeptidase 2 Mus musculus 121-124 23932289-3 2013 In vivo study shows that after injection of the functionalized AuNPs to the tumor-bearing mice, the over-expressed protease of MMP-2 in tumor tissue and intracellular GSH can lead to the rapid release of the anti-tumor drug (doxorubicin) from the functionalized AuNPs to inhibit tumor growth and realize fluorescently imaging simultaneously. Doxorubicin 225-236 matrix metallopeptidase 2 Mus musculus 127-132 23471663-0 2013 Raloxifene upregulated mesangial cell MMP-2 activity via ER-beta through transcriptional regulation. Raloxifene Hydrochloride 0-10 matrix metallopeptidase 2 Mus musculus 38-43 23471663-2 2013 In this present study, we examined the effect of raloxifene on mesangial cell matrix metalloproteinase-2 (MMP-2) activity in streptozotocin-induced diabetic mice. Raloxifene Hydrochloride 49-59 matrix metallopeptidase 2 Mus musculus 78-104 23471663-2 2013 In this present study, we examined the effect of raloxifene on mesangial cell matrix metalloproteinase-2 (MMP-2) activity in streptozotocin-induced diabetic mice. Raloxifene Hydrochloride 49-59 matrix metallopeptidase 2 Mus musculus 106-111 23471663-2 2013 In this present study, we examined the effect of raloxifene on mesangial cell matrix metalloproteinase-2 (MMP-2) activity in streptozotocin-induced diabetic mice. Streptozocin 125-139 matrix metallopeptidase 2 Mus musculus 78-104 23471663-2 2013 In this present study, we examined the effect of raloxifene on mesangial cell matrix metalloproteinase-2 (MMP-2) activity in streptozotocin-induced diabetic mice. Streptozocin 125-139 matrix metallopeptidase 2 Mus musculus 106-111 23471663-3 2013 Raloxifene increased the MMP-2 level in a dose-dependent and receptor-mediated manner. Raloxifene Hydrochloride 0-10 matrix metallopeptidase 2 Mus musculus 25-30 23471663-4 2013 An antibody against estrogen receptor-beta (ER-beta) blocked the effect of raloxifene on MMP-2 expression, suggesting that the effect of raloxifene on MMP-2 activity was mediated by ER-beta. Raloxifene Hydrochloride 75-85 matrix metallopeptidase 2 Mus musculus 89-94 23471663-4 2013 An antibody against estrogen receptor-beta (ER-beta) blocked the effect of raloxifene on MMP-2 expression, suggesting that the effect of raloxifene on MMP-2 activity was mediated by ER-beta. Raloxifene Hydrochloride 75-85 matrix metallopeptidase 2 Mus musculus 151-156 23471663-4 2013 An antibody against estrogen receptor-beta (ER-beta) blocked the effect of raloxifene on MMP-2 expression, suggesting that the effect of raloxifene on MMP-2 activity was mediated by ER-beta. Raloxifene Hydrochloride 137-147 matrix metallopeptidase 2 Mus musculus 89-94 23471663-4 2013 An antibody against estrogen receptor-beta (ER-beta) blocked the effect of raloxifene on MMP-2 expression, suggesting that the effect of raloxifene on MMP-2 activity was mediated by ER-beta. Raloxifene Hydrochloride 137-147 matrix metallopeptidase 2 Mus musculus 151-156 23471663-5 2013 In addition, the transcription factor AP-2, that plays an important role in MMP-2 gene transcription, was overexpressed under raloxifene simulation. Raloxifene Hydrochloride 126-136 matrix metallopeptidase 2 Mus musculus 76-81 23471663-6 2013 The effect of MMP-2 was blocked by a selective inhibitor of the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathway, PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 155-162 matrix metallopeptidase 2 Mus musculus 14-19 23471663-7 2013 Our results suggested that raloxifene-induced MMP-2 activity increases function through ERK/MAPK signaling via AP-2. Raloxifene Hydrochloride 27-37 matrix metallopeptidase 2 Mus musculus 46-51 23471663-8 2013 In addition, we also found that the effect of raloxifene on MMP-2 expression was mediated via its binding to ER-beta. Raloxifene Hydrochloride 46-56 matrix metallopeptidase 2 Mus musculus 60-65 24077247-2 2013 Matrix metalloproteinases (MMPs) are Zn-dependent enzymes that regulate ECM turnover in concert with their inhibitors, tissue inhibitors of metalloproteinases (TIMPs). Zinc 37-39 matrix metallopeptidase 2 Mus musculus 27-31 24112050-12 2013 In summary, we show that MMPs are involved in ICV as determined by Cy5.5-AF443, a new optical marker to longitudinally and non-invasively follow MMP activity in acute skin inflammation in vivo. cyanine dye 5 67-70 matrix metallopeptidase 2 Mus musculus 25-29 24084445-15 2013 CD59 could inhibit the formation of atherosclerotic vulnerable plaque by suppressing the MMP-2 expression, which was further confirmed by HE staining. Helium 138-140 matrix metallopeptidase 2 Mus musculus 89-94 23820014-4 2013 A designer RNAi plasmid was developed, and complexed with the gene carrier polyethylenimine (PEI), in an effort to specifically suppress MMP-2 expression in tumor cells. Polyethyleneimine 75-91 matrix metallopeptidase 2 Mus musculus 137-142 23731681-9 2013 Real-time polymerase chain reaction of both aortic wall and perivascular adipose tissue demonstrated the expression of tumor necrosis factor-alpha, interleukin-6, and matrix metalloproteinase-2 was significantly decreased in eplerenone group, and that of monocyte chemoattractant protein-1 in the aortic wall was also significantly decreased. Eplerenone 225-235 matrix metallopeptidase 2 Mus musculus 167-193 24507390-14 2013 The expression of MMP-2 in the bleomycin plus stem cell group was lower than the bleomycin group [(1.59 +- 0.59) vs (2.37 +- 0.68), P < 0.05], but there was no difference between the control group and the stem cell group [(0.80 +- 0.69) vs (0.84 +- 0.77), P > 0.05]. Bleomycin 31-40 matrix metallopeptidase 2 Mus musculus 18-23 24507390-14 2013 The expression of MMP-2 in the bleomycin plus stem cell group was lower than the bleomycin group [(1.59 +- 0.59) vs (2.37 +- 0.68), P < 0.05], but there was no difference between the control group and the stem cell group [(0.80 +- 0.69) vs (0.84 +- 0.77), P > 0.05]. Bleomycin 81-90 matrix metallopeptidase 2 Mus musculus 18-23 24141049-2 2013 Matrix metalloproteinase-2 (MMP-2), a Zn(2+)-dependent proteolytic enzyme, is involved in a wide variety of pathological and physiological pathways. Zinc 38-44 matrix metallopeptidase 2 Mus musculus 0-26 24141049-2 2013 Matrix metalloproteinase-2 (MMP-2), a Zn(2+)-dependent proteolytic enzyme, is involved in a wide variety of pathological and physiological pathways. Zinc 38-44 matrix metallopeptidase 2 Mus musculus 28-33 23820014-4 2013 A designer RNAi plasmid was developed, and complexed with the gene carrier polyethylenimine (PEI), in an effort to specifically suppress MMP-2 expression in tumor cells. Polyethyleneimine 93-96 matrix metallopeptidase 2 Mus musculus 137-142 23891792-11 2013 Although rtPA exacerbated this effect, pyruvate prevented it while sharply lowering MMP2/TIMP2 ratio and increasing phosphorylation of p70s6 kinase, Akt and Erk. Pyruvic Acid 39-47 matrix metallopeptidase 2 Mus musculus 84-88 23844899-4 2013 (4) Adipose tissue development in matrix metalloproteinase (MMP)-2 deficient mice, kept on a high-fat diet, was significantly impaired following administration of tolylsam (100 mg/kg per day for 15 weeks). 3-methyl-2-(4-(3-p-tolyl(1,2,4)oxadiazol-5-yl)benzenesulfonylamino)butyric acid 163-171 matrix metallopeptidase 2 Mus musculus 34-66 23844899-6 2013 (5) Treatment of MMP-2-deficient mice with tolylsam (100 mg/kg per day, 15 weeks) was associated with the preservation of collagen and a reduction in blood vessel size in adipose tissues in vivo. 3-methyl-2-(4-(3-p-tolyl(1,2,4)oxadiazol-5-yl)benzenesulfonylamino)butyric acid 43-51 matrix metallopeptidase 2 Mus musculus 17-22 23844899-7 2013 (6) Furthermore, plasma levels of triglycerides and free fatty acids were reduced by tolylsam treatment of MMP-2-deficient mice (100 mg/kg per day, 15 weeks), whereas nutrient adsorption in the intestine was not affected. Triglycerides 34-47 matrix metallopeptidase 2 Mus musculus 107-112 23844899-7 2013 (6) Furthermore, plasma levels of triglycerides and free fatty acids were reduced by tolylsam treatment of MMP-2-deficient mice (100 mg/kg per day, 15 weeks), whereas nutrient adsorption in the intestine was not affected. Fatty Acids, Nonesterified 52-68 matrix metallopeptidase 2 Mus musculus 107-112 23844899-7 2013 (6) Furthermore, plasma levels of triglycerides and free fatty acids were reduced by tolylsam treatment of MMP-2-deficient mice (100 mg/kg per day, 15 weeks), whereas nutrient adsorption in the intestine was not affected. 3-methyl-2-(4-(3-p-tolyl(1,2,4)oxadiazol-5-yl)benzenesulfonylamino)butyric acid 85-93 matrix metallopeptidase 2 Mus musculus 107-112 23831366-7 2013 The results showed that the 2 mg/kg/d late donepezil treatment was the optimal dosage and could ameliorate clinical and pathological parameters, improve magnetic resonance imaging outcomes, reduce the permeability of BBB, inhibit the production of MMP-2 and MMP-9, modulate the expression of NGF and proNGF, increase Th2 bias and the phosphorylation of Akt in the brains of EAE mice. Donepezil 43-52 matrix metallopeptidase 2 Mus musculus 248-253 23172826-7 2013 GW5074, a Raf inhibitor, and LY294002, a PI3K inhibitor, inhibited MMP-2 and -9 activities and invasion in CT-26 cells. 5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone 0-6 matrix metallopeptidase 2 Mus musculus 67-79 23172826-7 2013 GW5074, a Raf inhibitor, and LY294002, a PI3K inhibitor, inhibited MMP-2 and -9 activities and invasion in CT-26 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 matrix metallopeptidase 2 Mus musculus 67-79 23899323-3 2013 Triazole-substituted MMPIs, discovered by our group, are highly potent inhibitors of MMP-2, -8, -9, and -13. Triazoles 0-8 matrix metallopeptidase 2 Mus musculus 85-90 24069197-9 2013 In addition, LiCl or atorvastatin could reduce MMP-2/9 activity in the aortic arch but not in the ligated area of the CCA. Lithium Chloride 13-17 matrix metallopeptidase 2 Mus musculus 47-52 24069197-9 2013 In addition, LiCl or atorvastatin could reduce MMP-2/9 activity in the aortic arch but not in the ligated area of the CCA. Atorvastatin 21-33 matrix metallopeptidase 2 Mus musculus 47-52 23676255-7 2013 Consistent with the in vivo data, TLR3 deficiency suppressed MMP-2 activity induced by TNF-alpha or polyinosine-polycytidylic acid in macrophages from Apoe(-/-)Npc1(-/-) mice. polyinosine-polycytidylic acid 100-130 matrix metallopeptidase 2 Mus musculus 61-66 23940734-10 2013 HI or Ibo produced activation of MMP-2 activities 6 hours post-insult, in cortices of WT mice but not in t-PA-/- mice. isobutyramide 6-9 matrix metallopeptidase 2 Mus musculus 33-38 22627943-8 2013 DAPT-treated melanomas also exhibited an up-regulation of MMP-2 and VEGFR1, both known as VM mediators. dapt 0-4 matrix metallopeptidase 2 Mus musculus 58-63 23904380-9 2013 The ovarian and uterine weights, and the expression levels of MMP-2, ANG and CD34 were significantly increased in DS147-treated groups when compared with COS group. ds147 114-119 matrix metallopeptidase 2 Mus musculus 62-67 23904380-10 2013 The TIMP-2 expression level was much lower in DS147-treated mice than in COS mice and the ratio of MMP-2/TIMP-2 was much higher in DS147-treated group than in COS group, and even higher than normal control group. ds147 131-136 matrix metallopeptidase 2 Mus musculus 99-104 23904380-10 2013 The TIMP-2 expression level was much lower in DS147-treated mice than in COS mice and the ratio of MMP-2/TIMP-2 was much higher in DS147-treated group than in COS group, and even higher than normal control group. carbonyl sulfide 159-162 matrix metallopeptidase 2 Mus musculus 99-104 23636169-5 2013 Compared to fistulae of vehicle-treated mice, the fistulae of simvastatin-treated mice had the expected decrease in VEGF-A and MMP-9 but also showed a significant reduction in MMP-2 expression with a significant decrease in VNH and a significant increase in the mean lumen vessel area. Simvastatin 62-73 matrix metallopeptidase 2 Mus musculus 176-181 23684930-9 2013 EA also reversed epithelial to mesenchymal transition by up-regulating E-cadherin and inhibiting the expression of Snail, MMP-2 and MMP-9. Ellagic Acid 0-2 matrix metallopeptidase 2 Mus musculus 122-127 23707755-8 2013 As anticipated from these findings, livers from pilocarpine-treated mice exhibited reduced expression of key players in fibrosis (alpha1 collagen, alpha-smooth muscle actin, TGF-beta1, PGDF, TGF-beta1R, PGDFR) and decreased mRNA levels for molecules that regulate extracellular matrix formation (TIMP-1, TIMP-2, MMP-2, MMP-13). Pilocarpine 48-59 matrix metallopeptidase 2 Mus musculus 312-317 23526212-7 2013 We also examined the effects of estradiol and Faslodex on MMP2 expression and activity in tuberin-deficient cells in vitro. Fulvestrant 46-54 matrix metallopeptidase 2 Mus musculus 58-62 23526212-8 2013 Estradiol resulted in a marked reduction of Type IV collagen deposition in xenograft tumors, associated with 2-fold greater MMP2 concentrations compared with placebo-treated mice. Estradiol 0-9 matrix metallopeptidase 2 Mus musculus 124-128 23526212-10 2013 In vitro, estradiol enhanced MMP2 transcripts, protein accumulation, and activity. Estradiol 10-19 matrix metallopeptidase 2 Mus musculus 29-33 23526212-11 2013 These estradiol-induced changes in MMP2 were blocked by Faslodex. Estradiol 6-15 matrix metallopeptidase 2 Mus musculus 35-39 23526212-11 2013 These estradiol-induced changes in MMP2 were blocked by Faslodex. Fulvestrant 56-64 matrix metallopeptidase 2 Mus musculus 35-39 23526212-12 2013 In TSC2-deficient cells, estradiol increased MMP2 concentrations in vitro and in vivo, and induced extracellular matrix remodeling. Estradiol 25-34 matrix metallopeptidase 2 Mus musculus 45-49 23554457-7 2013 In mitral valves from SOD1-deficient mice, expression of CTGF, MMP2, Nox2, and Nox4 was significantly increased, suggesting that ROS can independently activate pro-fibrotic and matrix remodelling gene expression patterns. Reactive Oxygen Species 129-132 matrix metallopeptidase 2 Mus musculus 63-67 23806407-0 2013 Alterations in deoxyribonucleic acid (DNA) methylation patterns of Calca, Timp3, Mmp2, and Igf2r are associated with chronic cystitis in a cyclophosphamide-induced mouse model. Cyclophosphamide 139-155 matrix metallopeptidase 2 Mus musculus 81-85 23755735-8 2013 Collectively, these findings indicate that activation of Wnt5a-Ror2 signaling in epithelial cells undergoing EMT may play an important role in disrupting TBM via MMP-2 induction during renal fibrosis. metsulfuron methyl 154-157 matrix metallopeptidase 2 Mus musculus 162-167 23649370-0 2013 Bis(alpha-furancarboxylato)oxovanadium(IV) exerts durable antidiabetic effects and suppresses matrix metalloproteinase-2 activity in spontaneous type 2 diabetic KKAy mice. bis(alpha-furancarboxylato)oxovanadium 0-38 matrix metallopeptidase 2 Mus musculus 94-120 23688254-5 2013 (R)-2-(4-(4-Fluorobenzamido)phenylsulfonamido)-3-(1H-indol-3-yl)propanoic acid (7) exhibited the best in vitro binding properties: MMP2 IC50 = 1.8 nM, MMP9 IC50 = 7.2 nM. (r)-2-(4-(4-fluorobenzamido)phenylsulfonamido)-3-(1h-indol-3-yl)propanoic acid 0-78 matrix metallopeptidase 2 Mus musculus 131-135 23122666-10 2013 In contrast, MMP2 and MMP7 were significantly upregulated in the EET-treated groups, whereas TIMP1 and TNF-alpha were downregulated. EET 65-68 matrix metallopeptidase 2 Mus musculus 13-17 23442578-3 2013 The Enzchek gelatinase/collagenase assay showed that rBJ46a inhibited MMP activities (IC50=0.119 mg/ml). rbj46a 53-59 matrix metallopeptidase 2 Mus musculus 70-73 23442578-4 2013 Kinetic analyses using a series of double reciprocal Lineweaver-Burk plots (1/V vs. 1/S) showed a competitive mode of inhibition with rBJ46a with inhibitory efficiency against MMPs (Ki=13.6 nmol/l). rbj46a 134-140 matrix metallopeptidase 2 Mus musculus 176-180 23442578-14 2013 Thus, rBJ46a can inhibit the invasion and metastasis of tumor cells by reducing MMP2/MMP9 activities, indicating that rBJ46a may be a novel therapeutic agent for antimetastasis of tumor cells. rbj46a 6-12 matrix metallopeptidase 2 Mus musculus 80-84 23442578-14 2013 Thus, rBJ46a can inhibit the invasion and metastasis of tumor cells by reducing MMP2/MMP9 activities, indicating that rBJ46a may be a novel therapeutic agent for antimetastasis of tumor cells. rbj46a 118-124 matrix metallopeptidase 2 Mus musculus 80-84 26798667-7 2013 RESULTS: Indomethacin treatment led to a statistically significant reduction of aortic elastin degeneration and macrophage infiltration, as well as a lessening of MMP-2, MMP-9, and MMP-12 upregulation. Indomethacin 9-21 matrix metallopeptidase 2 Mus musculus 163-168 23649370-7 2013 Gelatin zymography showed that serum MMP2 activity was significantly reduced and immunoblotting assays further showed that MMP2 expression was markedly downregulated in the liver after 1 month of treatment with 70 mumol/kg and 4 months after BFOV withdrawal (P <0.05 in all vs. diabetic controls). bis(alpha-furancarboxylato)oxovanadium(IV) 242-246 matrix metallopeptidase 2 Mus musculus 123-127 23412976-9 2013 MMP-2 expression was lower in the primary tumours in the cisplatin plus 4-HR combination group than in the cisplatin-only group (p<0.001). Cisplatin 57-66 matrix metallopeptidase 2 Mus musculus 0-5 23734997-0 2013 Resolution of liver fibrosis by isoquinoline alkaloid berberine in CCl4-intoxicated mice is mediated by suppression of oxidative stress and upregulation of MMP-2 expression. Tubocurarine 32-53 matrix metallopeptidase 2 Mus musculus 156-161 23734997-0 2013 Resolution of liver fibrosis by isoquinoline alkaloid berberine in CCl4-intoxicated mice is mediated by suppression of oxidative stress and upregulation of MMP-2 expression. Berberine 54-63 matrix metallopeptidase 2 Mus musculus 156-161 23734997-9 2013 The high-dose berberine (9 mg/kg) ameliorated oxidative stress, decreased TNF-alpha and TGF-beta1 expression, increased the levels of matrix metalloproteinase (MMP)-2, and stimulated the elimination of fibrous deposits. Berberine 14-23 matrix metallopeptidase 2 Mus musculus 134-166 23734997-12 2013 The results of this study suggest that berberine could ameliorate liver fibrosis through the suppression of hepatic oxidative stress and fibrogenic potential, concomitantly stimulating the degradation of collagen deposits by MMP-2. Berberine 39-48 matrix metallopeptidase 2 Mus musculus 225-230 23412976-9 2013 MMP-2 expression was lower in the primary tumours in the cisplatin plus 4-HR combination group than in the cisplatin-only group (p<0.001). Cisplatin 107-116 matrix metallopeptidase 2 Mus musculus 0-5 23312504-8 2013 Beta-glycerophosphate administration induced calcium deposition in MMP-2(+/+) aorta-derived cultured SMCs, and this calcium deposition was significantly suppressed in MMP-2(-/-) aorta-derived cultured SMCs. beta-glycerophosphoric acid 0-21 matrix metallopeptidase 2 Mus musculus 67-72 23678518-9 2004 CGS25966 is a broad-spectrum, small-molecule inhibitor of MMPs (11). N-hydroxy-2-(((4'-methoxyphenyl)sulfonyl)benzylamino)-3-methylbutanamide 0-8 matrix metallopeptidase 2 Mus musculus 58-62 23077110-0 2013 Inducible nitric oxide synthase inhibition increases MMP-2 activity leading to imbalance between extracellular matrix deposition and degradation after polypropylene mesh implant. Nitric Oxide 10-22 matrix metallopeptidase 2 Mus musculus 53-58 23077110-0 2013 Inducible nitric oxide synthase inhibition increases MMP-2 activity leading to imbalance between extracellular matrix deposition and degradation after polypropylene mesh implant. Polypropylenes 151-164 matrix metallopeptidase 2 Mus musculus 53-58 23077110-3 2013 We hypothesized that nitric oxide produced by nitric oxide synthase 2 (NOS2) and MMP-2 and -9 participate in response induced by mesh implants in the abdominal wall and, consequently, affect the outcome of the surgical procedure. Nitric Oxide 21-33 matrix metallopeptidase 2 Mus musculus 81-93 23077110-9 2013 Polypropylene mesh implant induced a pro-inflammatory environment mediated by intense MMP-2 and -9 activities, NO release, and interleukin-1beta production peaking in 7 days and gradually decreasing after 15 days. Polypropylenes 0-13 matrix metallopeptidase 2 Mus musculus 86-98 23349314-3 2013 The imaging agent used to visualize tumors was MMP-activatable photoacoustic probe, Alexa750-CXeeeeXPLGLAGrrrrrXK-BHQ3. alexa750-cxeeeexplglagrrrrrxk 84-113 matrix metallopeptidase 2 Mus musculus 47-50 23349314-4 2013 Cleavage of the MMP-activatable agent was imaged after intratumoral and intravenous injections in living mice optically, observing the increase in Alexa750 fluorescence, and photoacoustically, using a dual-wavelength imaging method. alexa750 147-155 matrix metallopeptidase 2 Mus musculus 16-19 23312504-8 2013 Beta-glycerophosphate administration induced calcium deposition in MMP-2(+/+) aorta-derived cultured SMCs, and this calcium deposition was significantly suppressed in MMP-2(-/-) aorta-derived cultured SMCs. beta-glycerophosphoric acid 0-21 matrix metallopeptidase 2 Mus musculus 167-172 23312504-8 2013 Beta-glycerophosphate administration induced calcium deposition in MMP-2(+/+) aorta-derived cultured SMCs, and this calcium deposition was significantly suppressed in MMP-2(-/-) aorta-derived cultured SMCs. Calcium 45-52 matrix metallopeptidase 2 Mus musculus 67-72 23312504-8 2013 Beta-glycerophosphate administration induced calcium deposition in MMP-2(+/+) aorta-derived cultured SMCs, and this calcium deposition was significantly suppressed in MMP-2(-/-) aorta-derived cultured SMCs. Calcium 116-123 matrix metallopeptidase 2 Mus musculus 167-172 23621233-11 2013 Cisplatin upregulated the expression of MMP-2 in both recurrent tumours and HCCLM3, while genistein abolished cisplatin-induced MMP-2 expression. Genistein 90-99 matrix metallopeptidase 2 Mus musculus 128-133 24377539-6 2013 The GdCl3 pretreatment had no effect on the quantity of Kupffer cells, but clearly restrained their functions, with decrease of TNF-alpha and IFN-gamma levels and elevation of MMP2. gadolinium chloride 4-9 matrix metallopeptidase 2 Mus musculus 176-180 23322905-6 2013 In response to phorbol ester-induced inflammation, mice deficient in matrix metalloproteinase 2 (MMP2) showed reduced accumulation of serum proteins in the skin and exhibited different proteolytic networks from those of wild-type mice. Phorbol Esters 15-28 matrix metallopeptidase 2 Mus musculus 69-95 23322905-6 2013 In response to phorbol ester-induced inflammation, mice deficient in matrix metalloproteinase 2 (MMP2) showed reduced accumulation of serum proteins in the skin and exhibited different proteolytic networks from those of wild-type mice. Phorbol Esters 15-28 matrix metallopeptidase 2 Mus musculus 97-101 23621233-11 2013 Cisplatin upregulated the expression of MMP-2 in both recurrent tumours and HCCLM3, while genistein abolished cisplatin-induced MMP-2 expression. Cisplatin 0-9 matrix metallopeptidase 2 Mus musculus 40-45 23621233-11 2013 Cisplatin upregulated the expression of MMP-2 in both recurrent tumours and HCCLM3, while genistein abolished cisplatin-induced MMP-2 expression. Cisplatin 110-119 matrix metallopeptidase 2 Mus musculus 128-133 23621233-12 2013 CONCLUSIONS: Genistein reinforced the inhibitory effect of cisplatin on HCC cell proliferation and tumour recurrence and metastasis after curative hepatectomy in nude mice, possibly through mitigation of cisplatin-induced MMP-2 upregulation. Genistein 13-22 matrix metallopeptidase 2 Mus musculus 222-227 23621233-12 2013 CONCLUSIONS: Genistein reinforced the inhibitory effect of cisplatin on HCC cell proliferation and tumour recurrence and metastasis after curative hepatectomy in nude mice, possibly through mitigation of cisplatin-induced MMP-2 upregulation. Cisplatin 59-68 matrix metallopeptidase 2 Mus musculus 222-227 23621233-12 2013 CONCLUSIONS: Genistein reinforced the inhibitory effect of cisplatin on HCC cell proliferation and tumour recurrence and metastasis after curative hepatectomy in nude mice, possibly through mitigation of cisplatin-induced MMP-2 upregulation. Cisplatin 204-213 matrix metallopeptidase 2 Mus musculus 222-227 23509775-9 2013 Moreover, we assessed the distribution of matrix metalloproteinase- (MMP-) 9, MMP-2, and MMP-3 in developing mouse palates and these MMPs were observed in the MES. 2-(N-morpholino)ethanesulfonic acid 159-162 matrix metallopeptidase 2 Mus musculus 133-137 23069707-0 2013 PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. peg-co-pcl 0-10 matrix metallopeptidase 2 Mus musculus 39-44 23069707-1 2013 By taking advantage of the dramatically upregulated expression of matrix metalloproteinases MMP-2 and MMP-9 in glioblastomas and the powerful transport ability of low molecular weight protamine (LMWP), we constructed an activatable low molecular weight protamine (ALMWP) and conjugated it to PEG-PCL nanoparticles (NP) to develop a "smart" drug delivery system for enhanced targeted glioblastoma therapy. lmwp 195-199 matrix metallopeptidase 2 Mus musculus 92-97 23373992-11 2013 Incubation of A549 cells with simvastatin significantly reduced the levels of CD44, MMP2 and MMP9 (p <0.01), while significantly increased p53 (p < 0.01). Simvastatin 30-41 matrix metallopeptidase 2 Mus musculus 84-88 23573143-6 2013 Moreover, experimental results demonstrated that GLY decreased the protein expression and enzyme activity of MMP-2 and MMP-9. Glycine 49-52 matrix metallopeptidase 2 Mus musculus 109-114 24393555-0 2013 Osthole regulates TGF-beta1 and MMP-2/9 expressions via activation of PPARalpha/gamma in cultured mouse cardiac fibroblasts stimulated with angiotensin II. osthol 0-7 matrix metallopeptidase 2 Mus musculus 32-37 24393555-4 2013 RESULTS: Following treatment of cells with osthole at 2.5, 5, 10 and 20 mug/mL, the NF-kappaB and TGF-beta1 expressions were dose-dependently decreased, while the expressions of PPARalpha/gamma and MMP-2/9 were dose-dependently increased. osthol 43-50 matrix metallopeptidase 2 Mus musculus 198-205 24393555-6 2013 CONCLUSION: Osthole could inhibit the NF-kappaB and TGF-beta1 expressions by activation of PPARalpha/gamma, and subsequently enhance the MMP-2/9 expressions in cultured CFs, and these effects of osthole may play the beneficial roles in the prevention and treatment of myocardial fibrosis. osthol 12-19 matrix metallopeptidase 2 Mus musculus 137-142 24393555-6 2013 CONCLUSION: Osthole could inhibit the NF-kappaB and TGF-beta1 expressions by activation of PPARalpha/gamma, and subsequently enhance the MMP-2/9 expressions in cultured CFs, and these effects of osthole may play the beneficial roles in the prevention and treatment of myocardial fibrosis. osthol 195-202 matrix metallopeptidase 2 Mus musculus 137-142 23028104-8 2013 Serum levels of blood urea nitrogen and creatinine and urinary excretion levels of albumin and N-acetyl-beta-D-glucosaminidase were significantly elevated in diabetic MMP-2 KO mice when compared with wild-type diabetic littermates. Urea 22-26 matrix metallopeptidase 2 Mus musculus 167-172 23028104-8 2013 Serum levels of blood urea nitrogen and creatinine and urinary excretion levels of albumin and N-acetyl-beta-D-glucosaminidase were significantly elevated in diabetic MMP-2 KO mice when compared with wild-type diabetic littermates. Nitrogen 27-35 matrix metallopeptidase 2 Mus musculus 167-172 23028104-8 2013 Serum levels of blood urea nitrogen and creatinine and urinary excretion levels of albumin and N-acetyl-beta-D-glucosaminidase were significantly elevated in diabetic MMP-2 KO mice when compared with wild-type diabetic littermates. Creatinine 40-50 matrix metallopeptidase 2 Mus musculus 167-172 23031629-8 2013 HP-treated BMSCs (HP-BMSCs) showed a higher level of expression of proteins associated with migration, including CXC chemokine receptor type 4 (CXCR4), matrix metalloproteinase 2 (MMP-2), and MMP-9. Hematoporphyrins 0-2 matrix metallopeptidase 2 Mus musculus 152-178 23031629-8 2013 HP-treated BMSCs (HP-BMSCs) showed a higher level of expression of proteins associated with migration, including CXC chemokine receptor type 4 (CXCR4), matrix metalloproteinase 2 (MMP-2), and MMP-9. Hematoporphyrins 0-2 matrix metallopeptidase 2 Mus musculus 180-185 23109387-9 2013 Cy5.5-AF489 showed a specific tumor uptake, which was blocked by pre-injection of the unlabeled MMPI, and discriminated between tumors with high or low MMP-2/-9 expressions. cy5.5-af489 0-11 matrix metallopeptidase 2 Mus musculus 152-160 22795564-7 2012 RESULTS: The myricetin had no effects on the cell viability of the HGF and decreased the mRNA expression and enzyme activity of MMP-1, MMP-2 and MMP-8 in the HGF. myricetin 13-22 matrix metallopeptidase 2 Mus musculus 135-140 23144462-8 2012 Treatment with a broad spectrum MMP inhibitor (PD166793) prevented the Ang II-induced AAA in Timp3(-/-) and Timp3(-/-)/Mmp2(-/-) mice. (R)-2-(4'-bromo-biphenyl-4-sulfonyl-amino)-3-methyl-butyric acid 47-55 matrix metallopeptidase 2 Mus musculus 119-123 23108646-6 2012 These data point to a direct role for cardiomyocyte mineralocorticoid receptor in both deoxycorticosterone/salt-induced tissue inflammation and remodeling and suggest potential mechanisms for the cardioprotective effects of selective mineralocorticoid receptor blockade in cardiomyocytes that may involve regulation of matrix metalloproteinase 2/matrix metalloproteinase 9 activity and the transforming growth factor-beta-connective tissue growth factor profibrotic pathway. Salts 107-111 matrix metallopeptidase 2 Mus musculus 319-345 22957844-7 2012 Moreover, we revealed that TES inhibited the invasion and angiogenesis of breast cancer partially through miR-29b-mediated MMP-2 inhibition. mir-29b 106-113 matrix metallopeptidase 2 Mus musculus 123-128 23346299-9 2012 The activity of MMP-2 was decreased significantly by 84%, 70%, and 63% while MMP-9 activity was decreased significantly by 74%, 62%, and 39% with the increased resveratrol concentrations of 10, 20, and 40 micromol/L, respectively (P < 0.05). Resveratrol 160-171 matrix metallopeptidase 2 Mus musculus 16-21 23129308-6 2012 In this article, we have deepened the pattern of the beta-DG ectodomain digestion by MMP-2 by using a combined approach based on SDS-PAGE, Orbitrap, and HPLC-ESI-IT mass spectrometry. Sodium Dodecyl Sulfate 129-132 matrix metallopeptidase 2 Mus musculus 85-90 22886392-6 2012 Hcy treatment leads to activation of matrix metalloproteinases (MMPs) in cerebral circulation by inducing redox stress and ROS. Homocysteine 0-3 matrix metallopeptidase 2 Mus musculus 64-68 22886392-6 2012 Hcy treatment leads to activation of matrix metalloproteinases (MMPs) in cerebral circulation by inducing redox stress and ROS. Reactive Oxygen Species 123-126 matrix metallopeptidase 2 Mus musculus 64-68 22886392-7 2012 The hypothesis is that Hcy induces MMPs and suppresses tissue inhibitors of metalloproteinase (TIMPs), in part, by inhibiting the GABA-A receptor. Homocysteine 23-26 matrix metallopeptidase 2 Mus musculus 35-39 22962014-11 2012 Interestingly, cell apoptosis was not increased by annexin V treatment both in lung specimens and BAL fluid, but macrophages from mice treated with both PPE and annexin V expressed higher MMP-2 mRNA levels and had a trend for higher MMP-12 mRNA expression. ppe 153-156 matrix metallopeptidase 2 Mus musculus 188-193 24471092-6 2012 Moreover, oral administration of CTP prevented UVB-induced MMP-3 and -13 activities as well as MMP-2 and -9 expressions. Cytidine Triphosphate 33-36 matrix metallopeptidase 2 Mus musculus 95-107 23058919-7 2012 The palmitate-rich diet significantly increased plasma FA concentrations (P<0.01), enhanced atherosclerotic lesions (P<0.01), decreased plaque collagen content (P<0.01) and upregulated MMP-2 (P<0.05) in the aorta. Palmitates 4-13 matrix metallopeptidase 2 Mus musculus 194-199 22923507-14 2012 Matrix metalloproteinase-2 transcript levels were downregulated in LP (LP = 0.47 +- 0.03 vs. NP = 1 +- 0.01, normalized to NP, P < 0.001) and was restored at PP7 (0.70 +- 0.1, P < 0.001 vs. LP). leucylproline 67-69 matrix metallopeptidase 2 Mus musculus 0-26 23055317-3 2012 In this study, we were interested to see whether suramin could affect metalloproteinases (MMP) and improve the functional activity of the mdx diaphragm muscle. Suramin 49-56 matrix metallopeptidase 2 Mus musculus 90-93 22287125-1 2012 The purpose of this study was to use a near-infrared (NIR) fluorescent cyclic His-Try-Gly-Phe peptide to characterize and image the expressions of matrix metalloproteinases (MMPs), which are correlated with cancer promotion, in an inflammation-induced colorectal cancer (ICRC) model. cyclic his 71-81 matrix metallopeptidase 2 Mus musculus 174-178 22287125-1 2012 The purpose of this study was to use a near-infrared (NIR) fluorescent cyclic His-Try-Gly-Phe peptide to characterize and image the expressions of matrix metalloproteinases (MMPs), which are correlated with cancer promotion, in an inflammation-induced colorectal cancer (ICRC) model. Glycine 86-89 matrix metallopeptidase 2 Mus musculus 174-178 22287125-1 2012 The purpose of this study was to use a near-infrared (NIR) fluorescent cyclic His-Try-Gly-Phe peptide to characterize and image the expressions of matrix metalloproteinases (MMPs), which are correlated with cancer promotion, in an inflammation-induced colorectal cancer (ICRC) model. phe peptide 90-101 matrix metallopeptidase 2 Mus musculus 174-178 22287125-12 2012 The use of Cy5.5-C6 to target MMP-2 has the potential to be developed into an effective molecular imaging agent to monitor ICRC progress. cyanine dye 5 11-14 matrix metallopeptidase 2 Mus musculus 30-35 21962816-14 2012 Inhibition of Gbetagamma reduced peak MMP-2 activity at d 1 but not at d 7 and also reduced peak MMP-9 activity at d 3. gbetagamma 14-24 matrix metallopeptidase 2 Mus musculus 38-43 23359979-12 2012 The expression level of activated MMP-2 in the RSR group was down-regulated when compared with the blank control group, the Herceptin group, and the combination group (P < 0.05). arginylserylarginine 47-50 matrix metallopeptidase 2 Mus musculus 34-39 22923507-14 2012 Matrix metalloproteinase-2 transcript levels were downregulated in LP (LP = 0.47 +- 0.03 vs. NP = 1 +- 0.01, normalized to NP, P < 0.001) and was restored at PP7 (0.70 +- 0.1, P < 0.001 vs. LP). leucylproline 71-73 matrix metallopeptidase 2 Mus musculus 0-26 22923507-14 2012 Matrix metalloproteinase-2 transcript levels were downregulated in LP (LP = 0.47 +- 0.03 vs. NP = 1 +- 0.01, normalized to NP, P < 0.001) and was restored at PP7 (0.70 +- 0.1, P < 0.001 vs. LP). leucylproline 71-73 matrix metallopeptidase 2 Mus musculus 0-26 23259320-0 2012 Curcumin delays endometriosis development by inhibiting MMP-2 activity. Curcumin 0-8 matrix metallopeptidase 2 Mus musculus 56-61 23035046-6 2012 Treatment with simvastatin markedly inhibited MMP-2, MMP-3, and MMP-9 levels in lung and prevented alveolar destruction. Simvastatin 15-26 matrix metallopeptidase 2 Mus musculus 46-51 23035046-7 2012 The combination of rapamycin and simvastatin prevented both growth of TSC2-null lesions and lung destruction by inhibiting MMP-2, MMP-3, and MMP-9. Sirolimus 19-28 matrix metallopeptidase 2 Mus musculus 123-128 23035046-7 2012 The combination of rapamycin and simvastatin prevented both growth of TSC2-null lesions and lung destruction by inhibiting MMP-2, MMP-3, and MMP-9. Simvastatin 33-44 matrix metallopeptidase 2 Mus musculus 123-128 23259320-10 2012 In addition, curcumin inhibited production of active MMP-2 by down-regulating MT1MMP expression. Curcumin 13-21 matrix metallopeptidase 2 Mus musculus 53-58 23259320-11 2012 Moreover, endometriotic progression was directly linked with increased MMP-2/TIMP-2 ratio which was delayed by curcumin pretreatment. Curcumin 111-119 matrix metallopeptidase 2 Mus musculus 71-76 23013480-14 2012 The expression and secretion of MMP-2 were lower in the genistein-treated cultures than in the untreated cultures. Genistein 56-65 matrix metallopeptidase 2 Mus musculus 32-37 22859309-5 2012 In the absence of insulin, O-GlcNAc accumulation induced by thiamet-G, a specific OGA inhibitor, was able to increase the gene expression of differentiation markers, as well as the activity of MMP-2 and -9. o-glcnac 27-35 matrix metallopeptidase 2 Mus musculus 193-205 22859309-5 2012 In the absence of insulin, O-GlcNAc accumulation induced by thiamet-G, a specific OGA inhibitor, was able to increase the gene expression of differentiation markers, as well as the activity of MMP-2 and -9. thiamet G 60-69 matrix metallopeptidase 2 Mus musculus 193-205 22745359-0 2012 Anacardic acid inhibits the catalytic activity of matrix metalloproteinase-2 and matrix metalloproteinase-9. anacardic acid 0-14 matrix metallopeptidase 2 Mus musculus 50-107 22745359-4 2012 Our gelatin zymography studies on these two secreted gelatinases, present in the conditioned media from 3T3-L1 cells, established that anacardic acid directly inhibited the catalytic activities of both MMP-2 and MMP-9. anacardic acid 135-149 matrix metallopeptidase 2 Mus musculus 202-207 22745359-5 2012 Our docking studies suggested that anacardic acid binds into the MMP-2/9 active site, with the carboxylate group of anacardic acid chelating the catalytic zinc ion and forming a hydrogen bond to a key catalytic glutamate side chain and the C15 aliphatic group being accommodated within the relatively large S1" pocket of these gelatinases. anacardic acid 35-49 matrix metallopeptidase 2 Mus musculus 65-70 22745359-5 2012 Our docking studies suggested that anacardic acid binds into the MMP-2/9 active site, with the carboxylate group of anacardic acid chelating the catalytic zinc ion and forming a hydrogen bond to a key catalytic glutamate side chain and the C15 aliphatic group being accommodated within the relatively large S1" pocket of these gelatinases. carboxylate 95-106 matrix metallopeptidase 2 Mus musculus 65-70 22745359-5 2012 Our docking studies suggested that anacardic acid binds into the MMP-2/9 active site, with the carboxylate group of anacardic acid chelating the catalytic zinc ion and forming a hydrogen bond to a key catalytic glutamate side chain and the C15 aliphatic group being accommodated within the relatively large S1" pocket of these gelatinases. anacardic 35-44 matrix metallopeptidase 2 Mus musculus 65-70 22745359-5 2012 Our docking studies suggested that anacardic acid binds into the MMP-2/9 active site, with the carboxylate group of anacardic acid chelating the catalytic zinc ion and forming a hydrogen bond to a key catalytic glutamate side chain and the C15 aliphatic group being accommodated within the relatively large S1" pocket of these gelatinases. Hydrogen 178-186 matrix metallopeptidase 2 Mus musculus 65-70 22745359-5 2012 Our docking studies suggested that anacardic acid binds into the MMP-2/9 active site, with the carboxylate group of anacardic acid chelating the catalytic zinc ion and forming a hydrogen bond to a key catalytic glutamate side chain and the C15 aliphatic group being accommodated within the relatively large S1" pocket of these gelatinases. Glutamic Acid 211-220 matrix metallopeptidase 2 Mus musculus 65-70 22745359-6 2012 In agreement with the docking results, our fluorescence-based studies on the recombinant MMP-2 catalytic core domain demonstrated that anacardic acid directly inhibits substrate peptide cleavage in a dose-dependent manner, with an IC50 of 11.11 muM. anacardic acid 135-149 matrix metallopeptidase 2 Mus musculus 89-94 22745359-7 2012 In addition, our gelatinase zymography and fluorescence data confirmed that the cardol-cardanol mixture, salicylic acid, and aspirin, all of which lack key functional groups present in anacardic acid, are much weaker MMP-2/MMP-9 inhibitors. adipostatin A 80-86 matrix metallopeptidase 2 Mus musculus 217-222 22745359-7 2012 In addition, our gelatinase zymography and fluorescence data confirmed that the cardol-cardanol mixture, salicylic acid, and aspirin, all of which lack key functional groups present in anacardic acid, are much weaker MMP-2/MMP-9 inhibitors. cardanol 87-95 matrix metallopeptidase 2 Mus musculus 217-222 22745359-7 2012 In addition, our gelatinase zymography and fluorescence data confirmed that the cardol-cardanol mixture, salicylic acid, and aspirin, all of which lack key functional groups present in anacardic acid, are much weaker MMP-2/MMP-9 inhibitors. Salicylic Acid 105-119 matrix metallopeptidase 2 Mus musculus 217-222 22745359-7 2012 In addition, our gelatinase zymography and fluorescence data confirmed that the cardol-cardanol mixture, salicylic acid, and aspirin, all of which lack key functional groups present in anacardic acid, are much weaker MMP-2/MMP-9 inhibitors. Aspirin 125-132 matrix metallopeptidase 2 Mus musculus 217-222 22181324-1 2012 BACKGROUND AND OBJECTIVE: Although clarithromycin (CAM) has many biological functions, including regulation of MMPs, little is known about its effect on abdominal aortic aneurysms. Clarithromycin 35-49 matrix metallopeptidase 2 Mus musculus 111-115 22728078-8 2012 Quercetin also reduced the expression of matrix metalloproteinase (MMP)-2, MMP-9, cathepsin B, and cathepsin K in aortic tissue. Quercetin 0-9 matrix metallopeptidase 2 Mus musculus 41-73 22452531-5 2012 RESULTS: Cells secreted MMP-2 after 24 h with calcium hydroxide inducing significantly greater MMP-2 expression in relation to the control and the other root repair materials (P < 0.05). Calcium Hydroxide 46-63 matrix metallopeptidase 2 Mus musculus 24-29 22452531-5 2012 RESULTS: Cells secreted MMP-2 after 24 h with calcium hydroxide inducing significantly greater MMP-2 expression in relation to the control and the other root repair materials (P < 0.05). Calcium Hydroxide 46-63 matrix metallopeptidase 2 Mus musculus 95-100 22452531-9 2012 All materials had gelatinolytic activity for MMP-2 with calcium hydroxide being associated with the greatest activity. Calcium Hydroxide 56-73 matrix metallopeptidase 2 Mus musculus 45-50 22181324-1 2012 BACKGROUND AND OBJECTIVE: Although clarithromycin (CAM) has many biological functions, including regulation of MMPs, little is known about its effect on abdominal aortic aneurysms. Clarithromycin 51-54 matrix metallopeptidase 2 Mus musculus 111-115 22181324-10 2012 CONCLUSION: These findings suggest that CAM administration is useful to suppress periodontal bacteria-accelerated abdominal aortic aneurysms via MMP regulation. Clarithromycin 40-43 matrix metallopeptidase 2 Mus musculus 145-148 22505122-0 2012 Cryptotanshinone attenuates isoprenaline-induced cardiac fibrosis in mice associated with upregulation and activation of matrix metalloproteinase-2. cryptotanshinone 0-16 matrix metallopeptidase 2 Mus musculus 133-159 22614125-6 2012 UUO-renal fibrosis was also induced in MMP-2 deficient (MMP-2-/-) and MMP-2+/+ mice treated with minocycline (inhibitor of MMPs). Minocycline 97-108 matrix metallopeptidase 2 Mus musculus 123-127 22614125-10 2012 In contrast, the kidneys of MMP-2-/- mice and minocycline-treated MMP-2+/+ mice showed amelioration of renal fibrosis with reduced expression of markers of mesenchymal cells in tubular epithelial cells, inhibition of upregulated EMT-associated molecules, and suppression of macrophage infiltration. Minocycline 46-57 matrix metallopeptidase 2 Mus musculus 66-71 22828146-10 2012 Zymography confirmed that both MMP-2 and -9 were more active in PPE than PPE + doxycycline. ppe 64-67 matrix metallopeptidase 2 Mus musculus 31-43 22362388-7 2012 Reduced matrix metalloproteinase (MMP)-2 and MMP-9 expressions indicated a low profile of senescence-associated secretory phenotype (SASP) in the bleomycin-injured cav-1(-/-) mice. Bleomycin 146-155 matrix metallopeptidase 2 Mus musculus 8-40 22573549-6 2012 TNF-alpha and IL-1beta are the key cytokines involved in arthritis and also increase the activity of MMP-2 in RASF, which was antagonized by pretreatment with 15-LOX inhibitor PD146176 or knockdown of 15-LOX. 6,11-dihydro-5-thia-11-aza-benzo(a)-fluorene 176-184 matrix metallopeptidase 2 Mus musculus 101-106 22573549-8 2012 Treatment of glucocorticoid but not NSAIDs inhibited 15-(S)-HETE-induced expression of MMP-2. 15-hydroxy-5,8,11,13-eicosatetraenoic acid 53-64 matrix metallopeptidase 2 Mus musculus 87-92 22505122-4 2012 In this study we demonstrated that cryptotanshinone was able to significantly ameliorate isoprenaline-induced cardiac fibrosis, which was associated with a marked upregulation and activation of MMP-2 in the ventricular myocardium. cryptotanshinone 35-51 matrix metallopeptidase 2 Mus musculus 194-199 22505122-4 2012 In this study we demonstrated that cryptotanshinone was able to significantly ameliorate isoprenaline-induced cardiac fibrosis, which was associated with a marked upregulation and activation of MMP-2 in the ventricular myocardium. Isoproterenol 89-101 matrix metallopeptidase 2 Mus musculus 194-199 22505122-5 2012 Additionally, we demonstrated that cryptotanshinone dose-dependently upregulated and activated MMP-2 in cultured cardiac fibroblasts. cryptotanshinone 35-51 matrix metallopeptidase 2 Mus musculus 95-100 22505122-6 2012 Moreover, incubation with cryptotanshinone also prevented the isoprenaline-induced downregulation and inactivation of MMP-2 in cultured cardiac fibroblasts. cryptotanshinone 26-42 matrix metallopeptidase 2 Mus musculus 118-123 22505122-6 2012 Moreover, incubation with cryptotanshinone also prevented the isoprenaline-induced downregulation and inactivation of MMP-2 in cultured cardiac fibroblasts. Isoproterenol 62-74 matrix metallopeptidase 2 Mus musculus 118-123 22421441-8 2012 Levels of MMP-2 and MMP-9 activity, T1-alpha and thrombomodulin were also diminished in the DOX-treated group. Doxycycline 92-95 matrix metallopeptidase 2 Mus musculus 10-15 22550139-8 2012 Gelatin zymography and Western blot data showed that only doxycycline inhibited MMP-2 expression, whereas both drugs decreased Erk1/2 phosphorylation. Doxycycline 58-69 matrix metallopeptidase 2 Mus musculus 80-85 22550139-12 2012 CONCLUSIONS: These studies demonstrated that inhibition of MMP-2 by doxycycline delayed the manifestations of MFS, in part, through its ability to decrease active TGF-beta and the noncanonical signaling cascade downstream of TGF-beta. Doxycycline 68-79 matrix metallopeptidase 2 Mus musculus 59-64 22593944-14 2004 PEG-peptide-[(18)F]-TMR accumulated in HT1080 tumors (with high MMP2 expression) but not in MCF-7 tumors (with low MMP2 expression), as determined with optical imaging in nude mice. Polyethylene Glycols 0-4 matrix metallopeptidase 2 Mus musculus 64-68 22561688-6 2012 Mechanistically, we found that both nicotine and AngII activated AMPK-alpha2 in cultured vascular smooth muscle cells (VSMCs), resulting in the phosphorylation of activator protein 2alpha (AP-2alpha) and consequent matrix metallopeptidase 2 (MMP2) gene expression. Nicotine 36-44 matrix metallopeptidase 2 Mus musculus 215-240 22561688-6 2012 Mechanistically, we found that both nicotine and AngII activated AMPK-alpha2 in cultured vascular smooth muscle cells (VSMCs), resulting in the phosphorylation of activator protein 2alpha (AP-2alpha) and consequent matrix metallopeptidase 2 (MMP2) gene expression. Nicotine 36-44 matrix metallopeptidase 2 Mus musculus 242-246 22561688-7 2012 We conclude that smoking (through nicotine) instigates AAA through AMPK-alpha2-mediated AP-2alpha-dependent MMP2 expression in VSMCs. Nicotine 34-42 matrix metallopeptidase 2 Mus musculus 108-112 22369883-0 2012 Baicalein inhibits pulmonary carcinogenesis-associated inflammation and interferes with COX-2, MMP-2 and MMP-9 expressions in-vivo. baicalein 0-9 matrix metallopeptidase 2 Mus musculus 95-100 22261315-14 2012 The inhibitory effects of riccardin D on expressions of MMP-2 and MMP-9 were verified in H460 xenografts in mice and the decreases of vascular endothelial growth factor (VEGF) and Erk1/2 might associate with the inhibition of MMPs and NSCLC growth. riccardin D 26-37 matrix metallopeptidase 2 Mus musculus 56-61 22593944-14 2004 PEG-peptide-[(18)F]-TMR accumulated in HT1080 tumors (with high MMP2 expression) but not in MCF-7 tumors (with low MMP2 expression), as determined with optical imaging in nude mice. tetramethylrhodamine 20-23 matrix metallopeptidase 2 Mus musculus 64-68 22593948-13 2004 PEG-peptide-TMR accumulated in HT1080 tumors (with high MMP2 expression) but not in MCF-7 tumors (with low MMP2 expression), as determined with optical imaging in nude mice. peg-peptide 0-11 matrix metallopeptidase 2 Mus musculus 56-60 22593948-13 2004 PEG-peptide-TMR accumulated in HT1080 tumors (with high MMP2 expression) but not in MCF-7 tumors (with low MMP2 expression), as determined with optical imaging in nude mice. tetramethylrhodamine 12-15 matrix metallopeptidase 2 Mus musculus 56-60 22405766-4 2012 4-HNE induced the accumulation of inflammatory cells expressing high levels of MMP-2 and MMP-9. 4-hydroxy-2-nonenal 0-5 matrix metallopeptidase 2 Mus musculus 79-84 22365948-6 2012 In a mouse CaCl(2)-induced AAA model, the expression of HMGB1 was increased compared with that in sham, and was positively correlated with matrix metalloproteinase (MMP)-2 and MMP-9 activity. Calcium Chloride 11-18 matrix metallopeptidase 2 Mus musculus 139-171 21543204-3 2012 The aim of the present study was to analyze the suppressive effects of ferulic acid (FA), an abundant phenolic compound present in various dietary and medicinal plants, on UVB radiation-induced MMP-2 and -9 activities in mouse skin. ferulic acid 71-83 matrix metallopeptidase 2 Mus musculus 194-206 22042442-1 2012 OBJECTIVE: To assess the role of matrix metalloproteinase 2 (MMP-2) in the evolution of septic arthritis induced by group B streptococci (GBS) in mice. gbs 138-141 matrix metallopeptidase 2 Mus musculus 33-59 22042442-1 2012 OBJECTIVE: To assess the role of matrix metalloproteinase 2 (MMP-2) in the evolution of septic arthritis induced by group B streptococci (GBS) in mice. gbs 138-141 matrix metallopeptidase 2 Mus musculus 61-66 22042442-9 2012 Thus, MMP-2 should be regarded as a potential therapeutic target in GBS-induced arthritis. gbs 68-71 matrix metallopeptidase 2 Mus musculus 6-11 21448634-0 2012 Addition of zinc methacrylate in dental polymers: MMP-2 inhibition and ultimate tensile strength evaluation. Zinc methacrylate 12-29 matrix metallopeptidase 2 Mus musculus 50-55 21448634-1 2012 This study evaluated the effect of zinc methacrylate (ZM) on the inhibition of matrix metalloproteinase 2 (MMP-2) and the ultimate tensile strength (UTS) of an experimental polymer. Zinc methacrylate 35-52 matrix metallopeptidase 2 Mus musculus 79-105 21448634-1 2012 This study evaluated the effect of zinc methacrylate (ZM) on the inhibition of matrix metalloproteinase 2 (MMP-2) and the ultimate tensile strength (UTS) of an experimental polymer. Zinc methacrylate 35-52 matrix metallopeptidase 2 Mus musculus 107-112 21448634-1 2012 This study evaluated the effect of zinc methacrylate (ZM) on the inhibition of matrix metalloproteinase 2 (MMP-2) and the ultimate tensile strength (UTS) of an experimental polymer. zm 54-56 matrix metallopeptidase 2 Mus musculus 79-105 21448634-1 2012 This study evaluated the effect of zinc methacrylate (ZM) on the inhibition of matrix metalloproteinase 2 (MMP-2) and the ultimate tensile strength (UTS) of an experimental polymer. zm 54-56 matrix metallopeptidase 2 Mus musculus 107-112 22699690-6 2012 For heterologously expressed rod and cone CNG channels, extracellular exposure to MMPs dramatically increased the apparent affinity for cGMP and the efficacy of cAMP. Cyclic GMP 136-140 matrix metallopeptidase 2 Mus musculus 82-86 22699690-6 2012 For heterologously expressed rod and cone CNG channels, extracellular exposure to MMPs dramatically increased the apparent affinity for cGMP and the efficacy of cAMP. Cyclic AMP 161-165 matrix metallopeptidase 2 Mus musculus 82-86 22100390-3 2012 The aim of this study was to define the role of MMPs in regulating activation of trypsinogen and tissue damage in AP, which was induced by infusion of taurocholate into the pancreatic duct in mice. Taurocholic Acid 151-163 matrix metallopeptidase 2 Mus musculus 48-52 22100390-7 2012 Treatment with the broad-spectrum inhibitor of MMPs, BB-94, markedly reduced activation of trypsinogen, levels of CXCL2, infiltration of neutrophils, and tissue damage in AP. batimastat 53-58 matrix metallopeptidase 2 Mus musculus 47-51 22102319-12 2012 Effects of silymarin on TAA-induced chronic liver damage may be attributed to down-regulation of hepatic MMP-2, MMP-13, TIMP-1, TIMP-2, AP-1, KLF6, TGF-beta1, alpha-SMA and COL-alpha1. Silymarin 11-20 matrix metallopeptidase 2 Mus musculus 105-110 22088328-3 2012 Immunohistochemical staining and enzyme-linked immunosorbent assay demonstrated that MC-LR treatment (even at 1 nM) caused up-regulated expressions of hepatic MMP-2/-9. cyanoginosin LR 85-90 matrix metallopeptidase 2 Mus musculus 159-167 22326785-10 2012 Moreover, U0126, a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, also inhibited LM8 cell migration, invasion, adhesion, and metastasis, as well as the mRNA expression and protein activities of MMP-1, MMP-2, MMP-9, and MT1-MMP. U 0126 10-15 matrix metallopeptidase 2 Mus musculus 279-284 22326785-10 2012 Moreover, U0126, a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, also inhibited LM8 cell migration, invasion, adhesion, and metastasis, as well as the mRNA expression and protein activities of MMP-1, MMP-2, MMP-9, and MT1-MMP. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 84-92 matrix metallopeptidase 2 Mus musculus 279-284 22434630-1 2012 Two novel Gd-based contrast agents (CAs) for the molecular imaging of matrix metalloproteinases (MMPs) were synthetized and characterized in vitro and in vivo. Gadolinium 10-12 matrix metallopeptidase 2 Mus musculus 97-101 22434630-2 2012 These probes were based on the PLG*LWAR peptide sequence, known to be hydrolyzed between Gly and Leu by a broad panel of MMPs. Glycine 89-92 matrix metallopeptidase 2 Mus musculus 121-125 22434630-2 2012 These probes were based on the PLG*LWAR peptide sequence, known to be hydrolyzed between Gly and Leu by a broad panel of MMPs. Leucine 97-100 matrix metallopeptidase 2 Mus musculus 121-125 22434630-5 2012 Gd-K11 and Gd-K11N have a good affinity for beta-cyclodextrins (K(D) 310 and 670 micro m respectively) and for serum albumin (K(D) 350 and 90 micro m respectively), and can be efficiently cleaved in vitro at the expected site by MMP-2 and MMP-12. gd-k11 0-6 matrix metallopeptidase 2 Mus musculus 229-234 22088328-4 2012 Quantitative reverse-transcriptase PCR showed that the exposure to 80 nM MC-LR induced an increase of MMP-2/-9 mRNA levels by 1.0 and 1.9 fold. cyanoginosin LR 73-78 matrix metallopeptidase 2 Mus musculus 102-110 22088328-6 2012 Gelatin electrophoresis and quantitative PCR showed significant increases in cellular MMP-2/-9 expressions after MC-LR exposure. cyanoginosin LR 113-118 matrix metallopeptidase 2 Mus musculus 86-91 22088328-7 2012 This study indicated that chronic exposure to MC-LR could alter MMP-2/-9 expressions and stimulate cancer cell migration. cyanoginosin LR 46-51 matrix metallopeptidase 2 Mus musculus 64-72 22236605-10 2012 RESULTS: Silymarin caused a partial decrease in worm burden; hepatic tissue egg load, with an increase in percentage of dead eggs; modulation of granuloma size, with significant reduction of hepatic HYP content; tissue expression of MMP-2, TGF-beta1; number of mast cells, with conservation of hepatic reduced glutathione (GSH). Silymarin 9-18 matrix metallopeptidase 2 Mus musculus 233-238 22171591-6 2012 Strikingly, oral administration of the antioxidant dl-alpha-tocopherol acetate (vitamin E) decreased Hmox1, Mmp2 and Mmp14 mRNA expressions, and improved the skin tensile strength and structure of collagen fibres in TSOD mice. DL-alpha-Tocopherol acetate 51-78 matrix metallopeptidase 2 Mus musculus 108-112 22171591-6 2012 Strikingly, oral administration of the antioxidant dl-alpha-tocopherol acetate (vitamin E) decreased Hmox1, Mmp2 and Mmp14 mRNA expressions, and improved the skin tensile strength and structure of collagen fibres in TSOD mice. Vitamin E 80-89 matrix metallopeptidase 2 Mus musculus 108-112 22200376-9 2012 NaHS treatment decreased both the expressions of alpha5- and beta1-integrins and MMP-2. sodium bisulfide 0-4 matrix metallopeptidase 2 Mus musculus 81-86 22114177-10 2012 In Cl-IBMECA-treated mice, latent MMP-2 was decreased 20% 3 h postinjury, active MMP-3 was decreased 64% 3 h postinjury, and latent/active MMP-9 was decreased 417,631% 3 h postinjury and 20% 10 h postinjury. N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine 6-12 matrix metallopeptidase 2 Mus musculus 34-39 22244356-0 2012 Gentamicin supplemented polyvinylidenfluoride mesh materials enhance tissue integration due to a transcriptionally reduced MMP-2 protein expression. Gentamicins 0-10 matrix metallopeptidase 2 Mus musculus 123-128 22244356-0 2012 Gentamicin supplemented polyvinylidenfluoride mesh materials enhance tissue integration due to a transcriptionally reduced MMP-2 protein expression. polyvinylidenfluoride 24-45 matrix metallopeptidase 2 Mus musculus 123-128 22244356-10 2012 Both the 5 and 8 mug/mg gentamicin group showed significantly reduced levels of ss-galactosidase expression and MMP-2 positive stained cells when compared to the PVDF group on day 7, 21 and 90 respectively (5 mug/mg: p < 0.05 each; 8 mug/mg: p < 0.05 each). Gentamicins 24-34 matrix metallopeptidase 2 Mus musculus 112-117 22244356-13 2012 Gentamicin coating reduced MMP-2 transcription and protein expression. Gentamicins 0-10 matrix metallopeptidase 2 Mus musculus 27-32 22142190-1 2012 In this study, using an in vitro tube formation model, we observed that SZ117, a monoclonal antibody against matrix metalloproteinase-2 (MMP2), attenuated a capillary-like tube structure formed by tumor endothelial cell 3B11 and human sarcoma cell MG63. sz117 72-77 matrix metallopeptidase 2 Mus musculus 109-135 22142190-1 2012 In this study, using an in vitro tube formation model, we observed that SZ117, a monoclonal antibody against matrix metalloproteinase-2 (MMP2), attenuated a capillary-like tube structure formed by tumor endothelial cell 3B11 and human sarcoma cell MG63. sz117 72-77 matrix metallopeptidase 2 Mus musculus 137-141 22142190-1 2012 In this study, using an in vitro tube formation model, we observed that SZ117, a monoclonal antibody against matrix metalloproteinase-2 (MMP2), attenuated a capillary-like tube structure formed by tumor endothelial cell 3B11 and human sarcoma cell MG63. mg63 248-252 matrix metallopeptidase 2 Mus musculus 109-135 22142190-1 2012 In this study, using an in vitro tube formation model, we observed that SZ117, a monoclonal antibody against matrix metalloproteinase-2 (MMP2), attenuated a capillary-like tube structure formed by tumor endothelial cell 3B11 and human sarcoma cell MG63. mg63 248-252 matrix metallopeptidase 2 Mus musculus 137-141 22083158-11 2012 Folic acid also attenuated vascular remodeling and inflammation characterized by medial elastin breakdown and augmented matrix metalloproteinase 2 activity and activation of matrix metalloproteinase 9, as well as macrophage infiltration. Folic Acid 0-10 matrix metallopeptidase 2 Mus musculus 120-146 23338253-0 2012 Fluoride modulates preosteoblasts viability and matrix metalloproteinases-2 and -9 activities. Fluorides 0-8 matrix metallopeptidase 2 Mus musculus 48-82 23338253-1 2012 This study evaluated the influence of fluoride on cell viability and activity of matrix metalloproteinases (MMP) -2 and -9 secreted by preosteoblasts. Fluorides 38-46 matrix metallopeptidase 2 Mus musculus 81-122 21708884-6 2012 Vernolide-A administration downregulated the expression of matrix metalloproteinase-2 (MMP-2), MMP-9, extracellular-signal-regulated kinase-1 (ERK-1), ERK-2 and VEGF in the lung tissue of B16F-10 melanoma challenged animals. vernolide-A 0-11 matrix metallopeptidase 2 Mus musculus 59-85 23258984-0 2012 Ginseng and Its Active Components Ginsenosides Inhibit Adipogenesis in 3T3-L1 Cells by Regulating MMP-2 and MMP-9. Ginsenosides 34-46 matrix metallopeptidase 2 Mus musculus 98-103 23258984-6 2012 TGSs and individual GSs also significantly decreased MMP-2 and MMP-9 reporter gene activities in the presence of phorbol 12-myristate 13-acetate (PMA), the MMP inducer. tgss 0-4 matrix metallopeptidase 2 Mus musculus 53-58 23258984-6 2012 TGSs and individual GSs also significantly decreased MMP-2 and MMP-9 reporter gene activities in the presence of phorbol 12-myristate 13-acetate (PMA), the MMP inducer. Ginsenosides 1-4 matrix metallopeptidase 2 Mus musculus 53-58 23258984-6 2012 TGSs and individual GSs also significantly decreased MMP-2 and MMP-9 reporter gene activities in the presence of phorbol 12-myristate 13-acetate (PMA), the MMP inducer. Tetradecanoylphorbol Acetate 113-144 matrix metallopeptidase 2 Mus musculus 53-58 23258984-6 2012 TGSs and individual GSs also significantly decreased MMP-2 and MMP-9 reporter gene activities in the presence of phorbol 12-myristate 13-acetate (PMA), the MMP inducer. Tetradecanoylphorbol Acetate 146-149 matrix metallopeptidase 2 Mus musculus 53-58 23258984-9 2012 Moreover, GE and GSs reduced the expression of NF-kappaB and AP-1, the transcription factors of MMP-2 and MMP-9. Ginsenosides 17-20 matrix metallopeptidase 2 Mus musculus 96-101 23258984-10 2012 These results demonstrate that ginseng, in particular GSs, effectively inhibits adipogenesis and that this process may be mediated in part through the suppression of MMP-2 and MMP-9. Ginsenosides 54-57 matrix metallopeptidase 2 Mus musculus 166-171 21708884-6 2012 Vernolide-A administration downregulated the expression of matrix metalloproteinase-2 (MMP-2), MMP-9, extracellular-signal-regulated kinase-1 (ERK-1), ERK-2 and VEGF in the lung tissue of B16F-10 melanoma challenged animals. vernolide-A 0-11 matrix metallopeptidase 2 Mus musculus 87-92 21708884-9 2012 Vernolide-A could inhibit MMP-2 and MMP-9 protein expression in gelatin zymographic analysis of B16F-10 cells. vernolide-A 0-11 matrix metallopeptidase 2 Mus musculus 26-31 22007835-6 2012 Treatment of N(G) -nitro-L-arginine methyl ester [L-NAME, a non-selective nitric oxide synthase (NOS) inhibitor] reserved the expression of cav-1, inhibited MMPs activity, and reduced BBB permeability. NG-Nitroarginine Methyl Ester 13-48 matrix metallopeptidase 2 Mus musculus 157-161 22049175-10 2012 In addition, thiostrepton treatment of PTC cells or expression of FoxM1-specific small interfering RNA down-regulated expression of FoxM1 accompanied with decreased MMP-2 and MMP-9 expression. Thiostrepton 13-25 matrix metallopeptidase 2 Mus musculus 165-170 22049175-13 2012 Finally, treatment of PTC cell line xenografts with thiostrepton resulted in growth inhibition of tumors in nude mice via down-regulation of FoxM1 and MMP-9 and MMP-2. Thiostrepton 52-64 matrix metallopeptidase 2 Mus musculus 161-166 22312258-7 2012 Higher release of matrix metalloproteinases (MMPs), especially MMP-2, which could be attenuated by PTX, was found in L1210/VCR than in L1210 cells by gelatin zymography in electrophoretic gel. Pentoxifylline 99-102 matrix metallopeptidase 2 Mus musculus 45-49 22312258-7 2012 Higher release of matrix metalloproteinases (MMPs), especially MMP-2, which could be attenuated by PTX, was found in L1210/VCR than in L1210 cells by gelatin zymography in electrophoretic gel. Pentoxifylline 99-102 matrix metallopeptidase 2 Mus musculus 63-68 22312258-10 2012 Taken together, we conclude that PTX induces the sensitization of multidrug-resistant cells to VCR via downregulation of P-gp, stimulation of apoptosis and reduction of MMPs released from drug-resistant L1210/VCR cells. Pentoxifylline 33-36 matrix metallopeptidase 2 Mus musculus 169-173 22007835-6 2012 Treatment of N(G) -nitro-L-arginine methyl ester [L-NAME, a non-selective nitric oxide synthase (NOS) inhibitor] reserved the expression of cav-1, inhibited MMPs activity, and reduced BBB permeability. NG-Nitroarginine Methyl Ester 50-56 matrix metallopeptidase 2 Mus musculus 157-161 22007835-10 2012 Interestingly, the effects of L-NAME on MMPs activity and BBB permeability was partly reversed in cav-1 deficiency mice. NG-Nitroarginine Methyl Ester 30-36 matrix metallopeptidase 2 Mus musculus 40-44 22007835-12 2012 The effects of L-NAME on MMPs activity and BBB permeability are partly mediated by preservation of cav-1. NG-Nitroarginine Methyl Ester 15-21 matrix metallopeptidase 2 Mus musculus 25-29 21292466-7 2011 EGCG significantly inhibited HGF-induced phosphorylation of Met and cell growth, invasion and expression of MMP-2 and MMP-9. epigallocatechin gallate 0-4 matrix metallopeptidase 2 Mus musculus 108-113 21656169-4 2011 UV-induced mRNA and protein expression of MMP-13, MMP-9, MMP-3, and MMP-2 was significantly reduced by I-RTX. iodoresiniferatoxin 103-108 matrix metallopeptidase 2 Mus musculus 68-73 21170677-9 2011 BITC induced a significant reduction in the levels of matrix metalloproteinase (MMP)-2, MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1, and urokinase-type plasminogen activator in the sera and lungs of 4T1 cell-injected mice. benzyl isothiocyanate 0-4 matrix metallopeptidase 2 Mus musculus 54-86 21627988-9 2011 The treatment of curcumin, the anticancer drug along with HABP1, inhibited the migration, expression of MT1-MMP and activation of MMP-2 and finally tumor growth supports the involvement of HABP1 in tumor formation. Curcumin 17-25 matrix metallopeptidase 2 Mus musculus 130-135 21816213-6 2011 Diosgenyl saponins also showed strong suppression of enzyme activity of MMP-2 and -9. diosgenyl saponins 0-18 matrix metallopeptidase 2 Mus musculus 72-84 21905822-6 2011 Thujone administration downregulated the expression of matrix metalloproteinase (MMP)-2, MMP-9, extracellular signal-regulated kinase (ERK)-1, ERK-2, and vascular endothelial growth factor (VEGF) and also upregulated the expression of nm-23, tissue inhibitor of metalloproteinase (TIMP)-1, and TIMP-2 in the lung tissue of metastasis-induced animals. beta-thujone 0-7 matrix metallopeptidase 2 Mus musculus 55-87 21905822-7 2011 Treatment with thujone inhibited the activity of MMP-2 and MMP-9 in gelatin zymographic analysis. beta-thujone 15-22 matrix metallopeptidase 2 Mus musculus 49-54 21905822-10 2011 These results indicate that Thujone can inhibit the lung metastasis of B16F-10 cells through inhibition of tumor cell proliferation, adhesion, and invasion, as well as by regulating expression of MMPs, VEGF, ERK-1, ERK-2, TIMPs, nm23, and levels of proinflammatory cytokines and IL-2 in metastatic animals. beta-thujone 28-35 matrix metallopeptidase 2 Mus musculus 196-200 21858843-6 2011 Activity of secreted MMP-2 increased only after 6-h epinephrine treatment in both cell types. Epinephrine 52-63 matrix metallopeptidase 2 Mus musculus 21-26 20623151-0 2011 Inhibition of the activity of matrix metalloproteinase 2 by triethylene glycol dimethacrylate. triethylene glycol dimethacrylate 60-93 matrix metallopeptidase 2 Mus musculus 30-56 21703213-1 2011 BACKGROUND & AIMS: Matrix metalloproteinase (MMP)-9, a member of the gelatinase family of MMPs, mediates leukocyte migration during inflammation. Adenosine Monophosphate 12-15 matrix metallopeptidase 2 Mus musculus 94-98 20623151-1 2011 The aim of this study was to evaluate the effect of different concentrations of triethylene glycol dimethacrylate (TEGDMA) on the inhibition of matrix metalloproteinase 2 (MMP-2). triethylene glycol dimethacrylate 80-113 matrix metallopeptidase 2 Mus musculus 144-170 20623151-1 2011 The aim of this study was to evaluate the effect of different concentrations of triethylene glycol dimethacrylate (TEGDMA) on the inhibition of matrix metalloproteinase 2 (MMP-2). triethylene glycol dimethacrylate 80-113 matrix metallopeptidase 2 Mus musculus 172-177 20623151-1 2011 The aim of this study was to evaluate the effect of different concentrations of triethylene glycol dimethacrylate (TEGDMA) on the inhibition of matrix metalloproteinase 2 (MMP-2). triethylene glycol dimethacrylate 115-121 matrix metallopeptidase 2 Mus musculus 144-170 20623151-1 2011 The aim of this study was to evaluate the effect of different concentrations of triethylene glycol dimethacrylate (TEGDMA) on the inhibition of matrix metalloproteinase 2 (MMP-2). triethylene glycol dimethacrylate 115-121 matrix metallopeptidase 2 Mus musculus 172-177 20623151-6 2011 Data was plotted and submitted to linear regression to investigate MMP-2 inhibition as a function of TEGDMA concentration. triethylene glycol dimethacrylate 101-107 matrix metallopeptidase 2 Mus musculus 67-72 20623151-9 2011 Zymogene (72 kDa), intermediate (66 kDa) and active forms of MMP-2 (62 kDa) were inhibited by TEGDMA in a dose-dependent way. triethylene glycol dimethacrylate 94-100 matrix metallopeptidase 2 Mus musculus 61-66 20623151-10 2011 These findings suggest that TEGDMA could inhibit MMP-2 expression even at small concentrations. triethylene glycol dimethacrylate 28-34 matrix metallopeptidase 2 Mus musculus 49-54 21452059-7 2011 In addition, EZN-2208 down-regulated mRNA levels of HIF-1alpha targeted genes (MMP2, VEGF1, Glut1, Glut3 and TGFbeta1). EZN-2208 13-21 matrix metallopeptidase 2 Mus musculus 79-83 21621644-5 2011 Culture of peritoneal exudates derived macrophages from 7day Nattectin-mice and immature BMDCs with Nattectin markedly increased the surface expression of CD40, CD80, CD86, and MHC class II in a dose-dependent manner, and the production of MMP-2 and MMP-9 distributed in nucleus and cytoplasm of cells, that was associated with strong activity in the culture supernatant. nattectin 100-109 matrix metallopeptidase 2 Mus musculus 240-245 21666115-10 2011 H(2)O(2)-induced MMP-9 and MMP-2 activities were also significantly diminished by APN. Hydrogen Peroxide 0-8 matrix metallopeptidase 2 Mus musculus 27-32 21452059-8 2011 Further, western blot analyses of xenograft tumors demonstrated that EZN-2208 had significantly more effect than CPT-11 in down-regulating HIF-1alpha, VEGF, Glut1 and MMP2 protein levels. EZN-2208 69-77 matrix metallopeptidase 2 Mus musculus 167-171 21418186-0 2011 Doxycycline inhibits matrix metalloproteinase-2 secretion from TSC2-null mouse embryonic fibroblasts and lymphangioleiomyomatosis cells. Doxycycline 0-11 matrix metallopeptidase 2 Mus musculus 21-47 21452059-8 2011 Further, western blot analyses of xenograft tumors demonstrated that EZN-2208 had significantly more effect than CPT-11 in down-regulating HIF-1alpha, VEGF, Glut1 and MMP2 protein levels. Irinotecan 113-119 matrix metallopeptidase 2 Mus musculus 167-171 22362715-7 2011 Curcumin down-regulated the expression of cluster of differntiation (CD)147, matrix metalloproteinase 2, and matrix metalloproteinase 9 and inhibited the phosphorylation of epidermal growth factor receptor (EGFR), the phosphoinositilde 3-kinase (PI3K)/protein kinase B (Akt), p38 mitogen-activated protein kinase (MAPK), and p44/42MAPK in Hca-F cells. Curcumin 0-8 matrix metallopeptidase 2 Mus musculus 77-103 21730088-8 2011 The intra-articular injection of HKBA or L-Omp19 into the knee joint of mice resulted in the local induction of the proinflammatory mediators MMP-2 and MMP-9 and in the generation of a mixed inflammatory infiltrate. hkba 33-37 matrix metallopeptidase 2 Mus musculus 142-147 21730088-8 2011 The intra-articular injection of HKBA or L-Omp19 into the knee joint of mice resulted in the local induction of the proinflammatory mediators MMP-2 and MMP-9 and in the generation of a mixed inflammatory infiltrate. l-omp19 41-48 matrix metallopeptidase 2 Mus musculus 142-147 21827493-8 2011 CONCLUSIONS: Our findings show that the inorganic arsenic compounds arsenate and As(2) O(3) inhibit cell proliferation and prevent the invasive properties of melanoma cells, possibly by decreasing MMP-2 production from the cells. inorganic arsenic compounds 40-67 matrix metallopeptidase 2 Mus musculus 197-202 21185709-6 2011 As increased matrix metalloproteinase (MMP) 2 has been shown to be involved in the development of hepatic fibrosis, we then focused on the effect of PE administration on expression and activity of MMP-2 in liver of hyperhomocysteinemic mice and its impact on hepatic fibrosis development. pe 149-151 matrix metallopeptidase 2 Mus musculus 197-202 21185709-9 2011 We show that administration of PE had a beneficial effect (i) on MMP-2 expression via modulation of nitrotyrosine-modified total protein level and (ii) on MMP-2 activity via modulation of its activator/inhibitor balance. pe 31-33 matrix metallopeptidase 2 Mus musculus 65-70 21185709-9 2011 We show that administration of PE had a beneficial effect (i) on MMP-2 expression via modulation of nitrotyrosine-modified total protein level and (ii) on MMP-2 activity via modulation of its activator/inhibitor balance. pe 31-33 matrix metallopeptidase 2 Mus musculus 155-160 21185709-9 2011 We show that administration of PE had a beneficial effect (i) on MMP-2 expression via modulation of nitrotyrosine-modified total protein level and (ii) on MMP-2 activity via modulation of its activator/inhibitor balance. 3-nitrotyrosine 100-113 matrix metallopeptidase 2 Mus musculus 65-70 21827493-7 2011 Arsenate or As(2) O(3) at 0.2-10microg/ml significantly inhibited the amount of active MMP-2 and pro-MMP-2 secreted into the A375 cell culture supernatant (P<0.05). arsenic acid 0-8 matrix metallopeptidase 2 Mus musculus 87-92 21827493-8 2011 CONCLUSIONS: Our findings show that the inorganic arsenic compounds arsenate and As(2) O(3) inhibit cell proliferation and prevent the invasive properties of melanoma cells, possibly by decreasing MMP-2 production from the cells. arsenic acid 68-76 matrix metallopeptidase 2 Mus musculus 197-202 21827493-7 2011 Arsenate or As(2) O(3) at 0.2-10microg/ml significantly inhibited the amount of active MMP-2 and pro-MMP-2 secreted into the A375 cell culture supernatant (P<0.05). arsenic acid 0-8 matrix metallopeptidase 2 Mus musculus 101-106 21827493-8 2011 CONCLUSIONS: Our findings show that the inorganic arsenic compounds arsenate and As(2) O(3) inhibit cell proliferation and prevent the invasive properties of melanoma cells, possibly by decreasing MMP-2 production from the cells. Arsenic Trioxide 81-91 matrix metallopeptidase 2 Mus musculus 197-202 21827493-7 2011 Arsenate or As(2) O(3) at 0.2-10microg/ml significantly inhibited the amount of active MMP-2 and pro-MMP-2 secreted into the A375 cell culture supernatant (P<0.05). Arsenic 12-14 matrix metallopeptidase 2 Mus musculus 87-92 21666238-9 2011 (99)Tc-MDP treatment led to significant inhibition of macrophages infiltrating to CNV together with downregulated protein expressions of VEGF, ICAM-1, TNF-alpha, and MMP-2. technetium Tc 99m diphosphonate 4-10 matrix metallopeptidase 2 Mus musculus 166-171 21827493-7 2011 Arsenate or As(2) O(3) at 0.2-10microg/ml significantly inhibited the amount of active MMP-2 and pro-MMP-2 secreted into the A375 cell culture supernatant (P<0.05). Arsenic 12-14 matrix metallopeptidase 2 Mus musculus 101-106 21827493-7 2011 Arsenate or As(2) O(3) at 0.2-10microg/ml significantly inhibited the amount of active MMP-2 and pro-MMP-2 secreted into the A375 cell culture supernatant (P<0.05). (2) o(3) 14-22 matrix metallopeptidase 2 Mus musculus 87-92 21827493-7 2011 Arsenate or As(2) O(3) at 0.2-10microg/ml significantly inhibited the amount of active MMP-2 and pro-MMP-2 secreted into the A375 cell culture supernatant (P<0.05). (2) o(3) 14-22 matrix metallopeptidase 2 Mus musculus 101-106 22590832-10 2011 Losartan abolished the enhancing effect of every concentration of angiotensin II on MMP-2, MMP-13 and VEGF expression completely and in all incubation times. Losartan 0-8 matrix metallopeptidase 2 Mus musculus 84-89 21656908-4 2011 In contrast to the previously reported cis-ACCP, which was shown to inhibit MMP-2 for ~30 min, the new compounds inhibit MMP activity for the duration of measurement, lasting several hours. adenosylcobinamide 2-chlorophenyl phosphate 39-47 matrix metallopeptidase 2 Mus musculus 76-81 22013802-7 2011 The mRNA and protein expressions of MMP-2 and MMP-9 were measured using reverse transcription-polymerase chain reaction (RT-PCR) and SP method. TFF2 protein, human 133-135 matrix metallopeptidase 2 Mus musculus 36-41 21195159-5 2011 Arsenic also increased secretion of the active form of MMP-2 in both RET-MEN2A-transfectants and c-RET-transfectants. Arsenic 0-7 matrix metallopeptidase 2 Mus musculus 55-60 21059623-10 2011 V cinerea extract administration could suppress or downregulate the expression of matrix metalloproteinase (MMP)-2, MMP-9, lysyl oxidase, prolyl hydroxylase, K-ras, extracellular signal-regulated kinase (ERK)-1, ERK-2, and VEGF and also upregulate the expression of nm-23, tissue inhibitor of metalloproteinase (TIMP-1), and TIMP-2 in the lung tissue of metastasis-induced animals. cinerea 2-9 matrix metallopeptidase 2 Mus musculus 82-114 21454403-11 2011 These results may have implications with regard to EGFR inhibitor use in various cancers as well as in polycystic ovarian syndrome, where excess LH-driven ovarian androgen production might be controlled by MMP2/9 inhibition. Luteinizing Hormone 145-147 matrix metallopeptidase 2 Mus musculus 206-212 21277400-6 2011 As a result of dexamethasone treatment we have detected significant apoptotic cell death, and six genes, including Smad3, type-2 collagen alpha-1, type-9 collagen alpha-1, matrix metalloproteinase-2, bone morphogenetic protein-4 and bone morphogenetic protein-8 showed (BMP-8) significant changes in their expression on a time- and concentration-dependent manner. Dexamethasone 15-28 matrix metallopeptidase 2 Mus musculus 122-198 21464389-5 2011 Olmesartan increased the levels of collagen and elastin, reduced the level of macrophages in the aortic root, and reduced the mRNA and the activity of matrix metalloproteinase (MMP) 2 in aortic roots and thoracic aortas. olmesartan 0-10 matrix metallopeptidase 2 Mus musculus 151-183 21464389-7 2011 Bone marrow-derived endothelial progenitor cell-like c-Kit(+) cells from olmesartan-treated ApoE(-/-) mice showed marked impairment of cellular functions and lower expression of TLR2/TLR4 and MMP-2 compared with those of untreated controls. olmesartan 73-83 matrix metallopeptidase 2 Mus musculus 192-197 21233344-3 2011 We hypothesize that H2S induces MMP-2 activation and inhibits MMP-9 activation, thus promoting angiogenesis, and mitigates transition from compensatory cardiac hypertrophy to heart failure. Hydrogen Sulfide 20-23 matrix metallopeptidase 2 Mus musculus 32-37 21233344-6 2011 In the NaHS-treated AB 8 wk group, the expression of MMP-2, CD31, and VEGF was increased while the expression of MMP-9, endostatin, angiostatin, and tissue inhibitor of matrix metalloproteinase (TIMP)-3 was decreased compared with untreated control mice. sodium bisulfide 7-11 matrix metallopeptidase 2 Mus musculus 53-58 21170925-3 2011 The expressions of matrix metalloproteinase (MMP)-2 and MMP-9 in cells and the activities in the culture medium were also reduced by decursin and decursinol treatment. decursin 146-156 matrix metallopeptidase 2 Mus musculus 19-51 21170925-10 2011 Therefore, both decursin and decursinol may be beneficial antimetastatic agents, targeting MMPs and their upstream signaling molecules. decursin 16-24 matrix metallopeptidase 2 Mus musculus 91-95 21170925-10 2011 Therefore, both decursin and decursinol may be beneficial antimetastatic agents, targeting MMPs and their upstream signaling molecules. decursin 29-39 matrix metallopeptidase 2 Mus musculus 91-95 21454403-9 2011 Furthermore, MMP2 and MMP9 appear to regulate LH-induced steroidogenesis in mouse ovarian follicles, because a specific MMP2/9 inhibitor as well as the MMP2/9 inhibitor doxycycline suppress LH-induced follicular steroid production in vitro. Luteinizing Hormone 46-48 matrix metallopeptidase 2 Mus musculus 13-17 21454403-9 2011 Furthermore, MMP2 and MMP9 appear to regulate LH-induced steroidogenesis in mouse ovarian follicles, because a specific MMP2/9 inhibitor as well as the MMP2/9 inhibitor doxycycline suppress LH-induced follicular steroid production in vitro. Luteinizing Hormone 46-48 matrix metallopeptidase 2 Mus musculus 120-126 21454403-9 2011 Furthermore, MMP2 and MMP9 appear to regulate LH-induced steroidogenesis in mouse ovarian follicles, because a specific MMP2/9 inhibitor as well as the MMP2/9 inhibitor doxycycline suppress LH-induced follicular steroid production in vitro. Luteinizing Hormone 46-48 matrix metallopeptidase 2 Mus musculus 152-158 21454403-9 2011 Furthermore, MMP2 and MMP9 appear to regulate LH-induced steroidogenesis in mouse ovarian follicles, because a specific MMP2/9 inhibitor as well as the MMP2/9 inhibitor doxycycline suppress LH-induced follicular steroid production in vitro. Doxycycline 169-180 matrix metallopeptidase 2 Mus musculus 13-17 21454403-9 2011 Furthermore, MMP2 and MMP9 appear to regulate LH-induced steroidogenesis in mouse ovarian follicles, because a specific MMP2/9 inhibitor as well as the MMP2/9 inhibitor doxycycline suppress LH-induced follicular steroid production in vitro. Doxycycline 169-180 matrix metallopeptidase 2 Mus musculus 152-158 21454403-9 2011 Furthermore, MMP2 and MMP9 appear to regulate LH-induced steroidogenesis in mouse ovarian follicles, because a specific MMP2/9 inhibitor as well as the MMP2/9 inhibitor doxycycline suppress LH-induced follicular steroid production in vitro. Luteinizing Hormone 190-192 matrix metallopeptidase 2 Mus musculus 13-17 21454403-9 2011 Furthermore, MMP2 and MMP9 appear to regulate LH-induced steroidogenesis in mouse ovarian follicles, because a specific MMP2/9 inhibitor as well as the MMP2/9 inhibitor doxycycline suppress LH-induced follicular steroid production in vitro. Luteinizing Hormone 190-192 matrix metallopeptidase 2 Mus musculus 120-126 21454403-9 2011 Furthermore, MMP2 and MMP9 appear to regulate LH-induced steroidogenesis in mouse ovarian follicles, because a specific MMP2/9 inhibitor as well as the MMP2/9 inhibitor doxycycline suppress LH-induced follicular steroid production in vitro. Luteinizing Hormone 190-192 matrix metallopeptidase 2 Mus musculus 152-158 21454403-9 2011 Furthermore, MMP2 and MMP9 appear to regulate LH-induced steroidogenesis in mouse ovarian follicles, because a specific MMP2/9 inhibitor as well as the MMP2/9 inhibitor doxycycline suppress LH-induced follicular steroid production in vitro. Steroids 57-64 matrix metallopeptidase 2 Mus musculus 13-17 21366703-6 2011 In addition, the blockade of beta3-adrenoceptors reversed the increase in fibroblast proliferation and nitric oxide synthesis as well as the reduction of fibroblast migration, AKT phosphorylation and active matrix metalloproteinase-2 expression induced by epinephrine. Epinephrine 256-267 matrix metallopeptidase 2 Mus musculus 207-233 21233344-9 2011 These results show that H2S by inducing MMP-2 promotes VEGF synthesis and angiogenesis while it suppresses MMP-9 and TIMP-3 levels, inhibits antiangiogenic factors, reduces intracardiac fibrosis, and mitigates transition from compensatory hypertrophy to heart failure. Hydrogen Sulfide 24-27 matrix metallopeptidase 2 Mus musculus 40-45 21195159-7 2011 Interestingly, l-cysteine inhibited the arsenic-mediated tumor-promoting effects (activation of kinases and MMP-2 secretion) but not arsenic-mediated anti-cancer effects (PARP degradation and cell death). Cysteine 15-25 matrix metallopeptidase 2 Mus musculus 108-113 21195159-7 2011 Interestingly, l-cysteine inhibited the arsenic-mediated tumor-promoting effects (activation of kinases and MMP-2 secretion) but not arsenic-mediated anti-cancer effects (PARP degradation and cell death). Arsenic 40-47 matrix metallopeptidase 2 Mus musculus 108-113 21195159-8 2011 Our results suggest redox-linked regulation of arsenic-mediated activities of kinases and MMP-2 secretion but not arsenic-mediated cell death. Arsenic 47-54 matrix metallopeptidase 2 Mus musculus 90-95 21281787-6 2011 Overexpression of FoxM1 potentiated cell proliferation, cell transformation, and migration/invasion of CRC cells via up-regulation of FoxM1 target genes MMP2 and MMP9 and protected these cells from thiostrepton-mediated antiproliferative effects. Thiostrepton 198-210 matrix metallopeptidase 2 Mus musculus 153-157 21547672-7 2011 Furthermore, the activity of MMP-2, a key enzyme in tumor cell invasion, was significantly decreased in cells treated with the combination of paclitaxel and ATRA while other combinations and single agents did not significantly affect its activity. Paclitaxel 142-152 matrix metallopeptidase 2 Mus musculus 29-34 21547672-7 2011 Furthermore, the activity of MMP-2, a key enzyme in tumor cell invasion, was significantly decreased in cells treated with the combination of paclitaxel and ATRA while other combinations and single agents did not significantly affect its activity. Tretinoin 157-161 matrix metallopeptidase 2 Mus musculus 29-34 21547674-4 2011 LEJ showed potent inhibitory effects on MMP-2 and MMP-9 activities and expressions via down-regulation of NF-kappaB translocation to the nucleus in B16F10 cells. 1-(difluoromethyl)-N-[(4-fluorophenyl)methyl]-1H-pyrazole-3-carboxamide 0-3 matrix metallopeptidase 2 Mus musculus 40-45 21547674-7 2011 Moreover, we isolated the compounds ursolic acid and 2alpha-hydroxyursolic acid from LEJ and both compounds also significantly suppressed MMP-2 and MMP-9 activities, indicating that they are the active components of LEJ. ursolic acid 36-48 matrix metallopeptidase 2 Mus musculus 138-143 21547674-7 2011 Moreover, we isolated the compounds ursolic acid and 2alpha-hydroxyursolic acid from LEJ and both compounds also significantly suppressed MMP-2 and MMP-9 activities, indicating that they are the active components of LEJ. 2-hydroxyursolic acid 53-79 matrix metallopeptidase 2 Mus musculus 138-143 21608228-11 2011 The positive expressions of MMP-2 and MMP-9 in the XTSJD group and the OH group was significantly lower than that in the NS group (P <0.01). Nitrogen 121-123 matrix metallopeptidase 2 Mus musculus 28-33 21074539-5 2011 Subsequent analysis revealed significantly reduced proliferation and cell number, diminished collagen deposition, and elevated MMP-2 activity at the infarct zone of PFTa-treated hearts. pifithrin 165-169 matrix metallopeptidase 2 Mus musculus 127-132 21074539-8 2011 PFTa increases MMP-2 activity in a p53-dependent manner, which seems a major contributor to instability of the forming scar and consequently leads to infarct progression and ventricular rupture. pifithrin 0-4 matrix metallopeptidase 2 Mus musculus 15-20 21193743-10 2011 High glucose increased MMP-2, MMP-9, cleaved caspase-3 levels, and apoptosis, as well as decreased cell survival and dendrite outgrowth in cultured primary cortical neuron. Glucose 5-12 matrix metallopeptidase 2 Mus musculus 23-28 21030072-4 2011 In order to enhance cellular integration and promote retinal repopulation, we co-transplanted biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres that have the ability to deliver active MMP2 with retinal progenitor cells (RPCs) to the sub-retinal space of adult retinal degenerative Rho-/- mice. Polylactic Acid-Polyglycolic Acid Copolymer 108-136 matrix metallopeptidase 2 Mus musculus 198-202 20015203-8 2011 Furthermore, matrix metalloproteinase 2 and gelatinolytic activity were decreased in response to rosuvastatin and a condensed collagen-rich matrix was formed. Rosuvastatin Calcium 97-109 matrix metallopeptidase 2 Mus musculus 13-39 20956976-5 2011 AKI was also induced in MMP-2-deficient (MMP-2(-/-)) mice and MMP-2(+/+) mice treated with inhibitor of MMPs (minocycline and synthetic peptide MMP inhibitor). Minocycline 110-121 matrix metallopeptidase 2 Mus musculus 104-108 20956976-11 2011 Inhibitors of MMPs reduced ATI and improved renal dysfunction at 24 h. We conclude that MMPs, especially MMP-2 have a pathogenic role in ischemia-reperfusion AKI, and that inhibitors of MMPs can protect against ischemic AKI. 4-Amino-2,2,5,5-tetramethyl-3-imidazoli-ne-1-yloxyl free radical 27-30 matrix metallopeptidase 2 Mus musculus 14-18 20956976-11 2011 Inhibitors of MMPs reduced ATI and improved renal dysfunction at 24 h. We conclude that MMPs, especially MMP-2 have a pathogenic role in ischemia-reperfusion AKI, and that inhibitors of MMPs can protect against ischemic AKI. 4-Amino-2,2,5,5-tetramethyl-3-imidazoli-ne-1-yloxyl free radical 27-30 matrix metallopeptidase 2 Mus musculus 88-92 20956976-11 2011 Inhibitors of MMPs reduced ATI and improved renal dysfunction at 24 h. We conclude that MMPs, especially MMP-2 have a pathogenic role in ischemia-reperfusion AKI, and that inhibitors of MMPs can protect against ischemic AKI. 4-Amino-2,2,5,5-tetramethyl-3-imidazoli-ne-1-yloxyl free radical 27-30 matrix metallopeptidase 2 Mus musculus 88-92 21193743-12 2011 Inhibition of MMP by GM6001 treatment significantly decreased high glucose-induced cell death and apoptosis in cultured primary cortical neuron and oligodendrocytes but did not alter dendrite outgrowth in primary cortical neuron. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 21-27 matrix metallopeptidase 2 Mus musculus 14-17 21193743-12 2011 Inhibition of MMP by GM6001 treatment significantly decreased high glucose-induced cell death and apoptosis in cultured primary cortical neuron and oligodendrocytes but did not alter dendrite outgrowth in primary cortical neuron. Glucose 67-74 matrix metallopeptidase 2 Mus musculus 14-17 21873804-11 2011 Moreover, we found that NAC down-regulated the expression of VCAM-1, MMP2 and MMP9, accompanied by inhibition of NF-kappaB activation and reduced expression of RAGE. Acetylcysteine 24-27 matrix metallopeptidase 2 Mus musculus 69-73 21084858-8 2011 In conclusion, curcumin has the ability to inhibit the growth of engrafted melanoma VM channels through the regulation of vasculogenic factors that could be related to the down-regulation of the EphA2/PI3K/MMPs signaling pathway. Curcumin 15-23 matrix metallopeptidase 2 Mus musculus 206-210 20920565-11 2011 Moreover, solid melanoma grown in left oxter of mice was obviously inhibited after oral intake of 100 and 200 mg/kg of EO-CZ a day for 28 days, and CD34 expression indicating angiogenesis in melanoma reduced significantly compared with control; melanoma metastatic nodules in lung were detected to be inhibited, as well as MMP-2 and MMP-9 expression in serum. eo-cz 119-124 matrix metallopeptidase 2 Mus musculus 323-328 20840540-0 2011 Protocatechuic acid inhibits cancer cell metastasis involving the down-regulation of Ras/Akt/NF-kappaB pathway and MMP-2 production by targeting RhoB activation. protocatechuic acid 0-19 matrix metallopeptidase 2 Mus musculus 115-120 21597297-8 2011 In addition, rapamycin reduced wound lactate accumulation and enhanced MMP-2 protein expression, and both MMP-2 and MMP-9 activity. Sirolimus 13-22 matrix metallopeptidase 2 Mus musculus 71-76 21597297-9 2011 At day 14, wound tensile strength and hydroxyproline content were significantly lower along with an increase in MMP-2 and MMP-9 activity in rapamycin-treated mice. Sirolimus 140-149 matrix metallopeptidase 2 Mus musculus 112-117 21873804-0 2011 The antioxidant N-acetylcysteine promotes atherosclerotic plaque stabilization through suppression of RAGE, MMPs and NF-kappaB in ApoE-deficient mice. Acetylcysteine 16-32 matrix metallopeptidase 2 Mus musculus 108-112 21873804-12 2011 CONCLUSION: In the present study, we show novel data to suggest that NAC promotes atherosclerotic plaque stabilization through suppression of RAGE, MMPs and NF-kappaB in apoE(-/-) mice. Acetylcysteine 69-72 matrix metallopeptidase 2 Mus musculus 148-152 21209944-7 2010 Treatment of mice with resveratrol and TRAIL alone inhibited angiogenesis (as demonstrated by reduced number of blood vessels, and VEGF and VEGFR2 positive cells) and markers of metastasis (MMP-2 and MMP-9). Resveratrol 23-34 matrix metallopeptidase 2 Mus musculus 190-195 21967458-0 2011 Vernolide-A inhibits radiation-induced hypoxia-mediated tumor angiogenesis by regulating HIF-1alpha, MMP-2, MMP-9, and VEGF. vernolide-A 0-11 matrix metallopeptidase 2 Mus musculus 101-106 21967458-6 2011 Gelatin zymographic analysis showed that vernolide-A could also inhibit the radiation-induced activation of matrix metalloproteinases (MMPs). vernolide-A 41-52 matrix metallopeptidase 2 Mus musculus 135-139 21967458-7 2011 Our results indicate that vernolide-A inhibits radiation-induced tumor angiogenesis by regulating HIF-1alpha, MMP-2, MMP-9, and VEGF. vernolide-A 26-37 matrix metallopeptidase 2 Mus musculus 110-115 21858104-6 2011 We also demonstrate the inhibitory effect of kahweol on the endothelial cell potential to remodel extracellular matrix by targeting two key molecules involved in the process, MMP-2 and uPA. kahweol 45-52 matrix metallopeptidase 2 Mus musculus 175-180 21857898-7 2011 However, these alterations reduced when MMP-2 and -9 activities were inhibited by RNA interference strategy or by MMP inhibitor GM6001 in an in vitro BBB model. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 128-134 matrix metallopeptidase 2 Mus musculus 40-52 20934494-1 2010 In order to investigate the potential effects of microcystin-LR (MC-LR) on the expression of metalloproteinases (MMPs), Mice were orally administered with MC-LR in drinking water (0, 1, 40 and 80 mug/L) for 180 d, and hepatic MMP-2/-9 expression was evaluated at the levels of enzyme activity, protein level and mRNA expression. cyanoginosin LR 65-70 matrix metallopeptidase 2 Mus musculus 113-117 20883688-0 2010 Modulatory effect of hesperidin on benzo(a)pyrene induced experimental lung carcinogenesis with reference to COX-2, MMP-2 and MMP-9. Hesperidin 21-31 matrix metallopeptidase 2 Mus musculus 116-121 20883688-2 2010 The purpose of this study is to evaluate the effect of hesperidin in modulating the expressions of cyclooxygenase-2 (COX-2), mast cells (MCs) and matrix metalloproteinases (MMPs) during benzo(a)pyrene (B(a)P) induced lung carcinogenesis in mice. Hesperidin 55-65 matrix metallopeptidase 2 Mus musculus 173-177 20883688-4 2010 Supplementation of hesperidin (25 mg/kg body weight) to lung cancer bearing mice attenuated MCD and downregulated the expressions of COX-2, MMP-2 and MMP-9. Hesperidin 19-29 matrix metallopeptidase 2 Mus musculus 140-145 20883688-5 2010 These observations show that hesperidin exerts its anti-carcinogenic activity against lung cancer by altering the expressions of COX-2, MMP-2 and MMP-9. Hesperidin 29-39 matrix metallopeptidase 2 Mus musculus 136-141 20934494-3 2010 Immunohistochemical staining and enzyme-linked immunosorbent assay (ELISA) revealed that excess MMP-2/-9 proteins were produced in livers of the mice exposed to MC-LR at the higher concentrations. cyanoginosin LR 161-166 matrix metallopeptidase 2 Mus musculus 96-101 20934494-5 2010 Real time PCR showed that MMP-2/-9 mRNA expression was up-regulated by 6.9 fold and 5.0 fold after 80-mug/L-MC treatment, respectively. Methylcholanthrene 108-110 matrix metallopeptidase 2 Mus musculus 26-34 20934494-7 2010 ELISA demonstrated that MC-LR stimulated phosphorylation of mitogen-activated protein kinases, a potential signal transduction pathway of the MMP-2/-9 expression alteration. cyanoginosin LR 24-29 matrix metallopeptidase 2 Mus musculus 142-150 20934494-8 2010 This study revealed a significant alteration in hepatic MMP-2/-9 expression induced by MC-LR, which might be involved in cell invasion and metastasis. cyanoginosin LR 87-92 matrix metallopeptidase 2 Mus musculus 56-64 20683677-5 2010 Leptin is known to stimulate phosphorylation of p38 MAPK in cardiac cells and utilization of the p38 MAPK inhibitor, SB203580, demonstrated that this kinase also plays a role in regulating several extracellular matrix components, such that inhibition of p38 MAPK signaling prevented the leptin-induced increase in MMP-2 activation. SB 203580 117-125 matrix metallopeptidase 2 Mus musculus 314-319 20889203-2 2010 Doxycycline (DOXY) has been reported to control the extension of AA by regulation of MMP. Doxycycline 0-11 matrix metallopeptidase 2 Mus musculus 85-88 20889203-2 2010 Doxycycline (DOXY) has been reported to control the extension of AA by regulation of MMP. Doxycycline 13-17 matrix metallopeptidase 2 Mus musculus 85-88 20889203-9 2010 The DCRBF preserved elastin content and decreased MMP-2 and -9 in aortic tissue. dcrbf 4-9 matrix metallopeptidase 2 Mus musculus 50-62 20836997-5 2010 CAPE could also inhibit the activity of matrix metalloproteinases (MMPs) and induce the expression of RhoB, a tumor suppressor. caffeic acid phenethyl ester 0-4 matrix metallopeptidase 2 Mus musculus 67-71 20836997-7 2010 The results showed that blocking p75(NTR) could decrease the CAPE-induced expression of RhoB and the inactivation of MMP-2, -9 as well as the anti-invasion effect in C6 glioma cells. caffeic acid phenethyl ester 61-65 matrix metallopeptidase 2 Mus musculus 117-126 20956267-11 2010 IL-1beta, TNF-alpha, MMP-2 and MMP-9 mRNA levels were decreased in peritoneal cells of the SB203580 versus EM group (P < 0.01, P < 0.05, P < 0.05 and P < 0.05, respectively). SB 203580 91-99 matrix metallopeptidase 2 Mus musculus 21-26 20956267-12 2010 Concentrations of IL-1beta, TNF-alpha, MMP-2 and MMP-9 proteins in PF were reduced in the SB203580 versus EM group (P < 0.05, P < 0.01, P < 0.05 and P < 0.05, respectively). SB 203580 90-98 matrix metallopeptidase 2 Mus musculus 39-44 20976070-5 2010 The results showed that berberine attenuated clinical and pathological parameters of EAE, reduced the permeability of BBB, inhibited the activity and expression of MMP-9 but not MMP-2 in the CSF and brain of EAE mice. Berberine 24-33 matrix metallopeptidase 2 Mus musculus 178-183 21241594-0 2010 [Effect of carbon disulfide on expression of matrix metalloproteinase-2 and metalloproteinase-9 in embryo and uterus of pregnant mice]. Carbon Disulfide 11-27 matrix metallopeptidase 2 Mus musculus 45-95 21241594-1 2010 OBJECTIVE: To observe the effect of carbon disulfide (CS(2)) on the expression of matrix metalloproteinase (MMP)-2, MMP-9 in mouse embryo and uterus tissues and to explore the mechanism of embryo toxicity induced by CS(2). Carbon Disulfide 36-52 matrix metallopeptidase 2 Mus musculus 82-114 21241594-1 2010 OBJECTIVE: To observe the effect of carbon disulfide (CS(2)) on the expression of matrix metalloproteinase (MMP)-2, MMP-9 in mouse embryo and uterus tissues and to explore the mechanism of embryo toxicity induced by CS(2). Carbon Disulfide 54-59 matrix metallopeptidase 2 Mus musculus 82-114 21241594-8 2010 Exposure to CS(2) disturbs expression of MMP-2 and MMP-9 in embryo and uterus tissues, which might be one of the important factors contributed to embryo toxicity induced by CS(2). Cesium 12-14 matrix metallopeptidase 2 Mus musculus 41-46 21241594-8 2010 Exposure to CS(2) disturbs expression of MMP-2 and MMP-9 in embryo and uterus tissues, which might be one of the important factors contributed to embryo toxicity induced by CS(2). Cesium 173-175 matrix metallopeptidase 2 Mus musculus 41-46 20352463-12 2010 The treatment with H2S mitigated the vascular remodeling by normalizing the levels of redox stress, MMPs and TIMPs. Hydrogen Sulfide 19-22 matrix metallopeptidase 2 Mus musculus 100-104 21311678-4 2010 Coinfusion of metformin (150 mg/kg/24 h) with isoproterenol partially inhibited cardiac hypertrophy that was followed by reduced IL-6, TGF-beta, ANP, collagen I and III, and MMP-2. Metformin 14-23 matrix metallopeptidase 2 Mus musculus 174-179 21311678-4 2010 Coinfusion of metformin (150 mg/kg/24 h) with isoproterenol partially inhibited cardiac hypertrophy that was followed by reduced IL-6, TGF-beta, ANP, collagen I and III, and MMP-2. Isoproterenol 46-59 matrix metallopeptidase 2 Mus musculus 174-179 20663046-2 2010 Herein, we investigate the possible involvement of the plasminogen/plasmin system and endogenous MMPs inhibitor underlying the melatonin-mediated MMP-9 inhibition. Melatonin 127-136 matrix metallopeptidase 2 Mus musculus 97-101 20629735-11 2010 Stress and control + propranolol groups presented a delay in wound contraction, re-epithelialization, F4/80-positive macrophages, neutrophils and mast cells infiltration, cellular proliferation, angiogenesis, myofibroblastic differentiation, MMP-2 and MMP-9 activation and TNF-alpha expression, whereas an increase in the nitrite levels. Propranolol 21-32 matrix metallopeptidase 2 Mus musculus 242-247 20581102-2 2010 Nitric oxide (NO) is a potential regulator of matrix metalloproteinase (MMP) activity in MMP-NO-tissue inhibitor of metalloproteinase (TIMP) inhibitory tertiary complex. Nitric Oxide 0-12 matrix metallopeptidase 2 Mus musculus 72-75 20684827-10 2010 BHB-TZD treatment also reduced MMP-2 and MMP-9 expressions in aorta. 3-Hydroxybutyric Acid 0-3 matrix metallopeptidase 2 Mus musculus 31-36 20684827-10 2010 BHB-TZD treatment also reduced MMP-2 and MMP-9 expressions in aorta. tzd 4-7 matrix metallopeptidase 2 Mus musculus 31-36 20597071-8 2010 Indeed, CCl(4)-treated CB2(-/-) mice displayed lower levels of hepatic IL-6 messenger RNA and increased MMP-2 activity. Cefaclor 8-11 matrix metallopeptidase 2 Mus musculus 104-109 20479714-5 2010 The effect of inhibiting diabetes-induced retinal superoxide accumulation on MMP2 and its regulators was investigated in diabetic mice overexpressing mitochondrial superoxide dismutase (MnSOD). Superoxides 50-60 matrix metallopeptidase 2 Mus musculus 77-81 25901496-7 2010 METHODS: For this reason, the effects of 17beta-estradiol (E2) on MMP-2, MMP-13, and MMP-14 and estrogen receptor alpha and beta (ER-alpha and -beta) expression in the wound tissue of estrogen-deficient female mice with established type 2 diabetes mellitus (C57BL/6J-m Leprdb/2+) were studied. Estradiol 41-57 matrix metallopeptidase 2 Mus musculus 66-71 23654233-0 2010 1-Deoxynojirimycin inhibits metastasis of B16F10 melanoma cells by attenuating the activity and expression of matrix metalloproteinases-2 and -9 and altering cell surface glycosylation. 1-Deoxynojirimycin 0-18 matrix metallopeptidase 2 Mus musculus 110-144 20560878-1 2010 Earlier investigations from our laboratory demonstrated that the expression of matrix metalloproteinases (MMPs) was down-regulated by exogenously administered agmatine against ischemia-like injuries in the murine brain capillary endothelial (bEnd.3) cells. Agmatine 159-167 matrix metallopeptidase 2 Mus musculus 106-110 20560878-2 2010 In our present study, we intended to investigate the mechanism involved in the inhibition of MMPs in bEnd.3 cells infected with retroviral containing human arginine decarboxylase (hADC) gene which can synthesize agmatine endogenously (ADCDeltabEnd.3 cells). Agmatine 212-220 matrix metallopeptidase 2 Mus musculus 93-97 20560878-9 2010 These results suggest that the endogenous agmatine in ADCDeltabEnd.3 cells inhibits the MMPs expression mediated via the regulation of eNOS, NO and ATF3. Agmatine 42-50 matrix metallopeptidase 2 Mus musculus 88-92 20189193-2 2010 Recently we reported that doxycycline, a nonspecific inhibitor of matrix metalloproteinases 2 and 9, normalized aortic vasomotor function and suppressed aneurysm growth. Doxycycline 26-37 matrix metallopeptidase 2 Mus musculus 66-99 20189193-10 2010 Losartan potassium and doxycycline combined completely prevented thoracic aortic aneurysm and improved elastic fiber organization, also downregulating matrix metalloproteinases 2 and 9 and transforming growth factor beta and normalizing aortic contractile and relaxation functions to control values. Losartan 0-18 matrix metallopeptidase 2 Mus musculus 151-184 20189193-10 2010 Losartan potassium and doxycycline combined completely prevented thoracic aortic aneurysm and improved elastic fiber organization, also downregulating matrix metalloproteinases 2 and 9 and transforming growth factor beta and normalizing aortic contractile and relaxation functions to control values. Doxycycline 23-34 matrix metallopeptidase 2 Mus musculus 151-184 23654233-3 2010 1-DNJ significantly inhibited invasion, migration, and cell-matrix adhesion and markedly decreased MMP-2 and MMP-9 activity and mRNA expression. 1-Deoxynojirimycin 0-5 matrix metallopeptidase 2 Mus musculus 99-104 23654233-6 2010 Thus, the antimetastatic effects of 1-DNJ against B16F10 melanoma cells are likely associated with its attenuated activities and expression of MMP-2/9, enhancement of the TIMP-2 mRNA expression, and alterations of the cell surface-binding motif. 1-Deoxynojirimycin 36-41 matrix metallopeptidase 2 Mus musculus 143-150 20679550-7 2010 All of these effects were diminished by LY294002, an inhibitor of phosphatidylinositol 3-kinase; enhanced by deferoxamine, an HIF-1 alpha stabilizer; and impaired by knockout of MMP-2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 matrix metallopeptidase 2 Mus musculus 178-183 20679550-9 2010 CONCLUSIONS: ST can improve neovascularization in response to hypoxia via a phosphatidylinositol 3-kinase-dependent mechanism that is mediated by the HIF-1 alpha/vascular endothelial growth factor/MMP-2 pathway in advanced age. Phosphatidylinositols 76-96 matrix metallopeptidase 2 Mus musculus 197-202 20375993-6 2010 Treatment of cultured podocytes with candesartan resulted in an increase in MMP-2 activity. candesartan 37-48 matrix metallopeptidase 2 Mus musculus 76-81 20519536-11 2010 Inhibiting spinal MMP-9 or MMP-2 reduces chronic and/or acute morphine tolerance. Morphine 62-70 matrix metallopeptidase 2 Mus musculus 27-32 20353950-0 2010 AP-1 (Fra-1/c-Jun)-mediated induction of expression of matrix metalloproteinase-2 is required for 15S-hydroxyeicosatetraenoic acid-induced angiogenesis. 15-hydroxy-5,8,11,13-eicosatetraenoic acid 98-130 matrix metallopeptidase 2 Mus musculus 55-81 20462855-10 2010 Gelatin zymographic analysis showed the inhibitory effect of ursolic acid on the protein expression of matrix metalloproteinases MMP-2 and MMP-9. ursolic acid 61-73 matrix metallopeptidase 2 Mus musculus 129-134 20370796-9 2010 Compared to the control group and ethanol group, the production of MMP-2 reduced 26.8% and 23.6% in the aortic sinus and the activation of MMP-2 reduced 32.6% and 27.3% in the aortic arch in the yellow wine group; the production of MMP-2 reduced 25.7% and 22.4% in the aortic sinus and the activation of MMP-2 reduced 30.2% and 26.6% in the aortic arch in the red wine group. Ethanol 34-41 matrix metallopeptidase 2 Mus musculus 67-72 20370796-9 2010 Compared to the control group and ethanol group, the production of MMP-2 reduced 26.8% and 23.6% in the aortic sinus and the activation of MMP-2 reduced 32.6% and 27.3% in the aortic arch in the yellow wine group; the production of MMP-2 reduced 25.7% and 22.4% in the aortic sinus and the activation of MMP-2 reduced 30.2% and 26.6% in the aortic arch in the red wine group. Ethanol 34-41 matrix metallopeptidase 2 Mus musculus 139-144 20370796-9 2010 Compared to the control group and ethanol group, the production of MMP-2 reduced 26.8% and 23.6% in the aortic sinus and the activation of MMP-2 reduced 32.6% and 27.3% in the aortic arch in the yellow wine group; the production of MMP-2 reduced 25.7% and 22.4% in the aortic sinus and the activation of MMP-2 reduced 30.2% and 26.6% in the aortic arch in the red wine group. Ethanol 34-41 matrix metallopeptidase 2 Mus musculus 139-144 20370796-9 2010 Compared to the control group and ethanol group, the production of MMP-2 reduced 26.8% and 23.6% in the aortic sinus and the activation of MMP-2 reduced 32.6% and 27.3% in the aortic arch in the yellow wine group; the production of MMP-2 reduced 25.7% and 22.4% in the aortic sinus and the activation of MMP-2 reduced 30.2% and 26.6% in the aortic arch in the red wine group. Ethanol 34-41 matrix metallopeptidase 2 Mus musculus 139-144 20448088-8 2010 Expression of MMP2 and MMP9 in nicotine-treated RPE cells was decreased. Nicotine 31-39 matrix metallopeptidase 2 Mus musculus 14-18 20353950-3 2010 Inhibition of MMP-2 activity or depletion of its levels attenuated 15(S)-HETE-induced HDMVEC migration, tube formation, and Matrigel plug angiogenesis. Hydroxyeicosatetraenoic Acids 73-77 matrix metallopeptidase 2 Mus musculus 14-19 20127122-9 2010 Protein expression of TGF-beta1 and MMP-2 was significantly enhanced in mice treated with morphine. Morphine 90-98 matrix metallopeptidase 2 Mus musculus 36-41 20044279-8 2010 Expression of interferon (IFN)-gamma and interleukin (IL)-15 mRNAs and matrix metalloproteinase (MMP)-2 in allografts was significantly lower in telmisartan-treated mice than in control mice. Telmisartan 145-156 matrix metallopeptidase 2 Mus musculus 71-103 20429953-11 2010 RESULTS: THL inhibited the migration and invasion ability of various cancer cells in vitro, decreased the secretion of MMP-2, MMP-9, and uPA and the activity of ERK1/2 in cancer cells, and suppressed pulmonary metastasis of CT-26 cancer cells in syngenic mice. Orlistat 9-12 matrix metallopeptidase 2 Mus musculus 119-124 20429953-12 2010 Moreover, THL inhibited the migration, invasion, and tube formation of endothelial cells in vitro, decreased the secretion of MMP-2 and uPA in endothelial cells, and suppressed neovascularization in Matrigel plugs in mice. Orlistat 10-13 matrix metallopeptidase 2 Mus musculus 126-131 20118983-6 2010 These alterations activated MMP 2/9 and cell mobility and invasiveness, which were reversed by the NHE inhibitor, 5-(N-ethyl-N-isopropyl) amiloride (EIPA), suggesting a role for NHE in cancer metastasis. ethylisopropylamiloride 114-147 matrix metallopeptidase 2 Mus musculus 28-35 20118983-6 2010 These alterations activated MMP 2/9 and cell mobility and invasiveness, which were reversed by the NHE inhibitor, 5-(N-ethyl-N-isopropyl) amiloride (EIPA), suggesting a role for NHE in cancer metastasis. ethylisopropylamiloride 149-153 matrix metallopeptidase 2 Mus musculus 28-35 20060010-12 2010 Pretreatment with puerarin inhibited the expressions of COX-2, MMP-2 and MMP-9. puerarin 18-26 matrix metallopeptidase 2 Mus musculus 63-68 20155364-0 2010 Impact of gentamicin-supplemented polyvinylidenfluoride mesh materials on MMP-2 expression and tissue integration in a transgenic mice model. Gentamicins 10-20 matrix metallopeptidase 2 Mus musculus 74-79 20155364-0 2010 Impact of gentamicin-supplemented polyvinylidenfluoride mesh materials on MMP-2 expression and tissue integration in a transgenic mice model. polyvinylidenfluoride 34-55 matrix metallopeptidase 2 Mus musculus 74-79 20155364-3 2010 Because of its proven beneficial effect on tissue integration, the influence of gentamicin-supplemented polyvinylidenfluoride (PVDF) mesh materials on MMP-2 transcription and protein expression was investigated in transgenic reporter mice harboring MMP-2 regulatory sequence-1686/+423. Gentamicins 80-90 matrix metallopeptidase 2 Mus musculus 151-156 20155364-3 2010 Because of its proven beneficial effect on tissue integration, the influence of gentamicin-supplemented polyvinylidenfluoride (PVDF) mesh materials on MMP-2 transcription and protein expression was investigated in transgenic reporter mice harboring MMP-2 regulatory sequence-1686/+423. polyvinylidene fluoride 127-131 matrix metallopeptidase 2 Mus musculus 151-156 20155364-15 2010 The reduced MMP-2 protein expression and transcription after mesh coating with 8 microg/mg gentamicin together with the improved collagen type I/III hint on an advanced tissue integration even in the long-term. Gentamicins 91-101 matrix metallopeptidase 2 Mus musculus 12-17 19733005-3 2010 PDT increased the expression of the anti-apoptotic and pro-angiogenic proteins survivin, Akt, HIF-1alpha, MMP-2 and VEGF in tumor tissue and this expression decreased significantly when 17-AAG was included in the treatment regimen. tanespimycin 186-192 matrix metallopeptidase 2 Mus musculus 106-111 20023432-0 2010 Biological evaluation of paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery. Paclitaxel 25-35 matrix metallopeptidase 2 Mus musculus 70-74 20226009-12 2010 Pharmacologically, rosiglitazone, a peroxisome proliferator activated receptor-gamma (PPARgamma) agonist appeared to induce MKP-1 expression while reduce MMP-2 and CXCR4 expression. Rosiglitazone 19-32 matrix metallopeptidase 2 Mus musculus 154-159 20075196-7 2010 AMCM-induced tubular cell EMT in C1.1 cells was inhibited by broad-spectrum MMP inhibitor (GM6001), MMP-2/9 inhibitor, and in AMCM after MMP-9 removal by monoclonal Ab against MMP-9. amcm 0-4 matrix metallopeptidase 2 Mus musculus 100-107 20075196-8 2010 AMCM-induced EMT in primary tubular epithelial cells was inhibited by MMP-2/9 inhibitor. amcm 0-4 matrix metallopeptidase 2 Mus musculus 70-77 19830840-9 2010 Treatment with the broad-spectrum MMP inhibitor, BB-94, significantly decreased astrocyte reactivity and MMP-2 activity. batimastat 49-54 matrix metallopeptidase 2 Mus musculus 105-110 20334687-7 2010 However, in sections of ectopic tumours treated with Dz13, both MMP-2 and MMP-9 were downregulated. dz13 53-57 matrix metallopeptidase 2 Mus musculus 64-69 19268934-11 2010 CONCLUSION(S): LXA(4) may inhibit the progression of endometriosis possibly by lowering the concentrations and the activities of MMP-2 and MMP-9. N-(1H-benzimidazol-2-ylmethyl)-2-methoxyacetamide 15-18 matrix metallopeptidase 2 Mus musculus 129-134 19828778-0 2010 Mono-(2-ethylhexyl) phthalate-induced disruption of junctional complexes in the seminiferous epithelium of the rodent testis is mediated by MMP2. mono-(2-ethylhexyl)phthalate 0-29 matrix metallopeptidase 2 Mus musculus 140-144 19828778-3 2010 Previously, we reported that Sertoli cell injury in rodents after mono-(2-ethylhexyl) phthalate (MEHP) exposure results in the activation of matrix metalloproteinase 2 (MMP2) and increases the sensitivity of germ cells to undergo apoptosis. mono-(2-ethylhexyl)phthalate 66-95 matrix metallopeptidase 2 Mus musculus 141-167 19828778-3 2010 Previously, we reported that Sertoli cell injury in rodents after mono-(2-ethylhexyl) phthalate (MEHP) exposure results in the activation of matrix metalloproteinase 2 (MMP2) and increases the sensitivity of germ cells to undergo apoptosis. mono-(2-ethylhexyl)phthalate 66-95 matrix metallopeptidase 2 Mus musculus 169-173 19828778-3 2010 Previously, we reported that Sertoli cell injury in rodents after mono-(2-ethylhexyl) phthalate (MEHP) exposure results in the activation of matrix metalloproteinase 2 (MMP2) and increases the sensitivity of germ cells to undergo apoptosis. mono-(2-ethylhexyl)phthalate 97-101 matrix metallopeptidase 2 Mus musculus 141-167 19828778-3 2010 Previously, we reported that Sertoli cell injury in rodents after mono-(2-ethylhexyl) phthalate (MEHP) exposure results in the activation of matrix metalloproteinase 2 (MMP2) and increases the sensitivity of germ cells to undergo apoptosis. mono-(2-ethylhexyl)phthalate 97-101 matrix metallopeptidase 2 Mus musculus 169-173 19828778-5 2010 In this study, we investigate the functional participation of MMP2 in the mechanism underlying MEHP-induced disruption of junction complexes and the resultant loss of germ cells. mono-(2-ethylhexyl)phthalate 95-99 matrix metallopeptidase 2 Mus musculus 62-66 19828778-8 2010 Treatment with specific MMP2 inhibitors (TIMP2 and SB-3CT) both in vitro and in vivo significantly suppressed MEHP-induced germ cell sloughing and changes in the expression of these junctional proteins, indicating that MMP-2 plays a primary role in this process. mono-(2-ethylhexyl)phthalate 110-114 matrix metallopeptidase 2 Mus musculus 24-28 19828778-8 2010 Treatment with specific MMP2 inhibitors (TIMP2 and SB-3CT) both in vitro and in vivo significantly suppressed MEHP-induced germ cell sloughing and changes in the expression of these junctional proteins, indicating that MMP-2 plays a primary role in this process. mono-(2-ethylhexyl)phthalate 110-114 matrix metallopeptidase 2 Mus musculus 219-224 19944145-15 2010 High epinephrine concentrations increased murine skin fibroblast proliferation and nitric oxide synthesis, and strongly inhibited skin fibroblast migration and both pro- and active MMP-2. Epinephrine 5-16 matrix metallopeptidase 2 Mus musculus 181-186 20170548-13 2010 The activity of MMP-2 secreted by TGZ-treated cells was lower than that secreted by untreated cells. Troglitazone 34-37 matrix metallopeptidase 2 Mus musculus 16-21 20023432-4 2010 In the present study, we designed and synthesized two PTX prodrugs by conjugating PTX at different sites with an octapeptide (AcGPLGIAGQ) that can be cleaved by MMP2 at tumor sites. Paclitaxel 54-57 matrix metallopeptidase 2 Mus musculus 161-165 20023432-4 2010 In the present study, we designed and synthesized two PTX prodrugs by conjugating PTX at different sites with an octapeptide (AcGPLGIAGQ) that can be cleaved by MMP2 at tumor sites. Paclitaxel 82-85 matrix metallopeptidase 2 Mus musculus 161-165 20023432-4 2010 In the present study, we designed and synthesized two PTX prodrugs by conjugating PTX at different sites with an octapeptide (AcGPLGIAGQ) that can be cleaved by MMP2 at tumor sites. octapeptide 113-124 matrix metallopeptidase 2 Mus musculus 161-165 20023432-9 2010 Together, our results indicate the potential of the tumor-targeted delivery of PTX to exploit the specific recognition of MMP2, reduce toxicity, and selectively kill tumor cells. Paclitaxel 79-82 matrix metallopeptidase 2 Mus musculus 122-126 19940766-0 2010 Heparin inhibits the production of matrix metalloproteinase-2 and improves atherosclerosis in LDL receptor-deficient mice. Heparin 0-7 matrix metallopeptidase 2 Mus musculus 35-61 20395677-1 2010 BACKGROUND/AIMS: In this study we tested the hypothesis that H(2)S regulates collagen deposition, matrix metalloproteinases (MMP) and inflammatory molecules during hyperhomocysteinemia (HHcy) resulting in attenuation of glomerulosclerosis and improved renal function. Hydrogen Sulfide 61-66 matrix metallopeptidase 2 Mus musculus 125-128 19940766-12 2010 Coincidently, the expression of MMP-2 in the atherosclerotic lesions in the heparin group was 49.3% lower than that in the control group (P<0.001). Heparin 76-83 matrix metallopeptidase 2 Mus musculus 32-37 19940766-13 2010 CONCLUSION: Heparin can inhibit the production of MMP-2 in the atherosclerotic lesions and improve the atherosclerotic lesions in LDLr(-/-) mice. Heparin 12-19 matrix metallopeptidase 2 Mus musculus 50-55 20096070-10 2010 Microvessel density and expression of VEGF and MMP-2 were much lower in mice receiving LDM cisplatin than in the control and MTD groups. Cisplatin 91-100 matrix metallopeptidase 2 Mus musculus 47-52 19913585-12 2010 These effects were ameliorated by H(2)S and suggested that physiological levels of H(2)S supplementation may have therapeutic potential against HHcy-induced microvascular permeability, in part, by normalizing the MMP/TIMP ratio in the brain. Hydrogen Sulfide 83-88 matrix metallopeptidase 2 Mus musculus 213-216 19770485-0 2009 S-Adenosylhomocysteine promotes the invasion of C6 glioma cells via increased secretion of matrix metalloproteinase-2 in murine microglial BV2 cells. S-Adenosylhomocysteine 0-22 matrix metallopeptidase 2 Mus musculus 91-117 19770485-7 2009 Pretreatment of BV2 cells with an inhibitor specific for ERK (U0126) markedly abated the expression of ERK and MMP-2. U 0126 62-67 matrix metallopeptidase 2 Mus musculus 111-116 18849138-0 2009 Acetylsalicylic acid regulates MMP-2 activity and inhibits colorectal invasion of murine B16F0 melanoma cells in C57BL/6J mice: effects of prostaglandin F(2)alpha. Aspirin 0-20 matrix metallopeptidase 2 Mus musculus 31-36 19822495-15 2009 Western blotting analyses demonstrated that MMP-2 and MMP-2 fragments were down-regulated and nm23-M1 was up-regulated in H(22) cells treated with 2 micromol/L ATO for 48 hours. Arsenic Trioxide 160-163 matrix metallopeptidase 2 Mus musculus 44-49 19822495-15 2009 Western blotting analyses demonstrated that MMP-2 and MMP-2 fragments were down-regulated and nm23-M1 was up-regulated in H(22) cells treated with 2 micromol/L ATO for 48 hours. Arsenic Trioxide 160-163 matrix metallopeptidase 2 Mus musculus 54-59 19822495-16 2009 CONCLUSIONS: ATO at a low dose inhibits the metastatic potential of mouse hepatoma H(22) cells in vitro and in vivo, and involves down-regulation of MMP-2 and up-regulation of nm23-M1. Arsenic Trioxide 13-16 matrix metallopeptidase 2 Mus musculus 149-154 19814725-3 2009 We hypothesized that losartan would suppress MMP-2/-9 activation and improve aortic vasomotor function in this model. Losartan 21-29 matrix metallopeptidase 2 Mus musculus 45-50 19814725-9 2009 Losartan reduced the activity and protein expression of MMP-2 and MMP-9 at all ages. Losartan 0-8 matrix metallopeptidase 2 Mus musculus 56-61 19625610-6 2009 EGF also increased matrix metalloproteinase (MMP-2) expression levels and EGF-induced MMP2 expression was inhibited by caveolin-1 siRNA, FAK siRNA, LY-294002, Akt inhibitor, and PD-98059. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 148-157 matrix metallopeptidase 2 Mus musculus 86-90 19625610-6 2009 EGF also increased matrix metalloproteinase (MMP-2) expression levels and EGF-induced MMP2 expression was inhibited by caveolin-1 siRNA, FAK siRNA, LY-294002, Akt inhibitor, and PD-98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 178-186 matrix metallopeptidase 2 Mus musculus 86-90 19587312-6 2009 The Abeta-induced cognitive impairment in vivo as well as neurotoxicity in vitro was significantly alleviated in MMP-9 homozygous knockout mice and by treatment with MMP inhibitors. UNII-042A8N37WH 4-9 matrix metallopeptidase 2 Mus musculus 113-116 19808375-7 2009 Treatment of Ace2(-)(/y)-MI mice with irbesartan, an AT1 receptor blocker, reduced nicotinamide-adenine dinucleotide phosphate oxidase activity, infarct size, MMP activation, and myocardial inflammation, ultimately resulting in improved post-MI ventricular function. Irbesartan 38-48 matrix metallopeptidase 2 Mus musculus 159-162 18849138-5 2009 Gelatin-based zymography assays showed that acetylsalicylic acid inhibited the MMP-2 activity of B16F0 melanoma cells. Aspirin 44-64 matrix metallopeptidase 2 Mus musculus 79-84 18849138-7 2009 Acetylsalicylic acid can inhibit PGF(2)alpha synthesis and PGF(2)alpha is a key stimulator of MMP-2 production. Aspirin 0-20 matrix metallopeptidase 2 Mus musculus 94-99 18849138-7 2009 Acetylsalicylic acid can inhibit PGF(2)alpha synthesis and PGF(2)alpha is a key stimulator of MMP-2 production. Prostaglandins F 59-62 matrix metallopeptidase 2 Mus musculus 94-99 19320561-1 2009 Vascular remodeling associated with increased blood flow involves reactive oxygen species (ROS)-dependent activation of matrix metalloproteinases (MMPs). Reactive Oxygen Species 66-89 matrix metallopeptidase 2 Mus musculus 147-151 19462226-0 2009 Aspirin inhibits MMP-2 and MMP-9 expression and activity through PPARalpha/gamma and TIMP-1-mediated mechanisms in cultured mouse celiac macrophages. Aspirin 0-7 matrix metallopeptidase 2 Mus musculus 17-22 19462226-3 2009 The purpose of present study was to investigate the inhibitory effects of aspirin on MMP-2 and MMP-9 expression and activity in cultured mouse celiac macrophages, and to determine the possible mechanisms. Aspirin 74-81 matrix metallopeptidase 2 Mus musculus 85-90 19462226-4 2009 The results showed that MMP-2/9 mRNA expression and release were significantly decreased after cultured mouse celiac macrophages were treated with aspirin 12.5-50 microg/ml for 24 h, while the TIMP-1 mRNA expression and release, and peroxisome proliferator-activated receptor (PPAR) alpha/gamma mRNA expression were increased after the same treatment. Aspirin 147-154 matrix metallopeptidase 2 Mus musculus 24-31 19462226-5 2009 Moreover the aspirin-induced down-regulation of MMP-2/9 mRNA expression and reduction of MMP-9 release were notably alleviated after pretreatment with specific inhibitors of PPARalpha/gamma. Aspirin 13-20 matrix metallopeptidase 2 Mus musculus 48-55 19462226-6 2009 These results suggested that aspirin could inhibit the expression and release of MMP-2/9 by up-regulation of PPARalpha/gamma gene expression, and also inhibit the activity of MMP-2/9 by induction of TIMP-1 expression, which might be good for the stabilization of atherosclerotic plaques and the prevention of cardio-cerebrovascular events. Aspirin 29-36 matrix metallopeptidase 2 Mus musculus 81-86 19462226-6 2009 These results suggested that aspirin could inhibit the expression and release of MMP-2/9 by up-regulation of PPARalpha/gamma gene expression, and also inhibit the activity of MMP-2/9 by induction of TIMP-1 expression, which might be good for the stabilization of atherosclerotic plaques and the prevention of cardio-cerebrovascular events. Aspirin 29-36 matrix metallopeptidase 2 Mus musculus 175-180 19320561-1 2009 Vascular remodeling associated with increased blood flow involves reactive oxygen species (ROS)-dependent activation of matrix metalloproteinases (MMPs). Reactive Oxygen Species 91-94 matrix metallopeptidase 2 Mus musculus 147-151 19356734-5 2009 Celastrol reduced the total number of inflammatory cells in the bronchoalveolar lavage fluid and in peribronchial areas, and decreased the airway hyperresponsiveness, mRNA and protein expression levels for inflammatory cytokines such as interleukin (IL)-4, IL-13, TNF-alpha and IFN-gamma, and for MMPs and TIMPs, MAP kinases and NF-kappaB activities in the bronchoalveolar lavage cells and in the lung tissues increased in ovalbumin-induced allergic asthma in mice. celastrol 0-9 matrix metallopeptidase 2 Mus musculus 297-301 19766896-0 2009 Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice. Rosuvastatin Calcium 0-12 matrix metallopeptidase 2 Mus musculus 22-27 19766896-3 2009 Rosuvastatin may inhibit the secretion of MMP-2 and MMP-9 from vascular smooth muscle cells and macrophages in vitro. Rosuvastatin Calcium 0-12 matrix metallopeptidase 2 Mus musculus 42-47 19105229-0 2009 Ketoprofen in topical formulation decreases the matrix metalloproteinase-2 expression and pulmonary metastatic incidence in nude mice with osteosarcoma. Ketoprofen 0-10 matrix metallopeptidase 2 Mus musculus 48-74 19766896-8 2009 Meanwhile, levels of plasma total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and oxidized (ox)LDL in the rosuvastatin group were decreased as well as MMP-2 and MMP-9 expression in aortic arch with gelatin zymography and the production of MMP-2 in the aortic sinus through immunohistochemical methods. Rosuvastatin Calcium 145-157 matrix metallopeptidase 2 Mus musculus 190-195 19766896-8 2009 Meanwhile, levels of plasma total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and oxidized (ox)LDL in the rosuvastatin group were decreased as well as MMP-2 and MMP-9 expression in aortic arch with gelatin zymography and the production of MMP-2 in the aortic sinus through immunohistochemical methods. Rosuvastatin Calcium 145-157 matrix metallopeptidase 2 Mus musculus 278-283 19766896-11 2009 CONCLUSIONS: Rosuvastatin inhibits the expression of MMP-2/-9 and limits the progression of atherosclerosis in LDLR-deficient mice. Rosuvastatin Calcium 13-25 matrix metallopeptidase 2 Mus musculus 53-61 19422227-7 2009 The number of metastatic tumor-bearing mice, the number of affected organs, and the number of tumor foci as well as the MMP-2 and -9 activities in serum of mice were also significantly suppressed by oral administration of GLE. GLE 222-225 matrix metallopeptidase 2 Mus musculus 120-132 19356734-6 2009 Our data suggest that oral administration of celastrol suppresses ovalbumin-induced airway inflammation, hyperresponsiveness, and tissue remodeling by regulating the imbalance of MMP-2/-9 and TIMP-1/-2 by inflammatory cytokines via MAP kinases/NF-kappaB in inflammatory cells. celastrol 45-54 matrix metallopeptidase 2 Mus musculus 179-187 19367295-7 2009 Significant glutamate-evoked concentration-dependent release of tissue-type plasminogen activator (t-PA) and matrix metalloproteinases (MMPs) activities was found in supernatants of neonatal, but not in adult BMECs. Glutamic Acid 12-21 matrix metallopeptidase 2 Mus musculus 136-140 19367295-8 2009 The glutamate-mediated release of t-PA, MMP-2, and MMP-9 proteolytic activities in neonatal BMECs was blocked by MK-801. Glutamic Acid 4-13 matrix metallopeptidase 2 Mus musculus 40-45 19367295-8 2009 The glutamate-mediated release of t-PA, MMP-2, and MMP-9 proteolytic activities in neonatal BMECs was blocked by MK-801. Dizocilpine Maleate 113-119 matrix metallopeptidase 2 Mus musculus 40-45 19276073-5 2009 When MMP-2 activity was inhibited either by the metalloproteinase inhibitor GM-6001 or in MMP-2-deficient fibroblasts, an increase in the basal amount of FN together with a decrease of its levels in response to CTGF was observed. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 76-83 matrix metallopeptidase 2 Mus musculus 5-10 19430489-7 2009 Mechanistic studies showed that VSMC-derived intracellular and extracellular CypA are required for ROS generation and matrix metalloproteinase-2 activation. vsmc 32-36 matrix metallopeptidase 2 Mus musculus 118-144 19594013-0 2009 [Inhibitory effect of curcumin on MMP-2 and MMP-9 expression induced by polyethylene wear particles and its mechanism]. Curcumin 22-30 matrix metallopeptidase 2 Mus musculus 34-39 19594013-0 2009 [Inhibitory effect of curcumin on MMP-2 and MMP-9 expression induced by polyethylene wear particles and its mechanism]. Polyethylene 72-84 matrix metallopeptidase 2 Mus musculus 34-39 19594013-1 2009 OBJECTIVE: To observe the effect of different dosage of curcumin on expression of MMP-2 and MMP-9 in the tissue of cystiform in air-pouch mouse models after the injection of polyethylene wear particles, and to investigate its mechanism of intervening inflammatory response induced by wear particles. Curcumin 56-64 matrix metallopeptidase 2 Mus musculus 82-87 19594013-15 2009 CONCLUSION: Ultra-high molecular weight polyethylene wear particles can stimulate expression of MMP-2 and MMP-9 in cystiform tissue. Polyethylene 40-52 matrix metallopeptidase 2 Mus musculus 96-101 19594013-16 2009 Curcumin can restrain expression of MMP-2 and MMP-9 in cystiform tissue of air-pouch animal models, and expression of MMP-2 and MMP-9 may be regulated by the activation of NF-kappaB. Curcumin 0-8 matrix metallopeptidase 2 Mus musculus 36-41 19150882-6 2009 GEE-mediated increases in vascular ROS were attenuated by Tempol-treatment, as were MMP-2 and TIMP-2; whereas BQ-123 ameliorated GEE-induced vascular expression of MMP-9, MMP-2, ROS, and ET-1. cyclo(Trp-Asp-Pro-Val-Leu) 110-116 matrix metallopeptidase 2 Mus musculus 171-176 19150882-6 2009 GEE-mediated increases in vascular ROS were attenuated by Tempol-treatment, as were MMP-2 and TIMP-2; whereas BQ-123 ameliorated GEE-induced vascular expression of MMP-9, MMP-2, ROS, and ET-1. glycine ethyl ester 0-3 matrix metallopeptidase 2 Mus musculus 171-176 19010991-11 2009 Methylprednisolone led to a complete resolution of lung mechanics, avoided fibroelastogenesis and the increase in the expression of MMP-9 and MMP-2 independent of steroid treatment design. Methylprednisolone 0-18 matrix metallopeptidase 2 Mus musculus 142-147 19050991-9 2009 Prevention of UVB-induced aging of the skin by topical application of the nonsugar fraction of brown sugar may be due to inhibition of increases in MMP-2 and VEGF expression. brown sugar 95-106 matrix metallopeptidase 2 Mus musculus 148-153 19217658-3 2009 We have previously demonstrated that the 20S proteasome is involved in mouse embryo implantation and its action is mediated via regulating the expression and activities of matrix metalloproteinase (MMP)-2 and MMP-9 in the EVTs. evts 222-226 matrix metallopeptidase 2 Mus musculus 172-204 18974264-5 2009 Saline-treated Rxfp1(-/-) mice had significantly increased myofibroblast differentiation and lung collagen deposition (both P < 0.05), decreased matrix metalloproteinase (MMP)-9 expression and activity (P < 0.05), but equivalent levels of MMP-2 and tissue inhibitor of metalloproteinases (TIMPs) to that measured in saline-treated Rxfp1(+/+) mice. Sodium Chloride 0-6 matrix metallopeptidase 2 Mus musculus 245-250 18974270-7 2009 The inhibitory effect of g-OxLDL on IAP cleavage appeared to be due to its ability to decrease the amount of activated MMP-2, the protease responsible for IAP cleavage. g-oxldl 25-32 matrix metallopeptidase 2 Mus musculus 119-124 19196320-0 2009 2-hydroxyethyl methacrylate as an inhibitor of matrix metalloproteinase-2. hydroxyethyl methacrylate 0-27 matrix metallopeptidase 2 Mus musculus 47-73 19072832-8 2009 Matrix metalloproteinase-2 (MMP-2) and MMP-9 mRNA increased more in the gp91(phox(-/-) ) than in WT mice after CCl(4.) Cefaclor 111-114 matrix metallopeptidase 2 Mus musculus 0-26 19171847-9 2009 Our data demonstrate that MMP-2 and MMP-9 activities were highly upregulated in wild-type (WT) mice treated with DSS, S.T., or TNBS whereas dKO mice were resistant to the development of colitis. dss 113-116 matrix metallopeptidase 2 Mus musculus 26-31 19171847-9 2009 Our data demonstrate that MMP-2 and MMP-9 activities were highly upregulated in wild-type (WT) mice treated with DSS, S.T., or TNBS whereas dKO mice were resistant to the development of colitis. Trinitrobenzenesulfonic Acid 127-131 matrix metallopeptidase 2 Mus musculus 26-31 19196320-1 2009 This study evaluated the effect of different concentrations of 2-hydroxyethyl methacrylate (HEMA) on the inhibition of matrix metalloproteinase-2 (MMP-2) in vitro. hydroxyethyl methacrylate 63-90 matrix metallopeptidase 2 Mus musculus 119-145 19196320-1 2009 This study evaluated the effect of different concentrations of 2-hydroxyethyl methacrylate (HEMA) on the inhibition of matrix metalloproteinase-2 (MMP-2) in vitro. hydroxyethyl methacrylate 63-90 matrix metallopeptidase 2 Mus musculus 147-152 19196320-1 2009 This study evaluated the effect of different concentrations of 2-hydroxyethyl methacrylate (HEMA) on the inhibition of matrix metalloproteinase-2 (MMP-2) in vitro. hydroxyethyl methacrylate 92-96 matrix metallopeptidase 2 Mus musculus 119-145 19196320-1 2009 This study evaluated the effect of different concentrations of 2-hydroxyethyl methacrylate (HEMA) on the inhibition of matrix metalloproteinase-2 (MMP-2) in vitro. hydroxyethyl methacrylate 92-96 matrix metallopeptidase 2 Mus musculus 147-152 19196320-6 2009 All forms of MMP-2 were inhibited by HEMA in a dose-dependent manner, implying that MMP-2 may be inhibited by HEMA in vivo. hydroxyethyl methacrylate 37-41 matrix metallopeptidase 2 Mus musculus 13-18 19196320-6 2009 All forms of MMP-2 were inhibited by HEMA in a dose-dependent manner, implying that MMP-2 may be inhibited by HEMA in vivo. hydroxyethyl methacrylate 37-41 matrix metallopeptidase 2 Mus musculus 84-89 19021146-14 2009 The results concluded that homocysteine generated nitrotyrosine in the vicinity of endothelium, caused MMP activation and endothelium-myocyte uncoupling. Homocysteine 27-39 matrix metallopeptidase 2 Mus musculus 103-106 19557586-5 2009 The presence of calcification was associated with greater amounts of matrix metalloproteinase-2, suggesting an association between calcium deposition and extracellular matrix degradation. Calcium 131-138 matrix metallopeptidase 2 Mus musculus 69-95 19566031-5 2009 Inactivation of gelatinase MMP-2 (matrix metalloproteinase) using pretreatment of the cells with the inhibitor of MMP, G6001, or specific antibodies to MMP-2 or MMP-9 resulted in decrease of 3T3-SV40 sensitivity to NK cells activity. g6001 119-124 matrix metallopeptidase 2 Mus musculus 27-32 19566031-5 2009 Inactivation of gelatinase MMP-2 (matrix metalloproteinase) using pretreatment of the cells with the inhibitor of MMP, G6001, or specific antibodies to MMP-2 or MMP-9 resulted in decrease of 3T3-SV40 sensitivity to NK cells activity. g6001 119-124 matrix metallopeptidase 2 Mus musculus 27-30 19566031-9 2009 However, both NAC and ALA pathway includes inactivation of MMP-2. Acetylcysteine 14-17 matrix metallopeptidase 2 Mus musculus 59-64 19566031-9 2009 However, both NAC and ALA pathway includes inactivation of MMP-2. Thioctic Acid 22-25 matrix metallopeptidase 2 Mus musculus 59-64 18780770-12 2008 Glomerular MMP-2 and MMP-9 activities as well as TIMP-1 expression were increased robustly in diabetic mice and normalized with CZ treatment. ciglitazone 128-130 matrix metallopeptidase 2 Mus musculus 11-16 18796497-10 2008 Using a mouse model, we showed that gNO promoted A549 metastasis to the lung through a mechanism involving the iNOS-dependent MMP-2 activity. CP 544326 36-39 matrix metallopeptidase 2 Mus musculus 126-131 18725259-11 2008 Increased MMP-2, MMP-9, collagen-III and TIMP-3 mRNA levels were found in GABA(A)-/-, CBS-/+, CBS-/+/GABA(A) double knockout compared to WT. gamma-Aminobutyric Acid 74-78 matrix metallopeptidase 2 Mus musculus 10-15 18725259-11 2008 Increased MMP-2, MMP-9, collagen-III and TIMP-3 mRNA levels were found in GABA(A)-/-, CBS-/+, CBS-/+/GABA(A) double knockout compared to WT. gamma-Aminobutyric Acid 101-105 matrix metallopeptidase 2 Mus musculus 10-15 18621044-5 2008 Significant reduction of matrix metalloproteinases (MMP)-9/MMP-2 ratio and urokinase-type plasminogen activator (uPA) expression was detected in brain of NZB/W F1 mice treated with cystamine as compared to control group. Cystamine 181-190 matrix metallopeptidase 2 Mus musculus 59-64 18956456-2 2008 The PCA2-switch agent incorporates a solubility switch, where cleavage of a peptide substrate by MMP-2 decreases the water solubility of the agent. Water 117-122 matrix metallopeptidase 2 Mus musculus 97-102 18767864-7 2008 B16-F1 cells treated with MACs at various concentrations showed reduced extracellular matrix (ECM) proteinases including matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) by gelatin zymography assay. macs 26-30 matrix metallopeptidase 2 Mus musculus 121-147 18767864-7 2008 B16-F1 cells treated with MACs at various concentrations showed reduced extracellular matrix (ECM) proteinases including matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) by gelatin zymography assay. macs 26-30 matrix metallopeptidase 2 Mus musculus 149-154 18767864-9 2008 Therefore, it was suggested that MACs could mediate B16-F1 cell metastasis by reduction of MMP-2 and MMP-9 activities involving the suppression of the Ras/PI3K signaling pathway. macs 33-37 matrix metallopeptidase 2 Mus musculus 91-96 18837800-5 2008 MATERIALS AND METHODS: 3T3-L1 adipocytes were incubated with or without 10 microg mL(-1) bFGF for 8 h in the presence or absence of the MMP inhibitor GM6001, vascular endothelial growth factor (VEGF), MMP-2 or anti-bFGF antibody to study the effect of bFGF on MMP-2 mRNA expression, MMP-2 activity, fat accumulation or 2-deoxyglucose uptake. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 150-156 matrix metallopeptidase 2 Mus musculus 136-139 18572362-10 2008 Effect of resveratrol on matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) gene expression was investigated with reverse transcriptase-polymerase chain reaction and Western blot. Resveratrol 10-21 matrix metallopeptidase 2 Mus musculus 25-51 18298463-4 2008 However, no reports are available on the relationship between the activity of MMPs and melatonin"s anti-inflammatory effects. Melatonin 87-96 matrix metallopeptidase 2 Mus musculus 78-82 18298463-5 2008 The aim of the present study was to evaluate whether the protective effect of melatonin observed in SCI is related to the regulation of MMP-9 and MMP-2 in mice. Melatonin 78-87 matrix metallopeptidase 2 Mus musculus 146-151 18298463-10 2008 We propose that melatonin"s ability to reduce SCI in mice is also related to a reduction in MMP-9 and MMP-2 activity and expression. Melatonin 16-25 matrix metallopeptidase 2 Mus musculus 102-107 18572362-10 2008 Effect of resveratrol on matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) gene expression was investigated with reverse transcriptase-polymerase chain reaction and Western blot. Resveratrol 10-21 matrix metallopeptidase 2 Mus musculus 53-58 18572362-15 2008 The elevated MMP-2 and VEGF levels might be important in the neuroprotective effect of resveratrol administration by inducing angiogenesis. Resveratrol 87-98 matrix metallopeptidase 2 Mus musculus 13-18 18782185-7 2008 DTD treatment inhibits the matrix metalloproteinase-2 production in endothelial and fibrosarcoma cells, but does not affect the cyclooxygenase-2 expression in endothelial cells, as assessed by western blot analysis. DITHIANE DIOL 0-3 matrix metallopeptidase 2 Mus musculus 27-53 18790756-3 2008 We have tested Galardin/GM6001, a potent MPI that reacts with most MMPs, in the MMTV-PymT transgenic breast cancer model. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 24-30 matrix metallopeptidase 2 Mus musculus 67-71 18790756-11 2008 We also found that primary tumors from Galardin-treated mice exhibited a lower histopathologic tumor grade, increased collagen deposition, and increased MMP-2 activity. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 39-47 matrix metallopeptidase 2 Mus musculus 153-158 18438431-9 2008 Moreover, MMP-2 inhibition induced apoptotic cell death in vitro, and suppressed tumor growth of preestablished U-251 intracranial xenografts in nude mice. u-251 112-117 matrix metallopeptidase 2 Mus musculus 10-15 18467449-5 2008 Furthermore, the invasiveness of HepG2-thyroid hormone receptor (TR) cells was significantly increased by T(3) treatment, perhaps due to furin processing of matrix metalloproteinase-2 and -9. Triiodothyronine 106-110 matrix metallopeptidase 2 Mus musculus 157-190 18507693-5 2008 In vitro, we examined the effects of Y-27632 and RhoC siRNA on MMP-2 and -9 expressions, invasiveness, and apoptosis in cultured tumor cells. Y 27632 37-44 matrix metallopeptidase 2 Mus musculus 63-75 18507693-8 2008 In vitro, Y-27632 and RhoC siRNA reduced MMP-2 and -9 expressions, as well as the chemotactic migration of tumor cells dose-dependently, and increased apoptosis eight times. Y 27632 10-17 matrix metallopeptidase 2 Mus musculus 41-53 18059072-0 2008 Matrix metalloproteinases 2 and 9 in central nervous system and their modification after vanadium inhalation. Vanadium 89-97 matrix metallopeptidase 2 Mus musculus 0-33 18487442-8 2008 MMP-2 gelatin zymographic activity increased 1.9- and 2.4-fold in TAC and TAC + Dox mice, respectively (P < 0.01 and P < 0.05 relative to respective sham-operated animals), but the difference between TAC + Dox and TAC mice did not reach statistical significance. Doxycycline 80-83 matrix metallopeptidase 2 Mus musculus 0-5 18487442-8 2008 MMP-2 gelatin zymographic activity increased 1.9- and 2.4-fold in TAC and TAC + Dox mice, respectively (P < 0.01 and P < 0.05 relative to respective sham-operated animals), but the difference between TAC + Dox and TAC mice did not reach statistical significance. Doxycycline 212-215 matrix metallopeptidase 2 Mus musculus 0-5 18468597-4 2008 In this context, our study aimed to evaluate the effect of PJ34 (N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-2-(N,N-dimethylamino)acetamide), a potent PARP inhibitor, on MMP-2 and MMP-9 levels and on hemorrhagic transformations in a model of permanent focal cerebral ischemia in mice. n-(6-oxo-5,6-dihydrophenanthridin-2-yl)-2-(n,n-dimethylamino)acetamide 65-135 matrix metallopeptidase 2 Mus musculus 166-171 18388324-0 2008 Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Doxycycline 10-21 matrix metallopeptidase 2 Mus musculus 135-168 18559520-5 2008 Ad-MMP-2-Si-CM decreased proliferation as determined by Ki-67 immunofluorescence and induced apoptosis in endothelial cells as determined by terminal deoxynucleotidyl-transferase-mediated dUTP nick-end labeling (TUNEL) assay. deoxyuridine triphosphate 188-192 matrix metallopeptidase 2 Mus musculus 0-11 18308946-7 2008 In vitro mono-treatment with either fluvastatin (100 nM) or SDF-1 (100 ng/ml) facilitated EPC proliferation and migration, inhibited EPC apoptosis, enhanced expression of matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9), and increased Akt phosphorylation and nitric oxide production. Fluvastatin 36-47 matrix metallopeptidase 2 Mus musculus 171-197 18308946-7 2008 In vitro mono-treatment with either fluvastatin (100 nM) or SDF-1 (100 ng/ml) facilitated EPC proliferation and migration, inhibited EPC apoptosis, enhanced expression of matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9), and increased Akt phosphorylation and nitric oxide production. Fluvastatin 36-47 matrix metallopeptidase 2 Mus musculus 199-212 18388324-14 2008 We concluded that long-term treatment with doxycycline, through the inhibition of MMP-2 and -9, is more effective than atenolol in preventing TAA in Marfan syndrome by preserving elastic fiber integrity, normalizing vasomotor function, and reducing transforming growth factor-beta activation. Doxycycline 43-54 matrix metallopeptidase 2 Mus musculus 82-94 18482668-1 2008 OBJECTIVES: Clarithromycin (CAM), a major macrolide antibiotic, has many biological functions, including matrix metalloproteinases (MMPs) regulation. Clarithromycin 12-26 matrix metallopeptidase 2 Mus musculus 132-136 18482668-1 2008 OBJECTIVES: Clarithromycin (CAM), a major macrolide antibiotic, has many biological functions, including matrix metalloproteinases (MMPs) regulation. Clarithromycin 28-31 matrix metallopeptidase 2 Mus musculus 132-136 18388324-0 2008 Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Atenolol 45-53 matrix metallopeptidase 2 Mus musculus 135-168 18388324-3 2008 We hypothesized that doxycycline, a nonspecific inhibitor of MMPs, would ameliorate TAA by attenuating elastic fiber degeneration and improving vasomotor function. Doxycycline 21-32 matrix metallopeptidase 2 Mus musculus 61-65 18388324-12 2008 Doxycycline augmented expression ratios of tissue inhibitors of MMP to MMPs. Doxycycline 0-11 matrix metallopeptidase 2 Mus musculus 64-67 18388324-12 2008 Doxycycline augmented expression ratios of tissue inhibitors of MMP to MMPs. Doxycycline 0-11 matrix metallopeptidase 2 Mus musculus 71-75 21318961-7 2008 Gelatin zymography and in situ zymography showed that pro- and active forms of MMP-2 and MMP-9 were more strongly expressed in ApoE-/-/iNOS+/+ than in ApoE-/-/iNOS-/- mice, nitrotyrosine and MMP-9 were co-expressed in the atheroma. 3-nitrotyrosine 173-186 matrix metallopeptidase 2 Mus musculus 79-84 21318961-8 2008 CONCLUSION: We conclude that induction of iNOS in atheroma of high-cholesterol-fed ApoE-/-/iNOS+/+ mice leads to increased production and activation of MMPs, with a subsequent decrease in collagen content, affording fragile plaque. Cholesterol 67-78 matrix metallopeptidase 2 Mus musculus 152-156 18287363-4 2008 Plasma levels of matrix metalloproteinase (MMP)-2 and vascular endothelial growth factor (VEGF) increased gradually in tumor-injected mice (tumor controls) following tumor injection but were markedly lowered by lycopene or beta-carotene supplementation. Lycopene 211-219 matrix metallopeptidase 2 Mus musculus 17-49 18313050-3 2008 Therefore we studied whether 17beta-estradiol (E(2)) modulates the expression and activity of the trimolecular complex (MMP-2, TIMP-2 and MMP-14), molecules which are of major importance for ECM turnover in RPE. Estradiol 29-45 matrix metallopeptidase 2 Mus musculus 120-125 18385789-11 2008 Olomoucine treatment of scratch wounded HCLE cells produced similar changes in MMP-9 and MMP-2 expression. olomoucine 0-10 matrix metallopeptidase 2 Mus musculus 89-94 18364034-0 2008 Matrix metalloproteinases MMP2 and MMP9 are upregulated by noradrenaline in the mouse neuroendocrine hypothalamus. Norepinephrine 59-72 matrix metallopeptidase 2 Mus musculus 26-30 18364034-5 2008 We investigated the possible regulation of the two gelatinases, MMP2 and MMP9, by noradrenaline (NA) in the mouse neuroendocrine hypothalamus. Norepinephrine 82-95 matrix metallopeptidase 2 Mus musculus 64-68 17765904-9 2008 Pretreatment with EPA attenuated the up-regulation of VCAM-1, ICAM-1 and MCP-1 in HUVECs as well as the expression of MMP-2 and MMP-9 in macrophage-like cells induced by TNF-alpha. Eicosapentaenoic Acid 18-21 matrix metallopeptidase 2 Mus musculus 118-123 18395095-9 2008 In contrast, thioacetamide caused more severe liver injury and fibrosis in K18 R89C as compared with WT and nontransgenic mice and resulted in increased messenger RNA levels of collagen, tissue inhibitor of metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 13. Thioacetamide 13-26 matrix metallopeptidase 2 Mus musculus 228-254 18438340-19 2008 CONCLUSIONS: By inhibiting COX-2, PGE(2) synthesis, and VEGF and MMP-2 mRNA expression in tumor tissue, celecoxib enhances tumor cell apoptosis, thereby inhibiting the growth and angiogenesis of orthotopically implanted tumors in a mouse model of human colorectal cancer. Celecoxib 104-113 matrix metallopeptidase 2 Mus musculus 65-70 18287363-4 2008 Plasma levels of matrix metalloproteinase (MMP)-2 and vascular endothelial growth factor (VEGF) increased gradually in tumor-injected mice (tumor controls) following tumor injection but were markedly lowered by lycopene or beta-carotene supplementation. beta Carotene 223-236 matrix metallopeptidase 2 Mus musculus 17-49 18226269-5 2008 In xenogrfated tumors, curcumin upregulated the expression of TRAIL-R1/DR4, TRAIL-R2/DR5, Bax, Bak, p21/WAF1, and p27/KIP1, and inhibited the activation of NFkappaB and its gene products such as cyclin D1, VEGF, uPA, MMP-2, MMP-9, Bcl-2 and Bcl-XL. Curcumin 23-31 matrix metallopeptidase 2 Mus musculus 217-222 18075496-4 2008 Twelve weeks after streptozotocin-induced diabetes, these transgenic mice showed a more severe proteinuria, mesangial expansion, and a decrease in matrix metalloproteinase-2 activity compared to diabetic wild-type mice. Streptozocin 19-33 matrix metallopeptidase 2 Mus musculus 147-173 17981034-3 2008 Towards this end, we have synthesized a series of 1-hydroxy-2-pyridinones that have excellent in vitro potency in inhibiting MMP-9 in addition to MMP-2. 1-hydroxy-2-pyridinones 50-73 matrix metallopeptidase 2 Mus musculus 146-151 18686102-0 2008 Amentoflavone inhibits experimental tumor metastasis through a regulatory mechanism involving MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, VEGF, ERK-1, ERK-2, STAT-1, NM23 and cytokines in lung tissues of C57BL/6 mice. amentoflavone 0-13 matrix metallopeptidase 2 Mus musculus 94-99 17981559-5 2008 In vivo, AsPC-1 xenografted tumors treated with EGCG showed significant reduction in volume, proliferation (Ki-67 and PCNA staining), angiogenesis (vWF, VEGF and CD31) and metastasis (MMP-2, MMP-7, MMP-9 and MMP-12) and induction in apoptosis (TUNEL), caspase-3 activity and growth arrest (p21/WAF1). epigallocatechin gallate 48-52 matrix metallopeptidase 2 Mus musculus 184-189 18686102-5 2008 Amentoflavone treatment markedly decreased the mRNA expression of MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, VEGF, ERK-1, ERK-2, TNF-alpha, IL-1beta, IL-6, and GM-CSF in lung tissues. amentoflavone 0-13 matrix metallopeptidase 2 Mus musculus 66-71 18198472-0 2008 Neuropsychotoxicity of abused drugs: involvement of matrix metalloproteinase-2 and -9 and tissue inhibitor of matrix metalloproteinase-2 in methamphetamine-induced behavioral sensitization and reward in rodents. Methamphetamine 140-155 matrix metallopeptidase 2 Mus musculus 52-136 18198472-5 2008 MMP-2/-9 inhibitors blocked the METH-induced behavioral sensitization and conditioned place preference (CPP), a measure of the rewarding effect of a drug, and reduced the METH-increased dopamine release in the NAc. Methamphetamine 32-36 matrix metallopeptidase 2 Mus musculus 0-5 18198472-5 2008 MMP-2/-9 inhibitors blocked the METH-induced behavioral sensitization and conditioned place preference (CPP), a measure of the rewarding effect of a drug, and reduced the METH-increased dopamine release in the NAc. Methamphetamine 171-175 matrix metallopeptidase 2 Mus musculus 0-5 18198472-5 2008 MMP-2/-9 inhibitors blocked the METH-induced behavioral sensitization and conditioned place preference (CPP), a measure of the rewarding effect of a drug, and reduced the METH-increased dopamine release in the NAc. Dopamine 186-194 matrix metallopeptidase 2 Mus musculus 0-5 18198472-6 2008 In MMP-2- and MMP-9-deficient mice, METH-induced behavioral sensitization and CPP as well as dopamine release were attenuated. Methamphetamine 36-40 matrix metallopeptidase 2 Mus musculus 3-8 18198472-6 2008 In MMP-2- and MMP-9-deficient mice, METH-induced behavioral sensitization and CPP as well as dopamine release were attenuated. Dopamine 93-101 matrix metallopeptidase 2 Mus musculus 3-8 18198472-7 2008 The MMP/TIMP system may be involved in METH-induced sensitization and reward by regulating extracellular dopamine levels. Methamphetamine 39-43 matrix metallopeptidase 2 Mus musculus 4-7 18198472-7 2008 The MMP/TIMP system may be involved in METH-induced sensitization and reward by regulating extracellular dopamine levels. Dopamine 105-113 matrix metallopeptidase 2 Mus musculus 4-7 18198472-3 2008 Repeated METH treatment induced behavioral sensitization, which was accompanied by an increase in MMP-2/-9/TIMP-2 activity in the brain. Methamphetamine 9-13 matrix metallopeptidase 2 Mus musculus 98-106 17974982-7 2007 Regarding the effects of STAT3 activation, exposure to norepinephrine resulted in an increase in invasion and matrix metalloproteinase (MMP-2 and MMP-9) production. Norepinephrine 55-69 matrix metallopeptidase 2 Mus musculus 136-141 19062520-2 2008 We compared the effect of N-acetylcystein (NAC) and alpha-lipoic acid (ALA) on two gelatinases, MMP-2 and MMP-9. N-Acetyl-L-cysteine 26-41 matrix metallopeptidase 2 Mus musculus 96-101 19062520-2 2008 We compared the effect of N-acetylcystein (NAC) and alpha-lipoic acid (ALA) on two gelatinases, MMP-2 and MMP-9. nac 43-46 matrix metallopeptidase 2 Mus musculus 96-101 19062520-2 2008 We compared the effect of N-acetylcystein (NAC) and alpha-lipoic acid (ALA) on two gelatinases, MMP-2 and MMP-9. Thioctic Acid 52-69 matrix metallopeptidase 2 Mus musculus 96-101 19062520-2 2008 We compared the effect of N-acetylcystein (NAC) and alpha-lipoic acid (ALA) on two gelatinases, MMP-2 and MMP-9. Thioctic Acid 71-74 matrix metallopeptidase 2 Mus musculus 96-101 19062520-4 2008 NAC action for 2-6 hours completely inhibited MMP-2 and MMP-9 activity in both cell lines. nac 0-3 matrix metallopeptidase 2 Mus musculus 46-51 19062520-7 2008 ALA decreased the MMP-2 activity in both cellular types. Thioctic Acid 0-3 matrix metallopeptidase 2 Mus musculus 18-23 17956082-5 2007 All prepared hydroxamate target compounds showed high in vitro MMP inhibition potencies for MMP-2, MMP-8, MMP-9, and MMP-13. hydroxamate 13-24 matrix metallopeptidase 2 Mus musculus 92-97 18178469-14 2008 Furthermore, mgR/mgR mice treated with doxycycline had lower MMP-2 and MMP-9 levels compared with untreated mgR/mgR mice. Doxycycline 39-50 matrix metallopeptidase 2 Mus musculus 61-66 18178469-15 2008 CONCLUSIONS: This study demonstrates that doxycycline significantly delays aneurysm rupture in MFS-like mice by inhibiting expression of tissue MMP-2 and MMP-9 and thus, degradation of the elastic matrix. Doxycycline 42-53 matrix metallopeptidase 2 Mus musculus 144-149 17959842-13 2007 Doxycycline inhibits the growth of engrafted melanoma and results in reduced expression of MMP-2, MMP-9, and VM formations. Doxycycline 0-11 matrix metallopeptidase 2 Mus musculus 91-96 17588309-3 2007 In the present study, we investigated the effect of agmatine on the expression of MMPs and nitric oxide (NO) production in cerebral endothelial cells (CECs) after oxygen-glucose deprivation (OGD)-reperfusion injury and its potential association with endothelial nitric oxide synthase (eNOS). Agmatine 52-60 matrix metallopeptidase 2 Mus musculus 82-86 17707768-3 2007 Zymography of N18TG2 culture medium revealed no gelatinolytic activity, whereas after carbachol treatment of cells both MMP-9 and activated MMP-2 forms were detected. Carbachol 86-95 matrix metallopeptidase 2 Mus musculus 140-145 17707768-5 2007 Carbachol treatment increased MMP-2 and MMP-9 gene expression in N18TG2 cells and higher levels for both genes were also observed in ChAT transfected cells. Carbachol 0-9 matrix metallopeptidase 2 Mus musculus 30-35 17938261-5 2007 IB05204 treatment inhibits matrix metalloproteinase-2 (MMP-2) production in endothelial and tumor cells, down-regulates endothelial cyclooxygenase-2 expression, and represses phosphorylation of endothelial Akt in response to serum stimulation, suggesting that IB05204 interferes with molecular mechanisms of cell migration and survival. IB05204 0-7 matrix metallopeptidase 2 Mus musculus 27-53 17938261-5 2007 IB05204 treatment inhibits matrix metalloproteinase-2 (MMP-2) production in endothelial and tumor cells, down-regulates endothelial cyclooxygenase-2 expression, and represses phosphorylation of endothelial Akt in response to serum stimulation, suggesting that IB05204 interferes with molecular mechanisms of cell migration and survival. IB05204 0-7 matrix metallopeptidase 2 Mus musculus 55-60 17588309-8 2007 RESULTS: Agmatine attenuated the expression of MMP-2 and MMP-9 induced by ischemic injury at the protein and mRNA level, while agmatine increased the expression of eNOS directly. Agmatine 9-17 matrix metallopeptidase 2 Mus musculus 47-52 17588309-10 2007 In the presence of a nitric oxide synthase (NOS) inhibitor, N(omega)-nitro-L-arginine methyl ester (L-NAME), the expression levels of MMP-2 were decreased, but the expression of MMP-9 was not decreased by agmatine administration. NG-Nitroarginine Methyl Ester 60-98 matrix metallopeptidase 2 Mus musculus 134-139 17588309-10 2007 In the presence of a nitric oxide synthase (NOS) inhibitor, N(omega)-nitro-L-arginine methyl ester (L-NAME), the expression levels of MMP-2 were decreased, but the expression of MMP-9 was not decreased by agmatine administration. NG-Nitroarginine Methyl Ester 100-106 matrix metallopeptidase 2 Mus musculus 134-139 17619015-8 2007 FN-439, an inhibitor of MMPs which possesses no effect on TACE, decreased MMP-2 and MMP-3 activity, but failed to affect tissue injury, TNF-alpha production or lethality. 4-aminobenzoyl-glycyl-prolyl-leucyl-alanine hydroxamic acid 0-6 matrix metallopeptidase 2 Mus musculus 24-28 17619015-8 2007 FN-439, an inhibitor of MMPs which possesses no effect on TACE, decreased MMP-2 and MMP-3 activity, but failed to affect tissue injury, TNF-alpha production or lethality. 4-aminobenzoyl-glycyl-prolyl-leucyl-alanine hydroxamic acid 0-6 matrix metallopeptidase 2 Mus musculus 74-79 17667592-8 2007 Low doses of 17-allylamino-17-demethoxygeldanamycin significantly inhibited migration of GL261 cells within 16 h of treatment, concomitant with the downregulation of phosphorylated focal adhesion kinase and matrix metalloproteinase 2 secretion. tanespimycin 13-51 matrix metallopeptidase 2 Mus musculus 207-233 18004245-1 2007 AIM: To study the influence of redox-active cobalt(III) complex with tetradentate Schiff base and nicotinamide as an axial ligand on the rate of superoxide radical-anions generation and levels of NO in tumor and normal tissues of Lewis lung carcinoma bearing mice as well as activity of matrix metalloproteinases 2 and 9 (MMPs) in tumor. cobalt(iii) 44-55 matrix metallopeptidase 2 Mus musculus 287-320 18004245-1 2007 AIM: To study the influence of redox-active cobalt(III) complex with tetradentate Schiff base and nicotinamide as an axial ligand on the rate of superoxide radical-anions generation and levels of NO in tumor and normal tissues of Lewis lung carcinoma bearing mice as well as activity of matrix metalloproteinases 2 and 9 (MMPs) in tumor. cobalt(iii) 44-55 matrix metallopeptidase 2 Mus musculus 322-326 18004245-3 2007 MMPs activities were determined by zymography in polyacrylamide gel. polyacrylamide 49-63 matrix metallopeptidase 2 Mus musculus 0-4 18004245-6 2007 CONCLUSION: It is supposed that the one of mechanisms of detected earlier antimetastatic effect of complex is based on its ability to induce the formation of high level of superoxide radical-anions selectively in the tumor tissue that results in the damage of its regulatory functions, in particular alteration in the regulation of NO-synthase, decrease of NO generation as well as activities of MMPs. Superoxides 172-190 matrix metallopeptidase 2 Mus musculus 396-400 17761639-10 2007 Beta-carotene treatment downregulates the expression of matrix metalloproteinase (MMP)-2, MMP-9, prolyl hydroxylase, and lysyl oxidase gene expression and upregulates the expression of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. beta Carotene 0-13 matrix metallopeptidase 2 Mus musculus 56-88 17606858-11 2007 Additionally, fenofibrate ameliorated the increased matrix metalloproteinase-2/tissue inhibitors of metalloproteinase-2 ratio and fibrosis seen in aldosterone-untreated hearts (P<0.05 for both). Fenofibrate 14-25 matrix metallopeptidase 2 Mus musculus 52-78 17475219-5 2007 Importantly, cardioprotection mediated by ischemic preconditioning (IPC) was completely abolished in MMP-2 Tg hearts, as shown by abnormalities in mitochondrial ultrastructure and impaired respiration, increased lipid peroxidation, cell necrosis and persistently reduced recovery of contractile performance during post-ischemic reperfusion. Thioguanine 107-109 matrix metallopeptidase 2 Mus musculus 101-106 17472698-2 2007 We have demonstrated that methamphetamine (METH)-induced behavioral sensitization and reward were markedly attenuated in MMP-2- and MMP-9 deficient [MMP-2-(-/-) and MMP-9-(-/-)] mice compared with those in wild-type mice, suggesting that METH-induced expression of MMP-2 and MMP-9 in the brain plays a role in the development of METH-induced sensitization and reward. Methamphetamine 238-242 matrix metallopeptidase 2 Mus musculus 121-137 17472698-2 2007 We have demonstrated that methamphetamine (METH)-induced behavioral sensitization and reward were markedly attenuated in MMP-2- and MMP-9 deficient [MMP-2-(-/-) and MMP-9-(-/-)] mice compared with those in wild-type mice, suggesting that METH-induced expression of MMP-2 and MMP-9 in the brain plays a role in the development of METH-induced sensitization and reward. Methamphetamine 238-242 matrix metallopeptidase 2 Mus musculus 121-126 17472698-4 2007 Furthermore, we studied a role of MMP/TIMP system in METH-induced behavioral changes and dopamine neurotransmission. Methamphetamine 53-57 matrix metallopeptidase 2 Mus musculus 34-37 17472698-7 2007 On the other hand, MMP-2/-9 inhibitors blocked the METH-induced behavioral sensitization and conditioned place preference, a measure of the rewarding effect, and reduced the METH-increased dopamine release in the NAc. Methamphetamine 51-55 matrix metallopeptidase 2 Mus musculus 19-24 17472698-7 2007 On the other hand, MMP-2/-9 inhibitors blocked the METH-induced behavioral sensitization and conditioned place preference, a measure of the rewarding effect, and reduced the METH-increased dopamine release in the NAc. Methamphetamine 174-178 matrix metallopeptidase 2 Mus musculus 19-24 17472698-7 2007 On the other hand, MMP-2/-9 inhibitors blocked the METH-induced behavioral sensitization and conditioned place preference, a measure of the rewarding effect, and reduced the METH-increased dopamine release in the NAc. Dopamine 189-197 matrix metallopeptidase 2 Mus musculus 19-24 17472698-10 2007 Repeated METH treatment also reduced dopamine D2 receptor agonist-stimulated [(35)S]GTPgammaS binding in wild-type mice, but such changes were significantly attenuated in MMP-2-(-/-) and MMP-9-(-/-) mice. Methamphetamine 9-13 matrix metallopeptidase 2 Mus musculus 171-176 17472698-11 2007 These results suggest that the MMP/TIMP system is involved in METH-induced behavioral sensitization and reward, by regulating dopamine release and receptor signaling. Methamphetamine 62-66 matrix metallopeptidase 2 Mus musculus 31-34 17472698-11 2007 These results suggest that the MMP/TIMP system is involved in METH-induced behavioral sensitization and reward, by regulating dopamine release and receptor signaling. Dopamine 126-134 matrix metallopeptidase 2 Mus musculus 31-34 17569779-5 2007 Additive effects of CCL18 overexpression and bleomycin injury were observed on pulmonary inflammation, particularly on T-cell infiltration, and increased levels of tumor necrosis factor-alpha, interferon-gamma, matrix metalloproteinase (MMP)-2, and MMP-9. Bleomycin 45-54 matrix metallopeptidase 2 Mus musculus 211-243 17569779-8 2007 Depletion of T cells with antilymphocyte serum or pharmacological inhibition of MMPs with GM6001 abrogated accumulation of collagen and increases in the levels of tumor necrosis factor-alpha, interferon-gamma, and active transforming growth factor-beta1. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 90-96 matrix metallopeptidase 2 Mus musculus 80-84 17472698-2 2007 We have demonstrated that methamphetamine (METH)-induced behavioral sensitization and reward were markedly attenuated in MMP-2- and MMP-9 deficient [MMP-2-(-/-) and MMP-9-(-/-)] mice compared with those in wild-type mice, suggesting that METH-induced expression of MMP-2 and MMP-9 in the brain plays a role in the development of METH-induced sensitization and reward. Methamphetamine 26-41 matrix metallopeptidase 2 Mus musculus 121-137 17472698-2 2007 We have demonstrated that methamphetamine (METH)-induced behavioral sensitization and reward were markedly attenuated in MMP-2- and MMP-9 deficient [MMP-2-(-/-) and MMP-9-(-/-)] mice compared with those in wild-type mice, suggesting that METH-induced expression of MMP-2 and MMP-9 in the brain plays a role in the development of METH-induced sensitization and reward. Methamphetamine 26-41 matrix metallopeptidase 2 Mus musculus 121-126 17472698-2 2007 We have demonstrated that methamphetamine (METH)-induced behavioral sensitization and reward were markedly attenuated in MMP-2- and MMP-9 deficient [MMP-2-(-/-) and MMP-9-(-/-)] mice compared with those in wild-type mice, suggesting that METH-induced expression of MMP-2 and MMP-9 in the brain plays a role in the development of METH-induced sensitization and reward. Methamphetamine 26-41 matrix metallopeptidase 2 Mus musculus 149-154 17472698-2 2007 We have demonstrated that methamphetamine (METH)-induced behavioral sensitization and reward were markedly attenuated in MMP-2- and MMP-9 deficient [MMP-2-(-/-) and MMP-9-(-/-)] mice compared with those in wild-type mice, suggesting that METH-induced expression of MMP-2 and MMP-9 in the brain plays a role in the development of METH-induced sensitization and reward. Methamphetamine 43-47 matrix metallopeptidase 2 Mus musculus 121-137 17472698-2 2007 We have demonstrated that methamphetamine (METH)-induced behavioral sensitization and reward were markedly attenuated in MMP-2- and MMP-9 deficient [MMP-2-(-/-) and MMP-9-(-/-)] mice compared with those in wild-type mice, suggesting that METH-induced expression of MMP-2 and MMP-9 in the brain plays a role in the development of METH-induced sensitization and reward. Methamphetamine 43-47 matrix metallopeptidase 2 Mus musculus 121-126 17472698-2 2007 We have demonstrated that methamphetamine (METH)-induced behavioral sensitization and reward were markedly attenuated in MMP-2- and MMP-9 deficient [MMP-2-(-/-) and MMP-9-(-/-)] mice compared with those in wild-type mice, suggesting that METH-induced expression of MMP-2 and MMP-9 in the brain plays a role in the development of METH-induced sensitization and reward. Methamphetamine 43-47 matrix metallopeptidase 2 Mus musculus 149-154 17472698-2 2007 We have demonstrated that methamphetamine (METH)-induced behavioral sensitization and reward were markedly attenuated in MMP-2- and MMP-9 deficient [MMP-2-(-/-) and MMP-9-(-/-)] mice compared with those in wild-type mice, suggesting that METH-induced expression of MMP-2 and MMP-9 in the brain plays a role in the development of METH-induced sensitization and reward. Methamphetamine 238-242 matrix metallopeptidase 2 Mus musculus 121-137 17472698-2 2007 We have demonstrated that methamphetamine (METH)-induced behavioral sensitization and reward were markedly attenuated in MMP-2- and MMP-9 deficient [MMP-2-(-/-) and MMP-9-(-/-)] mice compared with those in wild-type mice, suggesting that METH-induced expression of MMP-2 and MMP-9 in the brain plays a role in the development of METH-induced sensitization and reward. Methamphetamine 238-242 matrix metallopeptidase 2 Mus musculus 121-126 17614836-2 2007 However, no reports are available on the relationship between the activity of MMPs and gastric ulceration induced by alcohol. Alcohols 117-124 matrix metallopeptidase 2 Mus musculus 78-82 17614836-3 2007 Our objective was to investigate the effect of melatonin (N-acetyl-5-methoxytryptamine) on the regulation of MMP-9 and MMP-2 activities during prevention of ethanol-induced gastric ulcer. Melatonin 47-56 matrix metallopeptidase 2 Mus musculus 119-124 17614836-3 2007 Our objective was to investigate the effect of melatonin (N-acetyl-5-methoxytryptamine) on the regulation of MMP-9 and MMP-2 activities during prevention of ethanol-induced gastric ulcer. Melatonin 58-86 matrix metallopeptidase 2 Mus musculus 119-124 17499192-0 2007 Influence of early neutrophil depletion on MMPs/TIMP-1 balance in bleomycin-induced lung fibrosis. Bleomycin 66-75 matrix metallopeptidase 2 Mus musculus 43-47 17591550-5 2007 In MMP-2 inhibition assays, In-DTPA-CTT significantly inhibited the proteolytic activity in a concentration-dependent fashion. in-dtpa-ctt 28-39 matrix metallopeptidase 2 Mus musculus 3-8 18069628-12 2007 By gelatin zymography, the enzyme activity of MMP-9, actived-MMP-2 and MMP-2/proMMP-2 in ES, DOX and ES + DOX group was lower than that in the control group, but the enzyme activity of pro-MMP-2 among the four groups was not significantly different. Einsteinium 89-91 matrix metallopeptidase 2 Mus musculus 61-66 18069628-12 2007 By gelatin zymography, the enzyme activity of MMP-9, actived-MMP-2 and MMP-2/proMMP-2 in ES, DOX and ES + DOX group was lower than that in the control group, but the enzyme activity of pro-MMP-2 among the four groups was not significantly different. Einsteinium 89-91 matrix metallopeptidase 2 Mus musculus 71-76 18069628-12 2007 By gelatin zymography, the enzyme activity of MMP-9, actived-MMP-2 and MMP-2/proMMP-2 in ES, DOX and ES + DOX group was lower than that in the control group, but the enzyme activity of pro-MMP-2 among the four groups was not significantly different. Einsteinium 89-91 matrix metallopeptidase 2 Mus musculus 71-76 18069628-12 2007 By gelatin zymography, the enzyme activity of MMP-9, actived-MMP-2 and MMP-2/proMMP-2 in ES, DOX and ES + DOX group was lower than that in the control group, but the enzyme activity of pro-MMP-2 among the four groups was not significantly different. Doxycycline 93-96 matrix metallopeptidase 2 Mus musculus 71-76 18069628-12 2007 By gelatin zymography, the enzyme activity of MMP-9, actived-MMP-2 and MMP-2/proMMP-2 in ES, DOX and ES + DOX group was lower than that in the control group, but the enzyme activity of pro-MMP-2 among the four groups was not significantly different. Doxycycline 93-96 matrix metallopeptidase 2 Mus musculus 71-76 18069628-12 2007 By gelatin zymography, the enzyme activity of MMP-9, actived-MMP-2 and MMP-2/proMMP-2 in ES, DOX and ES + DOX group was lower than that in the control group, but the enzyme activity of pro-MMP-2 among the four groups was not significantly different. Einsteinium 101-103 matrix metallopeptidase 2 Mus musculus 71-76 18069628-12 2007 By gelatin zymography, the enzyme activity of MMP-9, actived-MMP-2 and MMP-2/proMMP-2 in ES, DOX and ES + DOX group was lower than that in the control group, but the enzyme activity of pro-MMP-2 among the four groups was not significantly different. Einsteinium 101-103 matrix metallopeptidase 2 Mus musculus 71-76 18069628-12 2007 By gelatin zymography, the enzyme activity of MMP-9, actived-MMP-2 and MMP-2/proMMP-2 in ES, DOX and ES + DOX group was lower than that in the control group, but the enzyme activity of pro-MMP-2 among the four groups was not significantly different. Doxycycline 106-109 matrix metallopeptidase 2 Mus musculus 71-76 18069628-12 2007 By gelatin zymography, the enzyme activity of MMP-9, actived-MMP-2 and MMP-2/proMMP-2 in ES, DOX and ES + DOX group was lower than that in the control group, but the enzyme activity of pro-MMP-2 among the four groups was not significantly different. Doxycycline 106-109 matrix metallopeptidase 2 Mus musculus 71-76 18069628-13 2007 CONCLUSION: The combined use of doxycycline and endostatin in melanoma can inhibit the expression of MMPs, influencing the formation of different microcirculation patterns in melanoma. Doxycycline 32-43 matrix metallopeptidase 2 Mus musculus 101-105 17440987-3 2007 Here, we report that Mmp2(-/-) mice with additional mutations that render type I collagen resistant to collagenase-mediated cleavage to TC(A) and TC(B) fragments (Col1a1(r/r) mice) have severe developmental defects resembling those observed in MMP2-null humans. Technetium 136-138 matrix metallopeptidase 2 Mus musculus 21-25 17440987-3 2007 Here, we report that Mmp2(-/-) mice with additional mutations that render type I collagen resistant to collagenase-mediated cleavage to TC(A) and TC(B) fragments (Col1a1(r/r) mice) have severe developmental defects resembling those observed in MMP2-null humans. Technetium 146-148 matrix metallopeptidase 2 Mus musculus 21-25 17376416-7 2007 The reduced expressions of MMP-2 and u-PA, as well as inhibition of cell invasion were obtained in the cultures treated with U0126 (ERK 1/2 inhibitor) and SB203580 (p38(MAPK) inhibitor). SB 203580 155-163 matrix metallopeptidase 2 Mus musculus 27-32 17513401-6 2007 The addition of CLA to the diet increased steady-state levels of messenger RNA (mRNA) of the matrix metalloproteinases (MMP) -2 and -9 in primary tumors removed from mice. Linoleic Acids, Conjugated 16-19 matrix metallopeptidase 2 Mus musculus 93-134 17513401-8 2007 The activity of MMP-2 was barely detectable, but gelatin zymography and an in vitro activity assay showed that MMP-9 activity was significantly decreased by CLA. Linoleic Acids, Conjugated 157-160 matrix metallopeptidase 2 Mus musculus 16-21 17386921-0 2007 Leptin-induced matrix metalloproteinase-2 secretion is suppressed by trans-10,cis-12 conjugated linoleic acid. trans-10,cis-12 69-84 matrix metallopeptidase 2 Mus musculus 15-41 17386921-0 2007 Leptin-induced matrix metalloproteinase-2 secretion is suppressed by trans-10,cis-12 conjugated linoleic acid. Linoleic Acid 96-109 matrix metallopeptidase 2 Mus musculus 15-41 17386921-3 2007 The present study is designed to evaluate whether trans-10,cis-12 conjugated linoleic acid (t-CLA) can suppress leptin-induced MMP-2 secretion in 3T3-L1 cells. trans-10 50-58 matrix metallopeptidase 2 Mus musculus 127-132 17386921-3 2007 The present study is designed to evaluate whether trans-10,cis-12 conjugated linoleic acid (t-CLA) can suppress leptin-induced MMP-2 secretion in 3T3-L1 cells. cis-12 59-65 matrix metallopeptidase 2 Mus musculus 127-132 17386921-3 2007 The present study is designed to evaluate whether trans-10,cis-12 conjugated linoleic acid (t-CLA) can suppress leptin-induced MMP-2 secretion in 3T3-L1 cells. Linoleic Acid 77-90 matrix metallopeptidase 2 Mus musculus 127-132 17376416-7 2007 The reduced expressions of MMP-2 and u-PA, as well as inhibition of cell invasion were obtained in the cultures treated with U0126 (ERK 1/2 inhibitor) and SB203580 (p38(MAPK) inhibitor). U 0126 125-130 matrix metallopeptidase 2 Mus musculus 27-32 17353509-9 2007 Fenofibrate also increased myocardial hypertrophy, cardiac fibrosis, and the ratio of matrix metalloproteinase-2/tissue inhibitor of matrix metalloproteinase-2 in PO PPARalpha-deficient mice. Fenofibrate 0-11 matrix metallopeptidase 2 Mus musculus 86-159 17348864-0 2007 Reduction of methamphetamine-induced sensitization and reward in matrix metalloproteinase-2 and -9-deficient mice. Methamphetamine 13-28 matrix metallopeptidase 2 Mus musculus 65-98 17404091-2 2007 S-3304 is a potent, orally active, noncytotoxic inhibitor of MMPs, primarily MMP-2 and MMP-9, that prolongs survival in mice xenografts and is well tolerated in healthy volunteers. S 3304 0-6 matrix metallopeptidase 2 Mus musculus 77-82 17283058-6 2007 Altogether these findings highlight a pivotal role for furin, MT1-MMP, and MMP2 in TNF-alpha-induced sphingolipid signaling, and they identify this system as a possible target to inhibit SMC proliferation in vascular diseases. Sphingolipids 101-113 matrix metallopeptidase 2 Mus musculus 75-79 17183585-10 2007 Moreover, PDGF-C prevented RA-induced inhibition of the migratory ability of mesenchymal cells in the first branchial arch, by regulating the expressions of MMP-2, MMP-14, and TIPM-2. Tretinoin 27-29 matrix metallopeptidase 2 Mus musculus 157-162 17183585-12 2007 The branchial arch malformations resulting from fetal RA exposure are caused at least partially by loss of PDGF-C and subsequent misregulations of the expressions of MMP-2, MMP-14, and TIMP-2. Tretinoin 54-56 matrix metallopeptidase 2 Mus musculus 166-171 17157570-3 2007 In studies to explore this hypothesis, we used a mouse calvarial injection model to (1) investigate whether mild injury caused by a daily subcutaneous injection of a glycerol-containing vehicle onto calvaria affected osteoblast/bone formation-associated histomorphometric parameters and gene expression (mRNA encoding GAL, GAL receptors, TNFalpha, IL-1beta, collagen type I, MMP-2 and -13) compared to non-injected, control mice and (2) determine the effect of GAL+vehicle treatment on these entities. Glycerol 166-174 matrix metallopeptidase 2 Mus musculus 375-388 17215487-3 2007 Polymers induced MMP-2 promoter activity in macrophages within the foreign body granuloma via sequences -1686/+423 with concomitantly up-regulated protein synthesis and enzymatic activity. Polymers 0-8 matrix metallopeptidase 2 Mus musculus 17-22 17348864-4 2007 Repeated METH treatment induced behavioural sensitization, which was accompanied by an increase in MMP-2 and MMP-9 activity in the brain. Methamphetamine 9-13 matrix metallopeptidase 2 Mus musculus 99-104 17348864-5 2007 In MMP-2- and MMP-9-deficient mice [MMP-2-(-/-) and MMP-9-(-/-)], METH-induced behavioural sensitization and conditioned place preference, a measure of the rewarding effect, as well as METH-increased dopamine release in the nucleus accumbens (NAc) were attenuated compared with those in wild-type mice. Methamphetamine 66-70 matrix metallopeptidase 2 Mus musculus 3-8 17348864-7 2007 The [(3)H]dopamine uptake into striatal synaptosomes was reduced in wild-type mice after repeated METH treatment, but METH-induced changes in [(3)H]dopamine uptake were significantly attenuated in MMP-2-(-/-) and MMP-9-(-/-) mice. Methamphetamine 118-122 matrix metallopeptidase 2 Mus musculus 197-202 17348864-8 2007 These results suggest that both MMP-2 and MMP-9 play a crucial role in METH-induced behavioural sensitization and reward by regulating METH-induced dopamine release and uptake in the NAc. Methamphetamine 71-75 matrix metallopeptidase 2 Mus musculus 32-37 17348864-8 2007 These results suggest that both MMP-2 and MMP-9 play a crucial role in METH-induced behavioural sensitization and reward by regulating METH-induced dopamine release and uptake in the NAc. Methamphetamine 135-139 matrix metallopeptidase 2 Mus musculus 32-37 17348864-8 2007 These results suggest that both MMP-2 and MMP-9 play a crucial role in METH-induced behavioural sensitization and reward by regulating METH-induced dopamine release and uptake in the NAc. Dopamine 148-156 matrix metallopeptidase 2 Mus musculus 32-37 17184743-11 2007 There was a significant reduction in BBB permeability seen with 10% dimethyl sulfoxide (DMSO) alone, which was used to dissolve the selective MMP-2 and-9 inhibitor, SB-3CT. Dimethyl Sulfoxide 68-86 matrix metallopeptidase 2 Mus musculus 142-153 17275288-9 2007 This data supports a role for 1,25D in heart ECM metabolism and suggests that MMPs and TIMPs expression may be modulated by vitamin D. Vitamin D 124-133 matrix metallopeptidase 2 Mus musculus 78-82 17184743-11 2007 There was a significant reduction in BBB permeability seen with 10% dimethyl sulfoxide (DMSO) alone, which was used to dissolve the selective MMP-2 and-9 inhibitor, SB-3CT. Dimethyl Sulfoxide 88-92 matrix metallopeptidase 2 Mus musculus 142-153 16626720-9 2007 Furthermore, immunohistochemical analysis demonstrated that CS-505 significantly reduced the number of macrophages and expression of matrix metalloproteinase (MMP)-2, MMP-9, and MMP-13. Cesium 60-62 matrix metallopeptidase 2 Mus musculus 133-165 16644105-0 2007 A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Camptothecin 15-27 matrix metallopeptidase 2 Mus musculus 173-181 17251494-11 2007 AG3340 (MMP-2- and -9-selective inhibitor) and DPC-A37668 (MMP-2-selective inhibitor) resulted in 65% and 52% inhibition, respectively, when administered by intravitreal injection immediately after variable-oxygen exposure. prinomastat 0-6 matrix metallopeptidase 2 Mus musculus 8-13 17251494-11 2007 AG3340 (MMP-2- and -9-selective inhibitor) and DPC-A37668 (MMP-2-selective inhibitor) resulted in 65% and 52% inhibition, respectively, when administered by intravitreal injection immediately after variable-oxygen exposure. DPC-A37668 47-57 matrix metallopeptidase 2 Mus musculus 59-64 17251494-11 2007 AG3340 (MMP-2- and -9-selective inhibitor) and DPC-A37668 (MMP-2-selective inhibitor) resulted in 65% and 52% inhibition, respectively, when administered by intravitreal injection immediately after variable-oxygen exposure. Oxygen 207-213 matrix metallopeptidase 2 Mus musculus 59-64 16924668-0 2007 Salvianolic acid B attenuates MMP-2 and MMP-9 expression in vivo in apolipoprotein-E-deficient mouse aorta and in vitro in LPS-treated human aortic smooth muscle cells. salvianolic acid B 0-18 matrix metallopeptidase 2 Mus musculus 30-35 17251494-15 2007 There was a 75% (P < 0.001) and 44% (P < 0.01) reduction in preretinal neovascularization in oxygen-exposed MMP-2(-/-) and -9(-/-) mice at postnatal day 19, respectively, compared with wild-type control mice. Oxygen 99-105 matrix metallopeptidase 2 Mus musculus 114-119 17251494-16 2007 CONCLUSIONS: The results of this study suggest that MMP-2 plays a predominant role in retinal angiogenesis in both the mouse and rat models of oxygen-induced retinopathy. Oxygen 143-149 matrix metallopeptidase 2 Mus musculus 52-57 17110907-10 2006 Staining with H8 was first observed three days post injury, two days after MMP2 expression in CNV lesions, becoming most intense five days following laser injury and extending beyond the area of neovascularization. N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide 14-16 matrix metallopeptidase 2 Mus musculus 75-79 17633135-7 2007 The losartan dose dependently increased MMP-2 (p = 0.02) and MMP-9 (ns). Losartan 4-12 matrix metallopeptidase 2 Mus musculus 40-45 17633135-8 2007 PD123319 at 10(-5) M significantly reduced MMP-2 and MMP-9 activities compared with the Ang II group (p = 0.014 and p = 0.02, respectively). PD 123319 0-8 matrix metallopeptidase 2 Mus musculus 43-48 17633135-9 2007 The doses of PD123319 at 10(-6) and 10(-7) M increased the MMP-2 and MMP-9 enzymatic activities significantly above the Ang II only group. PD 123319 13-21 matrix metallopeptidase 2 Mus musculus 59-64 17228733-1 2006 To examine the effect of salidroside on the expression and activities of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in bone marrow (BM) of BM depressed anemic mice by immunohistochemistry and gelatin zymography respectively, and to explore its roles in hematopoietic regulation. rhodioloside 25-36 matrix metallopeptidase 2 Mus musculus 73-99 17228733-1 2006 To examine the effect of salidroside on the expression and activities of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in bone marrow (BM) of BM depressed anemic mice by immunohistochemistry and gelatin zymography respectively, and to explore its roles in hematopoietic regulation. rhodioloside 25-36 matrix metallopeptidase 2 Mus musculus 101-106 17228733-3 2006 Compared with control group, the expression of MMP-2 and MMP-9 was obviously increased in the model group, low-dose, middle-dose and high-dose salidroside. rhodioloside 143-154 matrix metallopeptidase 2 Mus musculus 47-52 17228733-4 2006 At day 4 after treatment of radiation and chemotherapy, the peak of the expression of MMP-2 and MMP-9 was found in middle-dose salidroside . rhodioloside 127-138 matrix metallopeptidase 2 Mus musculus 86-91 17228733-5 2006 At day 8 after treatment of radiation and chemotherapy, the peak of the expression of MMP-2 and MMP-9 was found in low-dose and middle-dose salidroside respectively. rhodioloside 140-151 matrix metallopeptidase 2 Mus musculus 86-91 17228733-8 2006 These results suggest that salidroside could promote the recovery of hematopoietic function of BM depressed anemic mice by increasing the expression and activity of MMPs, releasing the cytokines from ECM or cell membrane, repairing impaired microvessels of HM and promotion proliferation, migration and differentiation of HSCs. rhodioloside 27-38 matrix metallopeptidase 2 Mus musculus 165-169 17065436-10 2006 Furthermore, pharmacological inhibition of the MMPs with N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide (GM 6001) increased brain interstitial fluid Abeta levels and elimination of half-life in APPsw mice. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 57-138 matrix metallopeptidase 2 Mus musculus 47-51 17065436-10 2006 Furthermore, pharmacological inhibition of the MMPs with N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide (GM 6001) increased brain interstitial fluid Abeta levels and elimination of half-life in APPsw mice. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 140-147 matrix metallopeptidase 2 Mus musculus 47-51 16980344-6 2007 Responses to PE were reduced in hypoxic MMP-2(-/-) mice compared with MMP-2(+/+) mice. Phenylephrine 13-15 matrix metallopeptidase 2 Mus musculus 40-45 17151446-2 2006 In the present study, we examined the effects of auraptene on MMP-2, -7, and -9 expression in colonic mucosa from dextran sulfate sodium (DSS)-induced ulcerative colitis mice. aurapten 49-58 matrix metallopeptidase 2 Mus musculus 62-79 17151446-3 2006 Auraptene remarkably suppressed the DSS-induced gelatinolytic activity of MMP-7 as well as the expression of MMP-2 and -9, suggesting that it might be useful in anti-metastatic therapies via the targeting of MMPs. aurapten 0-9 matrix metallopeptidase 2 Mus musculus 109-121 17151446-3 2006 Auraptene remarkably suppressed the DSS-induced gelatinolytic activity of MMP-7 as well as the expression of MMP-2 and -9, suggesting that it might be useful in anti-metastatic therapies via the targeting of MMPs. aurapten 0-9 matrix metallopeptidase 2 Mus musculus 208-212 17151446-3 2006 Auraptene remarkably suppressed the DSS-induced gelatinolytic activity of MMP-7 as well as the expression of MMP-2 and -9, suggesting that it might be useful in anti-metastatic therapies via the targeting of MMPs. Dextran Sulfate 36-39 matrix metallopeptidase 2 Mus musculus 208-212 16979597-7 2006 The inhibition of MMP2/9 ((2R)-2-[(4-biphenylylsulfonyl) amino]-3-phenylpropionic acid) significantly decreased myogenic tone in WT and had no effect in KO mice. (2r)-2-[(4-biphenylylsulfonyl) amino]-3-phenylpropionic acid 26-86 matrix metallopeptidase 2 Mus musculus 18-24 17121916-9 2006 Tumors of mice treated with AEE788 and AEE788 plus chemotherapy exhibited down-regulation of activated EGFR and VEGFR-2, increased tumor and endothelial cell apoptosis, and decreased microvessel density, which correlated with a decrease in the level of matrix metalloproteinase-9 and matrix metalloproteinase-2 expression and a decrease in the incidence of vascular metastasis. AEE 788 28-34 matrix metallopeptidase 2 Mus musculus 284-310 17121916-9 2006 Tumors of mice treated with AEE788 and AEE788 plus chemotherapy exhibited down-regulation of activated EGFR and VEGFR-2, increased tumor and endothelial cell apoptosis, and decreased microvessel density, which correlated with a decrease in the level of matrix metalloproteinase-9 and matrix metalloproteinase-2 expression and a decrease in the incidence of vascular metastasis. AEE 788 39-45 matrix metallopeptidase 2 Mus musculus 284-310 17374213-9 2006 CONCLUSION: Doxycycline and endostatin are able to inhibit the expression of MMPs and promote expression of TIMP, which ultimately inhibits the growth of B16 melonoma. Doxycycline 12-23 matrix metallopeptidase 2 Mus musculus 77-81 16574994-9 2006 Pretreatment with 2-[(4-biphenylsulfonyl) amino]-3-phenyl-propionic acid, an MMP-2/MMP-9 inhibitor (5 mg/kg), minimized gap formation after Gal/ET and Gal/TNF treatment. 2-((4-biphenylsulfonyl)amino)-3-phenylpropionic acid 18-72 matrix metallopeptidase 2 Mus musculus 77-82 16699069-7 2006 MMP-2 transcription and translation were inhibited by perfusion with 1.0 mM hydroxyl radical scavenger N-(-2-mercaptopropionyl)-glycine. Hydroxyl Radical 76-92 matrix metallopeptidase 2 Mus musculus 0-5 16699069-7 2006 MMP-2 transcription and translation were inhibited by perfusion with 1.0 mM hydroxyl radical scavenger N-(-2-mercaptopropionyl)-glycine. Tiopronin 103-135 matrix metallopeptidase 2 Mus musculus 0-5 16936130-1 2006 PURPOSE: To determine the impact of repetitive nonlethal oxidant injury with hydroquinone (HQ) on regulation of cell membrane blebbing and molecules, which are essential in extracellular matrix turnover (ECM) maintenance, especially matrix metalloproteinase (MMP)-2, tissue inhibitor of MMP (TIMP)-2, and type IV collagen in cultured RPE. hydroquinone 77-89 matrix metallopeptidase 2 Mus musculus 233-265 16780996-0 2006 Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2, VEGF and ICAM-1. Thioacetamide 24-37 matrix metallopeptidase 2 Mus musculus 172-177 16780996-0 2006 Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2, VEGF and ICAM-1. Ethanol 59-66 matrix metallopeptidase 2 Mus musculus 172-177 16967187-8 2006 All these findings suggested that the fused expressed His-DR inhibited the activity of natural DDR2, and relevant MMP-1 and MMP-2 expression in synoviocytes and NIH3T3 cells provoked by collagen II. Histidine 54-57 matrix metallopeptidase 2 Mus musculus 124-129 16951375-8 2006 MMP-2 protein expression and activity were up-regulated in WT mice treated with DSS or S.T. dss 80-83 matrix metallopeptidase 2 Mus musculus 0-5 16951375-9 2006 MMP-2(-/-) mice were highly susceptible to the development of colitis induced by DSS (or S.T.) dss 81-84 matrix metallopeptidase 2 Mus musculus 0-5 16609149-1 2006 Our hypothesis is that impairment of peroxisome proliferator-activated receptor-gamma (PPARgamma) initiates renal dysfunction by increasing renal glomerular matrix metalloproteinase-2 (MMP-2) activity because of increased renal homocysteine (Hcy) and decreased nitric oxide (NO) levels. Homocysteine 242-245 matrix metallopeptidase 2 Mus musculus 185-190 16609149-1 2006 Our hypothesis is that impairment of peroxisome proliferator-activated receptor-gamma (PPARgamma) initiates renal dysfunction by increasing renal glomerular matrix metalloproteinase-2 (MMP-2) activity because of increased renal homocysteine (Hcy) and decreased nitric oxide (NO) levels. Nitric Oxide 261-273 matrix metallopeptidase 2 Mus musculus 185-190 16945185-6 2006 Furthermore, treatment with glycyrrhizin or saikosaponin a, rather than paeoniflorin or naringin, moderately inhibited the matrix metalloproteinase (MMP)-2 activity of the splenocytes from PCl-CS mice, and the combination of all four components showed a strong inhibition against MMP-2. Glycyrrhizic Acid 28-40 matrix metallopeptidase 2 Mus musculus 123-155 16945185-6 2006 Furthermore, treatment with glycyrrhizin or saikosaponin a, rather than paeoniflorin or naringin, moderately inhibited the matrix metalloproteinase (MMP)-2 activity of the splenocytes from PCl-CS mice, and the combination of all four components showed a strong inhibition against MMP-2. Glycyrrhizic Acid 28-40 matrix metallopeptidase 2 Mus musculus 280-285 16945185-6 2006 Furthermore, treatment with glycyrrhizin or saikosaponin a, rather than paeoniflorin or naringin, moderately inhibited the matrix metalloproteinase (MMP)-2 activity of the splenocytes from PCl-CS mice, and the combination of all four components showed a strong inhibition against MMP-2. saikosaponin D 44-58 matrix metallopeptidase 2 Mus musculus 123-155 16945185-6 2006 Furthermore, treatment with glycyrrhizin or saikosaponin a, rather than paeoniflorin or naringin, moderately inhibited the matrix metalloproteinase (MMP)-2 activity of the splenocytes from PCl-CS mice, and the combination of all four components showed a strong inhibition against MMP-2. saikosaponin D 44-58 matrix metallopeptidase 2 Mus musculus 280-285 16945185-6 2006 Furthermore, treatment with glycyrrhizin or saikosaponin a, rather than paeoniflorin or naringin, moderately inhibited the matrix metalloproteinase (MMP)-2 activity of the splenocytes from PCl-CS mice, and the combination of all four components showed a strong inhibition against MMP-2. pcl-cs 189-195 matrix metallopeptidase 2 Mus musculus 123-155 16651433-7 2006 We found that tamoxifen in combination with estradiol increased tumor MMP-2/MMP-9 in vivo activity, endostatin levels, and decreased tumor vascularization compared with estradiol treatment only. Tamoxifen 14-23 matrix metallopeptidase 2 Mus musculus 70-75 16699168-8 2006 Exposure to CS increased the number of macrophages, neutrophils, lymphocytes (B cells and activated CD4- and CD8-positive T cells), and activity of MMP-2 and -9 in the bronchoalveolar lavage fluid (BALF). Cesium 12-14 matrix metallopeptidase 2 Mus musculus 148-160 16847049-7 2006 Co-administration of TGFbeta with the siRNA reverses this neovascular inhibitory effect, which is in turn abrogated by cis-9-octadecenoyl-N-hydroxylamide, consistent with the involvement of a metalloproteinase such as MMP-2. cis-9-octadecenoyl-n-hydroxylamide 119-153 matrix metallopeptidase 2 Mus musculus 218-223 17026855-10 2006 At day 1, bleomycin enhanced TIMP-1, MMP-2 and MMP-9 protein levels in BALF, and induced corresponding genes in lung tissue of both strains. Bleomycin 10-19 matrix metallopeptidase 2 Mus musculus 37-42 16651433-11 2006 The regulation of endostatin generation by modulation of MMP-2/MMP-9 activities suggests a previously unrecognized mechanism of estradiol and tamoxifen, which may have implications for the pathogenesis of breast cancer. Tamoxifen 142-151 matrix metallopeptidase 2 Mus musculus 57-62 16651433-7 2006 We found that tamoxifen in combination with estradiol increased tumor MMP-2/MMP-9 in vivo activity, endostatin levels, and decreased tumor vascularization compared with estradiol treatment only. Estradiol 44-53 matrix metallopeptidase 2 Mus musculus 70-75 16651433-11 2006 The regulation of endostatin generation by modulation of MMP-2/MMP-9 activities suggests a previously unrecognized mechanism of estradiol and tamoxifen, which may have implications for the pathogenesis of breast cancer. Estradiol 128-137 matrix metallopeptidase 2 Mus musculus 57-62 16489579-4 2006 The expression of MMP-2 and -9 was studied in sulfur mustard (SM)-exposed ear skin from mice to determine their role in tissue vesicant injury. Mustard Gas 46-60 matrix metallopeptidase 2 Mus musculus 18-30 16489579-4 2006 The expression of MMP-2 and -9 was studied in sulfur mustard (SM)-exposed ear skin from mice to determine their role in tissue vesicant injury. Mustard Gas 62-64 matrix metallopeptidase 2 Mus musculus 18-30 16784656-8 2006 On metastasis-related gene proteins, the expression of nm23 and TIMP2 was significantly increased, with significantly decreased expression of MMP2 in paraffin sections of NCTD group when compared with control group (P < 0.05); The expression of nm23-H1 mRNA, TIMP2 mRNA was significantly increased, with significantly decreased expression of MMP2 mRNA in NCTD group. Paraffin 150-158 matrix metallopeptidase 2 Mus musculus 142-146 16455267-0 2006 Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice. Doxorubicin 100-111 matrix metallopeptidase 2 Mus musculus 39-72 16505197-4 2006 We, thus, hypothesized that selective disruption of the MMP 2 gene could ameliorate PO-induced cardiac hypertrophy and dysfunction in mice. Polonium 84-86 matrix metallopeptidase 2 Mus musculus 56-61 16469749-5 2006 Timp-3 deficiency accelerated pro-MMP-2 activation in response to both cytochalasin D and concanavalin A. Exogenous TIMP-2 and N-TIMP-3 inhibited this activation, whereas TIMP-3 containing matrix from wild-type MEFs did not rescue the enhanced MMP-2 activation in Timp-3(-/-) cells. Cytochalasin D 71-85 matrix metallopeptidase 2 Mus musculus 34-39 16539848-11 2006 Furthermore, IL-10 significantly inhibited matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of matrix metalloproteinase (TIMP) activation after CCl4 intoxication. Carbon Tetrachloride 152-156 matrix metallopeptidase 2 Mus musculus 43-69 16455267-1 2006 We investigated the expression of the genes for matrix metalloproteinases (MMP)-2 and MMP-9 in the ventricle for 1, 2 and 4 days after acute treatment with doxorubicin (DOX) to induce cardiomyopathy in mice, at a single dose of 25 mg kg(-1). Doxorubicin 156-167 matrix metallopeptidase 2 Mus musculus 48-81 16455267-1 2006 We investigated the expression of the genes for matrix metalloproteinases (MMP)-2 and MMP-9 in the ventricle for 1, 2 and 4 days after acute treatment with doxorubicin (DOX) to induce cardiomyopathy in mice, at a single dose of 25 mg kg(-1). Doxorubicin 169-172 matrix metallopeptidase 2 Mus musculus 48-81 16455267-4 2006 Northern blot hybridisation revealed that MMP-2 and MMP-9 gene transcripts increased in the ventricle of DOX-treated mice on day 2. Doxorubicin 105-108 matrix metallopeptidase 2 Mus musculus 42-47 16455267-5 2006 MMP-2 mRNA approximately doubled in the DOX-treated mice on days 1 and 2, measured using quantitative real-time reverse transcription polymerase chain reaction. Doxorubicin 40-43 matrix metallopeptidase 2 Mus musculus 0-5 16455267-7 2006 Consequently, MMP-2 and MMP-9 gene expressions are induced in the ventricle after treatment with DOX, indicating that they might play an important role in the development of DOX-induced cardiotoxicity. Doxorubicin 97-100 matrix metallopeptidase 2 Mus musculus 14-19 16455267-7 2006 Consequently, MMP-2 and MMP-9 gene expressions are induced in the ventricle after treatment with DOX, indicating that they might play an important role in the development of DOX-induced cardiotoxicity. Doxorubicin 174-177 matrix metallopeptidase 2 Mus musculus 14-19 16504062-15 2006 Bleomycin elicit a raise of TGF-beta protein, MMP-2 and TIMP-1 protein and mRNA in BAL fluids and lung respectively, and no significant difference was observed between MMP-12 -/- and WT mice considering those parameters. Bleomycin 0-9 matrix metallopeptidase 2 Mus musculus 46-51 16613515-8 2006 Moreover, Melanocin A significantly suppressed UV-induced morphologic skin changes and MMP-2 and MMP-9 expression. melanocin A 10-21 matrix metallopeptidase 2 Mus musculus 87-92 16546677-8 2006 In biodistribution and microPET imaging studies, (64)Cu-DOTA-CTT was taken up by MMP-2/9-positive B16F10 murine melanoma tumors. cu-dota-ctt 53-64 matrix metallopeptidase 2 Mus musculus 81-86 16461932-8 2006 LY294002, a specific inhibitor of phosphoinositide 3-kinase, was able to counteract the effect of anti-CD9 mAb and AS-CD9 on outgrowth ability and production of MMP-2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 matrix metallopeptidase 2 Mus musculus 161-166 16386243-0 2006 Matrix metalloproteinase 2 secretion in WEHI 164 fibrosarcoma cells is nitric oxide-related and modified by morphine. Nitric Oxide 71-83 matrix metallopeptidase 2 Mus musculus 0-26 16386243-0 2006 Matrix metalloproteinase 2 secretion in WEHI 164 fibrosarcoma cells is nitric oxide-related and modified by morphine. Morphine 108-116 matrix metallopeptidase 2 Mus musculus 0-26 16386243-5 2006 We report that MMP-2 is under the control of nitric oxide (NO)/nitric oxide synthase (NOS) system. Nitric Oxide 45-57 matrix metallopeptidase 2 Mus musculus 15-20 16386243-7 2006 Finally, we provide evidence that morphine, when administrated at low, non-toxic concentrations (<10(-9) M) attenuates MMP-2 activity. Morphine 34-42 matrix metallopeptidase 2 Mus musculus 122-127 15970706-5 2005 Nembutal reduced cellular cAMP concentration in colon cancer cells and resulted in a dose and time dependent decrease in MMP-2 and MMP-9 levels. Pentobarbital 0-8 matrix metallopeptidase 2 Mus musculus 121-126 16872482-14 2006 We studied the expression of MMP-2 in the presence of PKC isoform-specific inhibitors and found that the PKCdelta inhibitor rottlerin inhibits MIF-induced RA synovial fibroblast MMP-2 production. rottlerin 124-133 matrix metallopeptidase 2 Mus musculus 29-34 16872482-14 2006 We studied the expression of MMP-2 in the presence of PKC isoform-specific inhibitors and found that the PKCdelta inhibitor rottlerin inhibits MIF-induced RA synovial fibroblast MMP-2 production. rottlerin 124-133 matrix metallopeptidase 2 Mus musculus 178-183 16123349-7 2005 These studies indicate that MMPs contribute to islet fibrosis and insulin insufficiency in ZDF rats. zdf 91-94 matrix metallopeptidase 2 Mus musculus 28-32 16219541-3 2005 METHODS: BMSCs exposed to VP-16 were evaluated for MMP-2 expression by gelatin zymography, ELISA, and western blot. Etoposide 26-31 matrix metallopeptidase 2 Mus musculus 51-56 16219541-5 2005 RESULTS: BMSC exposure to VP-16 resulted in an immediate, transient, increase in MMP-2, followed by reduced MMP-2 protein expression. Etoposide 26-31 matrix metallopeptidase 2 Mus musculus 81-86 16219541-5 2005 RESULTS: BMSC exposure to VP-16 resulted in an immediate, transient, increase in MMP-2, followed by reduced MMP-2 protein expression. Etoposide 26-31 matrix metallopeptidase 2 Mus musculus 108-113 16219541-9 2005 VP-16-induced reduction of BMSC support of hematopoietic cell migration was restored by supplementing cultures with recombinant MMP-2 protein. Etoposide 0-5 matrix metallopeptidase 2 Mus musculus 128-133 15938647-5 2005 We report that compared to non-EGCG-treated tumors, topical application of EGCG in UV-induced tumors resulted in inhibition of protein expression and activity of matrix metalloproteinase (MMP)-2 and MMP-9, which play crucial roles in tumor growth and metastasis. epigallocatechin gallate 31-35 matrix metallopeptidase 2 Mus musculus 162-194 15938647-5 2005 We report that compared to non-EGCG-treated tumors, topical application of EGCG in UV-induced tumors resulted in inhibition of protein expression and activity of matrix metalloproteinase (MMP)-2 and MMP-9, which play crucial roles in tumor growth and metastasis. epigallocatechin gallate 75-79 matrix metallopeptidase 2 Mus musculus 162-194 16091136-10 2005 In animals treated with 15 mg/day fenofibrate, this effect was associated with a reduction in TNF-alpha, KC, MIP-2 and MCP-1 levels, as well as in MMP-2 and MMP-9 activity. Fenofibrate 34-45 matrix metallopeptidase 2 Mus musculus 147-152 15990687-8 2005 The dose-dependent inhibitory effect of dexamethasone on MMP-2 activity was significantly less than that of the tested NSAIDs at concentrations of 10-80 microg/ml, while it increased at doses of >100 microg/ml compared with piroxicam. Dexamethasone 40-53 matrix metallopeptidase 2 Mus musculus 57-62 15914324-9 2005 These results suggest that glycyrrhizin may act as one of the active constituents of Si-Ni-San in inhibiting delayed-type hypersensitivity reaction via down-regulating the MMP production and the cell adhesion to extracellular matrix. Glycyrrhizic Acid 27-39 matrix metallopeptidase 2 Mus musculus 172-175 15990687-8 2005 The dose-dependent inhibitory effect of dexamethasone on MMP-2 activity was significantly less than that of the tested NSAIDs at concentrations of 10-80 microg/ml, while it increased at doses of >100 microg/ml compared with piroxicam. Piroxicam 227-236 matrix metallopeptidase 2 Mus musculus 57-62 15990687-10 2005 CONCLUSIONS: Our findings suggest that dexamethasone is able to induce apoptosis and suppress MMP-2 activity. Dexamethasone 39-52 matrix metallopeptidase 2 Mus musculus 94-99 16113801-9 2005 Exposure of neonatal mice to chronic hypoxia (10% O2), a stimulus that leads to an arrest of lung development, resulted in upregulation of MMP-2 with a concomitant downregulation of TIMP-2. Oxygen 50-52 matrix metallopeptidase 2 Mus musculus 139-144 15681708-9 2005 The results suggest that nitro generation activated MMP and PAR-1, leading to endothelial-myocyte uncoupling. nitro 25-30 matrix metallopeptidase 2 Mus musculus 52-55 15665032-6 2005 When MMI270 (a broad-spectrum MMP inhibitor) was added together with HGF, decreases in FN-CCB domain expression and FAK phosphorylation by HGF were restored, and these events were associated with an inhibition of HGF-induced apoptosis, suggesting that increased activities of MMPs underlie the major mechanism of HGF-mediated apoptosis in myofibroblasts. CGS 27023A 5-11 matrix metallopeptidase 2 Mus musculus 276-280 15799868-7 2005 In vitro zymography and enzyme assays showed for both hydroxamic acid and carboxylic acid compounds a good inhibition activity and a high selectivity for MMP-2. Hydroxamic Acids 54-69 matrix metallopeptidase 2 Mus musculus 154-159 15799868-7 2005 In vitro zymography and enzyme assays showed for both hydroxamic acid and carboxylic acid compounds a good inhibition activity and a high selectivity for MMP-2. Carboxylic Acids 74-89 matrix metallopeptidase 2 Mus musculus 154-159 15919492-10 2005 RPM treatment was associated with increased activation of pro-MMP-9, a significant decrease in MMP-2 tissue levels, and corresponding increases in TIMP-2 and TIMP-3 expression. Sirolimus 0-3 matrix metallopeptidase 2 Mus musculus 95-100 15919492-12 2005 Alterations in eNOS expression, in addition to changes in MMP/TIMP ratios and MMP-2 and MMP-9 activation, may partially explain the changes observed in the aorta of treated Apo-E-/- mice induced by RPM. Sirolimus 198-201 matrix metallopeptidase 2 Mus musculus 78-83 15665032-8 2005 Furthermore, administration of recombinant HGF to bleomycin-treated mice increased lung MMP activities and enhanced myofibroblast apoptosis, while in vivo MMI270 injections together with HGF inhibited such MMP activation, leading to suppressed myofibroblast apoptosis. Bleomycin 50-59 matrix metallopeptidase 2 Mus musculus 88-91 15627474-6 2005 The result revealed that the treatment of carnosol could diminish the activity of MMP-9 more than MMP-2. carnosol 42-50 matrix metallopeptidase 2 Mus musculus 98-103 15674236-11 2005 MCAO-induced pro-MMP-2 was downregulated by minocycline treatment in wt mice but remained in MMP-9 ko mice at the same level as in saline-treated wt mice. Minocycline 44-55 matrix metallopeptidase 2 Mus musculus 17-22 15674236-11 2005 MCAO-induced pro-MMP-2 was downregulated by minocycline treatment in wt mice but remained in MMP-9 ko mice at the same level as in saline-treated wt mice. Sodium Chloride 131-137 matrix metallopeptidase 2 Mus musculus 17-22 15674236-13 2005 Minocycline may provide protection by interfering with MMPs. Minocycline 0-11 matrix metallopeptidase 2 Mus musculus 55-59 15853913-5 2005 The tolerability and inhibitory effect of LVA on matrix metalloproteinase-2 (MMP-2) were tested using WEHI-164 cell line and zymography method. mevinolinic acid 42-45 matrix metallopeptidase 2 Mus musculus 49-75 15962112-6 2005 We demonstrated that selective PDE4 inhibitor RP 73-401 reduced matrix metalloproteinase (MMP)-9 activity and TGF-beta1 release during LPS-induced lung injury in mice and that CI-1044 inhibited the production of MMP-1 and MMP-2 from human lung fibroblasts stimulated by pro-inflammatory cytokines. morin 176-178 matrix metallopeptidase 2 Mus musculus 222-227 15763341-3 2005 METHODS: MMP-2 was analyzed in livers of IL-6-/- and IL-6+/+ mice following CCl(4) administration. Cefaclor 76-79 matrix metallopeptidase 2 Mus musculus 9-14 15853913-5 2005 The tolerability and inhibitory effect of LVA on matrix metalloproteinase-2 (MMP-2) were tested using WEHI-164 cell line and zymography method. mevinolinic acid 42-45 matrix metallopeptidase 2 Mus musculus 77-82 15627474-12 2005 Taken together, these results indicate that carnosol targets MMP-mediated cellular events in cancer cells and provides a new mechanism for its anticancer activity. carnosol 44-52 matrix metallopeptidase 2 Mus musculus 61-64 15724816-8 2005 8-Bromo-cGMP and SNAP reduced the production of MMP in 3T3 cells but not in t3T3 with HAb18G/CD147 expression. 8-bromocyclic GMP 0-12 matrix metallopeptidase 2 Mus musculus 48-51 15724816-12 2005 These results suggest that HAb18G/CD147 attenuates adhesion potentials in fibroblasts by enhancing the secretion of MMP through NO/cGMP-sensitive capacitative Ca2+ entry. hab18g 27-33 matrix metallopeptidase 2 Mus musculus 116-119 15724816-0 2005 HAb18G/CD147 enhances the secretion of matrix metalloproteinases (MMP) via cGMP/NO-sensitive capacitative calcium entry (CCE) and accordingly attenuates adhesion ability of fibroblasts. Cyclic GMP 75-79 matrix metallopeptidase 2 Mus musculus 66-69 15724816-0 2005 HAb18G/CD147 enhances the secretion of matrix metalloproteinases (MMP) via cGMP/NO-sensitive capacitative calcium entry (CCE) and accordingly attenuates adhesion ability of fibroblasts. Calcium 106-113 matrix metallopeptidase 2 Mus musculus 66-69 15724816-1 2005 The present study examined the effect of hepatoma-associated antigen HAb18G (homologous to CD147) expression on the NO/cGMP-regulated Ca2+ mobilization to induce matrix metalloproteinases (MMP) production and attenuate adhesion ability of mouse fibroblast NIH/3T3 cells. Cyclic GMP 119-123 matrix metallopeptidase 2 Mus musculus 189-192 15724816-12 2005 These results suggest that HAb18G/CD147 attenuates adhesion potentials in fibroblasts by enhancing the secretion of MMP through NO/cGMP-sensitive capacitative Ca2+ entry. Cyclic GMP 131-135 matrix metallopeptidase 2 Mus musculus 116-119 15629234-5 2005 In vitro investigations have indicated that RWPCs and GTPs are able to inhibit several key events of the angiogenic process such as proliferation and migration of endothelial cells and vascular smooth muscle cells and the expression of two major proangiogenic factors, vascular endothelial growth factor (VEGF) and matrix metalloproteinase-2, by both redox-sensitive and redox-insensitive mechanisms. gtps 54-58 matrix metallopeptidase 2 Mus musculus 315-341 16132110-4 2005 The positive effect of the Y397F mutant on v-Src-stimulated invasion was correlated with an increased expression of matrix metalloproteinase-2, both of which were inhibited by the specific phosphatidylinositol 3-kinase inhibitor wortmannin or a dominant negative mutant of AKT, suggesting a critical role for the phosphatidylinositol 3-kinase/AKT pathway in both events. Wortmannin 229-239 matrix metallopeptidase 2 Mus musculus 116-142 16132110-4 2005 The positive effect of the Y397F mutant on v-Src-stimulated invasion was correlated with an increased expression of matrix metalloproteinase-2, both of which were inhibited by the specific phosphatidylinositol 3-kinase inhibitor wortmannin or a dominant negative mutant of AKT, suggesting a critical role for the phosphatidylinositol 3-kinase/AKT pathway in both events. Phosphatidylinositols 313-333 matrix metallopeptidase 2 Mus musculus 116-142 16114507-7 2005 The dose-dependent inhibitory effect of pyrimethamine on MMP-2 activity was significantly less than that of methotrexate at concentrations of 1-8 microg/ml. Pyrimethamine 40-53 matrix metallopeptidase 2 Mus musculus 57-62 16114507-9 2005 Our data suggest that pyrimethamine enables suppression of MMP-2 activity and induces apoptosis that could be assumed for chemoprevention therapy. Pyrimethamine 22-35 matrix metallopeptidase 2 Mus musculus 59-64 16132110-4 2005 The positive effect of the Y397F mutant on v-Src-stimulated invasion was correlated with an increased expression of matrix metalloproteinase-2, both of which were inhibited by the specific phosphatidylinositol 3-kinase inhibitor wortmannin or a dominant negative mutant of AKT, suggesting a critical role for the phosphatidylinositol 3-kinase/AKT pathway in both events. Phosphatidylinositols 189-209 matrix metallopeptidase 2 Mus musculus 116-142 15743030-4 2004 MEK inhibitors (PD98059 and U0126) inhibited the production of MMP-2, MMP-9 and high MW uPA, and upregulated TIMPs (TIMP-1, TIMP-2 and TIMP-3). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 16-23 matrix metallopeptidase 2 Mus musculus 63-68 15701277-6 2005 After 48 h of exposure to rapamycin, the glioma cell lines (but not HOG cells) showed downregulation of the membrane type-1 matrix metalloproteinase (MMP) invasion molecule. Sirolimus 26-35 matrix metallopeptidase 2 Mus musculus 150-153 15701277-7 2005 In U-87 cells, MMP-2 was downregulated, and in D-54 cells, both MMP-2 and MMP-9 were downregulated after treatment with rapamycin. Sirolimus 120-129 matrix metallopeptidase 2 Mus musculus 64-69 15701277-10 2005 Gelatin zymography showed marked reduction of MMP-2 in the mice with subcutaneous U-87 xenografts that were treated with rapamycin as compared with controls treated with phosphatebuffered saline. Sirolimus 121-130 matrix metallopeptidase 2 Mus musculus 46-51 15386368-0 2004 Prostate carcinoma and green tea: (-)epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2 activation and invasion in murine TRAMP model. epigallocatechin gallate 34-63 matrix metallopeptidase 2 Mus musculus 96-101 15386368-8 2004 Nevertheless, while tumor-released pro-MMP-2 is activated by co-incubation of TRAMP-C1 cells with PMNs, in the presence of 10 microM EGCG the activation is almost abolished. epigallocatechin gallate 133-137 matrix metallopeptidase 2 Mus musculus 39-44 15456921-2 2005 The purpose of this study was to examine the involvement of matrix metalloproteinases (MMPs) in the hepatic microvascular injury elicied by APAP. Acetaminophen 140-144 matrix metallopeptidase 2 Mus musculus 87-91 15456921-5 2005 The levels of mRNAs and activities of MMP-2 and MMP-9 in the liver were increased from 1 h through 6 h after APAP gavage. Acetaminophen 109-113 matrix metallopeptidase 2 Mus musculus 38-43 15456921-9 2005 The present study showed that increased MMPs during APAP intoxication are associated with hepatocellular damage and with hepatic microcirculatory dysfunction including impaired sinusoidal perfusion and infiltration of erythrocytes in Disse space. Acetaminophen 52-56 matrix metallopeptidase 2 Mus musculus 40-44 15574782-7 2004 Furthermore, green tea polyphenol infusion resulted in marked inhibition of markers of angiogenesis and metastasis most notably vascular endothelial growth factor, urokinase plasminogen activator, and matrix metalloproteinases 2 and 9. Polyphenols 23-33 matrix metallopeptidase 2 Mus musculus 164-234 15743030-4 2004 MEK inhibitors (PD98059 and U0126) inhibited the production of MMP-2, MMP-9 and high MW uPA, and upregulated TIMPs (TIMP-1, TIMP-2 and TIMP-3). U 0126 28-33 matrix metallopeptidase 2 Mus musculus 63-68 15386490-0 2004 Expression of matrix metalloproteinase-2 and -9 in exudates associated with polydimethyl siloxane and gelatin tubes implanted in mice. baysilon 76-97 matrix metallopeptidase 2 Mus musculus 14-47 15240428-7 2004 Five major gelatinase bands of activity were detected and inhibited by the MMP inhibitors, EDTA or 1,10-phenanthroline, but not by PMSF, a serine protease inhibitor. Edetic Acid 91-95 matrix metallopeptidase 2 Mus musculus 75-78 15240428-7 2004 Five major gelatinase bands of activity were detected and inhibited by the MMP inhibitors, EDTA or 1,10-phenanthroline, but not by PMSF, a serine protease inhibitor. 1,10-phenanthroline 99-118 matrix metallopeptidase 2 Mus musculus 75-78 15351400-1 2004 The synthesis and biological evaluation of caffonyl pyrrolidine derivatives as MMPs inhibitors are reported in this paper. caffonyl pyrrolidine 43-63 matrix metallopeptidase 2 Mus musculus 79-83 15331411-4 2004 Using SC-964, a potent inhibitor of several MMPs (MMP-2, -3, -8, -9, and -13), we investigated the role of MMPs in the 5T2MM murine model. sc-964 6-12 matrix metallopeptidase 2 Mus musculus 50-76 15347449-7 2004 Total protein concentration was determined according to the method of Bradford, while MMPs activities were measured with SDS-PAGE type substrate gels embedded with type I gelatin (zymography). Sodium Dodecyl Sulfate 121-124 matrix metallopeptidase 2 Mus musculus 86-90 15219947-0 2004 Effect of curcumin on gelatinase A (MMP-2) activity in B16F10 melanoma cells. Curcumin 10-18 matrix metallopeptidase 2 Mus musculus 22-34 15259001-7 2004 The expression of MMP-2 mRNA in zymosan-treated mice was strongly up-regulated in liver tissue only. Zymosan 32-39 matrix metallopeptidase 2 Mus musculus 18-23 15259001-10 2004 However, in the liver, lungs, and especially the spleen of zymosan-treated animals, significantly increased activity of proform and active MMP-2 and -9 was observed with time. Zymosan 59-66 matrix metallopeptidase 2 Mus musculus 139-151 15175040-7 2004 Moreover, oral administration of GTP also resulted in inhibition of UVB-induced expression of matrix degrading MMP, such as MMP-2 (67%), MMP-3 (63%), MMP-7 (62%), and MMP-9 (60%) in hairless mouse skin. Guanosine Triphosphate 33-36 matrix metallopeptidase 2 Mus musculus 124-129 15212943-8 2004 In addition, treatment of TNX-/- fibroblasts with SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, and genistein, a tyrosine kinase inhibitor, suppressed the increased level of proMMP-2 and increased MMP-2 promoter activity in TNX-/- fibroblasts. pyrazolanthrone 50-58 matrix metallopeptidase 2 Mus musculus 184-189 15212943-8 2004 In addition, treatment of TNX-/- fibroblasts with SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, and genistein, a tyrosine kinase inhibitor, suppressed the increased level of proMMP-2 and increased MMP-2 promoter activity in TNX-/- fibroblasts. Genistein 107-116 matrix metallopeptidase 2 Mus musculus 184-189 15163180-1 2004 In this communication we describe the design, synthesis, and evaluation of novel sultam hydroxamates 4 as MMP-2, -9, and -13 inhibitors. sultam hydroxamates 81-100 matrix metallopeptidase 2 Mus musculus 106-111 15177499-1 2004 Halofuginone, a widely used alkaloid coccidiostat, is a potent inhibitor of collagen alpha 1 (I) and matrix metalloproteinase 2 gene expression. halofuginone 0-12 matrix metallopeptidase 2 Mus musculus 101-127 15177499-1 2004 Halofuginone, a widely used alkaloid coccidiostat, is a potent inhibitor of collagen alpha 1 (I) and matrix metalloproteinase 2 gene expression. Alkaloids 28-36 matrix metallopeptidase 2 Mus musculus 101-127 15087022-11 2004 Expression of VEGF protein, MMP-2 progelatinase and MMP-2 mRNA levels in the xenografts treated with rofecoxib were lower than those of control group. rofecoxib 101-110 matrix metallopeptidase 2 Mus musculus 28-33 15296945-8 2004 At this concentration, DMSO also reduced the gelatinolytic activity by approximately 70%, pointing to a central role of CBD-substrate interactions during MMP-2 cleavage of gelatin. Dimethyl Sulfoxide 23-27 matrix metallopeptidase 2 Mus musculus 154-159 15296945-13 2004 In the presence of rCBD, approximately 65% of the MMP-derived gelatinolytic activity was eliminated. rcbd 19-23 matrix metallopeptidase 2 Mus musculus 50-53 15139760-10 2004 Optimal activity against MMP-2 among the cycloalkyl derivatives was shown by N-cyclopentylcarbamoylphosphonic acid (3m). N-cyclopentylcarbamoylphosphonic acid 77-114 matrix metallopeptidase 2 Mus musculus 25-30 14993222-6 2004 MMP-2 induction was blocked by the PI 3-kinase inhibitors LY294002 and wortmannin, by overexpression of a dominant-negative Akt or wild-type PTEN (phosphatase and tensin homologue deleted on chromosome 10), and by rapamycin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 58-66 matrix metallopeptidase 2 Mus musculus 0-5 14993222-6 2004 MMP-2 induction was blocked by the PI 3-kinase inhibitors LY294002 and wortmannin, by overexpression of a dominant-negative Akt or wild-type PTEN (phosphatase and tensin homologue deleted on chromosome 10), and by rapamycin. Wortmannin 71-81 matrix metallopeptidase 2 Mus musculus 0-5 14993222-7 2004 In contrast, a MEK inhibitor PD98059 failed to reduce MMP-2 promoter activation and actually increased MMP-2 mRNA and protein synthesis by up to 30%. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 29-36 matrix metallopeptidase 2 Mus musculus 103-108 15181819-6 2004 The MTT colorimetric assay revealed that the transfectants increased the expression of the MMP-2 of tumor cells while they did not change the trend of tumor cells" growth. monooxyethylene trimethylolpropane tristearate 4-7 matrix metallopeptidase 2 Mus musculus 91-96 15087022-11 2004 Expression of VEGF protein, MMP-2 progelatinase and MMP-2 mRNA levels in the xenografts treated with rofecoxib were lower than those of control group. rofecoxib 101-110 matrix metallopeptidase 2 Mus musculus 52-57 14690372-5 2003 CAPE (6 microg/mL)-treated CT26 cells showed not only inhibited cell invasion by 47.8% but also decreased expression of matrix metalloproteinase (MMP)-2 and -9. caffeic acid phenethyl ester 0-4 matrix metallopeptidase 2 Mus musculus 120-159 15047130-9 2004 Statistical significance was determined with analysis of variance (ANOVA) RESULTS: Zymograms revealed a greater than 10-fold increase in active MMP-9 and greater than 4-fold increase in active MMP-2 from HI + PBS compared to no HI + PBS (P < 0.05). Lead 209-212 matrix metallopeptidase 2 Mus musculus 193-198 15047130-10 2004 HI + anti-PMN antibody demonstrated reduction of both active MMP-2 and -9 levels to that of the nonischemic group. hi + 0-4 matrix metallopeptidase 2 Mus musculus 61-73 15028246-2 2004 In this article, we describe the labeling of a phage display selected cyclic decapeptide containing the HWGF (histidine-tryptophane-glycine-phenylalanine) sequence to target MMP-2 and MMP-9. cyclic decapeptide 70-88 matrix metallopeptidase 2 Mus musculus 174-179 15028246-2 2004 In this article, we describe the labeling of a phage display selected cyclic decapeptide containing the HWGF (histidine-tryptophane-glycine-phenylalanine) sequence to target MMP-2 and MMP-9. histidine-tryptophane 110-131 matrix metallopeptidase 2 Mus musculus 174-179 15028246-2 2004 In this article, we describe the labeling of a phage display selected cyclic decapeptide containing the HWGF (histidine-tryptophane-glycine-phenylalanine) sequence to target MMP-2 and MMP-9. glycine-phenylalanine 132-153 matrix metallopeptidase 2 Mus musculus 174-179 14967734-6 2004 The role of MMPs in high pressure-induced vessel distensibility was confirmed by use of the MMP inhibitor FN-439, which prevented the shift in the pressure-diameter relationship. 4-aminobenzoyl-glycyl-prolyl-leucyl-alanine hydroxamic acid 106-112 matrix metallopeptidase 2 Mus musculus 12-16 14996727-2 2004 Using pharmacological and genetic approaches, we have examined the role of these MMPs in progression of SK-N-BE (2).10 human neuroblastoma tumors orthotopically xenotransplanted into immunodeficient mice. sk-n-be 104-111 matrix metallopeptidase 2 Mus musculus 81-85 14996727-3 2004 Mice treated with Prinomastat, a synthetic inhibitor of MMPs, showed an inhibition of tumor cell proliferation in implanted tumors and a prolonged survival (50 versus 39 days in control group, P < 0.035). prinomastat 18-29 matrix metallopeptidase 2 Mus musculus 56-60 14761770-7 2004 In this study, we examine the expression of MMP-2, its activator MT1-MMP and MMP-9 in BOS using murine trachea transplantation models. N-[4-(Aminosulfonyl)phenyl]-2-Mercaptobenzamide 86-89 matrix metallopeptidase 2 Mus musculus 44-49 14761770-21 2004 CONCLUSIONS: These results demonstrate that MMP-2, together with its activator MT1-MMP, may have an important role in the development of BOS, which is associated with destruction of the tracheal epithelium, leading to fibrosis. N-[4-(Aminosulfonyl)phenyl]-2-Mercaptobenzamide 137-140 matrix metallopeptidase 2 Mus musculus 44-49 14967600-2 2004 Exposure to CS increased macrophages, neutrophils, lymphocytes, and matrix metalloproteinase (MMP)-2 and MMP-9 content in bronchoalveolar lavage fluid. Cesium 12-14 matrix metallopeptidase 2 Mus musculus 68-100 14967600-4 2004 These results support a role for MMPs in CS-induced emphysema and indicate that smoking cessation allows restoration toward normal homeostasis. Cesium 41-43 matrix metallopeptidase 2 Mus musculus 33-37 15573686-0 2004 Effect of piroxicam on matrix metalloproteinase 2 and apoptosis. Piroxicam 10-19 matrix metallopeptidase 2 Mus musculus 23-49 15573686-6 2004 The results of this study show that piroxicam is able to diminish MMP-2 activity and induce apoptosis under in vitro conditions. Piroxicam 36-45 matrix metallopeptidase 2 Mus musculus 66-71 15573686-8 2004 In conclusion, piroxicam is able to induce apoptosis and suppress MMP-2 activity. Piroxicam 15-24 matrix metallopeptidase 2 Mus musculus 66-71 15028415-5 2004 The results showed that, compared with the control, the expression of MMP-2 and -9 mRNAs was decreased in L-NAME-treated uteri during peri-implantation. NG-Nitroarginine Methyl Ester 106-112 matrix metallopeptidase 2 Mus musculus 70-82 15028415-9 2004 The L-NAME-mediated effect on MMPs and TIMPs were significantly reversed when SNP was co-administered with L-NAME. NG-Nitroarginine Methyl Ester 4-10 matrix metallopeptidase 2 Mus musculus 30-34 15028415-9 2004 The L-NAME-mediated effect on MMPs and TIMPs were significantly reversed when SNP was co-administered with L-NAME. NG-Nitroarginine Methyl Ester 107-113 matrix metallopeptidase 2 Mus musculus 30-34 14975595-11 2004 In addition, alpha-LA inhibited the proteolytic activity of MMP2 and MMP9 only at very high doses. Thioctic Acid 13-21 matrix metallopeptidase 2 Mus musculus 60-64 14760389-9 2004 In the presence of 100 microM NS-398, Western blot hybridisation analysis and zymography demonstrated that both MMP-2 and MMP-9 protein levels and enzyme activity were decreased by approximately 25-30%. N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide 30-36 matrix metallopeptidase 2 Mus musculus 112-117 14561647-6 2004 Further investigations by reverse transcription-polymerase chain reaction and gelatin zymography showed that MMP-2 and MMP-9 mRNA expression, as well as the gelatinolytic activity of MMP-9 in the lactacystin-treated uterine horn, significantly decreased, whereas the activity of MMP-2 was not significantly affected. lactacystin 196-207 matrix metallopeptidase 2 Mus musculus 109-114 14561647-6 2004 Further investigations by reverse transcription-polymerase chain reaction and gelatin zymography showed that MMP-2 and MMP-9 mRNA expression, as well as the gelatinolytic activity of MMP-9 in the lactacystin-treated uterine horn, significantly decreased, whereas the activity of MMP-2 was not significantly affected. lactacystin 196-207 matrix metallopeptidase 2 Mus musculus 279-284 14691189-11 2004 Nicotine also reversed VEGF-induced suppression of MMP-2 activity. Nicotine 0-8 matrix metallopeptidase 2 Mus musculus 51-56 12805564-9 2003 After 3 days of ischemia, MMP-2 activity and MMP-3 and MMP-13 protein levels were increased in untreated and aminoguanidine-treated diabetic mice when compared with controls (P < 0.05). pimagedine 109-123 matrix metallopeptidase 2 Mus musculus 26-31 12963732-3 2003 Using a specific MMP2 and MMP9 inhibitor, Ro28-2653, GnRH-dependent EGFR transactivation was abrogated. Ro 28-2653 42-51 matrix metallopeptidase 2 Mus musculus 17-21 12963732-4 2003 Proving the specificity of the effect, transient transfection of alphaT3-1 cells with ribozymes directed against MMP2 or MMP9 specifically blocked EGFR tyrosine phosphorylation in response to GnRH stimulation. Tyrosine 152-160 matrix metallopeptidase 2 Mus musculus 113-117 12930146-2 2003 Potent and specific MMP-2, -3, -9, -13 inhibitors were obtained by regio- and stereoselective substitutions at positions 2 and 5 on the cyclopentane ring. Cyclopentanes 136-148 matrix metallopeptidase 2 Mus musculus 20-33 14504671-6 2003 In isolated spleen cells from arthritic mice, increased potentials in proliferation, NO production, and MMP-2 and 9 activities were suppressed dose-dependently by the oral administration of astilbin. astilbin 190-198 matrix metallopeptidase 2 Mus musculus 104-109 12840218-11 2003 Oral feeding of GTP as the sole source of drinking fluid to TRAMP mice results in significant inhibition of VEGF, MMP-2 and MMP-9. Guanosine Triphosphate 16-19 matrix metallopeptidase 2 Mus musculus 114-119 12728254-5 2003 To test this hypothesis, we treated breast, melanoma, leukemia, osteosarcoma, and normal breast epithelial cells with (2R)-2-[(4-biphenylsulfonyl)amino]-3-phenylproprionic acid (compound 5a), an organic inhibitor of MMP-2/MMP-9, alone or in combination with TNFalpha or other apoptotic agents. (2r)-2-[(4-biphenylsulfonyl)amino]-3-phenylproprionic acid 118-176 matrix metallopeptidase 2 Mus musculus 216-221 12750313-0 2003 Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. NADP 108-114 matrix metallopeptidase 2 Mus musculus 69-95 12750313-0 2003 Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. NADP 108-114 matrix metallopeptidase 2 Mus musculus 97-102 12750313-0 2003 Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Reactive Oxygen Species 132-155 matrix metallopeptidase 2 Mus musculus 69-95 12750313-0 2003 Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Reactive Oxygen Species 132-155 matrix metallopeptidase 2 Mus musculus 97-102 12750313-13 2003 These results indicate that mechanical stretch induces ROS formation via the NAD(P)H oxidase and thereby enhances MMP-2 mRNA expression and pro-MMP-2 release. Reactive Oxygen Species 55-58 matrix metallopeptidase 2 Mus musculus 114-119 12750313-13 2003 These results indicate that mechanical stretch induces ROS formation via the NAD(P)H oxidase and thereby enhances MMP-2 mRNA expression and pro-MMP-2 release. Reactive Oxygen Species 55-58 matrix metallopeptidase 2 Mus musculus 144-149 12750313-14 2003 These results are consistent with the notion that in arterial hypertension, reactive oxygen species are involved in vascular remodeling via MMP activation. Reactive Oxygen Species 76-99 matrix metallopeptidase 2 Mus musculus 140-143 12738993-6 2003 Tetraarsenic oxide induced cell cycle arrest of bFGF-stimulated BCE cells in the G2/M phase and inhibited the secretion of matrix metalloproteinase-2 from BCE cells. Arsenic Trioxide 0-18 matrix metallopeptidase 2 Mus musculus 123-149 12815208-10 2003 To demonstrate the mechanism for inhibition of metastasis, the inhibitory effect of reticulol for matrix metalloproteinase-2 or -9 involved in melanoma metastasis was investigated; however, they were not observed on zymogram gel. reticulol 84-93 matrix metallopeptidase 2 Mus musculus 98-130 12831513-5 2003 In the supernatants collected, the activity of matrix metalloproteinases (MMPs) MMP-2 and MMP-9 was remarkably inhibited by astilbin. astilbin 124-132 matrix metallopeptidase 2 Mus musculus 74-78 12738748-6 2003 NAMI-A bound to collagen is active on tumor cells as shown in vitro by an invasion test, using a modified Boyden chamber and Matrigel, and it inhibits the matrix metallo-proteinases MMP-2 and MMP-9 at micromolar concentrations, as shown in vitro by a zimography test. imidazolium-bis(imidazole)dimethylsulfoxideimidazotetrachlororuthenate(III) 0-6 matrix metallopeptidase 2 Mus musculus 182-187 12742210-13 2003 Active MMP-2 increased 51% after HI (Group 1, 3,230 +/- 86 DU versus Group 4, 1,599 +/- 327 DU, p < 0.05). hi 33-35 matrix metallopeptidase 2 Mus musculus 7-12 12742210-13 2003 Active MMP-2 increased 51% after HI (Group 1, 3,230 +/- 86 DU versus Group 4, 1,599 +/- 327 DU, p < 0.05). du 59-61 matrix metallopeptidase 2 Mus musculus 7-12 12742210-14 2003 Neutrophil depletion decreased the HI-induced activation of MMP-2 by 43% (Group 2, 1,829 +/- 471 DU versus Group 1, 3,230 +/- 86 DU, p < 0.05). hi 35-37 matrix metallopeptidase 2 Mus musculus 60-65 12742210-14 2003 Neutrophil depletion decreased the HI-induced activation of MMP-2 by 43% (Group 2, 1,829 +/- 471 DU versus Group 1, 3,230 +/- 86 DU, p < 0.05). du 97-99 matrix metallopeptidase 2 Mus musculus 60-65 12831513-5 2003 In the supernatants collected, the activity of matrix metalloproteinases (MMPs) MMP-2 and MMP-9 was remarkably inhibited by astilbin. astilbin 124-132 matrix metallopeptidase 2 Mus musculus 80-85 12831513-6 2003 These results suggest that astilbin may inhibit delayed-type hypersensitivity reactions through selectively suppressing the lymphocyte functions, including cell migration, via down-regulating MMP activity. astilbin 27-35 matrix metallopeptidase 2 Mus musculus 192-195 12626552-7 2003 Disulfiram (DSF), an inhibitor of SOD-1, strongly inhibited the release of TNF-alpha, vascular endothelial growth factor, and MMP-2 and MMP-9 from cultured activated PEM. Disulfiram 0-10 matrix metallopeptidase 2 Mus musculus 126-131 12473670-5 2003 We also investigated the mechanism of action of curcumin (diferulolylmethane) on OPN-induced NF kappa B-mediated activation of pro-MMP-2 in B16F10 cells. Curcumin 48-56 matrix metallopeptidase 2 Mus musculus 131-136 12473670-5 2003 We also investigated the mechanism of action of curcumin (diferulolylmethane) on OPN-induced NF kappa B-mediated activation of pro-MMP-2 in B16F10 cells. diferulolylmethane 58-76 matrix metallopeptidase 2 Mus musculus 131-136 12473670-10 2003 The OPN-induced pro-MMP-2 activation and MT1-MMP expression were also drastically reduced by curcumin. Curcumin 93-101 matrix metallopeptidase 2 Mus musculus 20-25 12473670-12 2003 Most importantly, curcumin suppressed the OPN-induced tumor growth in nude mice, and the levels of pro-MMP-2 expression and activation in OPN-induced tumor were inhibited by curcumin. Curcumin 174-182 matrix metallopeptidase 2 Mus musculus 103-108 12473670-13 2003 To our knowledge, this is the first report that OPN induces NF kappa B activity through phosphorylation and degradation of I kappa B alpha by activating IKK that ultimately triggers the activation of pro-MMP-2 and further demonstrates that curcumin potently suppresses OPN-induced cell migration, tumor growth, and NF kappa B-mediated pro-MMP-2 activation by blocking the IKK/I kappa B alpha signaling pathways. Curcumin 240-248 matrix metallopeptidase 2 Mus musculus 204-209 12473670-13 2003 To our knowledge, this is the first report that OPN induces NF kappa B activity through phosphorylation and degradation of I kappa B alpha by activating IKK that ultimately triggers the activation of pro-MMP-2 and further demonstrates that curcumin potently suppresses OPN-induced cell migration, tumor growth, and NF kappa B-mediated pro-MMP-2 activation by blocking the IKK/I kappa B alpha signaling pathways. Curcumin 240-248 matrix metallopeptidase 2 Mus musculus 339-344 12626552-7 2003 Disulfiram (DSF), an inhibitor of SOD-1, strongly inhibited the release of TNF-alpha, vascular endothelial growth factor, and MMP-2 and MMP-9 from cultured activated PEM. Disulfiram 12-15 matrix metallopeptidase 2 Mus musculus 126-131 12581869-0 2003 Cytochalasin D disruption of actin filaments in 3T3 cells produces an anti-apoptotic response by activating gelatinase A extracellularly and initiating intracellular survival signals. Cytochalasins 0-12 matrix metallopeptidase 2 Mus musculus 108-120 12516105-3 2003 Our purpose was to determine the therapeutic efficacy of a selective-spectrum MMPI, ONO-4817 (inhibits MMP-2 and MMP-9 but not MMP-1), against established lung micrometastasis in combination with a cytotoxic anticancer drug, DOC, in a nude mouse model. N-hydroxy-5-ethoxymethyloxy-2-methyl-4-(4-phenoxybenzoyl)aminopentanamide 84-92 matrix metallopeptidase 2 Mus musculus 103-108 12735482-6 2003 These changes were consecutive to the expression of matrix metalloproteinases (MMP) -2 and -9 which were present as zymogens (inactive forms) in controls and supposed to be present in their active and inactive forms in magnesium-deficient mice (zymography). Magnesium 219-228 matrix metallopeptidase 2 Mus musculus 52-93 12591918-0 2003 Elevated glucose inhibits VEGF-A-mediated endocardial cushion formation: modulation by PECAM-1 and MMP-2. Glucose 9-16 matrix metallopeptidase 2 Mus musculus 99-104 12591918-7 2003 The MMP inhibitor GM6001 blocks invasion, whereas explants from PECAM-1 deficient mice exhibit MMP-2 induction and normal EMT in high glucose. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 18-24 matrix metallopeptidase 2 Mus musculus 4-7 12591918-10 2003 Our findings suggest that high glucose-induced inhibition of AV cushion morphogenesis results from decreased myocardial VEGF-A expression and is, in part, mediated by persistent endocardial cell PECAM-1 expression and failure to up-regulate MMP-2 expression. Glucose 31-38 matrix metallopeptidase 2 Mus musculus 241-246 12866360-6 2003 GPLGV pentapeptide was used as a substrate for MMP-2 and MMP-9, where the cleavage of Gly-Val bond by MMP was expected. Glycine 86-89 matrix metallopeptidase 2 Mus musculus 47-52 12623110-2 2003 (2R)-2- [4-(6-[(18)F]Fluorohex-1-ynyl)-benzenesulfonylamino]-3-methylbutyric acid ([(18)F]SAV03), a new fluorine-18 labeled MMP-2 inhibitor developed for tumor imaging with PET, was biologically evaluated using in vivo tumor model. (2r)-2- [4-(6-[(18)f]fluorohex-1-ynyl)-benzenesulfonylamino]-3-methylbutyric acid 0-81 matrix metallopeptidase 2 Mus musculus 124-129 12623110-2 2003 (2R)-2- [4-(6-[(18)F]Fluorohex-1-ynyl)-benzenesulfonylamino]-3-methylbutyric acid ([(18)F]SAV03), a new fluorine-18 labeled MMP-2 inhibitor developed for tumor imaging with PET, was biologically evaluated using in vivo tumor model. sav03 90-95 matrix metallopeptidase 2 Mus musculus 124-129 12866360-6 2003 GPLGV pentapeptide was used as a substrate for MMP-2 and MMP-9, where the cleavage of Gly-Val bond by MMP was expected. Glycine 86-89 matrix metallopeptidase 2 Mus musculus 47-50 12866360-6 2003 GPLGV pentapeptide was used as a substrate for MMP-2 and MMP-9, where the cleavage of Gly-Val bond by MMP was expected. Valine 90-93 matrix metallopeptidase 2 Mus musculus 47-52 12866360-6 2003 GPLGV pentapeptide was used as a substrate for MMP-2 and MMP-9, where the cleavage of Gly-Val bond by MMP was expected. Valine 90-93 matrix metallopeptidase 2 Mus musculus 47-50 12384564-10 2002 Inhibition of MMP activity by ONO-4817 suppressed lung metastasis by the cell lines that expressed MMPs, but not those that did not express MMP, via the inhibition of MMP activity of lung tumors. N-hydroxy-5-ethoxymethyloxy-2-methyl-4-(4-phenoxybenzoyl)aminopentanamide 30-38 matrix metallopeptidase 2 Mus musculus 99-103 12453184-10 2002 This induction of MMP2 resulted in significant increases of migration by melanoblasts on laminin or on laminin-5 substrates, while concomitant treatment with GM6001 blocked that induced migration. N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide 158-164 matrix metallopeptidase 2 Mus musculus 18-22 12379227-0 2002 Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential-is also a selective and potent inhibitor of gelatinase A expression. trichostatin A 0-14 matrix metallopeptidase 2 Mus musculus 125-137 12379227-3 2002 In the present paper we demonstrate that increased histone acetylation by TSA-treated 3T3 cells decreases mRNA as well as zymographic activity of gelatinase A, a matrix metalloproteinase, which is itself, implicated in tumorigenesis and metastasis. trichostatin A 74-77 matrix metallopeptidase 2 Mus musculus 146-158 12379227-4 2002 Furthermore, TSA inhibits cytochalasin D-induced activation of gelatinase A, but TSA does not affect other members of the gelatinase A activation complex, MT1-MMP and TIMP-2. trichostatin A 13-16 matrix metallopeptidase 2 Mus musculus 63-75 12645796-4 2003 We investigated the expression of matrix metalloproteinases-2 and -8 and laminin-5 gamma2-chain in dextran sulfate sodium-induced mice by immunohistochemistry and in situ hybridization. Dextran Sulfate 99-121 matrix metallopeptidase 2 Mus musculus 34-68 12645796-7 2003 In dextran sulfate sodium-induced colon, matrix metalloproteinase-2 immunoreactivity was detected in epithelial cells in the lower parts of the crypt and surrounding the degraded crypts. Dextran Sulfate 3-25 matrix metallopeptidase 2 Mus musculus 41-67 12438253-4 2002 MEF overexpression induced morphological changes, such as the conversion of normally loose cell-cell contacts to strong interactions similar to those seen in the presence of matrix metalloproteinase (MMP) inhibitor BB94. batimastat 215-219 matrix metallopeptidase 2 Mus musculus 200-203 12379227-4 2002 Furthermore, TSA inhibits cytochalasin D-induced activation of gelatinase A, but TSA does not affect other members of the gelatinase A activation complex, MT1-MMP and TIMP-2. Cytochalasin D 26-40 matrix metallopeptidase 2 Mus musculus 63-75 12379227-5 2002 Thus, TSA is a selective and potent inhibitor of expression and activation of gelatinase A. trichostatin A 6-9 matrix metallopeptidase 2 Mus musculus 78-90 12379227-6 2002 This finding not only strengthens the rationale for continuing to investigate the therapeutic utility of TSA in cancer, but also, provides evidence that TSA inhibition of gelatinase A expression and activation can be used as a biological marker to monitor and determine end-points of clinical trials involving TSA. trichostatin A 153-156 matrix metallopeptidase 2 Mus musculus 171-183 12379227-6 2002 This finding not only strengthens the rationale for continuing to investigate the therapeutic utility of TSA in cancer, but also, provides evidence that TSA inhibition of gelatinase A expression and activation can be used as a biological marker to monitor and determine end-points of clinical trials involving TSA. trichostatin A 153-156 matrix metallopeptidase 2 Mus musculus 171-183 12013508-4 2002 A well-known hydroxamate-based inhibitor of the MMPs, Batimastat (BB-94), was also used. batimastat 54-64 matrix metallopeptidase 2 Mus musculus 48-52 12361695-3 2002 By using the isolated spleen cells from the mice with PCl-CS, we demonstrated the inhibitory effects of RN-ext on matrix metalloproteinase-2 (MMP-2) and MMP-9 activities. pcl-cs 54-60 matrix metallopeptidase 2 Mus musculus 114-140 12361695-3 2002 By using the isolated spleen cells from the mice with PCl-CS, we demonstrated the inhibitory effects of RN-ext on matrix metalloproteinase-2 (MMP-2) and MMP-9 activities. pcl-cs 54-60 matrix metallopeptidase 2 Mus musculus 142-147 12485487-6 2002 RESULTS: Both gelatinase A and B were seldom detected in the kidney tissue in 8 week old mice, Increased expressions of both latent and activated form enzymes of MMP-2/9 were identified in kidney extraction by SDS-PAGE gelatin zymography and immunohistochemical staining showed both MMP-2 and MMP-9 were obviously up-regulated within glomerulus as well as tubular-interstitium in mice at the age of 16 and 24 weeks. Sodium Dodecyl Sulfate 210-213 matrix metallopeptidase 2 Mus musculus 14-32 12485487-6 2002 RESULTS: Both gelatinase A and B were seldom detected in the kidney tissue in 8 week old mice, Increased expressions of both latent and activated form enzymes of MMP-2/9 were identified in kidney extraction by SDS-PAGE gelatin zymography and immunohistochemical staining showed both MMP-2 and MMP-9 were obviously up-regulated within glomerulus as well as tubular-interstitium in mice at the age of 16 and 24 weeks. Sodium Dodecyl Sulfate 210-213 matrix metallopeptidase 2 Mus musculus 162-167 12485487-7 2002 In situ zymography showed markedly increased gelatinase activities in kidney tissue consistent with the results of immunohistochemical staining, it is mainly derived from MMPs and inhibited by EDTA but not by PMSF or aprotinin. Edetic Acid 193-197 matrix metallopeptidase 2 Mus musculus 171-175 18759028-2 2002 The results indicated that RU486 could significantly inhibit embryo implantation and change the expression of MMP-2 and TIMP-1,-3 in a dose-dependent pattern. Mifepristone 27-32 matrix metallopeptidase 2 Mus musculus 110-115 18759028-5 2002 After RU486 treatment, the generation of TIMP-1,3 was decreased while the MMP-2 was significantly increased, indicating that the normal balance between the activators and their inhibitors in the tissue was broken and the extracellular matrix was excessively degraded, subsequently the embryo implantation was inhibited. Mifepristone 6-11 matrix metallopeptidase 2 Mus musculus 74-79 18759028-6 2002 Therefore, it is suggested that the anti-implantation effect of RU486 may be mediated by MMPs and their inhibitors TIMPs. Mifepristone 64-69 matrix metallopeptidase 2 Mus musculus 89-93 11812761-9 2002 Thus, 25 mmol/l glucose induced reversible changes in MMP-2, TGF-beta(1), and type I collagen in MC of sclerosis-resistant mice but not in MC from sclerosis-prone mice. Glucose 16-23 matrix metallopeptidase 2 Mus musculus 54-59 11854129-7 2002 LV matrix metalloproteinase (MMP)-2 and MMP-13 were increased in myocardial infarction, which was attenuated in fluvastatin-treated mice. Fluvastatin 112-123 matrix metallopeptidase 2 Mus musculus 3-35 11454467-2 2001 The incorporated octapeptide, Gly-Pro-Gln-Arg-Ile-Ala-Gly-Gln, in A-DP2 is not cleaved by activated MMP2 and MMP9 in contrast to Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln incorporated in A-DP1 that is cleaved efficiently by activated MMP2 and MMP9 liberating a doxorubicin tetrapeptide. Arginine 42-45 matrix metallopeptidase 2 Mus musculus 224-228 11564733-7 2001 OPN also enhanced cell migration and ECM invasion by interacting with alpha(v)beta(3) integrin, but these effects were reduced drastically when the MMP-2-specific antisense S-oligonucleotide was used to suppress MMP-2 expression. Oligonucleotides 173-190 matrix metallopeptidase 2 Mus musculus 148-153 11564733-7 2001 OPN also enhanced cell migration and ECM invasion by interacting with alpha(v)beta(3) integrin, but these effects were reduced drastically when the MMP-2-specific antisense S-oligonucleotide was used to suppress MMP-2 expression. Oligonucleotides 173-190 matrix metallopeptidase 2 Mus musculus 212-217 11564733-10 2001 Both tumor size and MMP-2 expression were reduced dramatically when anti-MMP-2 antibody or antisense S-oligonucleotide-transfected cells were injected into the nude mice. Oligonucleotides 101-118 matrix metallopeptidase 2 Mus musculus 20-25 11911256-7 2001 Gelatin zymography revealed that ONO-4817 inhibited the enzymatic activity of MMP-2 produced by Renca cells in a concentration-dependent manner. N-hydroxy-5-ethoxymethyloxy-2-methyl-4-(4-phenoxybenzoyl)aminopentanamide 33-41 matrix metallopeptidase 2 Mus musculus 78-83 11454467-1 2001 Two doxorubicin albumin conjugates (A-DP1 and A-DP2), which differ in their substrate specificity for the matrix metalloproteinases MMP2 and MMP9, were prepared by binding maleimide doxorubicin peptide derivatives to the cysteine-34 position of human serum albumin. Doxorubicin 4-15 matrix metallopeptidase 2 Mus musculus 132-136 11739124-5 2002 Estradiol stimulated MMP-2 activity by increasing MMP-2 protein levels in a dose-dependent manner. Estradiol 0-9 matrix metallopeptidase 2 Mus musculus 21-26 11739124-5 2002 Estradiol stimulated MMP-2 activity by increasing MMP-2 protein levels in a dose-dependent manner. Estradiol 0-9 matrix metallopeptidase 2 Mus musculus 50-55 11739124-8 2002 The ability of estradiol to increase AP-2 protein expression, AP-2/DNA binding activity, MMP-2 protein expression, and metalloproteinase activity was reversed by PD-98059, a selective inhibitor of the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signaling cascade. Estradiol 15-24 matrix metallopeptidase 2 Mus musculus 89-94 11739124-8 2002 The ability of estradiol to increase AP-2 protein expression, AP-2/DNA binding activity, MMP-2 protein expression, and metalloproteinase activity was reversed by PD-98059, a selective inhibitor of the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signaling cascade. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 162-170 matrix metallopeptidase 2 Mus musculus 89-94 11606407-5 2001 The MMP inhibitor, BB-94, blocked MMP-2 activity and invasion associated with Akt1- and v-akt-expressing cells. batimastat 19-24 matrix metallopeptidase 2 Mus musculus 34-39 11606407-6 2001 The proteasome inhibitor, lactacystin, markedly increased MMP-2 levels and invasion in control cells but not in Akt1- and v-akt-expressing cells. lactacystin 26-37 matrix metallopeptidase 2 Mus musculus 58-63 11454467-2 2001 The incorporated octapeptide, Gly-Pro-Gln-Arg-Ile-Ala-Gly-Gln, in A-DP2 is not cleaved by activated MMP2 and MMP9 in contrast to Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln incorporated in A-DP1 that is cleaved efficiently by activated MMP2 and MMP9 liberating a doxorubicin tetrapeptide. ile-ala-gly-gln 46-61 matrix metallopeptidase 2 Mus musculus 224-228 11454467-2 2001 The incorporated octapeptide, Gly-Pro-Gln-Arg-Ile-Ala-Gly-Gln, in A-DP2 is not cleaved by activated MMP2 and MMP9 in contrast to Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln incorporated in A-DP1 that is cleaved efficiently by activated MMP2 and MMP9 liberating a doxorubicin tetrapeptide. gly-pro-gln- 30-42 matrix metallopeptidase 2 Mus musculus 224-228 11564614-6 2001 Our findings suggest that Clara cells inhibit pulmonary inflammation induced by crystalline silica via MMPs in vivo. Silicon Dioxide 92-98 matrix metallopeptidase 2 Mus musculus 103-107 11408924-5 2001 The amount of mRNA for MMP-2 increased in the CCl4-treated livers as compared with normal livers, and CBO140C12 cells constitutively expressed mRNA for MT1-MMP in early amplification cycles by RT-PCR. Carbon Tetrachloride 46-50 matrix metallopeptidase 2 Mus musculus 23-28 11451381-0 2001 Phorbol ester tumour promoter mediated altered expression and regulation of matrix metalloproteinase-2 in a H-ras transformed cell line capable of benign tumour formation. Phorbol Esters 0-13 matrix metallopeptidase 2 Mus musculus 76-102 11276015-1 2001 Bleomycin-induced pulmonary fibrosis is known to be associated with the increased activity of two gelatinases, matrix metalloproteinase (MMP)-2 and MMP-9, in bronchoalveolar lavage (BAL). Bleomycin 0-9 matrix metallopeptidase 2 Mus musculus 111-143 11276015-8 2001 Batimastat treatment was effective in reducing MMP-2 and MMP-9 activity as well as the tissue inhibitor of metalloproteinase-1 (TIMP-1) level in BAL. batimastat 0-10 matrix metallopeptidase 2 Mus musculus 47-52 11451381-2 2001 The present study demonstrates alterations in the regulation of matrix metalloproteinase-2 (MMP-2) expression in response to the phorbol ester tumour promoter, PMA, in a H-ras transformed cell line, NR3, which is capable of benign tumour formation. Phorbol Esters 129-142 matrix metallopeptidase 2 Mus musculus 64-90 11451381-2 2001 The present study demonstrates alterations in the regulation of matrix metalloproteinase-2 (MMP-2) expression in response to the phorbol ester tumour promoter, PMA, in a H-ras transformed cell line, NR3, which is capable of benign tumour formation. Phorbol Esters 129-142 matrix metallopeptidase 2 Mus musculus 92-97 10969037-9 2000 Myocardial matrix metalloproteinase-2 activity, measured with gelatin zymography, was increased with MI after 7 and 28 days, which was attenuated in MI+DMTU. 1,3-dimethylthiourea 152-156 matrix metallopeptidase 2 Mus musculus 11-37 11113133-7 2001 Addition of heparin, which competes for the binding of TSP2 to LRP coreceptor proteoglycans, inhibited adhesion of control but not TSP2-null cells, and a blocking antibody to LRP as well as the LRP inhibitor, receptor-associated protein, also inhibited adhesion and increased MMP2 levels only in control fibroblasts. Heparin 12-19 matrix metallopeptidase 2 Mus musculus 276-280 11813512-3 2001 During neointima formation after electric injury of the femoral artery, expression of MMP-2 and MMP-9 (gelatinase A and B) is strongly enhanced, independently of the presence or absence of plasminogen or of the physiological tissue-type (t-PA) or urokinase-type (u-PA) plasminogen activators. t-pa 238-242 matrix metallopeptidase 2 Mus musculus 86-91 11813512-3 2001 During neointima formation after electric injury of the femoral artery, expression of MMP-2 and MMP-9 (gelatinase A and B) is strongly enhanced, independently of the presence or absence of plasminogen or of the physiological tissue-type (t-PA) or urokinase-type (u-PA) plasminogen activators. t-pa 238-242 matrix metallopeptidase 2 Mus musculus 103-121 11099465-1 2000 We have previously demonstrated that halofuginone, a low molecular weight quinazolinone alkaloid, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. halofuginone 37-49 matrix metallopeptidase 2 Mus musculus 146-172 11099465-1 2000 We have previously demonstrated that halofuginone, a low molecular weight quinazolinone alkaloid, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. halofuginone 37-49 matrix metallopeptidase 2 Mus musculus 174-179 11099465-1 2000 We have previously demonstrated that halofuginone, a low molecular weight quinazolinone alkaloid, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Quinazolinones 74-87 matrix metallopeptidase 2 Mus musculus 174-179 11006154-2 2000 The objective of this study was to characterize further the expression of matrix metalloproteinases 2 and 9 in the mouse uterus during early pregnancy and oil-induced decidualization. Oils 155-158 matrix metallopeptidase 2 Mus musculus 74-107 11006154-3 2000 mRNA encoding matrix metalloproteinase 2 was detected in pregnant uteri and uteri undergoing oil-induced decidualization by northern blot analyses. Oils 93-96 matrix metallopeptidase 2 Mus musculus 14-40 11006154-7 2000 Immunoreactive matrix metalloproteinases 2 and 9 were detected in the uterus during early pregnancy and oil-induced decidualization by immunohistochemistry, localized to the endometrial stroma, but the staining progressively became weaker and was absent in areas that had undergone decidualization. Oils 104-107 matrix metallopeptidase 2 Mus musculus 15-48 10749873-3 2000 In calvarial culture obtained from normal ddy mice, both PGE(2) and dibutyryl cyclic AMP (Bt(2)cAMP) stimulated bone resorption and induced MMPs including MMP-2 and MMP-13. Dinoprostone 57-63 matrix metallopeptidase 2 Mus musculus 155-160 10749873-3 2000 In calvarial culture obtained from normal ddy mice, both PGE(2) and dibutyryl cyclic AMP (Bt(2)cAMP) stimulated bone resorption and induced MMPs including MMP-2 and MMP-13. Bucladesine 68-88 matrix metallopeptidase 2 Mus musculus 155-160 10749873-3 2000 In calvarial culture obtained from normal ddy mice, both PGE(2) and dibutyryl cyclic AMP (Bt(2)cAMP) stimulated bone resorption and induced MMPs including MMP-2 and MMP-13. Bucladesine 90-99 matrix metallopeptidase 2 Mus musculus 155-160 10749873-9 2000 Induction of MMP-2 and MMP-13 by PGE(2) was greatly impaired in calvarial culture from EP4-knockout mice, but Bt(2)cAMP stimulated MMPs induction similarly in the wild-type and EP4-knockout mice. Dinoprostone 33-39 matrix metallopeptidase 2 Mus musculus 13-18 10866312-10 2000 There was a significant reduction of tumor MMP-2 activity in mice treated with BB-94, gemcitabine, or gemcitabine and BB-94. batimastat 79-84 matrix metallopeptidase 2 Mus musculus 43-48 10473075-0 1999 Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. halofuginone 88-100 matrix metallopeptidase 2 Mus musculus 14-40 11467767-0 2000 Different levels of TGFbeta, IL-10, IFNgamma and gelatinase A occur in experimental white and black metastases induced by bryostatin 1 or by phorbol ester-treated BL6T murine melanoma cells. bryostatin 1 122-134 matrix metallopeptidase 2 Mus musculus 49-61 11467767-0 2000 Different levels of TGFbeta, IL-10, IFNgamma and gelatinase A occur in experimental white and black metastases induced by bryostatin 1 or by phorbol ester-treated BL6T murine melanoma cells. Phorbol Esters 141-154 matrix metallopeptidase 2 Mus musculus 49-61 10463616-1 1999 We have previously demonstrated that halofuginone, a widely used alkaloid coccidiostat, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 gene expression. halofuginone 37-49 matrix metallopeptidase 2 Mus musculus 136-162 10866312-10 2000 There was a significant reduction of tumor MMP-2 activity in mice treated with BB-94, gemcitabine, or gemcitabine and BB-94. gemcitabine 86-97 matrix metallopeptidase 2 Mus musculus 43-48 10866312-10 2000 There was a significant reduction of tumor MMP-2 activity in mice treated with BB-94, gemcitabine, or gemcitabine and BB-94. gemcitabine 102-113 matrix metallopeptidase 2 Mus musculus 43-48 10866312-10 2000 There was a significant reduction of tumor MMP-2 activity in mice treated with BB-94, gemcitabine, or gemcitabine and BB-94. batimastat 118-123 matrix metallopeptidase 2 Mus musculus 43-48 10866312-11 2000 Serum levels of active MMP-2 were reduced in all treated groups, with the greatest reduction occurring in mice treated with gemcitabine and BB-94. gemcitabine 124-135 matrix metallopeptidase 2 Mus musculus 23-28 10866312-11 2000 Serum levels of active MMP-2 were reduced in all treated groups, with the greatest reduction occurring in mice treated with gemcitabine and BB-94. batimastat 140-145 matrix metallopeptidase 2 Mus musculus 23-28 10727754-5 2000 Priming murine macrophages with interferon-gamma (IFN-gamma) inhibited JBT 3002-stimulated production of both MMP-9 and MMP-2 and further inhibited production of MME by a mechanism involving nitric oxide (NO). JBT-3002 71-79 matrix metallopeptidase 2 Mus musculus 120-125 11467767-11 2000 Therefore, in murine melanoma cells, the treatment with bryostatin I induces the appearance of a white population expressing different levels of TGFbeta, IFNgamma, IL-10 and gelatinase A. bryostatin 1 56-68 matrix metallopeptidase 2 Mus musculus 174-186 10553417-2 1999 BPHA potently inhibits MMP-2, 9 and 14 but not MMP-1, 3 or 7. N-benzoyl-N-phenylhydroxylamine 0-4 matrix metallopeptidase 2 Mus musculus 23-28 10595743-3 1999 Treatment of tumor cells with hypothemycin resulted in reduced expression of Ras-inducible genes, including MMP (matrix metalloproteinase)-1, MMP-9, transforming growth factor-beta (TGF-beta), and vascular endothelial growth factor (VEGF), but not that of the constitutively expressed gene, MMP-2. hypothemycin 30-42 matrix metallopeptidase 2 Mus musculus 291-296 10526099-11 1999 Both pro-MMP-9 (96 kDa) and pro-MMP-2 (72 kDa) were seen in the control specimens, and were markedly increased after FCI. fci 117-120 matrix metallopeptidase 2 Mus musculus 32-37 10473075-5 1999 We now report that expression of the MMP-2 gene by murine (MBT2-t50) and human (5637) bladder carcinoma cells is highly susceptible to inhibition by halofuginone. halofuginone 149-161 matrix metallopeptidase 2 Mus musculus 37-42 10473075-7 1999 This inhibition is due to an effect of halofuginone on the activity of the MMP-2 promoter, as indicated by a pronounced suppression of chloramphenicol acetyltransferase activity driven by the MMP-2 promoter in transfected MBT2 cells. halofuginone 39-51 matrix metallopeptidase 2 Mus musculus 75-80 10473075-7 1999 This inhibition is due to an effect of halofuginone on the activity of the MMP-2 promoter, as indicated by a pronounced suppression of chloramphenicol acetyltransferase activity driven by the MMP-2 promoter in transfected MBT2 cells. halofuginone 39-51 matrix metallopeptidase 2 Mus musculus 192-197 10426384-5 1999 Total collagen degradation was reduced by 58 +/- 18% in diabetic NOD-MCs, which correlated with a constitutive decrease in MMP-2 activity and mRNA levels, and nearly undetectable MMP-9 activity and mRNA. nod-mcs 65-72 matrix metallopeptidase 2 Mus musculus 123-128 10426384-7 1999 The addition of recombinant IGF-1 to nondiabetic NOD-MC resulted in a decrease in MMP-2 and TIMP activity. nod-mc 49-55 matrix metallopeptidase 2 Mus musculus 82-87 10473075-9 1999 Halofuginone-treated cells failed to invade through reconstituted basement-membrane (Matrigel) coated filters, in accordance with the inhibition of MMP-2 gene expression. halofuginone 0-12 matrix metallopeptidase 2 Mus musculus 148-153 10426384-8 1999 Furthermore, treatment of diabetic NOD-MC with a neutralizing antibody against IGF-1 increased the latent form, and restored the active form, of MMP-2. nod-mc 35-41 matrix metallopeptidase 2 Mus musculus 145-150 10473075-13 1999 These results indicate that the potent antimetastatic activity of halofuginone is due primarily to a transcriptional suppression of the MMP-2 gene, which results in a decreased enzymatic activity, matrix degradation, and tumor cell extravasation. halofuginone 66-78 matrix metallopeptidase 2 Mus musculus 136-141 10426384-9 1999 In conclusion, the excessive production of IGF-1 contributes to the altered ECM turnover in diabetic NOD-MC, largely through a reduction of MMP-2 activity. nod-mc 101-107 matrix metallopeptidase 2 Mus musculus 140-145 10415735-1 1999 We studied AG3340, a potent metalloproteinase (MMP) inhibitor with pM affinities for inhibiting gelatinases (MMP-2 and -9), MT-MMP-1 (MMP-14), and collagenase-3 (MMP-13) in many tumor models. prinomastat 11-17 matrix metallopeptidase 2 Mus musculus 109-121 10220303-6 1999 DETC was shown to exert multiple beneficial mechanisms, including 1) a decrease in circulating NO, as determined by plasma nitrite/nitrate levels, 2) a reduction in plasma tumor necrosis factor-alpha after lipopolysaccharide induction, and 3) decreased expressions of metalloproteinases such as gelatinase A and B which may be responsible for cellular release of cytokines. Ditiocarb 0-4 matrix metallopeptidase 2 Mus musculus 295-307 10357914-1 1999 BACKGROUND: We have shown previously that the metalloproteinase inhibitor, BB-94, prolongs survival and attenuates MMP-2 activity in a murine model of pancreatic cancer. batimastat 75-80 matrix metallopeptidase 2 Mus musculus 115-120 10357914-12 1999 CONCLUSIONS: The previously described salutary effects of MMP blockade in mice implanted with pancreatic cancer can be explained in vitro by a dose-dependent diminution of MMP-2 activity and activation in PANC cells exposed to BB-94. batimastat 227-232 matrix metallopeptidase 2 Mus musculus 172-177 10328230-0 1999 Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. batimastat 38-48 matrix metallopeptidase 2 Mus musculus 14-26 10328230-0 1999 Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. batimastat 38-48 matrix metallopeptidase 2 Mus musculus 28-33 10328230-0 1999 Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Captopril 53-62 matrix metallopeptidase 2 Mus musculus 14-26 10328230-0 1999 Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Captopril 53-62 matrix metallopeptidase 2 Mus musculus 28-33 10328230-3 1999 Here we report that captopril treatment resulted in decreased transcription and protein levels of gelatinase A by 3LL cells. Captopril 20-29 matrix metallopeptidase 2 Mus musculus 98-110 10328230-4 1999 Both BB-94 and captopril also prevented substrate degradation by gelatinase A and B released in conditioned medium by cultured cells. batimastat 5-10 matrix metallopeptidase 2 Mus musculus 65-83 10328230-4 1999 Both BB-94 and captopril also prevented substrate degradation by gelatinase A and B released in conditioned medium by cultured cells. Captopril 15-24 matrix metallopeptidase 2 Mus musculus 65-83 9889060-11 1999 Active MMP-2 was present in both groups but significantly decreased in animals treated with BB-94. batimastat 92-97 matrix metallopeptidase 2 Mus musculus 7-12 9890310-4 1999 Cells treated with PPS showed a decrease in cell number beginning 24 h after treatment, which was maintained for 5 d. For matrix accumulation and degradation studies, cells were treated for 5 d and collagen types I and IV protein were measured by enzyme-linked immunosorbent assay as well as matrix metalloproteinases (MMP) measured by zymography. Pentosan Sulfuric Polyester 19-22 matrix metallopeptidase 2 Mus musculus 319-322 9890310-6 1999 By zymography, MMP-2 was significantly increased after treatment with PPS (P < 0.001) and heparin (P < 0.05). Pentosan Sulfuric Polyester 70-73 matrix metallopeptidase 2 Mus musculus 15-20 9890310-6 1999 By zymography, MMP-2 was significantly increased after treatment with PPS (P < 0.001) and heparin (P < 0.05). Heparin 93-100 matrix metallopeptidase 2 Mus musculus 15-20 9890310-11 1999 In conclusion, PPS alters extracellular matrix turnover through the induction of MMP-2 and alterations in the TIMP profile and may be useful in decreasing progressive glomerulosclerosis. Pentosan Sulfuric Polyester 15-18 matrix metallopeptidase 2 Mus musculus 81-86 9889060-14 1999 Furthermore, attenuated levels of active MMP-2 in animals treated with the enzyme inhibitor BB-94 suggest that previously observed improvements in survival correlate with the level of MMP-2 activity. batimastat 92-97 matrix metallopeptidase 2 Mus musculus 41-46 9889060-14 1999 Furthermore, attenuated levels of active MMP-2 in animals treated with the enzyme inhibitor BB-94 suggest that previously observed improvements in survival correlate with the level of MMP-2 activity. batimastat 92-97 matrix metallopeptidase 2 Mus musculus 184-189 9389579-0 1997 Inhibitory effects of oleic and docosahexaenoic acids on lung metastasis by colon-carcinoma-26 cells are associated with reduced matrix metalloproteinase-2 and -9 activities. oleic and docosahexaenoic acids 22-53 matrix metallopeptidase 2 Mus musculus 129-162 10419836-2 1999 We have investigated the effects of betamethasone, cyclosporin, and nedocromil on MMP2 and MMP9 activities, on TNF-alpha and IL-10 release, as well as on the recruitment of inflammatory cells in the bronchoalveolar lavage (BAL) fluid after aerosol administration of lipopolysaccharide (LPS) in mice. Nedocromil 68-78 matrix metallopeptidase 2 Mus musculus 82-86 10419836-3 1999 When mice were pretreated with betamethasone (5 mg/kg, po), MMP2 and MMP9 activities, TNF-alpha in BAL fluids, and the enhanced neutrophil number of LPS-exposed mice were reduced, whereas the level of IL-10 was increased. Betamethasone 31-44 matrix metallopeptidase 2 Mus musculus 60-64 10419836-7 1999 However, since betamethasone reduced the LPS-induced pulmonary inflammation and production of MMPs, these results suggest that corticosteroids may decrease tissue remodelling associated with acute lung injury. Betamethasone 15-28 matrix metallopeptidase 2 Mus musculus 94-98 9417058-6 1998 Both the vitronectin-induced MMP-2 production and vitronectin-enhanced invasion were blocked by the peptide ligand Arg-Gly-Asp-Ser (RGDS). arginyl-glycyl-aspartyl-serine 115-130 matrix metallopeptidase 2 Mus musculus 29-34 9417058-8 1998 MMP-2 and MMP-2/TIMP-2 interaction with the plasma membrane of melanoma cells resulted in enhanced catalytic activity against 14C-labeled gelatin, suggesting that membrane association may function in posttranslational regulation of MMP-2 activity. Carbon-14 126-129 matrix metallopeptidase 2 Mus musculus 0-5 9417058-8 1998 MMP-2 and MMP-2/TIMP-2 interaction with the plasma membrane of melanoma cells resulted in enhanced catalytic activity against 14C-labeled gelatin, suggesting that membrane association may function in posttranslational regulation of MMP-2 activity. Carbon-14 126-129 matrix metallopeptidase 2 Mus musculus 10-15 9417058-8 1998 MMP-2 and MMP-2/TIMP-2 interaction with the plasma membrane of melanoma cells resulted in enhanced catalytic activity against 14C-labeled gelatin, suggesting that membrane association may function in posttranslational regulation of MMP-2 activity. Carbon-14 126-129 matrix metallopeptidase 2 Mus musculus 10-15 9389579-6 1997 Investigation of the gelatinolytic activity of the 57-kDa and 92-kDa isoforms of type-IV collagenase (MMP-2 and MMP-9, respectively) showed a clear reduction in the former by treatment with OA, while DHA, but not DHA plus LA or EPA, caused a decrease in the 92-kDa isoform, which was well correlated with AA content in tumor tissues (r = 0.900, p < 0.001). Docosahexaenoic Acids 213-216 matrix metallopeptidase 2 Mus musculus 102-107 9389579-6 1997 Investigation of the gelatinolytic activity of the 57-kDa and 92-kDa isoforms of type-IV collagenase (MMP-2 and MMP-9, respectively) showed a clear reduction in the former by treatment with OA, while DHA, but not DHA plus LA or EPA, caused a decrease in the 92-kDa isoform, which was well correlated with AA content in tumor tissues (r = 0.900, p < 0.001). Eicosapentaenoic Acid 228-231 matrix metallopeptidase 2 Mus musculus 102-107 9502424-5 1998 Of the MMPs tested, bleomycin treatment resulted in the up-regulation of gelatinase A and macrophage metalloelastase gene expression in whole-lung homogenates, whereas gelatinase B, stromelysin-1, and interstitial collagenase gene expression was not significantly changed. Bleomycin 20-29 matrix metallopeptidase 2 Mus musculus 73-85 9389579-6 1997 Investigation of the gelatinolytic activity of the 57-kDa and 92-kDa isoforms of type-IV collagenase (MMP-2 and MMP-9, respectively) showed a clear reduction in the former by treatment with OA, while DHA, but not DHA plus LA or EPA, caused a decrease in the 92-kDa isoform, which was well correlated with AA content in tumor tissues (r = 0.900, p < 0.001). Oleic Acid 190-192 matrix metallopeptidase 2 Mus musculus 102-107 9389579-6 1997 Investigation of the gelatinolytic activity of the 57-kDa and 92-kDa isoforms of type-IV collagenase (MMP-2 and MMP-9, respectively) showed a clear reduction in the former by treatment with OA, while DHA, but not DHA plus LA or EPA, caused a decrease in the 92-kDa isoform, which was well correlated with AA content in tumor tissues (r = 0.900, p < 0.001). Docosahexaenoic Acids 200-203 matrix metallopeptidase 2 Mus musculus 102-107 9062395-1 1997 In this study, we describe the activity of CT1746, an orally-active synthetic MMP inhibitor that has a greater specificity for gelatinase A, gelatinase B and stromelysin than for interstitial collagenase and matrilysin, in a nude mouse model that better mimics the clinical development of human colon cancer. CT 1746 43-49 matrix metallopeptidase 2 Mus musculus 127-139 9378540-5 1997 Northern blotting and zymography of primary-tumor crude extracts revealed that treatment with either razoxane or dacarbazine for one generation approximately doubled the expression of MMP-2 and MMP-9, while lacking any effect on that of 1.0 and of 3.5 kb TIMP-2. Razoxane 101-109 matrix metallopeptidase 2 Mus musculus 184-189 9378540-5 1997 Northern blotting and zymography of primary-tumor crude extracts revealed that treatment with either razoxane or dacarbazine for one generation approximately doubled the expression of MMP-2 and MMP-9, while lacking any effect on that of 1.0 and of 3.5 kb TIMP-2. Dacarbazine 113-124 matrix metallopeptidase 2 Mus musculus 184-189 9339552-4 1997 Theaflavin and theaflavin digallate also inhibited MMPs from the culture medium of these tumor cells, as did (-)-epigallocatechin gallate. theaflavin 0-10 matrix metallopeptidase 2 Mus musculus 51-55 9339552-4 1997 Theaflavin and theaflavin digallate also inhibited MMPs from the culture medium of these tumor cells, as did (-)-epigallocatechin gallate. theaflavin digallate 15-35 matrix metallopeptidase 2 Mus musculus 51-55 9254887-9 1997 However, the combination of substantial levels of mRNA for stromelysin-1, stromelysin-2, collagenase, membrane type 1 MMP, and gelatinase A occurred only in TPA-treated cells in the absence of TAM67. Tetradecanoylphorbol Acetate 157-160 matrix metallopeptidase 2 Mus musculus 127-139 7705924-3 1995 As assessed by zymographic analysis, NAC completely inhibited the gelatinolytic activity of type-IV collagenases in the cells tested (gelatinases A and B). Acetylcysteine 37-40 matrix metallopeptidase 2 Mus musculus 134-153 8895542-6 1996 Na[trans-RuCl4(DMSO)Im] also influences a proteolytic system which has the potential of degrading the basement membrane and has been related to metastatic aggressiveness: it markedly reduces, in a dose-dependent manner, MMP-2/TIMP-2 balance, but not that of MMP-9/TIMP-1. trans-rucl4 3-14 matrix metallopeptidase 2 Mus musculus 220-225 8895542-6 1996 Na[trans-RuCl4(DMSO)Im] also influences a proteolytic system which has the potential of degrading the basement membrane and has been related to metastatic aggressiveness: it markedly reduces, in a dose-dependent manner, MMP-2/TIMP-2 balance, but not that of MMP-9/TIMP-1. Dimethyl Sulfoxide 15-19 matrix metallopeptidase 2 Mus musculus 220-225 7782289-8 1995 In each case, an N-glycosylated 27-kDa protein was generated, that, like TIMP-1 and TIMP-2, inhibited collagenase-1, stromelysin-1, and gelatinases A and B. Nitrogen 17-18 matrix metallopeptidase 2 Mus musculus 136-155 7755562-10 1995 Both compounds dose-dependently inhibited 1,25-dihydroxyvitamin D3 (10(-8) M)-stimulated degradation of type-I collagen by mouse calvarial osteoblasts; however, complete inhibition of collagenolysis was only achieved at concentrations at which CT1166 and Ro 31-7467 act as general MMP inhibitors. Calcitriol 42-66 matrix metallopeptidase 2 Mus musculus 281-284 9816289-2 1996 Batimastat, also known as BB-94, acts as an inhibitor of metalloproteinase activity by binding the zinc ion in the active site of MMPs. batimastat 0-10 matrix metallopeptidase 2 Mus musculus 130-134 9816289-2 1996 Batimastat, also known as BB-94, acts as an inhibitor of metalloproteinase activity by binding the zinc ion in the active site of MMPs. batimastat 26-31 matrix metallopeptidase 2 Mus musculus 130-134 8565829-10 1996 mRNA and protein for gelatinase A, stromelysin-1 and uPA were weakly induced, if at all, in hydrocortisone-treated mice. Hydrocortisone 92-106 matrix metallopeptidase 2 Mus musculus 21-33 8565829-11 1996 Furthermore, mRNA for membrane-type matrix metalloproteinase decreased after hydrocortisone treatment and paralleled the almost complete inhibition of activation of latent gelatinase A. Hydrocortisone 77-91 matrix metallopeptidase 2 Mus musculus 172-184 33809405-8 2021 Rolipram also normalized the vascular MMP2 expression and MMP activity, preserving the elastin integrity and improving the vascular remodelling. Rolipram 0-8 matrix metallopeptidase 2 Mus musculus 38-42 7841542-11 1994 Quantitative ELISAs confirmed the blotting data and showed that taxol blocked MMP-2 but not TIMP-1 production in these advanced tumors. Paclitaxel 64-69 matrix metallopeptidase 2 Mus musculus 78-83 33809405-8 2021 Rolipram also normalized the vascular MMP2 expression and MMP activity, preserving the elastin integrity and improving the vascular remodelling. Rolipram 0-8 matrix metallopeptidase 2 Mus musculus 38-41 34822863-8 2022 Furthermore, microglial depletion and inactivation were shown to abrogate rotenone-induced activation of matrix metalloproteinases 2 and 9 (MMP-2/-9), two important factors to regulate tight junction degradation and BBB permeability, in mice. Rotenone 74-82 matrix metallopeptidase 2 Mus musculus 105-138 33034320-4 2020 In this study, we developed a matrix metalloproteinase-2 (MMP-2) activatable nanoprobe (PEG-PepMMP2-MNP-Gd), which was composed of water-insoluble gadolinium-chelated melanin (MNP-Gd), MMP-2 cleaved peptide and enzymatic detachable polyethylene glycol (PEG). Water 131-136 matrix metallopeptidase 2 Mus musculus 30-56 33034320-4 2020 In this study, we developed a matrix metalloproteinase-2 (MMP-2) activatable nanoprobe (PEG-PepMMP2-MNP-Gd), which was composed of water-insoluble gadolinium-chelated melanin (MNP-Gd), MMP-2 cleaved peptide and enzymatic detachable polyethylene glycol (PEG). Water 131-136 matrix metallopeptidase 2 Mus musculus 58-63 33034320-4 2020 In this study, we developed a matrix metalloproteinase-2 (MMP-2) activatable nanoprobe (PEG-PepMMP2-MNP-Gd), which was composed of water-insoluble gadolinium-chelated melanin (MNP-Gd), MMP-2 cleaved peptide and enzymatic detachable polyethylene glycol (PEG). Gadolinium 147-157 matrix metallopeptidase 2 Mus musculus 30-56 33034320-4 2020 In this study, we developed a matrix metalloproteinase-2 (MMP-2) activatable nanoprobe (PEG-PepMMP2-MNP-Gd), which was composed of water-insoluble gadolinium-chelated melanin (MNP-Gd), MMP-2 cleaved peptide and enzymatic detachable polyethylene glycol (PEG). Gadolinium 147-157 matrix metallopeptidase 2 Mus musculus 58-63 33034320-4 2020 In this study, we developed a matrix metalloproteinase-2 (MMP-2) activatable nanoprobe (PEG-PepMMP2-MNP-Gd), which was composed of water-insoluble gadolinium-chelated melanin (MNP-Gd), MMP-2 cleaved peptide and enzymatic detachable polyethylene glycol (PEG). Polyethylene Glycols 232-251 matrix metallopeptidase 2 Mus musculus 30-56 33034320-4 2020 In this study, we developed a matrix metalloproteinase-2 (MMP-2) activatable nanoprobe (PEG-PepMMP2-MNP-Gd), which was composed of water-insoluble gadolinium-chelated melanin (MNP-Gd), MMP-2 cleaved peptide and enzymatic detachable polyethylene glycol (PEG). Polyethylene Glycols 232-251 matrix metallopeptidase 2 Mus musculus 58-63 33034320-4 2020 In this study, we developed a matrix metalloproteinase-2 (MMP-2) activatable nanoprobe (PEG-PepMMP2-MNP-Gd), which was composed of water-insoluble gadolinium-chelated melanin (MNP-Gd), MMP-2 cleaved peptide and enzymatic detachable polyethylene glycol (PEG). Polyethylene Glycols 88-91 matrix metallopeptidase 2 Mus musculus 30-56 33034320-4 2020 In this study, we developed a matrix metalloproteinase-2 (MMP-2) activatable nanoprobe (PEG-PepMMP2-MNP-Gd), which was composed of water-insoluble gadolinium-chelated melanin (MNP-Gd), MMP-2 cleaved peptide and enzymatic detachable polyethylene glycol (PEG). Polyethylene Glycols 88-91 matrix metallopeptidase 2 Mus musculus 58-63 33034320-4 2020 In this study, we developed a matrix metalloproteinase-2 (MMP-2) activatable nanoprobe (PEG-PepMMP2-MNP-Gd), which was composed of water-insoluble gadolinium-chelated melanin (MNP-Gd), MMP-2 cleaved peptide and enzymatic detachable polyethylene glycol (PEG). Polyethylene Glycols 88-91 matrix metallopeptidase 2 Mus musculus 185-190 33034320-5 2020 In the presence of MMP-2 activity, PEG-coating on the surface was peeled off and the "hidden" hydrophobic segment was then exposed, which initiated the aggregation and size increase of nanoprobes. Polyethylene Glycols 35-38 matrix metallopeptidase 2 Mus musculus 19-24 29847555-7 2018 RESULTS: Gemcabene significantly downregulated hepatic mRNA markers of inflammation (TNF-alpha, MCP-1, MIP-1beta, CCR5, CCR2, NF-kappaB), lipogenesis and lipid modulation (ApoC-III, ACC1, ADH-4, Sulf-2), and fibrosis (TIMP-1 and MMP-2). gemcabene 9-18 matrix metallopeptidase 2 Mus musculus 229-234 34822863-8 2022 Furthermore, microglial depletion and inactivation were shown to abrogate rotenone-induced activation of matrix metalloproteinases 2 and 9 (MMP-2/-9), two important factors to regulate tight junction degradation and BBB permeability, in mice. Rotenone 74-82 matrix metallopeptidase 2 Mus musculus 140-148 34822863-9 2022 Moreover, SB-3CT, a widely used MMP-2/-9 inhibitor, increased BBB integrity and simultaneously elevated expressions of tight junction proteins in rotenone-intoxicated mice. Rotenone 146-154 matrix metallopeptidase 2 Mus musculus 32-40 34822863-11 2022 Altogether, this study revealed that rotenone elicited cognitive impairments in mice through microglia-mediated BBB disruption and neuronal apoptosis via MMP-2/-9, providing a novel aspect for the pathogenesis of pesticide-induced neurotoxicity and Parkinson"s disease (PD)-related dementia. Rotenone 37-45 matrix metallopeptidase 2 Mus musculus 154-162 34970414-6 2021 Immunohistochemical and zymography results show that CIH upregulated the expression and activity of MMP2 and MMP9 and upregulated MCP1 expression while downregulating alpha-SMA expression. cih 53-56 matrix metallopeptidase 2 Mus musculus 100-104 34856183-6 2022 Hexarelin rescued smooth muscle cell contractile phenotype with increased alpha-SMA and decreased MMP2. hexarelin 0-9 matrix metallopeptidase 2 Mus musculus 98-102 34392748-11 2022 DPP-IV inhibitors (sitagliptin, vildagliptin, alogliptin, and teneligliptin) were all shown to attenuate AAA formation in murine models by reducing monocyte differentiation, the release of reactive oxygen species (ROS), and metalloproteinases (MMP-2 and MMP-9). Sitagliptin Phosphate 19-30 matrix metallopeptidase 2 Mus musculus 244-249 34392748-11 2022 DPP-IV inhibitors (sitagliptin, vildagliptin, alogliptin, and teneligliptin) were all shown to attenuate AAA formation in murine models by reducing monocyte differentiation, the release of reactive oxygen species (ROS), and metalloproteinases (MMP-2 and MMP-9). Vildagliptin 32-44 matrix metallopeptidase 2 Mus musculus 244-249 34392748-11 2022 DPP-IV inhibitors (sitagliptin, vildagliptin, alogliptin, and teneligliptin) were all shown to attenuate AAA formation in murine models by reducing monocyte differentiation, the release of reactive oxygen species (ROS), and metalloproteinases (MMP-2 and MMP-9). alogliptin 46-56 matrix metallopeptidase 2 Mus musculus 244-249 34392748-11 2022 DPP-IV inhibitors (sitagliptin, vildagliptin, alogliptin, and teneligliptin) were all shown to attenuate AAA formation in murine models by reducing monocyte differentiation, the release of reactive oxygen species (ROS), and metalloproteinases (MMP-2 and MMP-9). 3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine 62-75 matrix metallopeptidase 2 Mus musculus 244-249 34618622-7 2021 Furthermore, tofacitinib also suppressed the cuprizone-induced increase in matrix metalloproteinases (MMP)-9 and MMP-2 levels. tofacitinib 13-24 matrix metallopeptidase 2 Mus musculus 113-118 34488161-12 2021 Moreover, the expression of genes related to TGFbeta/PPARgamma/MMP-2 signaling pathway was perturbed in the PCB126-treated hearts. 3,4,5,3',4'-pentachlorobiphenyl 108-114 matrix metallopeptidase 2 Mus musculus 63-68 34618622-7 2021 Furthermore, tofacitinib also suppressed the cuprizone-induced increase in matrix metalloproteinases (MMP)-9 and MMP-2 levels. Cuprizone 45-54 matrix metallopeptidase 2 Mus musculus 113-118 34944575-6 2021 5-azacytidine restored tuberin expression with a reduction of MMP-2 and MMP-7 levels and inhibits motility, similarly to rapamycin and anti-EGFR antibody. Sirolimus 121-130 matrix metallopeptidase 2 Mus musculus 62-67 34944575-9 2021 MMPs appears sensitive to rapamycin and anti-EGFR antibody only during cellular migration. Sirolimus 26-35 matrix metallopeptidase 2 Mus musculus 0-4 34944575-6 2021 5-azacytidine restored tuberin expression with a reduction of MMP-2 and MMP-7 levels and inhibits motility, similarly to rapamycin and anti-EGFR antibody. Azacitidine 0-13 matrix metallopeptidase 2 Mus musculus 62-67 34631222-9 2021 Finally, systematic administration of alpha-lipoic acid significantly suppressed STZ-induced mechanical allodynia by inhibiting MMP-9 and rescuing MMP-2 activity. Thioctic Acid 38-55 matrix metallopeptidase 2 Mus musculus 147-152 34802438-2 2021 In the present work, MMPs-degradable gelatin nanoparticles (GNPs) are simultaneously loaded with photosensitizer indocyanine green (ICG) along with signal transducer activator of transcription 3 (STAT3) inhibitor NSC74859 (NSC, N) for efficient photothermal therapy (PTT) and immunotherapy of HNSCCs. Indocyanine Green 113-130 matrix metallopeptidase 2 Mus musculus 21-25 34804364-0 2021 Lidocaine Alleviates Sepsis-Induced Acute Lung Injury in Mice by Suppressing Tissue Factor and Matrix Metalloproteinase-2/9. Lidocaine 0-9 matrix metallopeptidase 2 Mus musculus 95-123 34804364-10 2021 Moreover, in vitro and in vivo, lidocaine could increase the expression of p-AMPK and SOCS3 and subsequently decrease the expression of p-ASK1, p-p38, TF, and the activity of MMP-2/9. Lidocaine 32-41 matrix metallopeptidase 2 Mus musculus 175-182 34777244-6 2021 By inhibiting MMP-2 and MMP-9 with SB-3CT, collagen deposition disorder of the skin in streptozotocin-induced diabetes mice was alleviated. Streptozocin 87-101 matrix metallopeptidase 2 Mus musculus 14-19 34912527-9 2021 In ACE KO mice, increased MMP2 and decreased MMP9 activity were found in the AAI-treated mice compared with AAI-untreated control (P < 0.01). aristolochic acid I 77-80 matrix metallopeptidase 2 Mus musculus 26-30 34631222-3 2021 Here, we report that the gelatinases MMP-9 and MMP-2 play a critical role in axonal demyelination and DNP in rodents. dnp 102-105 matrix metallopeptidase 2 Mus musculus 47-52 34702968-8 2021 Moreover, ONO-0260164 inhibited in vivo proteolytic activity of MMP-2 in association with up-regulation of tissue inhibitor of metalloproteinase (TIMP)-3. ono-0260164 10-21 matrix metallopeptidase 2 Mus musculus 64-69 34671017-5 2021 Bilobalide also induces robust expression of Abeta degrading enzymes like NEP, IDE, and MMP2 to facilitate astrocyte-mediated Abeta clearance. bilobalide 0-10 matrix metallopeptidase 2 Mus musculus 88-92 34685761-10 2021 Finally, the bioluminescent images and immunostaining of MMP-2, cluster of differentiation 31 (CD31), and the VEGF receptor 1 (VEGFR1) revealed attenuated tumor progression in the combination of the FABP6-knocked-down and temozolomide (TMZ)-treated group in an orthotopic xenograft mouse tumor model. Temozolomide 222-234 matrix metallopeptidase 2 Mus musculus 57-62 34685761-10 2021 Finally, the bioluminescent images and immunostaining of MMP-2, cluster of differentiation 31 (CD31), and the VEGF receptor 1 (VEGFR1) revealed attenuated tumor progression in the combination of the FABP6-knocked-down and temozolomide (TMZ)-treated group in an orthotopic xenograft mouse tumor model. Temozolomide 236-239 matrix metallopeptidase 2 Mus musculus 57-62 34607973-22 2021 In vitro study, the protein levels of p-PI3K, p-AKT, p-mTOR, VEGF, COX2, and MMP2 were significantly increased in the Allicin-treated Tie2 expressing macrophages. allicin 118-125 matrix metallopeptidase 2 Mus musculus 77-81 34631222-4 2021 MMP-9 may contribute to streptozotocin (STZ)-induced DNP via inducing axonal demyelination and spinal central sensitization, while MMP-2 may serve as a negative regulator. Streptozocin 24-38 matrix metallopeptidase 2 Mus musculus 131-136 34631222-9 2021 Finally, systematic administration of alpha-lipoic acid significantly suppressed STZ-induced mechanical allodynia by inhibiting MMP-9 and rescuing MMP-2 activity. Streptozocin 81-84 matrix metallopeptidase 2 Mus musculus 147-152 34631222-4 2021 MMP-9 may contribute to streptozotocin (STZ)-induced DNP via inducing axonal demyelination and spinal central sensitization, while MMP-2 may serve as a negative regulator. Streptozocin 40-43 matrix metallopeptidase 2 Mus musculus 131-136 34631222-4 2021 MMP-9 may contribute to streptozotocin (STZ)-induced DNP via inducing axonal demyelination and spinal central sensitization, while MMP-2 may serve as a negative regulator. dnp 53-56 matrix metallopeptidase 2 Mus musculus 131-136 34284287-4 2021 We found IGU decreased pulmonary inflammation and fibrosis and expression of fibrosis-related genes such as Collagen I, alpha-smooth muscle actin (alpha-SMA) and matrix metalloproteinase-2 (MMP-2) induced by bleomycin. Bleomycin 208-217 matrix metallopeptidase 2 Mus musculus 162-188 34284287-4 2021 We found IGU decreased pulmonary inflammation and fibrosis and expression of fibrosis-related genes such as Collagen I, alpha-smooth muscle actin (alpha-SMA) and matrix metalloproteinase-2 (MMP-2) induced by bleomycin. Bleomycin 208-217 matrix metallopeptidase 2 Mus musculus 190-195 34603071-12 2021 Further, the activations of HSCs and TLR4 signaling pathway were observed after DSS + CCl4 treatment, presenting with the increase in expression of alpha-SMA, vimentin, TGF-beta, collagen type I, collagen type II, TIMP-2, TLR4, TRAF6, and NF-kappaB p65, and a decrease in GFAP and MMP-2 expression. Dextran Sulfate 80-83 matrix metallopeptidase 2 Mus musculus 281-286 34086144-7 2021 The protective effect of NBP on BSCB destruction is related to the regulation of MMP-2/9 induced by SCI. 3-n-butylphthalide 25-28 matrix metallopeptidase 2 Mus musculus 81-88 34175826-9 2021 We found that PM2.5 DMSO extracts, which promoted the contraction and migration of hASMCs, was accompanied by an increase in the levels of BRD4, kallikrein 14 (KLK14), bradykinin 2 receptor (B2R), matrix metalloproteinases2(MMP-2), matrix metalloproteinases9(MMP-9), vimentin and bradykinin (BK) secretion, while ZL0420 and BRD4 gene silencing could reverse this response. Dimethyl Sulfoxide 20-24 matrix metallopeptidase 2 Mus musculus 204-229 34062170-4 2021 We also verified whether corilagin can reverse atherosclerosis by regulating matrix metalloproteinase (MMP)-1, -2, and -9 in vitro and in vivo. corilagin 25-34 matrix metallopeptidase 2 Mus musculus 77-121 34086144-7 2021 The protective effect of NBP on BSCB destruction is related to the regulation of MMP-2/9 induced by SCI. bscb 32-36 matrix metallopeptidase 2 Mus musculus 81-88 34167292-0 2021 MMP-2-Activatable Photoacoustic Tumor Imaging Probes Based on Al- and Si-Naphthalocyanines. Aluminum 62-65 matrix metallopeptidase 2 Mus musculus 0-5 34364922-10 2021 Moreover, we used the luciferase reporter gene assay to confirm the relationship between miR-17-5p and HOTAIR or MMP2. mir-17-5p 89-98 matrix metallopeptidase 2 Mus musculus 113-117 34364922-11 2021 In this study, we found that MMP2 and HOTAIR were upregulated and miR-17-5p was downregulated in PQ-induced EMT. Paraquat 97-99 matrix metallopeptidase 2 Mus musculus 29-33 34364922-12 2021 The knockdown of HOTAIR decreased the expression of MMP2, and the upregulation of miR-17-5p suppressed HOTAIR and MMP2. mir-17-5p 82-91 matrix metallopeptidase 2 Mus musculus 114-118 34364922-13 2021 Apparently, the downregulation of miR-17-5p increased the expression of HOTAIR and MMP2. mir-17-5p 34-43 matrix metallopeptidase 2 Mus musculus 83-87 34364922-15 2021 In addition, the luciferase reporter gene assay confirmed that HOTAIR and MMP2 had direct binding sites with miR-17-5p. mir-17-5p 109-118 matrix metallopeptidase 2 Mus musculus 74-78 34364922-16 2021 In conclusion, this study showed that the HOTAIR could act as a ceRNA for miR-17-5p to regulate MMP2 expression in PQ-induced pulmonary EMT. mir-17-5p 74-83 matrix metallopeptidase 2 Mus musculus 96-100 34364922-16 2021 In conclusion, this study showed that the HOTAIR could act as a ceRNA for miR-17-5p to regulate MMP2 expression in PQ-induced pulmonary EMT. Paraquat 115-117 matrix metallopeptidase 2 Mus musculus 96-100 34167292-0 2021 MMP-2-Activatable Photoacoustic Tumor Imaging Probes Based on Al- and Si-Naphthalocyanines. si-naphthalocyanines 70-90 matrix metallopeptidase 2 Mus musculus 0-5 34167292-2 2021 In this study, aluminum and silicon naphthalocyanines (AlNc and SiNc, respectively) conjugated with matrix metalloprotease-2 (MMP-2)-responsive PLGLAG peptide sequence and poly(ethylene glycol) (PEG) as an axial ligand were designed and synthesized. Aluminum 15-23 matrix metallopeptidase 2 Mus musculus 100-124 34167292-2 2021 In this study, aluminum and silicon naphthalocyanines (AlNc and SiNc, respectively) conjugated with matrix metalloprotease-2 (MMP-2)-responsive PLGLAG peptide sequence and poly(ethylene glycol) (PEG) as an axial ligand were designed and synthesized. Aluminum 15-23 matrix metallopeptidase 2 Mus musculus 126-131 34167292-2 2021 In this study, aluminum and silicon naphthalocyanines (AlNc and SiNc, respectively) conjugated with matrix metalloprotease-2 (MMP-2)-responsive PLGLAG peptide sequence and poly(ethylene glycol) (PEG) as an axial ligand were designed and synthesized. silicon naphthalocyanines 28-53 matrix metallopeptidase 2 Mus musculus 126-131 34167292-5 2021 The treatment of MNc-peptide-PEG conjugates (M = Al, Si) with MMP-2 smoothly induced the cleavage of the PLGLAG sequence to release the hydrophilic PEG moiety, resulting in the aggregation of MNcs. Peptides 21-28 matrix metallopeptidase 2 Mus musculus 62-67 34167292-5 2021 The treatment of MNc-peptide-PEG conjugates (M = Al, Si) with MMP-2 smoothly induced the cleavage of the PLGLAG sequence to release the hydrophilic PEG moiety, resulting in the aggregation of MNcs. Polyethylene Glycols 29-32 matrix metallopeptidase 2 Mus musculus 62-67 34167292-5 2021 The treatment of MNc-peptide-PEG conjugates (M = Al, Si) with MMP-2 smoothly induced the cleavage of the PLGLAG sequence to release the hydrophilic PEG moiety, resulting in the aggregation of MNcs. Aluminum 49-51 matrix metallopeptidase 2 Mus musculus 62-67 34167292-5 2021 The treatment of MNc-peptide-PEG conjugates (M = Al, Si) with MMP-2 smoothly induced the cleavage of the PLGLAG sequence to release the hydrophilic PEG moiety, resulting in the aggregation of MNcs. Polyethylene Glycols 148-151 matrix metallopeptidase 2 Mus musculus 62-67 34167292-6 2021 By comparing the PA signal intensity changes at 680 and 760 nm, the photoacoustic signal intensity ratios were shown to be enhanced by 3-5 times after incubation with MMP-2. Protactinium 17-19 matrix metallopeptidase 2 Mus musculus 167-172 34167292-7 2021 We demonstrated that MNc-peptide-PEG conjugates (M = Al, Si) could work as activatable photoacoustic probes in the in vitro experiment of MMP-2-overexpressed cell line HT-1080 as well as the in vivo photoacoustic imaging of HT-1080-bearing mice. Peptides 25-32 matrix metallopeptidase 2 Mus musculus 138-143 34167292-7 2021 We demonstrated that MNc-peptide-PEG conjugates (M = Al, Si) could work as activatable photoacoustic probes in the in vitro experiment of MMP-2-overexpressed cell line HT-1080 as well as the in vivo photoacoustic imaging of HT-1080-bearing mice. Polyethylene Glycols 33-36 matrix metallopeptidase 2 Mus musculus 138-143 34142887-9 2021 In vitro, 11,12-EET treatment attenuated nicotine-induced MMP2 upregulation via SIRT1-mediated YAP deacetylation. 11,12-epoxy-5,8,14-eicosatrienoic acid 10-19 matrix metallopeptidase 2 Mus musculus 58-62 34142887-9 2021 In vitro, 11,12-EET treatment attenuated nicotine-induced MMP2 upregulation via SIRT1-mediated YAP deacetylation. Nicotine 41-49 matrix metallopeptidase 2 Mus musculus 58-62 34139508-4 2021 Gold nanorods (AuNRs) covalently coupled with amphiphilic polyTLR7/8a and MMP-2-sensitive R9-PEG conjugate (AuNRs-IMQD-R9-PEG) were developed as a new biocompatible PTT agent with favorable photothermal efficiency and stability. Polyethylene Glycols 93-96 matrix metallopeptidase 2 Mus musculus 74-79 34169637-2 2021 Here, we found that curcumin not only inhibited the growth of xenografts in chronically stressed nude mice, but also decreased the expression of matrix metalloproteinase (MMP)-2/9 and CD147 in tumour tissues. Curcumin 20-28 matrix metallopeptidase 2 Mus musculus 145-179 34176284-9 2021 Mechanistically, excessive inorganic phosphate and calcium promoted vascular cell death, osteogenic differentiation, and MMP2/9 secretion ex vivo and in vitro. Phosphates 27-46 matrix metallopeptidase 2 Mus musculus 121-127 34176284-9 2021 Mechanistically, excessive inorganic phosphate and calcium promoted vascular cell death, osteogenic differentiation, and MMP2/9 secretion ex vivo and in vitro. Calcium 51-58 matrix metallopeptidase 2 Mus musculus 121-127 34169637-5 2021 In addition, blocking ERK1/2 expression with U0126 resulted in the down-regulated expression of CD147, which further led to the decreased expression of MMP-2 and MMP-9. U 0126 45-50 matrix metallopeptidase 2 Mus musculus 152-157 34349878-12 2021 CONCLUSIONS: The results confirm that quercetin inhibits adipose tissue differentiation and fat accumulation in 3T3-L1 cells, which could occur through inhibition of the angiogenesis process related to MMPs. Quercetin 38-47 matrix metallopeptidase 2 Mus musculus 202-206 34368136-8 2021 Pitavastatin increased plasma GLP-1 and APN levels and suppressed matrix metalloproteinase-2/-9 gene expressions and activities in the aortas. pitavastatin 0-12 matrix metallopeptidase 2 Mus musculus 66-95 34349878-3 2021 Therefore, this study investigated the role of quercetin on adipogenesis in 3T3-L1 cells, acting through matrix metalloproteinases (MMPs). Quercetin 47-56 matrix metallopeptidase 2 Mus musculus 132-136 34349878-10 2021 Quercetin treatments reduced the mRNA expressions of VEGF-alpha, VEGFR-2, MMP-2, and MMP-9 in 3T3-L1 cells. Quercetin 0-9 matrix metallopeptidase 2 Mus musculus 74-79 34349878-11 2021 The activities and concentrations of MMP-2 and MMP-9 were also decreased significantly as the concentration of quercetin increased. Quercetin 111-120 matrix metallopeptidase 2 Mus musculus 37-42 34323034-8 2021 GNP@HA-CD-DOX showed a reduction in particle size after co-incubation with MMP-2. Doxorubicin 10-13 matrix metallopeptidase 2 Mus musculus 75-80 34323034-9 2021 The MMP-sensitive GNP@HA-CD-DOX had significantly improved cell uptake and better deep penetration in tumor spheres. Hyaluronic Acid 22-24 matrix metallopeptidase 2 Mus musculus 4-7 34323034-4 2021 Results: GNP@HA-CD-DOX nanoparticles had a particle size of (162.93+-2.55) nm, which could be degraded to release HA-CD-DOX with a particle size of about 40 nm under the treatment of MMP. LHRH (1-6) 9-12 matrix metallopeptidase 2 Mus musculus 183-186 34323034-9 2021 The MMP-sensitive GNP@HA-CD-DOX had significantly improved cell uptake and better deep penetration in tumor spheres. Cadmium 25-27 matrix metallopeptidase 2 Mus musculus 4-7 34323034-9 2021 The MMP-sensitive GNP@HA-CD-DOX had significantly improved cell uptake and better deep penetration in tumor spheres. Doxorubicin 28-31 matrix metallopeptidase 2 Mus musculus 4-7 34323034-4 2021 Results: GNP@HA-CD-DOX nanoparticles had a particle size of (162.93+-2.55) nm, which could be degraded to release HA-CD-DOX with a particle size of about 40 nm under the treatment of MMP. ha-cd 13-18 matrix metallopeptidase 2 Mus musculus 183-186 35316219-6 2022 Lastly, we found that topical treatment with AhR antagonists vitamin B12 and folic acid ameliorated UVB-induced wrinkle formation in mice while dampening MMP2 expression in the skin. Vitamin B 12 61-72 matrix metallopeptidase 2 Mus musculus 154-158 34323034-4 2021 Results: GNP@HA-CD-DOX nanoparticles had a particle size of (162.93+-2.55) nm, which could be degraded to release HA-CD-DOX with a particle size of about 40 nm under the treatment of MMP. Doxorubicin 19-22 matrix metallopeptidase 2 Mus musculus 183-186 34323034-4 2021 Results: GNP@HA-CD-DOX nanoparticles had a particle size of (162.93+-2.55) nm, which could be degraded to release HA-CD-DOX with a particle size of about 40 nm under the treatment of MMP. ha-cd-dox 114-123 matrix metallopeptidase 2 Mus musculus 183-186 34323034-8 2021 GNP@HA-CD-DOX showed a reduction in particle size after co-incubation with MMP-2. LHRH (1-6) 0-3 matrix metallopeptidase 2 Mus musculus 75-80 34323034-8 2021 GNP@HA-CD-DOX showed a reduction in particle size after co-incubation with MMP-2. ha-cd 4-9 matrix metallopeptidase 2 Mus musculus 75-80 34239271-8 2021 Furthermore, western blot and qPCR assays showed that the levels of alpha smooth muscle actin (alpha-SMA), matrix metalloproteinase 2 (MMP-2), MMP-9, and transforming growth factor beta 1 (TGF-beta1) were inhibited by Fasudil. fasudil 218-225 matrix metallopeptidase 2 Mus musculus 107-133 34239271-8 2021 Furthermore, western blot and qPCR assays showed that the levels of alpha smooth muscle actin (alpha-SMA), matrix metalloproteinase 2 (MMP-2), MMP-9, and transforming growth factor beta 1 (TGF-beta1) were inhibited by Fasudil. fasudil 218-225 matrix metallopeptidase 2 Mus musculus 135-140 34235177-5 2021 We found that GSK-3 inhibition down-modulates gene expression and protein levels of MMP-9, MMP-2, and their inhibitors TIMP-1 and TIMP-2 in inflammatory cells harvested from bronchoalveolar lavage fluid (BALF) of mice treated with bleomycin as well as in interstitial alveolar macrophages and cuboidalized epithelial alveolar cells. Bleomycin 231-240 matrix metallopeptidase 2 Mus musculus 91-96 34273265-6 2021 Furthermore, platycodin D inhibited 5637 cell migration by decreasing twist-related protein 1 (Twist1) and matrix metallopeptidase 2 (MMP2) expression and exerted significant tumour-suppressive effects in tumour-bearing nude mice. platycodin D 13-25 matrix metallopeptidase 2 Mus musculus 107-132 34273265-6 2021 Furthermore, platycodin D inhibited 5637 cell migration by decreasing twist-related protein 1 (Twist1) and matrix metallopeptidase 2 (MMP2) expression and exerted significant tumour-suppressive effects in tumour-bearing nude mice. platycodin D 13-25 matrix metallopeptidase 2 Mus musculus 134-138 35245631-16 2022 In vivo, dioscin could reduce lung nodules, lung injury, and mortality in mouse lung cancer model with reducing the expression of p-AKT, MMP2, PCNA and increasing the expression of active-caspase3. dioscin 9-16 matrix metallopeptidase 2 Mus musculus 137-141 35631654-11 2022 Furthermore, MM1-DOX reduced the expression of M2-TAM (CD-163) in tumors, which resulted in increased apoptosis (FADD) as well as decreased expression of MMP-2 and TGF-beta. Doxorubicin 17-20 matrix metallopeptidase 2 Mus musculus 154-159 35631654-11 2022 Furthermore, MM1-DOX reduced the expression of M2-TAM (CD-163) in tumors, which resulted in increased apoptosis (FADD) as well as decreased expression of MMP-2 and TGF-beta. Tamoxifen 50-53 matrix metallopeptidase 2 Mus musculus 154-159 34152136-10 2021 Moreover, the CHOP, IL-1beta, matrix metalloproteinase-2, and TGF-beta1 expressions were significantly decreased in HFD/DSS-induced colitis mice after post-treatment with PTS. Dextran Sulfate 120-123 matrix metallopeptidase 2 Mus musculus 30-56 34143400-15 2022 In addition, allicin inhibited the expression of MMP2 and MMP9 in metacestode-surrounding host tissues. allicin 13-20 matrix metallopeptidase 2 Mus musculus 49-53 34071594-6 2021 The productions of TNF-alpha, IL-6, MMP-2 and MMP- 9 were reduced by KMUP-1 pretreatment in LPS-induced inflammation of RAW264.7 cells. KMUP 1 69-75 matrix metallopeptidase 2 Mus musculus 36-41 34071594-7 2021 The expressions of iNOS, TNF-alpha, COX-2, MMP-2 and MMP-9 were also inhibited by KMUP-1 pretreatment. KMUP 1 82-88 matrix metallopeptidase 2 Mus musculus 43-48 34247563-8 2021 Additionally, non-cytotoxic concentrations of GT can suppress migration and invasion of CRC cells by inhibiting the expression and activity of matrix metalloproteinase (MMP)-2 and MMP-9 and epithelial-mesenchymal transition by downregulating the expression of mesenchymal markers including snail, twist, and vimentin. Hydrolyzable Tannins 46-48 matrix metallopeptidase 2 Mus musculus 143-175 35316219-6 2022 Lastly, we found that topical treatment with AhR antagonists vitamin B12 and folic acid ameliorated UVB-induced wrinkle formation in mice while dampening MMP2 expression in the skin. Folic Acid 77-87 matrix metallopeptidase 2 Mus musculus 154-158 35547769-5 2022 By incorporating four functional motifs that include D-peptidomimetic inhibitor of PD-L1, matrix metalloproteinase-2 (MMP-2) cleavable spacer, and MP9 with 4-arm PEG, a novel peptide-polymer conjugate (PEG-MP9-aPDL1) was obtained and identified as the most promising systemic delivery vehicle with PD-L1 targeting specificity and favorable pharmacokinetic properties. Polyethylene Glycols 162-165 matrix metallopeptidase 2 Mus musculus 90-116 34982187-7 2022 Moreover, DMF treatment reduced the hydrolysis of ECM proteins by MMP2 and MMP9. Dimethyl Fumarate 10-13 matrix metallopeptidase 2 Mus musculus 66-70 35471977-11 2022 Anlotinib treatment reduced PCNA, CDK1, and MMP2 protein expressions and increased E-cadherin protein expression in gastric cancer cells (p < 0.01). anlotinib 0-9 matrix metallopeptidase 2 Mus musculus 44-48 35547769-5 2022 By incorporating four functional motifs that include D-peptidomimetic inhibitor of PD-L1, matrix metalloproteinase-2 (MMP-2) cleavable spacer, and MP9 with 4-arm PEG, a novel peptide-polymer conjugate (PEG-MP9-aPDL1) was obtained and identified as the most promising systemic delivery vehicle with PD-L1 targeting specificity and favorable pharmacokinetic properties. Polymers 183-190 matrix metallopeptidase 2 Mus musculus 90-116 35547769-5 2022 By incorporating four functional motifs that include D-peptidomimetic inhibitor of PD-L1, matrix metalloproteinase-2 (MMP-2) cleavable spacer, and MP9 with 4-arm PEG, a novel peptide-polymer conjugate (PEG-MP9-aPDL1) was obtained and identified as the most promising systemic delivery vehicle with PD-L1 targeting specificity and favorable pharmacokinetic properties. Polymers 183-190 matrix metallopeptidase 2 Mus musculus 118-123 35235860-9 2022 Valsartan inhibited the cell migration by perturbation of MMP2/9. Valsartan 0-9 matrix metallopeptidase 2 Mus musculus 58-64 35463768-6 2022 Biolayer interferometry and AI/bioinformatics analyses indicated that crocin may inhibit MMP2 activity by direct binding. crocin 70-76 matrix metallopeptidase 2 Mus musculus 89-93 35451558-7 2022 Additionally, miR-450a inhibited the phosphorylation of phosphatidylinositol 3-kinase/V-akt murine thymoma viral oncogene homolog (PI3K/AKT) and the activities of matrix metalloproteinase-2/9 (MMP-2/9). mir-450a 14-22 matrix metallopeptidase 2 Mus musculus 163-191 35451558-7 2022 Additionally, miR-450a inhibited the phosphorylation of phosphatidylinositol 3-kinase/V-akt murine thymoma viral oncogene homolog (PI3K/AKT) and the activities of matrix metalloproteinase-2/9 (MMP-2/9). mir-450a 14-22 matrix metallopeptidase 2 Mus musculus 193-200 35450406-8 2022 17-DA significantly promoted cell proliferation and alleviated apoptosis by inhibiting the generation of intracellular reactive oxygen species (ROS) to downregulate cleaved caspase-3, matrix metallopeptidase- (MMP-) 2, MMP-9, and P-P65 in bEnd.3 cells after the injury. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 0-5 matrix metallopeptidase 2 Mus musculus 184-217 35450406-8 2022 17-DA significantly promoted cell proliferation and alleviated apoptosis by inhibiting the generation of intracellular reactive oxygen species (ROS) to downregulate cleaved caspase-3, matrix metallopeptidase- (MMP-) 2, MMP-9, and P-P65 in bEnd.3 cells after the injury. Reactive Oxygen Species 119-142 matrix metallopeptidase 2 Mus musculus 184-217 35450406-8 2022 17-DA significantly promoted cell proliferation and alleviated apoptosis by inhibiting the generation of intracellular reactive oxygen species (ROS) to downregulate cleaved caspase-3, matrix metallopeptidase- (MMP-) 2, MMP-9, and P-P65 in bEnd.3 cells after the injury. Reactive Oxygen Species 144-147 matrix metallopeptidase 2 Mus musculus 184-217 35450406-9 2022 As a result, we assumed that the HSP90 protein was activated post-TBI, and inhibition of HSP90 protein reduced the disruption of BBB and improved the neurobehavioral scores in a mouse model of TBI through the action of 17-DA, which inhibited ROS generation and regulated MMP-2, MMP-9, NF-kappaB, and caspase-associated pathways. 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin 219-224 matrix metallopeptidase 2 Mus musculus 271-276 35269673-10 2022 Therefore, we conclude that doxycycline in ApoE-/-/OVX animals promotes a reduction in atherosclerotic lesions by reducing ROS and MMP-2 activity and expression. Doxycycline 28-39 matrix metallopeptidase 2 Mus musculus 131-136 35342412-10 2022 The depletion of MMP2-AS1 enhanced miR-34c-5p expression and the expression of MMP2 was inhibited by miR-34c-5p in RCC cells. mir-34c-5p 101-111 matrix metallopeptidase 2 Mus musculus 79-83 35342412-11 2022 The protein levels of MMP2 were downregulated by MMP2-AS1 knockdown, while the inhibitor of miR-34c-5p rescued the expression of MMP2 in the cells. mir-34c-5p 92-102 matrix metallopeptidase 2 Mus musculus 22-26 35342412-11 2022 The protein levels of MMP2 were downregulated by MMP2-AS1 knockdown, while the inhibitor of miR-34c-5p rescued the expression of MMP2 in the cells. mir-34c-5p 92-102 matrix metallopeptidase 2 Mus musculus 129-133 35342412-12 2022 The treatment of miR-34c-5p mimic attenuated the cell viability, proliferation, invasion, and migration of RCC cells, in which MMP2 overexpression restored the phenotypes. mir-34c-5p 17-27 matrix metallopeptidase 2 Mus musculus 127-131 35342412-13 2022 MMP2-AS1 depletion-attenuated viability, proliferation, migration, and invasion of RCC cells were reversed by miR-34c-5p inhibitor. mir-34c-5p 110-120 matrix metallopeptidase 2 Mus musculus 0-4 35342412-8 2022 Mechanically, we predicted the potential interaction of miR-34c-5p with both MMP2-AS1 and MMP2. mir-34c-5p 56-66 matrix metallopeptidase 2 Mus musculus 77-81 35342412-8 2022 Mechanically, we predicted the potential interaction of miR-34c-5p with both MMP2-AS1 and MMP2. mir-34c-5p 56-66 matrix metallopeptidase 2 Mus musculus 90-94 35342412-10 2022 The depletion of MMP2-AS1 enhanced miR-34c-5p expression and the expression of MMP2 was inhibited by miR-34c-5p in RCC cells. alclofenac 39-42 matrix metallopeptidase 2 Mus musculus 17-21 35342412-10 2022 The depletion of MMP2-AS1 enhanced miR-34c-5p expression and the expression of MMP2 was inhibited by miR-34c-5p in RCC cells. mir-34c-5p 101-111 matrix metallopeptidase 2 Mus musculus 17-21 35269673-0 2022 Doxycycline Decreases Atherosclerotic Lesions in the Aorta of ApoE-/- and Ovariectomized Mice with Correlation to Reduced MMP-2 Activity. Doxycycline 0-11 matrix metallopeptidase 2 Mus musculus 122-127 35143032-8 2022 TMAO also increased the accumulation of the senescence markers p21 and p16, as well as of reactive oxygen species (ROS), matrix metalloproteinase-2 (MMP2), and matrix metalloproteinase-9 (MMP9) in vivo and in vitro. trimethyloxamine 0-4 matrix metallopeptidase 2 Mus musculus 121-147 35269673-2 2022 Thus, this study aims to evaluate aortic remodeling, MMP activity, and reactive oxygen species (ROS) levels after treatment with doxycycline in ApoE-/- and ovariectomized mice (OVX). Doxycycline 129-140 matrix metallopeptidase 2 Mus musculus 53-56 35143032-8 2022 TMAO also increased the accumulation of the senescence markers p21 and p16, as well as of reactive oxygen species (ROS), matrix metalloproteinase-2 (MMP2), and matrix metalloproteinase-9 (MMP9) in vivo and in vitro. trimethyloxamine 0-4 matrix metallopeptidase 2 Mus musculus 149-153 35093074-5 2022 Then, long-chain PEG5000, which was used to shield Fc to confer nanoparticle colloidal stability, was linked to the MSN surface via matrix metalloprotease-2 (MMP-2)-cleavable peptide (GPLGIAGQC). peg5000 17-24 matrix metallopeptidase 2 Mus musculus 132-156 35093074-5 2022 Then, long-chain PEG5000, which was used to shield Fc to confer nanoparticle colloidal stability, was linked to the MSN surface via matrix metalloprotease-2 (MMP-2)-cleavable peptide (GPLGIAGQC). peg5000 17-24 matrix metallopeptidase 2 Mus musculus 158-163 35093074-7 2022 RESULTS: Fc fragments of NISA can be exposed through hydrolysis of long-chain PEG5000 by highly expressed MMP-2 in tumor microenvironment. peg5000 78-85 matrix metallopeptidase 2 Mus musculus 106-111 35159480-6 2022 MES and celecoxib reduced the inflammation level of colon tissue, as indicated by its suppression on a panel of pro-inflammatory cytokines, including interleukin (IL)-1beta, IL-17, tumor necrosis factor alpha, and interferon gamma, and a group of inflammatory proteins, including intracellular adhesion molecule 1, vascular adhesion molecule 1, matrix metalloproteinase (MMP)-2, MMP-9, MMP-13, and inducible nitric oxidase. Celecoxib 8-17 matrix metallopeptidase 2 Mus musculus 345-377 35159480-6 2022 MES and celecoxib reduced the inflammation level of colon tissue, as indicated by its suppression on a panel of pro-inflammatory cytokines, including interleukin (IL)-1beta, IL-17, tumor necrosis factor alpha, and interferon gamma, and a group of inflammatory proteins, including intracellular adhesion molecule 1, vascular adhesion molecule 1, matrix metalloproteinase (MMP)-2, MMP-9, MMP-13, and inducible nitric oxidase. 2-(N-morpholino)ethanesulfonic acid 0-3 matrix metallopeptidase 2 Mus musculus 345-377